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Insulin like growth factor II (IGF-II) binds to Insulin Receptor isoform A (IR-A) to sustain 
cell growth and proliferation. This autocrine loop exists in many human carcinomas and 
provides an additional proliferation and survival pathway to the type 1 insulin-like growth 
factor (IGF-1R) signalling pathway. In addition, activation of the IGF-II/IR-A autocrine loop 
provides a mechanism of resistance drugs target the type 1 insulin-like growth factor (IGF-
1R). However, the mechanism of how IGF-II/IR-A differentiates itself from the IGF-II/IGF-
1R pathway is still unclear. Additionally, a novel phosphorylation site Thr1148 (numbered in 
IR-A) of IR was found in response to insulin stimulation and its phosphorylation in the 
absence of any Tyr1146, Tyr1150, and Tyr1151 phosphorylation. We thus hypothesis that the The 
phosphorylation of Thr1148 inhibits the phosphorylation of Tyr1146, Tyr1150, and Tyr1151 of the 
activation loop, which is possibly due to steric hindrance and electrostatic repulsion of the 
phosphate group on Thr1148 preventing interaction of the activation loop with the tyrosine 
kinase. 
The key areas of investigation included: 
1. Investigate the role of Thr1148 phosphorylation in IR-A by overexpress the wild-type 
IR-A and its mutants Thr1148Ala and Thr1148Asp in R- (Mouse fibroblast cells with IGF-
1R KO). 
2. Knock down the IR and IGF-1R separately in MDA-MB-231 and MCF-7 cells using 
inducible expressed miR30 shRNA and measure their characteristics (proliferation, 
migration, epithelial–mesenchymal transition) in response to insulin, IGF-I, and IGF-
II stimulation separately. 
3. Quantitative phosphoproteomics was conducted to compare the insulin/IR-A and IGF-
II/IR-A signalling pathway with MDA MB 231 IGF-1RKD cell. 
The key findings from this work included: 
 
1. Thr1148Ala and Thr1148Asp inhibit the insulin sensitivity of IR-A, which indicate the 
Thr1148 phosphorylation inhibits the IR activation. 
2. IRKD has no effect on proliferation of MCF-7 cells and the migration of MDA-MB-
231 cells, but increases the proliferation of MDA-MB-231 cells. 
3. IGF-1RKD inhibits the proliferation of both MCF-7 cells and MDA-MB-231 cells, 
but increases the migration of MDA-MB-231 cells. 
4. IGF-1R increases the insulin sensitivity of MDA-MB-231 cells, shown by the Akt 
activation. 
5. Insulin and IGF-II are confirmed to induce different signalling pathways confirmed by 
quantitative phosphoproteomics study. IGF-II is preferentially regulates the migration 
and stemness of MDA-MB-231 IGF-1RKD cells. Many markers are identified but 
verifications are still needed. Drug developed on the verified markers can be used to 
treat the patients who are resistant to anti-IGF-1R inhibitor. 
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The insulin-like growth factor (IGF) system is a complex and tightly regulated network that 
controls growth, proliferation, survival and metabolism. Different components are expressed 
in varying degrees in all tissues, thereby leading to different outcomes. Substantial evidence 
has shown that deregulation of the IGF system is associated with diseases such as diabetes 
and cancer. IGFs play a role in the promotion of tumour growth and metastasis. The 
characteristic that the IGF system regulates the physiology at both a whole organism level and 
cellular level increases the difficulty of evaluating its functions in cancer. In this introduction, 
functions of the IGF system components, IGF signalling pathways, the roles of the IGF 
system in cancer, and IGF system related cancer treatments are discussed. The gaps in our 
understanding that form the basis of this study are highlighted. 
1.1 IGF system overview 
The IGF system comprises three homologous ligands (insulin, insulin-like growth factor I 
(IGF-I), and insulin-like growth factor II (IGF-II)), three transmembrane receptors (the insulin 
receptor (IR), the IGF-I receptor (IGF-1R), and the cation-independent mannose 6-phosphate 
receptor (M6P/IGF-2R)), and six high affinity IGF binding proteins that regulate the 





 Figure 1.1: The IGF system. The IGF system includes the ligands (insulin, IGF-I, IGF-II; 
orange, grey and yellow circles), the receptors (IR-A grey/green, IR-B blue/green, IGF-1R 
orange/yellow, hybrids of IR/IGF-1R, IGF-2R black), the IGFBPs1-6 (coloured shapes) and 
acid labile subunit (ALS orange triangle). IGFs circulate in the serum mainly in an IGF: 
IGFBP-3:ALS complex. IGFBP proteolysis or binding to the ECM will lower the affinity for 
















The three ligands have different biological actions: insulin mainly regulates metabolic 
functions, whereas IGF-I and IGF-II mainly regulate mitogenic functions. Ligand signalling is 
mediated by interaction with the tyrosine kinase receptors, IR and IGF-1R. These two 
receptors are highly similar in sequence and structure, and thus can form IR/IGF-1R hybrid 
receptors. IR has two isoforms, IR-A (-exon11) and IR-B (+exon11) that arise by the 
alternative splicing of exon11. The isoforms are preferentially expressed in different growth 
stages and tissues, leading to their different biological functions. Because of the high 
structural similarity of the ligands and receptors, they share very similar downstream 
networks to form a very complex signalling system.  
While there are variations in binding affinities reported by various groups (Table 1.1) the 
consensus shows that insulin can bind to both isoforms of insulin receptor (IR-A and IR-B) 
with high affinity to regulate metabolic and mitogenic signalling. IGF-I binds to the IGF-1R 
with a high affinity (Table 1.1). IGF-II can also bind to IGF-1R, but at 2-3 fold lower affinity 
(Pandini et al., 2002a). IGF-II also binds to the IR-A with high affinity (Table 1.1). IGF-II can 
also bind to the IGF-2R, but this receptor is not a classic signalling receptor. Upon IGF-II 
binding to the IGF-2R the complex is internalized, and IGF-II is targeted to lysosome 
degradation. As a result, the IGF-2R controls the level of IGF-II in the circulation. Almost all 
circulating IGFs are bound to IGFBPs either in binary complexes or ternary complexes with 




Table 1.1: Binding affinities of ligands for receptors. 
  









0.2 0.6 >30.0 EC50 (Pandini et al., 2002b) 
0.8 4.4 >100.0 IC50 (Denley et al., 2004) 
 0.5 >1000.0 EC50 (Benyoucef et al., 
2007) 
0.019  3.8 EC50 (Slaaby et al., 2006) 
IR-A 
 
41.0  0.9 IC50 (Yamaguchi et al., 
1993) 
9.0 2.2 0.2 IC50 (Benyoucef et al., 
2007) 
>30.0 2.5 0.9 EC50 (Frasca et al., 1999) 
120.4 18.2 2.8 IC50 (Denley et al., 2004) 




390.0  1.6 IC50 (Yamaguchi et al., 
1993) 
>30.0 >20.0 1.0 EC50 (Frasca et al., 1999) 
90.0 10.0 0.5 IC50 (Benyoucef et al., 
2007) 
366.0 68.0 1.4 IC50 (Denley et al., 2004) 





0.5 0.6 3.7 EC50 (Pandini et al., 2002b) 
3.0  130.0 EC50 (Pierre-Eugene et al., 
2012) 




2.5 15 >100.0 EC50 (Pandini et al., 2002b) 
6.9  70.0 EC50 (Pierre-Eugene et al., 
2012) 
0.017  5.1 EC50 (Slaaby et al., 2006) 
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The deregulation of the IGF system has been detected in many diseases including 
neurodegeneration, Alzheimer' disease, cardiovascular disease, diabetes, and cancer. An 
elucidation of the intricate IGF signalling pathway is necessary for effective disease treatment. 
A more detailed description of the IGF system follows. 
1.1.1 Ligands 
Insulin is synthesized by beta cells in the pancreas as preproinsulin (Orci, 1986). It is then 
processed into proinsulin by the removal of the signal peptide. The amino-terminal B-chain 
and carboxyl-terminal A chain are connected by C-peptide in proinsulin. It is then processed 
into active insulin by releasing the C- peptide. The insulin contains two peptide chains, the A-
chain of 21 amino acids and the B chain of 30 amino acids. The chains are linked by two 
inter-disulfide bonds (residues A7-B7 and A20-B19), and there is a third intrachain disulfide 
bond (A6-A11) (De Meyts, 2004). The insulin freely circulates in the blood and controls 
metabolism by regulating the blood glucose concentration (Beardsall et al., 2008). The C-
peptide is also secreted into the blood and its circulating concentration is used to monitor type 
1 and type 2 diabetes (Jones and Hattersley, 2013). C-peptide can bind to the surface 
receptors to activate PI3K/Akt (Phosphoinositide 3-kinase/	 Protein kinase B) and MAPK 
(Mitogen-activated protein kinases) signalling pathways, thus regulates multiple cellular 
activities (Hills and Brunskill, 2008). 
IGF-I is predominantly produced in the liver under the regulation of growth hormone (GH) 
and acts in a paracrine manner, but is also secreted locally by most tissues. It is a single chain 
peptide of 70 amino acids, which includes four domains: B, C, A and D. The A and B 
domains are structurally similar to the A and B domains of insulin, arising from a 50% 
sequence similarity (Figure 1.2). The C domain is equivalent to the C-peptide in the 
proinsulin, but no D domain exists in the insulin (Humbel, 1990; Pavelic et al., 2007). Even 
though IGF-I is expressed at low level during the embryonic period; it is necessary for 
postnatal growth and development. 
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IGF-II synthesis is also mainly produced in the liver, but not under the control of growth 
hormone. It is expressed during the foetal development stage (Pavelic et al., 2007). The adult 
expression of IGF-II normally takes place in the liver and epithelial cells. It is a single chain 
with 67 amino acids, which also contains four domains similar to IGF-I. The primary 
sequence of the B- and A- chains is also 50% similar to that of the B- and A- chains of insulin 
(Figure 1.2). The three disulfide bonds are also located in equivalent positions to insulin 
(Rinderknecht and Humbel, 1976). The igf2 gene is imprinted, and only the paternal allele is 
expressed (Chao and D'Amore, 2008). It is crucial for placental development and foetal 
growth (Constancia et al., 2002).  
 
Figure 1.2: The amino acid sequences of Insulin, IGF-I, and IGF-II. Conservation across all 
three ligands is shown in light grey, whereas conservation between IGF-I and IGF-II is shown 
in dark grey. Insulin residues critical for IR binding and defined as site one residues are 
highlighted in bold type, and those defined as site two are underlined and in italics (Alvino et 
al., 2009). 
The sequence similarities (Figure 1.2) between IGFs and insulin translate into their similar 
tertiary structures (Figure 1.3). They adopt a similar core structure especially in the regions 
confined by the disulfide bonds. There are three α-helices in the B-domain and two α-helices 







10% 20% 30% 40% 50% 60% 70%
10% 20% 30% 40% 50% 60%
B% C% A% D%Domain%
FVNQHLCGSHLVEALYLVCGERGFFYTPKT            GIVEQCCTSICSLYQLENYCN Insulin%
B1% B30% A1% A21%B10% B20% A10%
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Figure 1.3: The tertiary structures of insulin, IGF-I, and IGF-II (From left to right). The blue 
ribbon indicates the α-helix in the B-chain, red and pink ribbons are α-helices in the A-chain 
and disulfide bonds are highlighted in yellow (Denley et al., 2005). 
 1.1.2 Receptors 
Insulin receptor (IR) 
Most of the RTKs dimerize or oligomerize upon ligand binding, thus leads to the activation of 
their kinase domains. Unlike most other RTKs, the IGF-1R and IR exist as preformed 
covalent dimers in the absence of the ligands (Heldin and Ostman, 1996).  
IR is encoded by 22 exons with 21 introns.  It comprises a α2β2-heterodimer, with the 
subunits covalently linked by three disulfide bridges (De Meyts and Whittaker, 2002) (Figure 
1.4). The two α- subunits are entirely extracellular and comprise the leucine-rich domains L1 
and L2, separated by a cysteine-rich (CR) domain, the fibronectin type III domains (FnIII-1, 
FnIII-2a/FnIII-2b, and FnIII-3), and an insert domain (ID) located between the FnIII-2a and 
2b segments. The two β-subunits include a transmembrane segment (TM) and an intracellular 
domain that comprises the tyrosine activation domain (TK) flanked by the juxtamembrane 
(JM) and C-terminal tail (De Meyts, 2004; De Meyts and Whittaker, 2002). Alternative 
expression of the amino acids encoded by exon 11 (12 amino acids, residues 718-729) at the 
C-terminus of the receptor α-subunit results in the IR-A (-exon11) and IR-B (+exon11) 
(Moller et al., 1989).   
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IR isoforms are preferentially expressed in different tissues. The IR-A is mainly expressed in 
foetal tissues, adult brain and kidney (Frasca et al., 1999), whereas IR-B predominantly exists 








Figure 1.4: Schematic diagram of the insulin receptor homodimer. L1, L2: leucine-rich 
repeated domains; CR: cysteine-rich region; FnIII-1, FnIII-2a/FnIII-2b and FnIII-3: 
fibronectin type III domains; ID: the insert region of FnIII-2. CT: The C-terminal 16 residues 
of the α-chain (the so-called CT-peptide); C-tail: carboxyl-terminal tail. The two monomers 
are linked together by disulphide bonds (black lines). The α and β subunits are also linked 





The IGF-1R expression is ubiquitous. It has a similar sequence to the IR, with 41-84% 
sequence similarity depending on the region being compared (Adams et al., 2000). It has the 
same domain arrangement as the IR and a similar ectodomain tertiary structure. Both 
receptors belong to the receptor tyrosine kinase (RTK) family (Hubbard and Till, 2000).  
Hybrids 
IR isoforms and IGF-1R share high sequence and structural similarities, and thus they not 
only form homodimers described above but also form heterodimers. These heterodimers have 
different affinities to insulin and IGFs (Table 1.1). An IR-A/IGF-1R hybrid has a high affinity 
for IGF-I (EC50=0.3 nM) and IGF-II (EC50=0.6 nM) but binds to insulin with a much lower 
affinity (EC50=3.7 nM) (Pandini et al., 2002b). Insulin can also induce the phosphorylation of 
specific IGF-1R substrates when binding to IR-A/IGF-1R (Pandini et al., 2002b; Zhang et al., 
2007). IR-B/IGF-1R only has high affinity for IGF-I (EC50=2.5 nM), much lower affinity to 
IGF-II (EC50=15 nM), but an insignificant affinity to insulin (EC50>100nM) (Pandini et al., 
2002b). However, other studies show there is no significant difference in insulin binding 
affinity between IR-A/IGF-1R and IR-B/IGF-1R hybrids (Slaaby et al., 2006), with hybrid 
receptors having an affinity for insulin that is at least 50 fold poorer affinity than for IGF-I 
(Benyoucef et al., 2007; Slaaby et al., 2006). These controversial conclusions about the 
ligands binding affinities could be due to the contamination of IGF-binding proteins in the 
commercial radioimmunoassay grade bovine serum albumin used in binding assays (De 
Meyts and Whittaker, 2002; Slaaby et al., 2006). Slaaby et al. conducted three different 
binding assays, and all the assays showed the poor affinity of insulin for both types of hybrid 
receptor (Slaaby et al., 2006). Slaaby’s data would be more reliable. 
In cells expressing both IR and IGF-1R, the proportion of IR homodimer, IGF-1R homodimer 
and IR/IGF-1R heterodimer are randomly formed (Bailyes et al., 1997; Frattali et al., 1992b). 
If one receptor type is expressed at low abundance, it is mainly found within a heterodimer. 
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However, in some cancer tissues, some unknown factors affect the hybrids formation (Pandini 
et al., 1999). 
In addition, formation of IR/IGF-1R hybrids will decrease insulin sensitivity due to their low 
affinity for insulin.  
IGF-2R 
IGF-2R is a monomeric membrane spanning glycoprotein, which contains one binding site for 
IGF-II and two binding sites for Mannose-6-Phosphate (M-6-P). However, IGF-2R has no 
intracellular signalling domain (Denley et al., 2005; Pavelic et al., 2007). Following binding 
of IGF-II, the IGF-2R: IGF-II is internalized, which leads to the lysosome degradation of 
IGF-II. As a result, the level of circulating IGF-II decreases (Denley et al., 2005; Pavelic et al., 
2007).  
1.1.3 IGFBPs 
The IGFBPs-1 to -6 are proteins of about 30 kDa (Hwa et al., 1999). They share a similar 
three-domain structure, with N- and C- terminal domains linked by a less structured linker 
domain. In the serum, the IGFBPs bind to IGFs with high affinity (Firth and Baxter, 2002).  
About 80% of the circulating IGF-I is carried by IGFBP-3/acid-labile complex (Lewitt et al., 
1994). This ternary complex cannot cross the vascular epithelial layer and act as an IGF 
reservoir within the circulation (Lewitt et al., 1994). The other IGFBPs also exist in the serum, 
but form binary complexes with IGFs. The smaller binary complex can cross the vascular 
epithelial layer so that they can deliver the IGFs to target tissues (Boes et al., 1992). The 
complex can be released by proteolysis of IGFBPs or binding of the IGFBPs to extracellular 
matrix (Firth and Baxter, 2002). Through these mechanisms, the IGFBPs play roles in the 
regulation of the levels of IGFs in the circulation. 
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1.2 IGF system in normal physiology 
The IGF system regulates the biological activities at both cellular level and whole organism 
level (Pollak, 2008) (Figure 1.5). The GH-releasing hormone (GHRH) and somatostatin 
(SMS) control the release of growth hormone (GH) from the pituitary gland, which regulates 
the secretion of IGF-I. IGF-II is also mainly produced in the liver but is not under the control 
of GH. However, both IGFs can be regulated by IGFBPs. At the same time, insulin is secreted 
from the pancreas. Its expression can be inhibited by SMS. The blood brings them into the 
target tissues. Other cells (e.g. epithelial cells) can also secret IGFs by autocrine and paracrine 
mechanisms. 
Under normal physiological conditions, ligands circulate the body with different 
concentrations: insulin at 0.1-1nM, IGF-I at about 20nM and IGF-II at about 90nM. With 
these ranges of ligand concentration, insulin can only bind to the insulin receptor, IGF-I can 
bind to IGF-1R or IR/IGF-1R hybrid, and IGF-II can bind to IR-A, IR-B, IGF-1R and 
IR/IGF-1R hybrids. 
Knockout mice verify the physiological functions of the IGF system. Mice lacking the liver 
igf-1 gene have an approximately 80% reduction in circulating total IGF-I levels (Svensson et 
al., 2008). The mice with igf-1 knockout have 60% birth weight of normal mice, while the igf-
1r knockout has 45% birth weight of normal mice (Liu et al., 1993). The phenotype of the igf-
1/igf-1r double knockout appeared identical to that of the igf-1r knockout, which indicates the 
IGF-I was acting exclusively through the IGF-IR (Liu et al., 1993). The mice with igf-2 
knockout have 60% birth weight of the normal ones (Liu et al., 1993). The igf-2/igf-1r double 
knockout had more severe growth retardation than the igf-1r knockout alone, suggesting that 
IGF-II acts through another receptor in addition to the IGF-1R (Baker et al., 1993).  Later 
studies find that the insulin receptor isoform A (IR-A) acts as a compensatory factor (Avnet et 





Figure 1.5: Key IGF system elements under normal physiological conditions. The principal 
source of IGF-I and IGF-II is the liver, while the only source of insulin is the pancreas. 
GHRH and SMS regulate the expression of GH in the pituitary and GH then controls IGF-I 
secretion. Blood vessels deliver the ligands to target tissues, which express IR and IGF-1R. 
SMS is released to inhibit insulin and glucagon secretion in the pancreas. IGFs: IGF-I, IGF-II; 
IGFBPs: IGF binding proteins; GH, growth hormone; GHRH, GH-releasing hormone; IRS, 




1.3 Structural basis of receptor activation 
1.3.1 Ectodomain structure  
The crystal structure of IR ectodomain was first reported by McKern et al (McKern et al., 
2006) and Smith et al. refined it (Smith et al., 2010). The conformation of each ectodomain 
was an inverted “V” (Figure 1.6). The cross-linking studies and alanine-scanning mutagenesis 
showed that there are two insulin-binding sites: site1 formed by the L1 domain and the 
carboxyl-terminal segment of the other monomer; site2 involved the loops of the first and 
second fibronectin domains of the second monomer (Whittaker et al., 2008). Upon ligand 
binding, the ectodomain will undergo structural changes and transduce the signal into the 
membrane. 
Uhles et al found that the 12 amino acids sequence encoded by exon 11 acts as a sorting 
signal rather than playing a structural role in the IR (Uhles et al., 2003). This motif is 
proposed to direct the different IR isoforms to different membrane domains. Thus IR-A and 







Figure 1.6: The IR ectodomain homodimer, showing the juxtaposition of domains between 
the monomers. One monomer is shown in tube representation, the other in atomic sphere 
representation. Individual domains are colored as follows: L1, brown; CR, yellow; L2, green; 
FnIII-1, magenta; FnIII-2, cyan; and FnIII-3, blue. The locations of potential N-linked 
glycosylation sites are shown in black (McKern et al., 2006). 
1.3.2 Tyrosine kinase domain activation 
The crystal structure of the unphosphorylated insulin receptor kinase domain shows the IR is 
cis-inhibited under basal conditions (Hubbard et al., 1994). The Tyr1150 of the activation loop 
is hydrogen-bonded to the catalytic loop, thus preventing the IR kinase activity (Hubbard et 
al., 1994). The juxtamembrane	(JM)	and α-C (α-helix at the N-terminal lobe of kinase 
domain) also inhibits auto phosphorylation (Cabail et al., 2015; Hubbard, 2013; Li et al., 
2003). The binding of insulin triggers autophosphorylation of the IR in the activation domain 
and thus induces the signalling cascade (Hubbard, 2013). Hubbard et al suggested that the 
kinase domains from two monomers were within a trans auto phosphorylation range (Cabail 
et al., 2015; Hubbard, 2013; Li et al., 2003). However, the crystal structure of the 
phosphorylated IR-JMTK dimer (Figure 1.7) shows that the activation loops from different 
monomers are far away from each other, adopting a back-to-back position (Cabail et al., 
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2015). If the two monomers in basal state formed a back-to-back position, the trans 
phosphorylation would be impossible. If the activation loops were face-to-face with each 
other ligand binding could induce trans phosphorylation and thus through charge repulsion 
promote the required rotation to allow the activation loop to move out of the catalytic site. As 
such, the crystal structure of the unphosphorylated IR-JMTK dimer will help us understand 
the auto phosphorylation process.  
 
Figure 1.7: Crystal structure of phosphorylated IR-JMTK dimer viewed from the front (left) 
and top (right). One of the dimer is shown with molecular surface and another is shown with 
ribbon and molecular surface with 50% transparency. The juxamembrane (JM) region is 
coloured pink, the	α-C (α-helix at the N-terminal lobe of kinase domain) is coloured blue, the 
activation loop is coloured green, the catalytic loop is coloured orange, the three tyrosines: 
Tyr1146,1150,1151 are coloured cyan, and Tyr1146, is coloured red. Adapted from Cabail et al 




A key step in the activation of the IR is the phosphorylation of the three tyrosines (1146, 1150, 
1151) in the activation loop (Figure 1.8), which generates recruitment sites for the 
downstream signalling proteins that contain phosphotyrosine recognition domains such as src 
homology-2 (SH2) domains and the binding (PTB) domains (Pawson, 1995). After ligand 
binding, the Tyr1150 are phosphorylated first. The Phosphorylated Tyr1150 then forms a 
hydrogen bond with the side chain of Arg1152. The subsequent phosphorylation of Tyr1151 
allows the formation of hydrogen bonds with Arg1143 and Gly1154. The formations of these 
hydrogen bonds stabilize the activation loop. The Phosphorylated Tyr1146 is free and exposed, 
suggesting it would be available to interact with downstream signalling proteins (Cabail et al., 
2015; Hubbard, 1997, 2013). 
 
Figure 1.8:  Structure of the tyrosine-kinase domain of the insulin receptor. (a): The inactive 
insulin receptor kinase. This figure illustrates the autoinhibition mechanism, whereby Tyr1150 
is bound to the active site, hydrogen-bonded to a conserved Asp1120 residue (green) in the 
catalytic loop. Tyr1150 in effect competes with protein substrates before autophosphorylation. 
(b): The activated kinase with bound ATP analog (AMP–PNP), peptide substrate and 
magnesium (Mg2+). Tyr1150 is one of the three tyrosines (Tyr1146,1150,1151) that is 
autophosphorylated in the activation loop (shown in white) in response to insulin. In the 
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activated state (b), the activation loop moves out of the active site and the three tyrosine 
residues in the activation loop are phosphorylated. The Tyr1151 becomes hydrogen-bonded to a 
conserved Arg1143 residue at the beginning of the activation loop, which stabilizes the 
repositioned loop. The peptide substrate, with the Tyr-Met-Xaa-Met (YMXM) motif and 
AMP–PNP, adenylyl imidodiphosphate are also shown. Numbering corresponds to the IR-A. 





1.4 IGF signalling pathway adaptor proteins 
The activation of the kinase domain and the following phosphorylation of different IR 
intracellular domain residues lead to the recruitment of adaptor proteins, kinases and 
phosphatases. The characterised interactions are highlighted in Table 1.2. The recruitment of 







Tyr960 IRS-1 Known to be involved in both metabolic and mitogenic signalling 
(Abe et al., 1998; Hribal et al., 2000) 
IRS-2 Involved in both metabolic and mitogenic signalling (Sawka-
Verhelle et al., 1996; Wu et al., 2008) 
IRS-3 IRS-3 is found in mouse only (Sesti, 2000; Xu et al., 1999) 
Shc Activates Erk via Grb2, SOS & Ras complex (Farooq et al., 1999) 
Cbl Regulates insulin-mediated glucose uptakes (Gupte and Mora, 
2006) 
SOCS-3 Inhibits IR-mediated activation of StatB without modifying the 




IRS-2 Involved in both metabolic and mitogenic signalling (Sawka-
Verhelle et al., 1996) 
IRS-4 Expressed in human and mouse embryonic stages (Sesti, 2000) 
APS Couple Cbl to IR. Enhances IR internalization but not degradation 
(Ahmed et al., 1999; Kishi et al., 2007) 
Grb7 Acts as an inhibitor for insulin signalling (Han et al., 2001; Kasus-
Jacobi et al., 2000) 
Grb10 Acts as an inhibitor for insulin signalling (Stein et al., 2001)  
Grb14 Acts as an inhibitor for insulin signalling (Goenaga et al., 2009) 
Thr1148 PKC-ε Acts as an inhibitor for insulin signalling (Petersen et al., 2016) 
Tyr1110 Grb2 Promote mitogenic responses (Hanke and Mann, 2009) 
PLCγ Phosphorylates of T1336 on IR upon activation (Hanke and Mann, 
2009) 
Tyr1316 PP120 Regulates insulin-induced mitogenic action (Soni et al., 2000) 
Thr1336 PKCδ Involved in IR internalization, blocking the activation of PKCδ 
abrogate IR internalization (Braiman et al., 2001) 
Table 1.2: Signalling molecules known to interact with the IR. The residues of the IR used as 
docking sites for signalling molecules are indicated. Also, comments regarding the biological 
activities of the signalling molecules are provided. 
	
	 22	
1.5  Downstream signalling pathways 
Two main signalling pathways are activated upon insulin binding to the IR (Taniguchi et al., 
2006): the mitogen-activated protein kinase (MAPK) pathway which mainly promotes 
proliferation; the PI3K/Akt pathway which mainly promotes metabolism (Figure 1.9).  
1.5.1 MAPK pathway 
The MAPK are a family of Ser/Thr protein kinases (Figure 1.9). When IR is activated, the 
Shc binds to phosphorylated Tyr960 and then forms the Shc-Grb2-Sos complex. The complex 
activates Ras, which then activates the following proteins: Raf, MEK1, Erk1/2 and p90rsk. 
p90rsk and Erk1/2 can phosphorylate or interact with a large number (>300) of cytosolic and 
nuclear substrates, including transcription factors (Yoon and Seger, 2006). Deregulation of 
the MAPK pathway affects the expression of genes involved in mitogenic outcomes and is 
reported in above 90% cancers. 
1.5.2 PI3K/Akt pathway 
The PI3K/Akt pathway (Figure 1.9) starts from the interaction of IRS with a p85 regulatory 
subunit of PI3K, following by the activation of catalytic subunit p110 of PI3K and the 
production of phospholipids: PIP3. PIP3 acts as a second messenger and activates PI3K-
dependent kinase-1 (PDK1) and the serine/threonine kinase Akt. Akt has a range of substrates 
and thus is recognised as a central node in cell signalling. Akt can activate or inhibit glucose 
uptake, lipolysis, gluconeogenesis, lipogenesis and protein synthesis through the regulation of 
substrates. Akt also regulates proliferation, growth, and survival through regulation of 
substrates (such as FRHR and NFKB).  
1.5.3 IR signalling pathways 
In R- mouse fibroblasts transfected with IR-A it has been shown that binding of insulin to the 
IR-A activates metabolic signalling, while IGF-II predominantly activates mitogenic effects 
in R- mouse fibroblasts transfected with IR-A (Frasca et al., 1999). Jensen et al. also found 
that the S597 (an insulin mimetic peptide) only induces metabolic signaling when bound to 
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the IR-A (Jensen et al., 2007). This evidence demonstrates that different ligands can induce 
different signalling outcomes presumably by the recruitment of different adaptor proteins 
(Mlinar et al., 2007).  
Several downstream proteins have been found to be differentially activated by insulin and 
IGF-II. With IGF-1R negative fibroblasts (R-, derived from IGF-1R knockout mice) 
overexpressing the IR-A (R-IR-A), Sacco et al. identified that IGF-II preferentially activated 
p70S6 kinase compared to insulin stimulation (Sacco et al., 2009). The same group 
(Morcavallo et al., 2011) performed a phosphotyrosine proteomic study and showed that 
while some signalling proteins were activated by both ligands, several proteins including IRS-
2 and SPIN90, were phosphorylated upon IGF-II activation and not insulin activation. In 






 Figure 1.9: IR signalling pathways. After ligand binding, the activated IR phosphorylates 
several substrates, such as IRS1/2. IRS proteins interact with the regulatory subunit of PI3K 
leading to the activation of Akt. Akt interacts with a range of substrates to regulate metabolic 
and mitogenic biological activities. For example, Akt regulates protein translation and cell 
growth by inhibiting the Tubero sclerosis complex 1 and 2 (TSC1/TSC2) and thus activating 
mTOR. Insulin activation of the IR also triggers mitogenic signalling via the 





1.6 IGF system in cancer 
The dysregulation of the IGF system has been found in many cancer types, such as breast, 
prostate and colon cancers (Fair et al., 2007; Freier et al., 1999; Tennant et al., 1996).  
Epidemiological studies also show that the higher levels of IGFs and insulin are related to 
high risks of cancer (Fierz et al., 2010; Pisani, 2008). It is well known that the IGF system 
plays roles in the initial steps of malignant transformation and the later stages of tumor 
progression and metastasis (Saldana et al., 2013). 
1.6.1 IGF-1R in cancer 
IGF-1R sustains the cell survival and proliferation in many types of cancers. For example, 
Eliasz et al. (Eliasz et al., 2010) found that Notch-1 stimulates the survival of adenocarcinoma 
of the lung (ACL) cells in hypoxic microenvironment by the up-regulation of the IGF-1R 
pathway, as Notch-1 is a direct regulator of the IGF-1R promoter (Eliasz et al., 2010). The 
IGF-1R also promotes the survival of hepatocellular carcinoma (HCC) cells when treated 
with gefitinib, a cancer drug that inhibits the epidermal growth factor receptor (EGFR) 
pathway (Bodzin et al., 2012). The higher expression of IGF-1R can promote resistance to 
apoptotic effects in murine Lewis lung carcinoma cells (Li et al., 2012). Furthermore, 
antisense RNA targeting the IGF-1R reduces the tumour growth in many cancer models 
(Chernicky et al., 2002; Schillaci et al., 2006; Scotlandi et al., 2002).  
1.6.2 IGF-II/IR-A autocrine loop in cancer 
The IGF-II/IR-A signalling has been shown to provide an alternate mitogenic signalling 
pathway to the IGF-1R pathway in cancer cells that have developed resistance to anti-IGF-1R 
treatment (Avnet et al., 2009; Ulanet et al., 2010; Zhang et al., 2010).  The IGF-II/IR-A 
signalling also stimulates cell migration (Sciacca et al., 2002). IR-A expression is increased in 
many types of cancer, such as breast and colon cancer (Brierley et al., 2010; Frasca et al., 
1999). IGF-II expression is also increased in these types of cancers, especially in Triple 
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Negative Breast cancers (TNBC) (Fiore et al., 2010; Radhakrishnan et al., 2015; Toretsky and 
Helman, 1996).  
1.6.3 IGF system and epithelial to mesenchymal transition (EMT) 
Epithelial to mesenchymal transition (EMT) promotes tumor invasion, metastasis, and drug 
resistance. The features of EMT include decreased expression of E-cadherin and increased 
levels of mesenchymal markers such as vimentin, fibronectin, and N-cadherin (Zeisberg and 
Neilson, 2009). 
The IGF-1R signalling can promote the epithelial to mesenchyme transition (EMT) in many 
cell types, such as ovarian carcinoma cells, human pancreatic carcinoma BxPC3 cells, 
childhood sarcomas and human chondrosarcoma cells (Burnier et al., 2011; Cheung et al., 
2011; Irie et al., 2005; Jaquish et al., 2011). IGF-II also induces the degradation of E-cadherin 
and thus increases EMT transition (Morali et al., 2001). However, other studies have shown 
that IGF-II can also promote EMT features via the IR-A and not through activation of the 
IGF-1R (Vella et al., 2002; Zhao et al., 2012; Ziegler et al., 2014). The IGF-1R depletion 
actually promoted the more aggressive Wnt1-mediated murine mammary tumours, through 
the concomitant increased expression of IGF-II and IR-A (Rota et al., 2014). However, the 
EMT is a much more complicated process, besides under the regulation of IGF-1R and IR. 
1.7 Current cancer treatments targeting the IGF system 
There are several strategies to inhibit IGF action in cancer. One strategy is to decrease the 
bioavailability of ligands or receptors by monoclonal antibodies (Table 1.3). Another is to 
inhibit the receptor function by small molecule tyrosine kinase inhibitors (TKIs) (Table 1.4). 
Other strategies include the use of a modified IGFBP or siRNA treatment to decrease the 
functional proteins in IGF system; the use PI3K/Akt, mTOR or MAPK signalling pathway 
inhibitors to inhibit the IGF downstream signalling.  
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1.7.1 Anti-ligand monoclonal antibodies 
Many monoclonal antibodies have been developed to target IGFs (Table 1.3). Two promising 
products are being tested in clinical trials, Xentuzumab and MEDI-573. Generally, antibody 
targeting the IGF induces a feedback to GH to produce more IGF and insulin as 
compensation, thus causing hyperinsulinemia, such as Xentuzumab (Boehringer Ingelheim) - 
the dual IGF-I/IGF-II monoclonal antibody (Mireuta et al., 2014). In tumor xenograft animal 
models, Xentuzumab can decrease tumor growth and even restore the sensitivity to the 
mutant-selective EGFR-TKI (WZ4002) (Martinez-Quetglas et al., 2016; Park et al., 2016a). 
However, its usage needs to be evaluated carefully, particularly the usage in children, because 
it inhibits the growth (Friedbichler et al., 2014).  
MEDI-573 (AstraZeneca plc) – another dual IGF-I/IGF-II monoclonal antibody, significantly 
inhibits tumour growth in mice (Zhong et al., 2016). The elevated levels of insulin and growth 
hormone are not observed in its phase I trial, maybe the maximum usage is not reached yet 
(Haluska et al., 2014). Patients are currently being recruited for the Phase 2 clinical studies. 
1.7.2 Anti-receptor monoclonal antibodies 
Anti-IGF-1R monoclonal antibodies can be used to block ligand binding to the IGF-1R and to 
induce IGF-1R internalization and degradation as a means to inhibit IGF-1R signalling and 
biological action. Unfortunately, this strategy invariably leads to hyperglycemia and 
hyperinsulinemia, as there is increased secretion of more insulin and IGFs from a feedback 
effect (Gualberto and Pollak, 2009; Haluska et al., 2007).  
Figitumumab failed to improve the overall survival of the patients in phase 3 clinical trials 
(Langer et al., 2014; Scagliotti et al., 2015). This failure resulted in discontinuation of its 
development. One possible reason for these failures is that cross talk exists between the IGF-
1R pathway and the estrogen receptor and receptor tyrosine-protein kinase erbB-2 signalling 
pathways (Fox et al., 2011; Gee et al., 2005). Another main reason is the unregulated 
	
	 28	
expression of IGF-II and IR-A, which provides an alternative signalling pathway for IGF-II 




Monoclonal antibody Stage of Development 
IGF-I monoclonal antibodies 
Novartis patent anti-IGF-1/E Preclinical 
Roche patent anti-IGF-1 Preclinical 
IGF-II monoclonal antibodies 
DX-2647 Preclinical 
NIH patent anti-IGF-2 Preclinical 
IGF-I and IGF-II monoclonal antibodies 
Xentuzumab (BI-836845) Phase 2 
MEDI-573 Phase 1 
IGF-1R monoclonal antibodies 
Figitumumab Phase 3 (Discontinued) 
Ganitumab Phase 3 
Cixutumumab Phase 2 
Dalotuzumab Phase 2 
Teprotumumab Phase 2 
Robatumumab Phase 2 
Istiratumab Phase 2 
AVE1642 Phase 1 
BIIB022 Phase 1 
Biogen EI-04 Preclinical 
Table 1.3: Antibodies that target the IGF system. Data are sourced from the Therapeutic 




1.7.3 Small molecule tyrosine kinase inhibitors 
Small molecule tyrosine kinase inhibitors (TKIs) compete for the ATP binding site in the 
catalytic domain of the IGF-1R and IR (Table 1.4). However, there is an overall lack of 
efficacy for TKIs used as sole agents to inhibit a range of cancer types due to the fact that the 
compensations of other signalling pathways (Bendell et al., 2015; Fassnacht et al., 2015). For 
example, Linsinib was ineffective in treating adrenocortical carcinoma and colorectal cancer 
in clinical trials, and any treatment with this drug was not recommended (Bendell et al., 2015; 
Fassnacht et al., 2015). The clinical trial of BMS- 754807 on patients with advanced or 
metastatic solid tumors was also terminated, due to the unreached expectations 
(ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT00908024?term=BMS-
+754807&rank=2). In addition,  the compensation effect arose when receptors were inhibited 










Stage of Development 
OSI-906 (Linsitinib) 35nM 75nM Phase 3 
BMS-754807 1.8nM 1.7nM Phase 2 
Picropodophyllin 
(PPP) 
1nM  Phase 1/2 
KW-2450 7.39nM 5.64nM Phase 1 
GSK1838705A 2nM 1.6nM Preclinical 
GSK1904529A 27nM 25nM Preclinical 
BMS-536924 100nM 73nM Preclinical 
NVP-AEW541 150nM 140nM Preclinical 
NVP-ADW742 170nM  Preclinical 
PQ401 <1μM  Preclinical 
AG-1024 7μM 54μM Preclinical 
A-928605   Preclinical 
Insm-18 (NDGA)   Preclinical 
XL-228 2nM  Preclinical 
ABDP   Preclinical 
Table 1.4: A selection of small molecule inhibitors that target the IGF-1R and IR. Data are 
sourced from Selleckchem Database (Oct 2016) (http://www.selleckchem.com/IGF-





1.7.4 Other treatment strategies 
The modified IGFBPs are under development to regulate circulating IGF levels (Soh et al., 
2015). Concern over the use of IGFBPs arises because IGFBPs are shown to have both IGF-
dependent and independent actions (Yu and Rohan, 2000). The modified IGFBP-2 reported 
by Soh et al., took this into account by mutating or removing motifs responsible for IGF-
independent actions while maintaining the ability to bind IGFs. This modified IGFBP was 
shown to inhibit breast tumour xenograft growth (Soh et al., 2015). 
The use of RNAi as cancer treatments has been improved in many aspects, especially in 
decreasing off-target effects and optimising the delivery system (Sanderson et al., 2015). . 
However, there is still long way to go. Death of a patient in a phase 3 clinical trial of 
Revusiran from world-renowned gene therapy company Alnylam cast a shadow over gene 
therapy's future (http://www.genengnews.com/gen-news-highlights/after-18-deaths-in-phase-
iii-alnylam-halts-revusiran-development/81253293). 
It is well known that the PI3K/Akt, and MAPK signalling pathways are downstream of the 
IGF-1R. The inhibitors that target the molecules of the PI3K/Akt and MAPK signalling 
pathways are being developed (Pivonello et al., 2016). The combined inhibition of IGF-1R/IR 
and downstream signalling mediators is a promising approach (Herkert et al., 2016; 
Lamhamedi-Cherradi et al., 2016). 
Several questions need to be addressed in the future: the crosstalk of the IGF system to other 
signalling pathways; the compensatory effects of increased levels of IGFs and insulin; the 
lack of biomarkers to select for sensitive and resistant patients; lack of optimisation of the 
dose and schedule; the lack of understanding of the role of IR-A/IGF-II signalling. A further 




1.8 Summary, Hypothesis and Aims 
Dysregulation of the IGF system leads to cancer cell proliferation, survival, and migration. As 
discussed before, there are shared and different signalling pathways downstream of the IR-A, 
IR-B, and IGF-1R. Furthermore, the IGF-II/IR-A autocrine loop has been identified as an 
alternative signalling pathway causing resistance to the anti-IGF-1R therapies. It is therefore 
desirable to develop anticancer therapies that target the IGF-II/IR-A autocrine pathway 
specifically, without impairing the metabolic effects of the insulin receptor. 
There have been many studies investigating the IGF-II/IR-A signalling pathway using various 
methods including standard immunoblotting (Frasca et al., 1999; Sciacca et al., 2002), 
microarray analysis (Pandini et al., 2003) and proteomics (Morcavallo et al., 2011). Overall 
these studies show that IGF-II is more potent in promoting mitogenic signals than insulin 
(Frasca et al., 1999; Sciacca et al., 2002). However, most studies so far have investigated 
IGF-II signalling via the IR-A using the R-IR-A fibroblast cell line rather than in cancer cells 
in which the IGF-II:IR-A autocrine loop components are expressed. However, the markers 
identified to differentiate the Insulin/IR-A and IGF-II/IR-A signalling pathway in R-IR-A 
cells are not always consistent with cancer cells. For example, the activation of the ephrin 
type-B receptor 4 (EphB4) through IR signalling is different between R-IR-A and MCF-7, the 
EphB4 was activated by IGF-II in R-IR-A cells while IGF-II was more effective to activate 
the EphB4 than insulin in MCF-7 cells (Morcavallo et al., 2011).  
Based on the evidence listed above, I hypothesize that insulin and IGF-II induce both shared 
and different IR-A activation patterns (or phosphorylation patterns) and downstream 
signalling cascades to promote cancer cell proliferation and migration. The differences in 
signalling could in the future be potentially exploited as targets to inhibit tumour growth and 
metastasis.  
The aims of this thesis were to: 
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1: Define the role of a previously undescribed phosphosite at residue Thr1148, which is in the 
middle of the three phosphotyrosine sites in the activation loop, in insulin signalling. In this 
thesis, I used site-directed mutagenesis to help understand the role the Thr1148 phosphorylation 
in IR activation. 
2: Identify a signature of kinase targets that is unique to IGF-II/IR-A autocrine signalling. To 
achieve this the following steps were taken:  
i. Construct model breast cancer cell lines expressing only the IGF-1R or the IR through 
receptor knockdown (IGF-1RKD and IRKD). 
ii. Analyse the biological activities of the model cell lines (proliferation assay, migration 
assay, EMT marker PCR) in response to insulin and IGF-II. 
iii. Optimize an appropriate quantitative phosphoproteomics method. 
iv. Identify the signature proteins that are differentially regulated between the Insulin/IR-A 
and IGF-II/IR-A signalling pathways in a breast cancer cell line predominantly expressing the 





2.1  Materials 
Materials Sources 
13C6-L-Arginine HCl Silantes GmbH (#201204102) 
13C6,15N2-L-Lysine HCl Silantes GmbH (#211604302) 
13C6,15N4-L-Arginine HCl Silantes GmbH (#201604102) 
2-log DNA ladder New England Biolabs, USA 
2% Bis Bio-Rad, Hercules, CA, USA 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, HEPES 
Scharlau, Barcelona, Spain 
4,4,5,5-D4-L-Lysine 2HCl Silantes GmbH (#211104113) 
40% Polyacrylamide Bio-Rad, Hercules, CA, USA 
Acetic acid, glacial VWR International, Radnor, PA, USA 
Acetonitrile Merck, Kenilworth, NJ, USA 
ACTRAPID (Insulin) Novo Nordisk Australia 
Agarose Sigma, St. Louis, MO, USA 
Ammonium bicarbonate  BDH (Poole, UK) 
Ammonium persulphate, APS Sigma, St. Louis, MO, USA 
Anti-rabbit HRP, 1:3000 dilution Jackson ImmunoResearch, USA 
Applied Biosystems Fast SYBR® Green 
Mastermix 
Life Technologies, Carlsbad, CA, USA 
Boric acid Sigma, St. Louis, MO, USA 
Bovine serum albumin, BSA Sigma, St. Louis, MO, USA 
Calcium chloride, CaCl2 Ajax chemicals Ltd., Sydney, Australia 
Charcoal Stripped Fetal Bovine Serum Thermo Fisher Scientific (#12676011) 
CHCA Bruker Daltonics 
Chloroform Sigma, St. Louis, MO, USA 
cOmplete ULTRA Tablets, Mini, EDTA-
free, EASYpack 
Roche 
Coomassie G-250 Sigma, St. Louis, MO, USA 
Crystal violet Sigma-Aldrich 
DC™ Protein Assay Kit II Bio-Rad (#5000112) 
DHB Bruker Daltonics 
Dialyzed fetal bovine serum, US origin Thermo Fisher Scientific 
Diethylpyrocarbonate (DEPC) Life Technologies, Carlsbad, CA, USA 
DMEM, high glucose, HEPES  Thermo Fisher Scientific (#12430-062) 
DMSO for molecular biology Sigma-Aldrich (Castle Hill, Australia) 
dNTPs New England Biolabs, USA 
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DTT Sigma-Aldrich (Castle Hill, Australia) 
DMEM - SILAC Sigma-Aldrich (#D9443) 
EDTA Sigma, St. Louis, MO, USA 
Empore™ SPE Disks 3M™ 
Ethanol Sigma, St. Louis, MO, USA 
Fetal Bovine Serum Thermo Fisher Scientific (#10099141) 
Formaldehyde solution, 37 wt. % in 
H2O 
Sigma-Aldrich (Castle Hill, Australia) 
Formic acid (FA, p.a., >98% purity)  Fluka Chemie (Neu-Ulm, Germany) 
Gateway® LR Clonase® Enzyme mix Thermo Fisher Scientific (#11791019) 
GelRed Biotium Inc., Hayward, CA, USA 
Geneticin® Selective Antibiotic (G418 
Sulfate) (50 mg/mL) 
Thermo Fisher Scientific (#10131027) 
GlutaMAX™ Supplement Thermo Fisher Scientific (#35050061) 
Glycine VWR International, Radnor, PA, USA 
Guanidine hydrochloride (GdmCl) Sigma-Aldrich (#G3272) 
HF Phusion® Polymerase and buffer New England Biolabs, USA 
High Capacity RNA to cDNA kit Life Technologies, Carlsbad, CA, USA 
Human gamma globulin Sigma-Aldrich (Castle Hill, Australia) 
Hydrochloric acid, HCl Sigma, St. Louis, MO, USA 
IGF-I Gropep, Australia 
IGF-II Gropep, Australia 
Iodoacetamide, IAA Sigma-Aldrich (Castle Hill, Australia) 
Isopropanol Sigma, St. Louis, MO, USA 
Lipofectamine® LTX with Plus™ 
Reagent 
ThermoFisher 
L-Arginine  Sigma-Aldrich (#A5006) 
L-Leucine Sigma-Aldrich (#L8912) 
L-Lysine Sigma-Aldrich (#L5501) 
LR3 IGF-I GroPep 
lysyl endopeptidase, biochemistry grade  WAKO (#12502543) 
Methanol RCI Labscan, Thailand 
Microcon YM-30 Millipore, Billerica, MA 
Normal rat serum Forbes Lab 
Normal mouse IgG1 Santa Cruz Biotechnology (#SC-3877) 
Penicillin-Streptomycin (10,000 U/mL) Thermo Fisher Scientific (#15140122) 





Protein Standard I Bruker Daltonics, Billerica, MA, USA 
Puromycin dihydrochloride  Sigma-Aldrich 
QIAGEN Plasmid Midi Kit QIAGEN 
Sodium chloride, NaCl Sigma, St. Louis, MO, USA 
Sodium dodecyl sulphate, SDS Bio-Rad, Hercules, CA, USA 
Sodium phosphate Ajax chemicals Ltd., Sydney, Australia 
Stage Tips C8 material 200uL tip 96pcs Thermo Fisher Scientific (#SP321) 
Streptavidin HRP R&D Systems, Minneapolis, MN, USA 
Sulphuric acid Ajax chemicals Ltd., Sydney, Australia 
Sulphuric acid, H2SO4 Sigma, St. Louis, MO, USA 
Supported nitrocellulose membrane GE Healthcare Life Sciences, 
Parramatta, NSW, Australia 
Syringe filter (0.22, 0.45 μm) Sartorius AG, Gottingen, Germany 
Tetramethylethylenediamine, TEMED Sigma, St. Louis, MO, USA 
Titansphere PHOS-TiO, 10um, 500mg GL Sciences (#5010-21315) 
TRI-reagent Sigma, St. Louis, MO, USA 
Trifluoroacetic acid, TFA Merck, Kenilworth, NJ, USA 
Tris Sigma, St. Louis, MO, USA 
Trypsin Promega (Madison, WI, USA) 
Trypsin-EDTA (0.5%), no phenol red Thermo Fisher Scientific (#15400054) 
Tween-20 Sigma, St. Louis, MO, USA 
Western Lightning Plus Perkin-Elmer, Turku, Finland 
X-ray film (Curix ortho HT-G 100 NIF 
Ecopac) 
Agfa, Belgium 
ZipTip Pipette Tips Merck Millipore 





All the primers used in this thesis for PCR, site- directed mutagenesis, sequencing and 
shRNA are shown in Table 2.2.  
Name Sequence Usage 






PCR, IR-A size: 
473bp, IR-B size: 
509bp  
IGF-1R  Forward: ACT TCT GCG CCA ACA TCC 
TCA 
Reverse: CCC TTT AGT CCC CGT CAC 
TTC C 
PCR, size: 572bp 
GAPDH  Forward: TGG TAT CGT GGA AGG 
ACT CAT GAC 
Reverse: 
ATGCCAGTGAGCTTCCCGTTCAGC 
PCR, size: 189bp 




PCR, size: 102bp 








of  IR Threonine 1148 
to Alanine 








of IR Threonine 1148 
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Amplification of the 
shRNA PCR product 









Tabel 2.2: Primer list. The shRNA targets are mapped using numbering from the IGF-1R 






Name Source Usage 
pMK-RQ_IR-A fragment Synthesized at GENEART Synthesize the IR-A 
fragment 
pMK-RQ_InsR_3×myc  Synthesized at GENEART Synthesize IR fragment 
with myc tag at the C-
terminal 
pcDNA3.1 (IR-B) Synthesized at GENEART Synthesize the IR-B 
cDNA 
pBluescript(KS+) Addgene Used for Site-directed 
mutagenesis 










Generated in this thesis Used for cell transfection 
and protein 
overexpression 
pLV-TRE3G-IRES- Puro Whitelaw Lab Lentivector backbone 
pENTR1a-dsRed-m30c Whitelaw Lab Used for Gibson assembly 
and sequencing 
pCMV-dvrp8.2 Addgene 2nd generation lentiviral 
packaging plasmid 
pRSV-Rev Addgene 3rd generation lentiviral 
packaging plasmid 




Whitelaw Lab Lentivector expressing 
shRNA negative control 







DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ– thi-1 gyrA96 relA 
DB3.1 F– gyrA462 endA1 Δ(sr1-recA) mcrB mrr hsdS20(rB–, mB–) supE44 
ara-14 galK2 lacY1 proA2 rpsL20(SmR) xyl-5 λ– leu mtl1 
Table 2.4: The E. coli strains used in this thesis. 
2.5 Cell lines 
Cell line Characteristics Source 
R- Mouse fibroblast cells 
with IGF-1R KO 
A gift from Professor R. 
Baserga (Philadelphia, 
USA) 
R- IR-Amyc R- cells overexpressing 
IR-A-myc 
Generated in this thesis 
R- T1148A IR-Amyc R- cells overexpressing 
IR-A-myc with Threonine 
1148 replaced by Alanine   
Generated in this thesis 
R- T1148D IR-Amyc R- cells overexpressing 
IR-A-myc with Threonine 
1148 replaced by Aspartic 
acid   
Generated in this thesis 
293T Highly transfectable 
derivative of human 
embryonic kidney 293 
cells 
American Type Culture 
Collection (Manassas, VA) 
MDA-MB-231 Negative for estrogen 
receptors, progesterone 
receptors, and HER2; 
Metastatic Breast Cancer 
American Type Culture 
Collection (Manassas, VA) 
MCF-7 Postive for estrogen 
receptors, progesterone 
receptors, and HER2; 
Non-metastatic Breast 
Cancer 
American Type Culture 
Collection (Manassas, VA) 

























Mouse ab69508 (abcam) 1:1000 

















Mouse GroPep 0.04 mg/ml 
beta-Tubulin 
antibody 

















































 P/N 925-32213 
(LI-COR) 
1:50,000 




4× SDS protein loading dye: 40% Glycerol; 240 mM Tris/HCl pH 6.8; 8% SDS, 0.04% 
bromophenol blue; 5% beta-mercaptoethanol (added fresh). 
6× DNA loading dye: 0.25% w/v bromophenol blue; 0.25% w/v xylene cyanol FF; 30% v/v 
glycerol. 
1X TBE: 89 mM Tris; 89 mM boric acid; 2 mM EDTA; pH 8.3. 
1X Sodium Borate (SB) Buffer: 0.8 g of NaOH; 2.35 g of boric acid in 1L deionized water. 
LB medium: 10 g of tryptone; 5 g of yeast extract; 10 of g NaCl in 1L deionized water, pH 
7.0 , autoclaved. 
HEPES lysis buffer: 20 mM HEPES; 150 mM NaCl; 1.5 mM MgCl2; 10% Glycerol; 1% 
Triton X-100; 1 mM EGTA; pH7.5. 100mM NaF, 2mM Na3VO4, 1% Protease Inhibitor 
Cocktail (Sigma-Aldrich) and 1% PhosSTOP (Roche) were added fresh. 
Coomassie Blue Stain: 10% (v/v) acetic acid; 0.006% (w/v) Coomassie Blue dye in MQH2O. 
Isopropanol Fixing Solution: 10% (v/v) acetic acid; 25% (v/v) isopropanol in MQH2O. 
GdmCl lysis buffer: 6 M GdmCl; 100 mM Tris pH 8.5; 10 mM TCEP; 40 mM CAA, 1% 
PhosSTOP (Roche). 
1× Phosphate buffered saline (PBS): 137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl, and 
pH of 7.4 
Disruption Buffer: 200 mg/l EDTA in PBS and was filtered (0.22 μm). 
Staining buffer: PBS containing 1% BSA and 0.01% sodium azide. 
RIPA buffer: 50 mM TRIS, 150 mM NaCl, 0.1% SDS, 0.5% sodiumdesoxycholate, 1% 
triton X-100.  
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GTS Running buffer:	25 mM Tris, 192 mM glycine, 0.1% SDS 






3.1 Molecular Biology 
3.1.1 Preparation of plasmid DNA 
Routine preparation of plasmid DNA was performed using the QIAprep Spin Plasmid 
Miniprep Kit (Qiagen), according to the manufacturer’s instructions. DNA was eluted using 
40 μL H2O and stored at −20°C. 
3.1.2 Large-scale plasmid purification 
When larger amounts of plasmid DNA were required, the QIAGEN Plasmid Midi Kit was 
used, according to the manufacturer’s instructions. Plasmid DNA was eluted with 400 μL TE 
buffer. 
3.1.3 Analysis of DNA size, purity and concentration 
DNA samples were assessed for size, purity and concentration using agarose gel 
electrophoresis. Agarose was mixed with 1X TBE or 1X SB (DNA size<1kb) and melted in a 
microwave oven and then cast into minigels ranging from 1% – 2.5% agarose. Prior to 
loading into the wells, DNA samples were mixed with 6x DNA loading dye in 1X TBE or 1X 
SB buffer. Gels were visualized using a UV transilluminator coupled to a CCD camera 
(ChemiDoc, Biorad) or ChemiDoc Imaging System. Comparison of DNA bands with DNA 
molecular markers (New England Biolabs) allowed estimation of DNA size and concentration. 
Accurate measurement of DNA concentration was performed using a NanoDrop 2000 
spectrophotometer (Thermo Scientific). 
3.1.4 Restriction enzyme digestion 
Restriction digests of DNA were performed using restriction enzymes from New England 
Bio- labs according to the manufacturer’s instructions. Reaction volumes ranged from 5–50 μl, 
reaction times ranged from 1 hour to overnight and reaction conditions and incubation 
temperatures were used as specified by the manufacturer. 
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3.1.5 Gel extraction of DNA fragments 
Digested DNA fragments or plasmids required for cloning were run on a large-well agarose 
gel at 90 V. The gel was then immersed in GelRed DNA stain (Biotium) for 20 minutes and 
DNA bands were visualized using a Safe Imager bright light transilluminator (Invitrogen). 
Bands were excised from gels using a clean scalpel blade, and DNA was purified using the 
QIAquick Gel Extraction Kit (Qiagen) according to the manufacturers instructions, with a 30 
μl elution volume. 1 μl of the gel extraction was checked for purity and concentration on an 
agarose gel or NanoDrop spectrophotometer. 
3.1.6 Treating digestions with Antarctic Phosphatase  
Linearized vectors with compatible ends were treated with Antarctic Phosphatase (New 
England Biolabs), which catalyzes the removal of 5’ phosphate groups from DNA thereby 
preventing self religation. Treatment with Antarctic Phosphatase thus reduced the background 
number of colonies on transformation plates resulting from religated, singly-cut vector 
without the desired insert. 5 units of Antarctic Phosphatase were added to restriction digests 
made up to 1x Antarctic Phosphatase buffer (New England Biolabs) and reactions were 
incubated for 15 minutes at 37°C and then heat inactivated at 65°C for 5 minutes. 
3.1.7 Ligating restricted DNA fragments into restricted vectors 
Ligations were performed in 10 μl reaction volumes, containing 0.5–2 units of T4 DNA ligase, 
1x ligase buffer (New England Biolabs) and an approximate 3:1 molar ratio of insert to vector 
DNA, with the concentration of vector DNA in the range 10–100 ng. A control reaction 
containing vector but lacking insert DNA was prepared identically to determine the number of 
background colonies resulting from the vector DNA alone. Following incubation for 1 hour at 
room temperature, 5 μl of the ligation reaction was transformed into competent cells. 
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3.1.8 Site-directed mutagenesis 
PCR set-up: 0.5 μl of Phusion High-Fidelity DNA Polymerase, 10 μl of 5× buffer, 1 μl of 10 
mM dNTP, 1.25 μl of 100 ng/μl forward primer, 1.25 μl of 100 ng/μl reverse primer, 50 ng of 
plasmid in 50 μl reaction.  
Cycling parameters: 
Segment Temperature Time Cycle number 
Initial denaturation 98°C 1 minute 1 
Denaturation  98°C 30 seconds 18 
Annealing 55°C 1 minute 
Extension 72°C 2.5 minutes 
Table3.1: Site-directed mutagenesis PCR cycling parameters. 
300 units of DpnI (New England Biolabs) were added into 20 μl of PCR products to digest 
the methylated, non-mutated DNA template and 5 μl of the digested products were used for 
transformation. 
3.1.9 Transformation 
Competent cells were thawed on ice (approximately 20-30 minutes). DNA (usually 100 pg to 
100 ng) was mixed into 20-50 μl of competent cells in a microcentrifuge tube. The competent 
cell/DNA mixture was left on ice for 20-30 minutes. The competent cell/DNA mixture was 
heat shocked for 45 seconds at 42°C. The tube was chilled again on ice for 2 min. LB or SOC 
media (500-900 μl, without antibiotic) was added and cultured in 37°C shaking incubator for 
45 minutes. Some or all of the transformation was plated onto a 10 cm LB agar plate 
containing the appropriate antibiotic (Ampicillin concentration at 100 μg/ml, Kanamycin 
concentration at 25 μg/ml) and incubated at 37°C overnight.  
	
	 51	
3.1.10 Generation of high Competency DH5α cells  
High competency cells were needed for transformation with Gibson Assembly products. The 
method is based on the original Inoue method (Inoue et al., 1990). Transformation buffer 
contains: 10 mM of PIPES (1,4-Piperazinediethanesulfonic acid), 15 mM of CaCl2-2H2O, 250 
mM of KCl and 55 mM of MnCl2 at pH 6.7-6.8. It was filtered (0.22 μm) and kept at 4°C. 
Cells were incubated on shaker (150-250 rpm) at 18°C to culture density between 0.4-0.6 O.D. 
(600 nm) and then centrifuged down at 3,000 rpm and chilled on ice. Cells were then washed 
by 1/3 volume of ice-cold transformation buffer and chilled on ice for 10 minutes before 
another spin down. Cells were re-suspended with 1/12.5 volume of ice-cold transformation 
buffer with 7% DMSO. Cells were diluted into 100 μl aliquots, frozen with dry ice and stored 
in -80°C. 
3.1.11 Gibson Assembly of DNA fragments 
Gibson assembly was performed with Gibson Assembly Master Mix (New England Biolabs), 
according to the manufacture’s instructions. Briefly, 25 ng of vector with the molar ratio of 
vector to DNA fragment 1: 5 and 2.5 μl of Gibson Assembly Master Mix were used in 5 μl 
volume. The reaction was incubated for 1 hour at 50°C and all 5 μl for transformation. 
3.1.12 Gateway LR cloning 
Gateway LR Clonase Enzyme mix (ThermoFisher) was used to construct the lentivector with 
shRNA fragment. Reaction set-up: 150 ng of entry vector, 150 ng of destination vector, 2 μl 
of 5×LR buffer, 1 μl of LR Clonase Enzyme mix in 10 μl of total reaction. The reaction was 
conducted at 25°C overnight and terminated by mixing with 1 μl of proteinase K solution for 
10minutes at 37°C.  
3.1.13 Big Dye Sequencing reactions 
DNA sequencing was performed using BigDye Terminator Version 3.1 (Applied Biosystems) 
according to the directions provided by the Australian Genomics Research Facility (AGRF) 
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sequencing service (http://www.agrf.org.au/index.php?id=72). Briefly, sequencing reactions 
contained 2μl BigDye v3.1 Ready Mix, 6 μl of 5x BigDye buffer, 250-500 ng of template and 
3 pmoles of primer in a total volume of 20 μl. Sequencing reactions were incubated in thin-
walled 0.2 ml PCR tubes at 96°C for 2 minutes, then 25 cycles of 96°C for 20 seconds, 50°C 
for 10 seconds and 60°C for 4 minute. Sequencing reactions were then precipitated by adding 
80 μl of 75% isopropanol and transferred to a 1.5 ml Eppendorf tube. Sequencing products 
were incubated at room temperature for 15 minutes and then collected by centrifugation at 
maximum speed at room temperature for 20 minutes. The pellet was then washed with 150 μl 
of 75% isopropanol, centrifuged for a further 5 minutes with the tubes in the same orientation, 
and the supernatant was removed. Samples were then dried. The resultant chromatograph and 
sequence files were viewed using ApE Plasmid Editor. 
3.1.14 RNA extraction 
RNA extraction was processed with TRI Reagent® (Sigma). 0.5 ml of TRI Reagent® (Sigma) 
was used for one well of 6-well plates. The other reagents were used with ratio according to 
the manufacturer’s instructions. Finally, RNA was dissolved in 30 μl of diethylpyrocarbonate 
(DEPC) treated water (DEPC treated water was prepared previously by making up 0.1% 
DEPC in MQ water and autoclaving). The isolated RNA was stored in -80°C until required.  
3.1.15 RNA quality check 
Upon extraction, RNA concentration was determined using a NanoDrop 2000 UV-Vis 
spectrophotometer (Thermo Scientific). Concentration of the RNA was determined at 260 nm 
while the ratios of absorbance at 260 nm/280 nm of 2.0 was considered pure. Besides a check  
by spectrophotometry, the quality of the extracted RNA (2 μg) was also checked using gel 
electrophoresis to detect the 18s and 28s ribosomal RNA.  
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3.1.16 cDNA synthesis 
2 μg of RNA was reverse transcribed to cDNA using the High-Capacity RNA-to-cDNA™ kit 
(Life Technologies) according to manufacturer’s instructions. Briefly, the reaction mix was 
prepared as outlined in Table 3.2. The cDNA was synthesised in a Peltier Thermal Cycler 200 
(MJ Research, CA, USA) using the cycling parameters: 37°C for 60 minutes followed by 
95°C for 5 minutes. When the transcription reaction is completed the cDNA was stored at  
-20°C.  
Component Volume (μL) 
2X RT buffer 10 
20X Enzyme Mix 1 
2 μg RNA X 
DEPC treated water 9-X 
Total volume 20 
Table 3.2: Volume of components needed for the reverse transcription reaction mix, x is the 
volume needed for 2 μg of RNA. 
3.1.17 Semi-quantitative PCR  
Taq DNA Polymerase (New England Biolabs) was used to conduct the semi-quantitative PCR 
according to manufacture’s instructions. Briefly, 100 ng of cDNA was used in a 25 μl 
reaction; the reaction mix was prepared as outlined in the Table 3.3: 
Component Component volume (μl) 
10X reaction buffer 2.5 
50mM MgSO4 0.5 
10mM dNTPs 0.5 
10μM forward primer 0.5 
10μM reverse primer 0.5 
cDNA Template (100 ng/μl) 1 
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DEPC water 19 
Taq polymerase 0.5 
Total volume 25 
Table 3.3: Volume of components needed for the PCR reaction mix.  
The PCR was performed in a Peltier Thermal Cycler 200 (MJ Research, CA, USA) using the 
cycling parameters in Table 3.4: 
Segment Temperature Time Cycle number 
Initial denaturation 98°C 3 minutes 1 
Denaturation  98°C 30 seconds 30 (except IR 
PCR using 40) 
Annealing 55°C 30 seconds 
Extension 72°C 1 minutes 
Final extension 72°C 10 minutes 1 
Table 3.4: PCR parameters. 
3.1.18 shRNA PCR 
Phusion High-Fidelity DNA Polymerase (New England Biolabs) was used to conduct the 
PCR according to manufacture’s instructions. Briefly, 1 μM of 97-mer shRNA template was 
used in a 50 μl reaction; the reaction mix was prepared as outlined in the Table 3.5: 
Component Component volume (μl) 
5X Phusion GC buffer 10 
10mM dNTPs 1 
10μM forward primer 1 
10μM reverse primer 1 
1 μM Template 1 
Milli-Q water 35.5 
Polymerase 0.5 
Total volume 50 
Table 3.5: Volume of components needed for the PCR reaction mix.  
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The PCR was performed in a Peltier Thermal Cycler 200 (MJ Research, CA, USA) using the 
cycling parameters in Table 3.6: 
Segment Temperature Time Cycle number 
Initial denaturation 98°C 30 seconds 1 
Denaturation  98°C 10 seconds 35 
Annealing 54°C 30 seconds 
Extension 72°C 6 seconds 
Final extension 72°C 10 minutes 1 
Table 3.6: PCR parameters. 
3.2 Biochemistry 
3.2.1 DC™ (detergent compatible) protein assay 
The DC™ (detergent compatible) protein assay (Bio-rad) is a colorimetric assay for protein 
concentration following detergent solubilisation. The reaction is similar to the well-
documented Lowry assay with modifications. Protein concentrations were measured with this 
kit, according to manufacture’s microassy instructions. The measurement was performed with 
2030 Multilabel Reader (Perkin Elmer). 
3.2.2 EZQ™ Protein Quantitation 
EZQ™ Protein Quantitation kit (Molecular Probes) was used for the protein samples for 
proteomic assays according to manufacturer’s instructions. The measurement was performed 
with Gel Doc EZ Imager (Bio-rad) using the set-up of SYPRO Ruby (excitation wavelength 
peak at 302 nm). The quantitation was performed with Image Quant. 
3.2.3 HEPES buffer cell lysis 
Cells in a 6-well plate were washed with PBS and then lysed with 300 μl of HEPES buffer 
followed by an incubation for 30 minutes at 4°C with shaking and centrifugation for 15 
minutes with 12,000×g at 4°C. The supernatant was transferred into a new tube in 100 μl 
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/tube aliquots. Protein concentration was determined as described in section 3.2.2. Remaining 
samples were stored at −80 °C. 
3.2.4 SDS-PAGE and Western blotting 
Proteins (30 μg) were loaded onto 7.5% polyacrylamide gels (Invitrogen, Carlsbad, CA, USA) 
after boiling in 4×SDS sample buffer containing 10% β-mercaptoethanol for 5 minutes at 
95°C. Electrophoresis was performed between100-120 V using GTS running buffer, 
following by transfer to a 0.2 μm PVDF membrane (GE Healthcare) at 170 mA for 2 hours 
using the transfer buffer. After transfer, the membrane was blocked in TBS Tween-20 (TBST) 
solution (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20) containing 3% BSA 
(#A6003, Sigma-Aldrich) for 1 h at room temperature with agitation. Membranes were 
incubated with specific antibodies (Table 2.7) using the concentrations and conditions 
recommended by the supplier in TBST containing 3% BSA (#A6003, Sigma-Aldrich) 
overnight at 4°C with agitation. After washing thrice with TBST for 10 minutes each, the blot 
was incubated with IRDye secondary antibody at 1/5000 dilution in 3% BSA-TBST for 
1 hour at room temperature with agitation. Following three washes with TBST for 10 minutes 
each, the blot was visualized using Odyssey CLx (LI-COR) Imaging system. The intensity of 
the signal was quantified using Image Studio™ Lite software (LI-COR). Tubulin was used as 
a loading control. Three biological replicates were conducted. 
3.2.5 Flow cytometry 
Cells were disrupted with disruption buffer and suspended to 5×106 cells/ml in staining buffer 
(PBS containing 1% BSA and 0.01% sodium azide). Fc receptors were blocked with purified 
human gamma globulin (50 μg per 106 of cells) at room temperature for 20 minutes. The 
blocked cell suspension (50 μl) was aliquoted to a round bottom tube, followed by 
centrifugation and re-suspension with 100 μl of IgG1 or antibodies (final concentration at 
0.04 mg/ml) at 4 °C for 40-60 minutes. The cells were then washed twice with staining buffer, 
followed by incubation with 100 μl of FITC-conjugated anti-IgG detection antibody diluted in 
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staining buffer containing 10% normal rat serum on ice in the dark for 30 minutes. The 
labeled cells were washed three times with staining buffer followed by fixtation with 3.7% 
formaldehyde in PBS in dark on ice for 20 minutes.  Cells were then re-suspended with 500 
μl of 1% formaldehyde in PBS and then detected on a BD Accuri™ C6 (BD Australia). A 
total of 10,000 events were recorded. Only viable cells were gated. The data was analysed 
with the BD Accuri™ C6. Three biological replicates were conducted.  
 
3.2.6 HPLC  
An Agilent 1100 capillary HPLC (LC) system was used for ligand concentration 
measurement. The system was operated using binary gradients of solvent A (0.1% TFA in 
ultrapure water) and solvent B (0.01% TFA, 80% ACN, 20% ultrapure water). A C4, 
4.6×150 mm, 10micron column (Vydac, USA) was used for separation. About 2 μg of ligands 
in 110 μl of 0.1%TFA were loaded separately. Analysis was performed using a 25-55% ACN 
gradient over 30 minutes in the presence of 0.1% TFA at a flow rate of 0.5 ml/min. Ligand 
amount was calculated using the absorbance area at 215 nm, comparing to LR3 IGF-I 
standard.  
3.3 Cell culture 
3.3.1 Maintenance of various cell lines 
MCF-7 and MDA-MB-231 cells were cultured routinely in Dulbecco modified Eagle medium 
(DMEM), supplemented with 10% fetal calf serum (FCS), 1% Penicillin-Streptomycin, 1% 
GlutaMAX™ Supplement.  
R- cells and the cells lines based on R- cells were cultured in the same medium as above with 




Before transfection, plasmids based on pcDNA3.1 backbone was linearized with PvuI (NEB) 
and purified with gel extraction. This linearized plasmid will decrease the likelihood of the 
vector integrating into the genome in a way that disrupts the gene of interest or other elements 
required for expression in mammalian cells. Transfection was processed with 
Lipofectamine® LTX with Plus™ Reagent (ThermoFisher), according to the manufacture’s 
instructions in a 24-well format. Briefly, cells were seeded 2 days before transfection with 
density of 1×104 cells/cm2, whereby the cells reach 70-80% confluence on the day of 
transfection. Medium was changed to antibiotic and serum free DMEM medium the night 
before transfection.  DNA, PLUS reagent and LTX reagent were diluted with 100 μl of 
antibiotic and serum free DMEM medium in order with the amounts of 500 ng, 0.5 μl, 1.5 μl 
separately and incubated for 30 minutes. The mixture was added dropwise onto the cells. 
Medium was changed to DMEM medium containing antibiotic and serum 4 hours after the 
transfection and cultured to grow at 37°C.   
3.3.3 Lentivirus production 
To produce retroviral supernatants, 293T packaging cells were transfected with 12.5 μg of 
specific or control lentivector, 3.75 μg of pMD2.G (VSV-G), 7.5 μg of pCMV-dvrp8.2 and 
6.25 μg of pRSV-Rev in 100-mm tissue culture dishes according to the transfection method 
described above. The medium was replaced 16 hours later, and virus-containing supernatants 
were harvested at 48 hours post-transfection. Supernatants were filtered through a 0.45 μm 
Minisart syringe filter and stored at -80°C. 
3.3.4 Lentiviral infection and titration 
Overnight incubation method: Cells were plated in a 60-mm tissue culture dish until 40% 
confluence. Cell medium was replaced with antibiotic free DMEM, followed by infection 
with viral supernatants with 8 μg/ml of polybrene. The supernatant was renewed by cell 
growth medium the following day.  
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Spin method:  Cells were plated in a 60-mm tissue culture dish until 40% confluence. Cell 
medium was replaced with antibiotic free DMEM, followed by infection with viral 
supernatants with 8 μg/ml of polybrene. The plates were centrifueged at 33°C for 2 hours at 
2250 rpm. The supernatant was replaced by cell growth medium.  
In the next 24 or 48 hours, cells were used for stable cell line selection or infection efficiency 
detection by adding 1 μg/ml of Doxycycline to induce the expression of dsRed fluorescent 
protein. About 48hours later, cells were detected under normal light and under a cy3 filter 
(575-625 nm) using Olympus IX70 Fluorescence Microscope. 
3.3.5 Kill curve 
Cells were seeded at density of 2×104 cells/cm2 for overnight culture. G418 was added at 
various concentrations of 0, 50, 100, 200, 400, 600, 800, and 1,000 μg/ml and changed every 
other day. The optimum dose was determined at which all cells were dead after 7 days. Kill 
curve of puromycin dihydrochloride was measured using the method above but with the 
concentrations of 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2, 3, 5 μg/ml. 
3.3.6 Stable cell line selection 
Twenty-four hours after transfection cells were seeded into a 6-well plate at a ratio of 1 in 10 
dilution. Optimized concentration of antibiotic were added into the medium the next day after 
subculture. Medium containing antibiotic was changed every other day. The cells were 
expanded if they reached confluence and used for an experiment or stored at -80°C. 
3.3.7 Inducible shRNA expression 
shRNA expression in cell lines was induced  with 1 μg/ml Doxycyline. Time course of knock 
down effect was processed at 24 hours, 48 hours, 72 hours, 96 hours and 120 hours.  
Induction for 96 hours before assay was selected unless otherwise indicated.  
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3.3.8 Cell stimulation 
Cells were seeded into plates and allowed to attach for 24 or 40 hours. They were washed 
with PBS and then starved by replacing with serum free DMEM medium supplemented with 
1%BSA overnight. Cells were subsequently incubated with various concentrations of ligands 
diluted in DMEM supplemented with 1%BSA for 10minutes at 37°C.  
3.3.9 Wound healing assay 
Cells were plated into 24-well cell culture plates in DMEM containing 10% FBS and were 
grown to confluence. Cells were washed with serum-free medium and serum starved for 16 h. 
A scratch was made across the cell layer with a 200μl sterile pipette tip. After washing with 
serum-free medium twice, plates were photographed immediately after scratching. Cells were 
treated with ligands diluted in serum-free DMEM containing 1% BSA. Plates were 
photographed after 24 h at the identical location of initial image.  
3.3.10 Proliferation assay 
Cells were cultured in T75 flask and Doxycycline treated for 3 days to induce knock down of 
IR or IGF-1R. Then cells were seeded into 48 well plate at a density of 4,000 cells per well, 
allowed to attach for 24 hours and starved in growth factor–depleted medium comprising 
DMEM supplemented with 2% charcoal-treated calf serum and 1 μg/ml Doxycyline for 4 
hours. Cells were incubated subsequently in various concentrations of ligands diluted in 
DMEM supplemented with 2% charcoal-treated calf serum and 1 μg/ml Doxycyline for 4 
days. Doxycyline was replenished everyday and ligands every other day. Cell growth was 
determined by measuring the amount of DNA in each well using crystal violet. 
3.3.11 Crystal Violet assay 
At the end of the incubation time, cells were washed with 500 μl of PBS, fixed and stained for 
10 min with 200μl of 4% paraformaldehyde and 1% crystal violet dye in PBS. Excess crystal 
violet dye was removed and plates were extensively washed with water to remove traces of 
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unbound crystal violet dye. After air-drying, the bound dye was dissolved in 200 μl of 1% 
SDS. Optical density was read at 540 nm using a plate reader. 
3.4 Quantitative Phosphoproteomics 
3.4.1 SILAC labeling 
Cells were cultured in DMEM deficient in L- arginine, L-lysine, L-leucine and supplemented 
with 10% dialyzed fetal bovine serum, penicillin/streptomycin, GlutaMAX and L-leucine and 
either L-arginine (Arg-0) and L-lysine (Lys-0), 13C6-L-Arginine HCl (Arg-6) and 4,4,5,5-D4-
L-Lysine 2HCl (Lys-4), or 13C6,15N4-L-Arginine HCl (Arg-10) and L-lysine 13C6,15N2-L-
Lysine HCl (Lys-8) for at least 3 passages with 1 in 10 dilutions. Concentration of Arg, Lys 
and Leu were at 84 μg/ml, 146 μg/ml and 105 μg/ml respectively, the same as found in 
DMEM medium. After 3 passages of growth time, the cells were used for incorporation 
efficiency determination and storage.  
 3.4.2 Determination of Isotope Incorporation Efficiency (should be > 95%) 
Cells from each sample (light, medium and heavy) in 6-well plate were lysed with 300 μl of 
RIPA buffer and processed with the Filter Aided Sample Preparation method (FASP) and 1 μl 
was used for HPLC-MS/MS analysis.  
3.4.3 Filter Aided Sample Preparation (FASP) Method 
1. Proteins in lysis buffer was made up to ~200uL with freshly made 7M urea / 100mM 
ammonium bicarbonate. 10uL of 1M DTT was added to final concentration of 50 mM 
and incubated at 20o C with slow agitation for 1 hour. The reduced samples were 
loaded into the Microcon YM-30 devices (Millipore, Billerica, MA) and centrifuged at 
14, 000 x g for 10 min. Residual DTT was removed by adding 100uL of 7M urea / 
100mM ammonium bicarbonate and centrifugation for 10 minutes at 14, 000 x g. 
Alkylation was carried out with the addition of 100uL of 55 mM IAA in 7M urea 
/100mM ammonium bicarbonate to the spin columns. They were centrifuged for just a 
few seconds to ensure the liquid was in close contact with the proteins retained by the 
filter and incubated in the dark for 20 minutes at 20o C with gentle agitation. Samples 
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were centrifuged at 14,000 x g for 10 minutes to remove IAA. The columns were then 
rinsed twice with the addition of 100uL of 7M urea / 100mM ammonium bicarbonate 
and centrifuged for 10 minutes at 14,000 x g. The columns were then rinsed twice 
with the addition of 100uL of 50mM ammonium bicarbonate and centrifuged for 10 
minutes at 14,000 x g. Final equilibration was carried out with the addition of 100uL 
5mM ammonium bicarbonate and centrifugation at 14,000 x g for 15 mins. The 
proteins were digested overnight at 30 °C with trypsin (Promega) (1 μg of trypsin: 100 
μg of protein). The peptides were collected from the filter by centrifugation followed 
by additional elution with water. The peptide-containing filtrate was dried until a few 
microliters liquid remained and reconstituted in 1% formic acid/2%ACN to 
concentrations between 100 ng/μl to 1 μg/μl. 
3.4.4 GdmCl buffer cell lysis 
Cells in 100-mm petri dish were solubilized in 1 ml of GdmCl lysis buffer (6 M GdmCl, 100 
mM Tris pH 8.5, 10 mM TCEP, 40 mM CAA), and heated for 5 minutes at 95 °C. Cell 
lysates were cooled on ice for 15 minutes, sonicated (Branson probe sonifier output 3-4, 50% 
duty cycle, 3× 30 s), and heated again (95 °C for 5 minutes), followed by centrifugation for 
30 minutes at 3,500 g (4 °C), and an aliquot removed to a clean tube, diluted 50% with milliQ 
H2O, and precipitated with acetone.  
3.4.5 Acetone Precipitation 
NaCl was added to the protein sample to a final concentration of 100 mM and then mixed 
with 6 times volume of pre-chilled acetone at -20°C. Protein was precipitated overnight and 
collected by centrifuging for 15 minutes at 20,000 g (-9 °C). Pellets were washed twice with 
−20 °C 80% acetone and air dried upside down for ~10 minutes at RT or until no residual 
acetone odor remained. Pellets were resuspended in 1 ml of TFE (2,2,2-trifluoroethanol) 
digestion buffer (10% TFE, 100 mM ammonium bicarbonate) with sonication (Bioruptor, 4 
°C for 5 minutes, or until a homogenous suspension was formed). Protein concentration was 
determined (EZQ assay) and samples diluted to equal concentration in 500 μl of TFE 
digestion buffer. Remaining samples were stored at −80 °C. 
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3.4.6 Trypsin/Lys-c digestion 
Briefly, the samples were digested in TFE buffer with 1:100 (enzyme:protein) LysC for 2 
hours, followed by digestion with 1:100 (enzyme:protein) trypsin overnight  with rapid 
agitation (1,000 r.p.m.) at 37 °C. 
3.4.7 TiO2 enrichment 
TiO2 beads were weighed out at a ratio of 10:1 (w:w) beads to protein. Beads were 
resuspended in Loading buffer 1 (80% ACN, 6% TFA) at a concentration of 100μl of 
Loading buffer 1 per sample. TiO2 bead suspension incubated in Bioruptor at 4°C for 1 min to 
disaggregate the beads. 
The digested peptides were incubated with 4 volumes of DHB buffer [200 mg/mL DHB, 80% 
(v/v) ACN, 6% (v/v) TFA] for 5 minutes at room temperature in a ThermoMixer at 1,000 rpm, 
followed by incubation with TiO2 beads for another 5 minutes at 40°C in a ThermoMixer at 
1,000 rpm. The sample was then washed once with 200 μl of DHB buffer and transferred into 
a new tube, followed by three washes with wash buffer [60% ACN (v/v), 1% TFA (v/v)] to 
remove the DHB and non-specific binding peptides. The beads were dried and eluted with 
60μl of elution buffer (15% NH4OH, 40% ACN). The sample was concentrated in the 
speedyVac for 5-10 min at 45 °C, or until about 30 μl remained, and was then acidified with 
10% TFA immediately.  
3.4.8 Desalting 
Stagetips were prepared beforehand by pressing 2 layers of disk (C18 or SDB-RPS) into 
200μl sterile pipette tip according to the protocols described in Rappsilber et al paper 
(Rappsilber et al., 2007). 
Samples were then desalted with C18 (or SDB-RPS) stagetips (where from???) before 
loading onto the HPLC.  C18 stagetips were activated and equilibrated with 50 μl of ACN, 50 
μl of 30%MeOH, 0.2% TFA and 50 μl of 0.2% TFA sequentially. Samples were loaded onto 
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the stagetips, which were then washed twice with 0.2% TFA, followed by elution with 30 μl 
of elution buffer (80% ACN, 0.1%TFA). The elute was concentrated in the speedyVac and 
re-suspended with 25 μl of MS loading buffer (2% ACN, 0.1% TFA). 
Ziptip:  Desalting was achieved using a Ziptip containing 0.6 μl C18 resin (Merck Millipore 
ZTC18S096) according to manufacture’s protocol. Briefly, the Ziptip was equilibrated 3 
times with 100% Acetonitrile, 3 times with 0.1% formic acid and the sample was loaded by 
pipetting the protein digest up and down 10 times through the Ziptip. The sample was washed 
6 times with 0.1% formic acid and eluted by pipetting up and down 10 times with 4 µl 60% 
acetonitrile/0.1% formic acid. The volume was increased to 25 μl with MS loading buffer 
(2% ACN, 0.1% TFA). 
3.4.9 MALDI-TOF 
Briefly, the sample (0.5 μl), was mixed in a 1:1 ratio with DHB matrix solution (10 mg/ml 
2,5-DHB dissolved in 50%ACN/0.05% TFA/0.05% PA) or α- Cyano- 4- hydroxycinnamic 
acid  (HCCA) matrix (10 mg/ml HCCA dissolved in 30%ACN/0.1% TFA) and spotted onto 
the steel MALDI target and dried.  MALDI TOF mass spectra were acquired using a Bruker 
ultraflex III MALDI-TOF/TOF mass spectrometer (Bruker Daltonics) operating in reflectron 
positive ion mode. FlexControl (version 3.1, Bruker Daltonics) software was used to control 
the analysis. 
3.4.10 HPLC-MS/MS 
Nano-LC-ESI-MS/MS was performed on an Ultimate 3000 RSLC system (Thermo-Fisher 
Scientific) coupled to a LTQ XL Orbitrap ETD MS instrument (Thermo-Fisher Scientific). 10 
μl of digested peptides were pre-concentrated on a trapping column (Thermo Fisher Scientific) 
(Acclaim PepMap100, C18, pore size 100 Å, particle size 3 μm, 75 μm ID × 2 cm length) at a 
flow rate of 1 μl/min for 10 min in 2% (v/v) ACN/0.1 (v/v) FA and then separated on 
ananalytical column (Thermo Fisher Scientific, Bremen, Germany) (Acclaim PepMap RSLC, 
C18, pore size 100 Å, particle size 2 μm, 75 μm inner diameter (ID) × 15 cm length) at a flow 
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rate of 300 nl/min using the following buffer system: (A) 2% ACN, 0.1% FA in water; (B) 
80% ACN, 0.1% FA in water. A two-steps gradient was applied from 5% to 40% B over 50 
minutes and to 90% B over 20 minutes, followed by 10 minutes wash in 90% B before 
equilibration with 5% B for 19.5 minutes.  
MS full scans were acquired in the Orbitrap analyser in the mass range of 300–1700 Da at a 
resolution of 60,000. The nine most intense precursor ions with charge states ≥2 with 
minimum signal intensity of 500 were selected for isolation and were subjected to CID 
fragmentation using a dynamic exclusion of 180 seconds. All unassigned charge states and a 
charge state of one were rejected. CID was set to use an activation of 0.25, activation time of 
15 ms and normalised collision energy of 35%.  
3.4.11 Data analysis 
Raw mass spectrometry data was analyzed with MaxQuant, using default parameters with 
minor changes.  Trypsin/p and Lys-C were used for digestion and up to two maximum missed 
cleavages was allowed. Default, R6K4 and R10K8 were selected for multiplicity parameter. 
Oxidized methionine (M), acetylation (protein N-term) and phospho (STY) were selected as 
variable modifications, and carbamidomethyl (C) as fixed modifications with maximum 
number of modifications and labeled peptides was set to three. The minimum required peptide 
length was 6 amino acids and maximum 25. Mass tolerances for precursor ions and fragment 
ions were set to 20 ppm and 0.5 Da, respectively. 
Unique and razor peptides were selected for quantification. Database searching was 
performed using the Andromeda search engine integrated into MaxQuant against the human 
SwissProt database (downloaded on September 2015), with a false-discovery rater (FDR) < 
0.01 at the level of proteins, peptides and modifications. Match between runs (MBR) was 
enabled with a matching time window of 0.7 min to match the biological and technical 
replicates.   
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Proteomics Quality Control (PTXQC) is used to evaluate the data from Maxquant output 
(Bielow et al., 2016).   
Network analysis, Pathway analysis and Gene Ontology analysis were performed with 
InnateDB and NetworkAnalyst (Breuer et al., 2013; Xia et al., 2014; Xia et al., 2015). The 
Gene Ontology Biological Processes (GOBP) and pathways that were significantly enriched 
with a P-value of less than 0.05 were used in the analysis. 
3.5 Statistics 
Data are presented as mean ± SD of at least three independent experiments unless stated 
otherwise. Significance of differences in knock down verification experiments were 
calculated by t-test.  Over-representation Analysis (ORA), the Hypergeometric algorithm and 
the Benjamini & Hochberg correction method were selected in InnateDB for network analysis. 
Proliferation and migration assays were evaluated by 2-way ANOVA. P-values below 0.05 






The insulin receptor (IR) is a receptor tyrosine kinase that mediates the actions of insulin. IR 
transduces signals through autophosphorylation and phosphorylation of other intracellular 
signalling molecules. More than 26 phosphorylation sites (including tyrosine, serine and 
threonine sites) are phosphorylated within the IR intracellular domain upon insulin 
stimulation (http://www.phosphosite.org/proteinAction.action?id=608&showAllSites=true) 
(Figure 4.1). At present, seven tyrosine residues have been identified as targets for 
autophosphorylation (Youngren, 2007): two tyrosine residues - Tyr953 and Tyr960 in the 
juxtamembrane region; three tyrosine residues- Tyr1146, Tyr1150 and Tyr1151 in the kinase 
domain; and two tyrosine sites- Tyr1316 and Tyr1322 located close to the C terminus. 
Additionally, Ser/Thr phosphorylation can activate or inhibit IR signalling. For example, the 
phosphorylation of Ser1275 and Ser1309 activates the IR (Tennagels et al., 2001), while the 
phosphorylation of Ser1293/1294  and Thr1336 inhibits IR signalling (Lewis et al., 1990a; Lewis et 
al., 1990b).  
As the IR can transduce different biological signals in response to insulin, IGF-II or insulin 
analogues, the Forbes lab aims to map the phosphorylation profile of the insulin receptor 
intracellular domain by combining insulin receptor pull down and mass spectrometry of beta 
subunit tryptic phosphopeptides. Preliminary data generated by Dr Peter McCarthy in 2013 
identified phosphorylation of Thr1148, which is located in the activation loop. At the time, there 
was no publically available data reporting detection by mass spectrometry of Thr1148 
phosphorylation, and the significance of Thr1148 phosphorylation with respect to IR tyrosine 
kinase activation was unknown. In fact only a single publication had investigated the 
influence of Tyr1146, Tyr1150 and Tyr 1151 on the ability of protein kinase CK2 to phosphorylate 
Thr1148 in vitro using synthetic peptides (Marin et al., 1996). Under those conditions Thr1148 
was only phosphorylated efficiently by CK2 if all three Tyr were also phosphorylated. In 
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contrast, in our preliminary study Thr1148 phosphorylation was only detected on peptides 
lacking phosphorylation of neighbouring Tyr1146, Tyr1150 and Tyr 1151 residues (Figure 4.2).  
We speculated that there are two possible reasons to explain why we did only detect tryptic 
peptides with phosphorylated Thr1148 in the absence of any Tyr1146, Tyr1150 and Tyr 1151 
phosphorylation: 1. Phosphorylation of Thr1148 and any of Tyr1146, Tyr1150 and Tyr 1151 can 
occur simultaneously, but the phosphorylated peptide was not detected by mass spectrometry 
under the conditions of the experiment due to both its multiple negative charges and/or low 
abundance; or 2. The phosphorylation of Thr1148 inhibits the phosphorylation of Tyr1146, Tyr1150 
and Tyr 1151 of the activation loop, which is possibly due to steric hindrance and electrostatic 
repulsion of the phosphate group on Thr1148 preventing interaction of the activation loop with 
the tyrosine kinase.  





Figure 4.1: Schematic representation of the IR-A domain structure and intracellular 
phosphorylation. Domain structure: L1 (Blue) and L2 (Red), large domains 1 and 2 (Leucine-
rich repeats); CR (Brown), cysteine rich domain; FnIII-1 (Green), FnIII-2 (Yellow), FnIII-3 
(Purple), fibronectin type III domains; ID (White), insert domain; α-CT (Orange), carboxy-
terminal α-chain; TM (White), transmembrane domain; JM (White), Juxtamembrane domain; 
TK (Black), tyrosine-kinase domain; C-tail (White), carboxy-terminal tail. Currently known 
tyrosine (solid), serine (open) and threonine (hatched) phosphorylation sites identified by a 
variety of techniques (IR-A numbering). * = Sites were determined using site-specific 
methods; # = Sites were determined using mass spectrometry. T: Thr, S: Ser, Y: Tyr. 
























































































Figure 4.2: Tryptic peptide containing the activation loop detected by MS/MS.  R-IR-A cells 
(IR-A overexpressing mouse fibroblast cells derived from IGF-1R knock out mice) were 
stimulated with 10 nM insulin for 10 minutes and the IR was enriched, digested and detected 
with HPLC-MS/MS. This data shows the phosphorylation of Thr1148 accompanied by the 


















































ion b⁺ b²⁺ Seq. y⁺ y²⁺ ion
1 116.03423 58.52075 D 9
2 229.11830 115.06279 I 1202.47655 601.74191 8
3 392.18162 196.59445 Y 1089.39248 545.19988 7
4 521.22422 261.11575 E 926.32916 463.66822 6
5 702.23823 351.62275 T-Phospho 797.28656 399.14692 5
6 817.26518 409.13623 D 616.27255 308.63991 4
7 980.32850 490.66789 Y 501.24560 251.12644 3
8 1143.39182 572.19955 Y 338.18228 169.59478 2






Site-directed mutagenesis is a commonly used way to elucidate the role of phosphorylation in 
the biological activity of a protein of interest. Mutation of Thr1148 in IR-A to Ala (A) or Asp 
(D) was performed to mimic the unphosphorylated or phosphorylated state of this residue 
respectively. Secondly, a myc-tag was also added to the C-terminus of the IR in order to 
facilitate immunoprecipitation. Figure 4.3 shows the exact molecular cloning steps. The 
construction of pcDNA3.1 (IR-Amyc) was achieved using an existing pcDNA3.1 (IR-B) 
clone. Two synthetic cDNA fragments were purchased from GeneArt: one fragment enabled 
the introduction of the IR-A sequence (ie a fragment encompassing the exon 10/exon 12 
boundary and lacking exon 11); and the other allowed the introduction of the sequence 
encoding a myc-tag at the C-terminus of IR. The IR-A fragment (without exon11) was 
flanked by BamHI and EcoRV enzyme digestion sites that were used to replace the equivalent 
IR-B fragment (Figure 4.3). The myc-tag was ligated to the 3’ end of IR-B cDNA with StuI 
and XbaI enzyme digestion sites. By ligation of these fragments into the pcDNA3.1 (IR-B) 
plasmid; the pcDNA3.1 (IR-Amyc) was generated.  
In order to conduct site-directed mutagenesis, the fragment encoding Thr1148 was ligated into 
the pBlueScript (SK+) vector with EcoRI and NotI enzyme digestion sites. The use of this 
strategy avoided unwanted introduction of errors to the large IR coding sequence and allowed 
for easy sequencing of the mutagenesis site. The site-directed mutagenesis was conducted 
using the primers in Table 2.2, and following sequencing, the correct fragments were ligated 
back into pcDNA3.1 (IR-Amyc) (Figure 4.3). 
The vectors pcDNA3.1 (IR-Amyc), pcDNA3.1 (T1148A IR-Amyc) and pcDNA3.1 (T1148D 
IR-Amyc) were used to transiently transfect the R- (mouse fibroblast cells derived from IGF-
1R knock out mice) cells separately. Cells were then stimulated with insulin and the IR 




Figure 4.3: Vector maps of the starting vector pcDNA3.1 (IR-B) (A) and final constructs 
pcDNA3.1 (IR-Amyc), pcDNA3.1 (T1148A IR-Amyc) or pcDNA3.1 (T1148D IR-Amyc) 
construction (B). Schematic diagrams of the fragments used to generate I. the wild type IR-
Amyc vector and II. The mutant IR-A myc vectors are shown. The wild type IR-Amyc vector 
was constructed using enzyme digestion and ligation into the starting vector pcDNA3.1 (IR-B) 
of two cDNA fragments synthesized by GeneArt: one fragment was the IR-A exon11- 
fragment (C, red) and the other fragment was the sequence encoding the myc-tag (blue) at the 
C-terminus of IR (purple) (D). The fragment without exon11 (red) was used to replace the 
equivalent IR-B fragment flanked by BamHI and EcoRV enzyme digestion sites. The myc-tag 
(blue) incorporated into a C-terminal fragment flanked by the StuI and XbaI enzyme digestion 
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generated in site-directed mutagenesis reactions to introduce the IR T1148A and T11148D 
mutations (brown) were ligated into pBlueScript (SK+) vector with EcoRI and NotI enzyme 
digestion sites. These fragments were subsequently used to replace the equivalent fragment in 
the wild type IR-Amyc construct. 
4.3 Results 
4.3.1 Vector verification by digestion and sequencing 
pcDNA3.1 (IR-Amyc), pcDNA3.1 (T1148A IR-Amyc) and pcDNA3.1 (T1148D IR-Amyc) 
were verified by enzyme digestion and sequencing (Figure 4.4). pcDNA3.1 (IR-Amyc) was 
digested with either BamHI/NotI or HindIII/XbaI separately. The length of the linear 
pcDNA3.1 (IR-Amyc) construct is 9575bp. The digestion with BamHI/NotI resulted in two 
fragments: 7401bp and 2174bp. The length of the linear pcDNA3.1 (IR-B) is 9506bp. The 
digestion with BamHI/NotI resulted in two fragments: 7422bp and 2084bp.The presence of 
the fragment with the size of 2174bp verified the deletion of exon11, which indicated the 
correct construction of IR-A cDNA. The digestion with HindIII/XbaI also resulted in two 
fragments: 5348 bp and 4227 bp (Figure 4.4). The fragment with the size of 4227bp (it would 
be 4122bp without myc-tag) verified the addition of myc-tag at the C-terminal of IR-A. The 
introduction of the alanine and aspartic acid mutations in the pcDNA3.1 (T1148A IR-Amyc) 




Figure 4.4: pcDNA3.1 (IR-Amyc), pcDNA3.1 (T1148A IR-Amyc) and pcDNA3.1 (T1148D 
IR-Amyc) verification. pcDNA3.1 (IR-Amyc) (A.) was digested with either BamHI/NotI or 
HindIII/XbaI separately according to the method described in section 3.1.4 to demonstrate 
correct incorporation of the IR-A exon 11- fragment and the IR C-terminus fragment and Myc 
tag. pcDNA3.1 (T1148A IR-Amyc) (B.) and  pcDNA3.1 (T1148D IR-Amyc) (C.) were 
verified by sequencing according to the method described in section 3.1.13.  
A C A T C T A C G A G G C C G A C T A C T A C A G A A A G G G C G G C A A G G G C C T G C T G C C A G T A C G G T G G A T G G C C C C T
560570580590600610620
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4.3.2 Thr1148Ala and Thr1148Asp decreases the IR-A sensitivity to insulin 
To investigate the role of Thr1148 phosphorylation in IR activation, I generated recombinant 
wild-type (WT) and mutant- Thr1148Ala and Thr1148Asp expression constructs and transiently 
transfected them into R- cells. The cells were serum starved, and then stimulated with 100 nM 
of insulin for 10 minutes. Untransfected R- cells were used as the background control. Cell 
lysates were analysed by immunoblotting. Phospho-IR/IGF1R (Tyr1158, Tyr1162, Tyr1163) 
antibody and Anti-Insulin Receptor beta antibody were used to measure IR activation and 
total IR expression, respectively (Figure 4.5).  
From Figure 4.5A, it is evident that the IR-A and its mutants were overexpressed to varying 
extents (Figure 4.5A upper panel). To assess the extent of activation the level of of Tyr1146, 
Tyr1150, and Tyr1151 phosphorylation was normalised to the overall amounts of transiently 
expressed receptor. With wild-type IR-A, insulin stimulated Tyr1146, Tyr1150, and Tyr1151 
phosphorylation more than 14-fold above basal. The basal levels of Tyr1146, Tyr1150, Tyr1151 
phosphorylation of the Thr1148Ala mutant receptor appeared higher than the basal wild type 
receptor Tyr1146, Tyr1150, Tyr1151 phosphorylation. However, when normalized against the total 
receptor levels this was not statistically significant. Insulin stimulated a 3.7 fold higher level 
of Tyr1146, Tyr1150, Tyr1151 phosphorlyation on the Thr1148Ala mutant receptor above basal. 
Similar to the Thr1148Ala mutant, the basal level of phosphorylated Tyr1146, Tyr1150 and Tyr1151 
on the Thr1148Asp mutant appeared higher than wild type receptor but this was not statistically 
significant. Insulin stimulated a 3 fold higher level of Tyr1146, Tyr1150, Tyr1151 phosphorlyation 
on the Thr1148Asp mutant receptor above basal. The fold change above basal for both mutants 
(3.7 and 3 fold, respectively) was significantly lower than for wild type (~14 fold).  Therefore, 
both Thr1148Ala and Thr1148Asp were found to be significantly less responsive to insulin than 





Figure 4.5: The activation of wild type IR and IR with Thr1148 mutations in response to insulin. 
The R- cells were transiently transfected with pcDNA3.1 (IR-Amyc), pcDNA3.1 (T1148A IR-
Amyc) or pcDNA3.1 (T1148D IR-Amyc) according to the methods described in section 3.3.8.   
The cells were stimulated with 100 nM insulin for 10 minutes according to the methods 
described in section 3.3.8. (A). The western blots were conducted according to the methods 
described in section 3.2.4. Phospho-IR/IGF1R (Tyr1158, Tyr1162, Tyr1163) Antibody 
(Invitrogen #44-806G), Anti-Insulin Receptor beta antibody (Abcam#65098) and beta-tubulin 
antibody (Life technologies #32-2600) were used according to the concentrations described in 
the Table 2.6. Tubulin was used as a loading control. Raw blot is shown in appendix 13. (B) 
Levels of phosphorylated IR relative to the total IR. Intensities of phosphorylated IR were 
normalized to intensities of total IR. (C) Fold change of phosphorylated IR with insulin 
stimulation comparing to starving condition. The bars show the S.E.M. of 3 biological 
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4.4 Discussion  
Our initial mass spectrometry experiment detected a peptide that was phosphorylated on 
Thr1148 without phosphorylation of Tyr1146, Tyr1150, and Tyr1151. This observation led us to 
hypothesise that the phosphorylation of Thr1148 has an inhibitory effect on the IR activation 
due to the introduction of a larger negatively charged modification at this residue. In order to 
verify this hypothesis, constructs encoding recombinant wild type IR and IR with Thr1148 
mutated to Ala or Asp were generated and IR were overexpressed in R- cells.  
The Thr1148Ala and Thr1148Asp mutants were introduced to either prevent phosphorylation or 
mimic a constitutively phosphorylated state at that residue, respectively. We already knew 
from our preliminary experiments that the IR-A cells express the kinase responsible for 
Thr1148 phosphorylation. If the hypothesis was correct that Thr1148 phosphorylation would 
inhibit IR Tyr1146, Tyr1150, and Tyr1151 phosphorylation then it was expected that insulin 
stimulation of cells expressing the Thr1148Ala mutant would lead to increased levels of IR 
Tyr1146, Tyr1150, and Tyr1151 phosphorylation. In contrast, the Thr1148Asp would mimic 
phosphorylation at this residue and there would be lower levels of insulin stimulated Tyr1146, 
Tyr1150, and Tyr1151 phosphorylation.  
There were substantial differences in the expression of each of the constructs used here which 
makes interpretation of the relative phosphorylation difficult. In the future it would be good to 
alter the experimental conditions so that similar levels of expression were achieved to assist in 
the interpretation of these results. However, having performed replicate experiments with 
transient expression we found that while it appeared that both mutants had a higher level of 
phosphorylation in the basal state this was not statistically significantly. This is consistent 
with the recent report by Petersen et al (Petersen et al., 2016) who saw no increase in basal 
phosphorylation with a GFP Thr1160Glu mutant (equivalent to Thr1148 in IR-A) expressed in 
HeLa cells or when the Thr1150Ala mutant was knocked into the mouse IR gene (the mouse 
IR-B residue equivalent to Thr1148 in IR-A). In hepatocytes of mice infused with glucose the 
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basal phosphorylation of the IR did not change. It is important to note there are several 
differences between that report and the current study, including the incorporation of the large 
GFP tag at the C-terminus and the use of and a different method of detection. For the GFP 
tagged Thr1160Glu mutant, an antibody directed to the beta subunit was used for 
immunoprecipitation followed by detection of receptor phosphorylation with an anti-phospho 
Tyr antibody, whereas in this study the antibody specific for Tyr1146, Tyr1150, and Tyr1151 
phosphorylation was used. It is possible that global Tyr phosphorylation was not altered but 
specific phosphorylation at the activation loop was affected (albeit not significantly here).  
Next, phosphorylation of the mutants in response to insulin was measured. Thr1148Ala and 
Thr1148Asp mutants both were phosphorylated in response to insulin (as detected by Phospho-
IR/IGF1R Tyr1158, Tyr1162, Tyr1163 antibody). There was a 3.7 fold and 3 fold induction of 
Thr1148Ala and Thr1148Asp mutants, respectively. The inhibitory effect of the negative charge 
of Asp on Tyr1146, Tyr1150, Tyr1151 phosphorylation is consistent with the recent report by 
Petersen et al (Petersen et al., 2016) who did not see an increased basal phosphorylation with 
the introduction of a negative charge with a GFP tagged Thr1160Glu mutant. They also saw a 
marked reduction in Tyr1158, Tyr1162, Tyr1163 phosphorylation to almost undetectable levels. 
This more dramatic effect may be due to the fact that Glu is sometimes a better mimic of 
phosphorylated Thr than Asp, as the Glu has a longer side chain than Asp. It could 
alternatively be that these mutants were analysed in different IR isoform backgrounds. 
Petersen et al. (Petersen et al., 2016) introduced mutants into the IR-B whereas this study 
used IR-A.  
Interestingly, since our phosphoproteomic study there have been many reports of Thr1148 
phosphorylation in the PhosphotitePlus database 
(http://www.phosphosite.org/proteinAction.action?id=608&showAllSites=true). Two studies 
have reported detection of peptides with phosphorylation of Thr1148 and either Tyr1151, Tyr1146 
or Tyr1150 phosphorylation (ie one pThr and one pTyr). In one study using samples from 
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Cholangiocarcinoma patients, pThr1148 was detected on a peptide also containing 
phosphorylated Tyr1150 and Tyr1151 (Gu et al., 2011). Another study was conducted on insulin 
stimulated 3T3 cells. Here it was shown that pThr1148 was present on a peptide also containing 
phosphorylated Tyr1146 and Tyr1151 (Humphrey et al., 2013). Furthermore, Petersen et al. also 
reported detection of peptides containing phospho Thr1148 and either phosphorylated Tyr1150 or  
Tyr1146, as well as a peptide with phospho Thr1148 and both phospho Tyr1146 and phospho Tyr1150 
(Petersen et al., 2016). This result seems contradictory to their implication that 
phosphorylation of Thr1148 inhibits Tyr1151, Tyr1146 or Tyr1150 phosphorylation. 
The inhibition of Tyr1146, Tyr1150, Tyr1151 phosphorylation by the Thr1148Ala mutation was not 
expected. This suggests that the absence of phosphorylation of the Thr1148Ala residue does not 
relieve any inhibition by a negatively charged phosphate group, as we would have expected 
an increase in Tyr1146, Tyr1150, Tyr1151 phosphorylation if that were the case. On the contrary it 
suggests either that an alanine at this position might alter the local structure and thereby 
influence the accessibility of the three Tyr to the kinase for autophosphorylation or that 
phosphorylation of Thr1148 has in fact a positive influence on kinase activity and its absence 
lead to a poorer response to insulin. Alternatively, phosphatases (T-Cell Protein Tyrosine 
Phosphatase) and adaptor proteins (Growth factor receptor-bound protein 7,10,14) are known 
to dephosphorylate the phopshoryaltated Tyr1146, Tyr1150, Tyr1151 (Goenaga et al., 2009; 
Goldstein et al., 2000; Han et al., 2001; Stein et al., 2001; Walchli et al., 2000). The 
Thr1148Ala mutation might also facilitates the interactions of phosphorylated of Tyr1146, Tyr1150, 
Tyr1151 to these molecules. 
Also, the lower phosphorylation of Tyr1146, Tyr1150, Tyr1151 in the IR-A Thr1148Ala mutant is not 
consistent with the report of Petersen et al (Petersen et al., 2016) who saw higher 
phosphorylation of Tyr1158, Tyr1162, Tyr1163 in the IR-B Thr1160Ala mutant. The experiment 
designs in the Petersen et al study and this study have huge differences: this study used the R- 
mouse fibroblasts transfected with IR-A as model and phosphorylation of Tyr1146, Tyr1150, 
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Tyr1151 in the IR-A to indicate the IR activation; While Petersen et al used the	High fat diet-
induced hepatic insulin resistance mice as study model and the phosphorylation of Tyr1162 of 
IR-B in the liver to indicate the IR activation. The differences of study models (cell line vs 
mice), the cell types (fibroblast vs liver cells), the IR isoforms (IR-A vs IR-B), IR expression 
levels (overexpressed vs normal) could all affect the outcomes. In addition, using 
phosphorylation of Tyr1162 of IR-B and phosphorylation of Tyr1146, Tyr1150, Tyr1151 in the IR-A 
as IR activation marker might reflect different IR activation stages. As explained previously, 
the IR activation has intermediate stages, the Tyr1162 are phosphorylated first, followed by the 
phosphorylation of other two sites (Cabail et al., 2015; Hubbard et al., 1994). The Thr1148Ala 
mutant could increase the phosphorylation of Tyr1162 of IR-B as shown by Peterson et al, but 
the changed structure inhibited the phosphorylation of the whole three Tyr as shown in this 
study. 
Finally, in vitro studies by Petersen et al and Marin et al provide evidence that phospholipase 
C epsilon (PKCε) and protein kinase CK2 can act as kinases at Thr1148, although neither study 
gives direct evidence of either kinase being responsible in vivo.  
In summary, IR activation in response to insulin is inhibited by mutation of Thr1148 to Asp and 
Ala in this study. The Thr1148Asp might inhibit the IR activation by the electrostatic repulsion 
of the negative charge group. Alternatively, the lack of response to insulin by both Thr1148Ala 
and Thr1148Asp may be due to the conformational change introduced in the activation loop. 
This may indirectly	either	alter the IR kinase	activity	or	the	access	of	downstream,kinases	to	







Breast cancer is a group of heterogeneous diseases that display enormous variations in their 
molecular and clinical behaviour. Based on the expression status of the oestrogen receptor 
(ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), 
breast cancers are categorized into 2 types: Triple-positive breast cancer (ER+, PR+ and 
HER2+) and Triple-negative breast cancer (ER-, PR- and HER2-).  Even though more 
intricate classifications are under investigation (Dawson et al., 2013) the current classification 
remains the fundamental basis for prognostic and clinical evaluation. Hormone positive breast 
cancers account for about 75-80% of all cases and are sensitive to hormone-based therapies 
which target the hormone receptors (Dawson et al., 2013).  Triple-negative breast cancers are 
sensitive to chemotherapy, which kills cancer cells by stopping them from dividing or by 
inducing apoptosis, but have a poorer prognosis and are aggressive with a high rate of 
recurrence.  
The IGF system is dysregulated in many types of cancers, including breast cancer 
(Malaguarnera and Belfiore, 2011; Park et al., 2016b; Pollak, 2008, 2012; Zhang et al., 2010). 
The IGF system can promote survival, proliferation and metastasis in breast cancer 
(Malaguarnera and Belfiore, 2011; Park et al., 2016b; Zhang et al., 2010). Within this 
complex system, the IGF-1R has attracted most of the research attention due to its prevalent 
overexpression in cancer, acting as the primary receptor for IGFs. Many different approaches 
have been developed to block IGF-1R signalling, including tyrosine kinase inhibitors and 
monoclonal antibodies that inhibit IGF binding or down regulate the receptor. However, 
clinical studies have shown that patients become resistant to these approaches (Baserga, 2013; 
Beckwith and Yee, 2015; Langer et al., 2014; Scagliotti et al., 2015). The mechanisms 
underlying the resistance are diverse, but can involve signalling via the IR-A stimulated by 
IGF-II (Frasca et al., 1999; Sciacca et al., 2002). 
	
	 84	
Overexpression of IGF-II and the IR-A has been shown to play a role in cancer growth and 
survival. The IR-A apparently provides an alternative pathway through which IGF-II can act 
(Avnet et al., 2009; Baserga, 2013; Frasca et al., 1999; Sciacca et al., 2002). The relative roles 
of the IR-A and IGF-1R in regulating growth, survival and migration are still not well 
understood in cancer cells co-expressing both receptors.  
IR-A/IGF-1R hybrids are also widely distributed in mammalian cells, and the signalling via 
hybrids results in similar outcomes as promoted via the IGF-1R in response to IGF-I and IGF-
II signals (Bailyes et al., 1997; Pandini et al., 1999; Slaaby, 2015).  
In order to study the specific roles of IR-A in cancer cells, it is necessary to eliminate the 
effects of the IGF-1R and the hybrids. This chapter aimed to address this knowledge gap of 
the relative roles played by the IR-A and IGF-1R by specifically knocking down either the IR 
or IGF-1R in the two breast cancer cell lines, MCF-7 (ER+, PR+ and HER2−) and MDA-MB-
231 (ER-, PR- and HER2-) cells. Both cell lines express IR-A, IGF-1R and IR-A/IGF-1R 
hybrids. However, there is controversy about the relative levels of IR and IGF-1R in MDA-
MB-231 and MCF-7 (Davison et al., 2011; Mancini et al., 2014; Zhang et al., 2007). 
Therefore, it was important to initially characterise the IR and IGF-1R expression in MDA-
MB-231 and MCF-7.  
In order to avoid phenotypic changes in either cell line when knocking down the receptors, a 
modified inducible knock down system based on the miR30 shRNA system was chosen. This 
system was developed in the laboratory of Whitelaw et al (Bersten et al., 2015; Dow et al., 
2012). The shRNA sequences were embedded in the miR30 shRNA, which is an 
endogenously expressed small microRNA (Figure 5.1) (Zeng et al., 2002). The 22mer length 
anti-sense/target sequence is linked by a miR30 loop structure into the miR30 context 
sequence. In cells, the transcribed sequence is directly processed by Drosha and Dicer to yield 
the mature small RNAs that enter the RNA-induced silencing complex (RISC) (Cullen, 2004). 
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In RISC, the guide strand binds to the targeted mRNA and causes its degradation (Cullen, 
2004; Dickins et al., 2005; Dow et al., 2012). 
The expression of the miR30-based shRNAs is regulated by a RNA Pol II promoter (pTRE3G) 
in this modified system (Dickins et al., 2005; Stegmeier et al., 2005) (Figure 5.1). The 
TRE3G promoter drives the expression of a single transcript encoding dsRED (a fluorescent 
indicator of expression) and the shRNA. Also included on the vector is the cDNA sequence 
encoding the Tet-On3G transactivator and the puromycin resistance protein, with an 
intervening IRES, with expression constitutively driven by the phosphoglycerate kinase-1 
promoter (pPGK). In the presence of doxycycline (Dox), a complex is formed between Dox 
and the Tet-On3G protein, leading to a structural change in the Tet-On3G that allows it to 
bind to the TRE3G promoter, thereby promoting the expression of dsRED and the miR30 
shRNA (Bersten et al., 2015; Dow et al., 2012; Stegmeier et al., 2005). Thus inducible gene 
silencing is achieved. 
In this chapter, I will: i. Construct model breast cancer cell lines expressing only the IGF-1R 
or the IR through receptor knockdown (IGF-1RKD and IRKD). ii. Analyse the signalling 
response to insulin and IGF-II and resultant biological activities of the model cell lines 






Figure 5.1: Structure of miR30 shRNA cassette (above) and inducible miR30 shRNA system 
(below). The miR30 shRNA cassette includes: sense/anti-sense strand 22mer (green/orange) 
and common miR30 context regions (black). After maturation, the guide strand (antisense 
strand, orange) will target the mRNA sequence and induce its degradation. This miR30 
shRNA cassette figure was edited from transomic technologies 
(http://www.transomic.com/Products/RNAi/shRNA.aspx#620f0f4d-5b24-4f1b-a843-
3084b2319e6b, 6689108). The inducible miR30 shRNA system includes: the pTRE3G, Tet-
On 3G promoter; dsRED, red fluorescent protein; pPGK, PGK promoter; Tet-On3G, Tet-On 











 5.2 Results 
5.2.1 IR and IGF-1R expression levels in breast cancer cells  
In order to characterise the MDA-MB-231 and MCF-7 cell lines, the mRNA levels of IR and 
IGF-1R were measured. Briefly, cells were cultured in DMEM medium supplemented with 
10% FBS and Penicillin-Streptomycin (100 U/mL). RNA was extracted and 100ng of 
template was used for PCR in a volume of 50 μl. 5 μl of PCR product was loaded onto a 2% 
SB agarose gel and stained with GelRed. The PCR indicated that MCF-7 cells express much 
higher levels of IGF-1R mRNA than MDA-MB-231 cells (normalised to a GAPDH control). 
The MCF-7 cells expressed slightly higher levels of total IR mRNA than the MDA-MB-231 
cells (Figure 5.2-A, B). In addition, the ratio of IR-A/B isoforms was similar to a previous 
report (Zhang et al., 2007) showing that MCF-7 cells expressed equal mRNA levels of IR-A 
and IR-B, whereas MDA-MB-231 cells predominantly expressed IR-A. 
The IGF-1R and IR cell surface protein expression was measured with flow cytometry 
according to the methods described in section 3.2.5. MCF-7 cells expressed higher levels of 
IGF-1R on the cell surface than MDA-MB-231 cells (Figure 5.2-C, D). This is expected and 
correlated with the PCR result (Figure 5.2-A). MCF-7 cells also expressed significantly 
higher IR surface levels than MDA-MB-231 cells (Figure 5.2-C, D). This was subtly different 
to what we saw with the mRNA levels (Figure 5.2-B). The post-translational processing and 
receptor internalization rates might account for the differences between the PCR and cell 
surface expression results. In summary, differences in receptor expression were confirmed 
here and these results provided a sound basis for studies of the roles of the IGF-1R and IR-A 





Figure 5.2: IR and IGF-1R expression levels in MDA-MB-231 and MCF-7 cells.  (A) The 
amplification of IGF-1R and GAPDH resulted in 572bp and 189bp products respectively. (B) 
PCR primers that flank exon11 were used to distinguish between IR-A (473bp) and IR-B 
(509bp). IGF-1R depleted mouse 3T3-like cells with human IR-A (R-IR-A) or IR-B (R-IR-B) 
isoform overexpression were used as controls. MCF-7 (C) and MDA-MB-231 (D) cell surface 
receptor levels were assessed by flow cytometry using specific antibodies as described in 
section 3.2.5. Curves indicate IgG1 isotope control (black), IR (red) and IGF-1R (green) 











































5.2.2 Design and selection of shRNA sequences targeting the human IR and human IGF-
1R 
To assess the relative roles of the IR and IGF-1R in the MCF-7 and MDA-MB-231 cell lines 
each receptor was knocked down individually, resulting in cell lines listed in Table 5.1. For 
this purpose, a set of shRNAs were designed to be used in a modified inducible knock down 
system based on the miR30 shRNA system.  
 MDA-MB-231 MCF-7 








shRNA negative control shGL3 shGL3 
Table 5.1: Stable cell lines generated in this study.  
In theory, any shRNA sequence can be inserted into the miR30 context to induce targeted 
mRNA degradation. However, not all shRNA sequences have high knock down efficiency 
due to the preferences of RISC loading and the multistep miRNA maturation steps (Fellmann 
et al., 2011). Studies with siRNA datasets show low GC content/high AU content at the 5’ 
end of the guide sequence is preferred by the RISC and required for efficient target mRNA 
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binding (Reynolds et al., 2004; Tomari and Zamore, 2005). By analysing the dataset of 
around 20,000 shRNAs, Fellmann et al (Fellmann et al., 2011) uncovered a set of parameters 
for effective shRNA design including: A/U at position 1, no A at position 20, A/U at position 
13 or U at position 14, and G at position 20 and 21. The shRNA with these parameters are 
strongly preferred by Drosha/DGCR8 cleavage, which promotes the transition from pre- to 
mature miRNAs (A/U in position 1 is also preferred for Dicer/TRBP cleavage and likely 
AGO2 loading (Fellmann et al., 2011). In summary, shRNA selection and design needs to be 
conducted according to the following parameters (Figure 5.3-A) for desirable knock down 
efficiency: A/U at position 1, 40-80% A/U content, >50% A/U content at positions 1-14, 
(A/U%1-14)/ (A/U%15-21) >1, no A at position 20, A/U at position 13 or U at position 14, 
no ‘AAAAA’ or ‘TTTTT’ or ‘CCCC’ or ‘GGGG’. Only the sequences that passed all the 
criteria were selected for cloning and screening in the current study.  
A mismatch at the 22nd base of the shRNA enables more efficient processing by the RNAi 
machinery by mimicking the structure of the endogenous miR30 (Figure 5.3-B). First, the 
reverse complement of the 21-mer guide strand (grey) is used to generate the 21-mer sense 
strand (or 21-mer target site; green); one nucleotide needs to be included at the 5’ end (orange) 
according to the nucleotide at the 5’ end of the 21-mer target site in the mRNA transcript 
(grey); if the 5’ end nucleotide in the mRNA is an A or U, the first base of the 22-mer sense 
strand becomes a C, and if the 5’ end nucleotide in the mRNA is a C or G, the first base of the 
22-mer sense strand becomes an A. The final 22-mer sense strand is then inserted into a 97-





Figure 5.3: shRNA sequence design parameters. (A) Example of predicted shRNA guide 
strands screened against a series of Sensor exclusion criteria (grey box). The example shows 
two potential 21-mer predictions targeting the Renilla luciferase cDNA. Each shRNA is given 
a numerical designation (e.g., Ren.713) that reflects the first nucleotide position of the target 
sequence in the mRNA transcript. Sequences that pass all criteria are selected for cloning and 
testing in vitro. (B) Process of transforming the 21-mer guide strand predictions into miR30-
based cloning templates. (C) The final 22-mer sense strand is then inserted into a 97-mer PCR 
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The Homo sapiens insulin-like growth factor 1 receptor (hIGF-1R) mRNA (gi|119220593) 
(Figure 5.4) and Homo sapiens insulin receptor (hIR) transcript variant 1 mRNA 
(>gi|119395735) (Figure 5.5) sequences were used as templates for in silico shRNA design. 
The methods for shRNA sequence selection were according to the parameters described 
above. The more parameters the sequence passed, the higher the score was. The four 
candidate sequences with the highest scores for each gene were selected and named as shIGF-
1R1-R4 or shIR1-R4 according to their rankings from highest to lowest score. The shIGF-
1R1, shIGF-1R3, shIR1, shIR2 and shIR3 were located in the three prime untranslated 
regions (3'-UTR) of the hIGF-1R and hIR sequences respectively, whereas shIGF-1R2, 





Figure 5.4: Homo sapiens insulin-like growth factor 1 receptor (hIGF-1R) mRNA sequence 
(gi|119220593) is truncated (see numbering) to allow all shRNAs to be mapped onto the IGF-
1R mRNA sequence. The sequence encodes two subunits: α-subunit (blue) and β-subunit 
(yellow). The shRNA candidate targeting sequences are marked in different colours. The 
entire 97 mer shRNA sequences are listed in Table 2.2.    
  
     1 ttttttttttttttttttgagaaaggggaatttcatcccaaataaaaggaatgaagtctg  
    … 
   901 acatcctcagcgccgagagcagcgactccgaggggtttgtgatccacgacggcgagtgca  
   961 tgcaggagtgcccctcgggcttcatccgcaacggcagccagagcatgtactgcatccctt  
  1021 gtgaaggtccttgcccgaaggtctgtgaggaagaaaagaaaacaaagaccattgattctg  
  1081 ttacttctgctcagatgctccaaggatgcaccatcttcaagggcaatttgctcattaaca  
  1141 tccgacgggggaataacattgcttcagagctggagaacttcatggggctcatcgaggtgg  
  … 
  2221 atttcctgcacaactccatcttcgtgcccagacctgaaaggaagcggagagatgtcatgc  
  2281 aagtggccaacaccaccatgtccagccgaagcaggaacaccacggccgcagacacctaca  
  2341 acatcaccgacccggaagagctggagacagagtaccctttctttgagagcagagtggata  
  2401 acaaggagagaactgtcatttctaaccttcggcctttcacattgtaccgcatcgatatcc  
  … 
  3361 tagcacctccaagcctgagcaagatgattcagatggccggagagattgcagacggcatgg  
  3421 catacctcaacgccaataagttcgtccacagagaccttgctgcccggaattgcatggtag  
  3481 ccgaagatttcacagtcaaaatcggagattttggtatgacgcgagatatctatgagacag  
  3541 actattaccggaaaggagggaaagggctgctgcccgtgcgctggatgtctcctgagtccc  
  3601 tcaaggatggagtcttcaccacttactcggacgtctggtccttcggggtcgtcctctggg  
  … 
  4141 cttcgacctgctgatccttggatcctgaatctgtgcaaacagtaacgtgtgcgcacgcgc  
  4201 agcggggtggggggggagagagagttttaacaatccattcacaagcctcctgtacctcag  
  4261 tggatcttcagaactgcccttgctgcccgcgggagacagcttctctgcagtaaaacacat  
  4321 ttgggatgttccttttttcaatatgcaagcagctttttattccctgcccaaacccttaac  
  4381 tgacatgggcctttaagaaccttaatgacaacacttaatagcaacagagcacttgagaac  
  4441 cagtctcctcactctgtccctgtccttccctgttctccctttctctctcctctctgcttc  
  4501 ataacggaaaaataattgccacaagtccagctgggaagccctttttatcagtttgaggaa  
  4561 gtggctgtccctgtggccccatccaaccactgtacacacccgcctgacaccgtgggtcat  
  4621 tacaaaaaaacacgtggagatggaaatttttacctttatctttcacctttctagggacat  
  4681 gaaatttacaaagggccatcgttcatccaaggctgttaccattttaacgctgcctaattt  
  … 
  6241 gccacggtggcccaagagcccctttgcttcttgctgggggaccagggctgtggtgctggc  
  6301 ccactttccctcggccaggaatccaggtccttggggcccaggggtcttgtcttgtttcat  
  6361 ttttagcacttctcaccagagagatgacagcacaagagttgcttctgggatagaaatgtt  
  6421 taggagtaagaacaaagctgggatacggtgattgctagttgtgactgaagattcaacaca  
  6481 gaaaagaaagtttatacggcttttttgctggtcagcagtttgtcccactgctttctctag  
  6541 tctctatcccatagcgtgttccctttaaaaaaaaaaaaaaggtattatatgtaggagttt  
  … 
  8581 tcttaagatgcggagtcacatttcaatggtacgaaaagtggcttcgtaaaatagaagagc  
  … 
 10921 aaaatttttttaagtaagaaaaaaaaaggtaataacatggccaatttgttacataaaatg  
 10981 actttctgtgtataaattattcctaaaaaatcctgtttatataaaaaatcagtagatgaa  
 11041 aaaaatttcaaaatgtttttgtatattctgttgtaagaatttattcctgttattgcgata  
 11101 tactctggattctttacataatggaaaaaagaaactgtctattttgaatggctgaagcta  
 11161 aggcaacgttagtttctcttactctgcttttttctagtaaagtactacatggtttaagtt  
 11221 aaataaaataattctgtatgca  
 
 









Figure 5.5: Homo sapiens insulin receptor (hIR), transcript variant 1, mRNA (>gi|119395735 
is truncated (see numbering) to allow all shRNAs to be mapped onto the IR mRNA sequence. 
The sequence encodes two subunits: α-subunit (blue) and β-subunit (yellow). shRNA 
candidate targeting sequences are marked in different colours. The entire 97 mer shRNA 
sequences are listed in Table 2.2. 
     1 gagaaggacgcgcggcccccagcgcctcttgggtggccgcctcggagcatgacccccgcg  
    … 
   841 tcagcccgacgaccccaccaagtgcgtggcctgccgcaacttctacctggacggcaggtg  
   901 tgtggagacctgcccgcccccgtactaccacttccaggactggcgctgtgtgaacttcag  
   961 cttctgccaggacctgcaccacaaatgcaagaactcgcggaggcagggctgccaccagta  
  1021 cgtcattcacaacaacaagtgcatccctgagtgtccctccgggtacacgatgaattccag  
  1081 caacttgctgtgcaccccatgcctgggtccctgtcccaaggtgtgccacctcctagaagg  
  1141 cgagaagaccatcgactcggtgacgtctgcccaggagctccgaggatgcaccgtcatcaa  
  … 
  2221 ttcggccggcgaatgctgctcctgtccaaagacagactctcagatcctgaaggagctgga  
  2281 ggagtcctcgtttaggaagacgtttgaggattacctgcacaacgtggttttcgtccccag  
  2341 aaaaacctcttcaggcactggtgccgaggaccctaggccatctcggaaacgcaggtccct  
  2401 tggcgatgttgggaatgtgacggtggccgtgcccacggtggcagctttccccaacacttc  
  … 
  3361 tcacgtggtgcgcctcctgggagtggtgtccaagggccagcccacgctggtggtgatgga  
  3421 gctgatggctcacggagacctgaagagctacctccgttctctgcggccagaggctgagaa  
  3481 taatcctggccgccctccccctacccttcaagagatgattcagatggcggcagagattgc  
  3541 tgacgggatggcctacctgaacgccaagaagtttgtgcatcgggacctggcagcgagaaa  
  3601 ctgcatggtcgcccatgattttactgtcaaaattggagactttggaatgaccagagacat  
  … 
  4141 tggagggtcctcgctgggtttcaagcggagctacgaggaacacatcccttacacacacat  
  4201 gaacggaggcaagaaaaacgggcggattctgaccttgcctcggtccaatccttcctaaca  
  4261 gtgcctaccgtggcgggggcgggcaggggttcccattttcgctttcctctggtttgaaag  
  4321 cctctggaaaactcaggattctcacgactctaccatgtccaatggagttcagagatcgtt  
  4381 cctatacatttctgttcatcttaaggtggactcgtttggttaccaatttaactagtcctg  
  4441 cagaggatttaactgtgaacctggagggcaaggggtttccacagttgctgctcctttggg  
  4501 gcaacgacggtttcaaaccaggattttgtgttttttcgttccccccacccgcccccagca  
  4561 gatggaaagaaagcacctgtttttacaaattctttttttttttttttttttttgctggtg  
  4621 tctgagcttcagtataaaagacaaaacttcctgtttgtggaacaaaagttcgaaagaaaa  
  4681 aacaaaacaaaaacacccagccctgttccaggagaatttcaagttttacaggttgagctt  
  … 
  6241 aattgtctattgctatcttatttatatgattcgggaaaatacagcatgtaaaaatattgc  
  6301 tgaggagcctcagtgattgggtacaagaagcaagagtacagaaattatttttgccaaatt  
  6361 tattttgtaaatatgagggtctgtacctaaatttaaaaaaaaaacacgtagaactaggta  
  6421 ttttgttctcttcttagtaaatttgtagtggttgtatactacactagctgcaattttcac  
  6481 atttttctaattcagaaaggtttttcttatattaggggaaaaagtatttattttaatata  
  6541 taaaatcactctgaaaatcactctcataaaaaatggagcgcatgtaaatttttatcaaag  
  6601 aaaaataaacaggtgaatgggggatagtgattttcttttttcagcacagtctacctcagt  
  … 
  8581 cttctgatactagtcaaggtccagaaccagccaccagccaaatttctatctgggtgcggg  
  8641 ccactgaaaatccttgttaaaaaccagatcacaaatctggggctcttggtcccattggag  
  8701 aaggaaggaagagcctcaaaataagtgtgcacccatgcacatattcaggaacagcttgtt  
  8761 tagtctttacactttgcctgaaagttgcttctcctcgtccctttgtgtgcctgggtggcc  
  8821 tcggccctgtgcgttggcaacgcaggatcaaatgtgctgcagcttttgcagaaaacaact  
  8881 cagaaacacaaaaccccccaacagctcaattattattttttcaatgttttcctacaagag  
  8941 ccaagtagcaccatgtacagaagacgcctttttttttggaatattgaaatcgttctgcat  
  9001 gtaaaatatgggataatgacctgtttatattaaaattctgattaaattatctgagaata  
 







5.2.3 Cloning strategy for miR30 shRNA inducible knock down system construction  
Having designed the shRNA sequences these were then cloned into the miR30 inducible 
knock down vector. The miR30 shRNA inducible knock down system construction included 
the following steps: 1. Amplification of the 97-mer template containing shRNA by PCR, and 
2. Ligation of the amplified shRNA template into pENTR1a vector by Gibson assembly. The 
resultant vector constructs were used for sequencing, 3. Insertion of the sequence-verified 
shRNA fragment into the lentivector pLVTPT by Gateway cloning (Figure 5.6). 
pENTR1a and lentivector pLVTPT were gifts from the Whitelaw lab, University of Adelaide 
(Plasmid map see Appendix 1). The 97-mer template containing shRNA were first amplified 
using the M30c Iso primer pair (Table 2.2) according to the method described in section 
3.1.18. The PCR introduces XhoI and EcoRV restriction enzyme sites and a short overhang 
sequence complementary to the pENTR1a vector. The pENTR1a vector and shRNA PCR 
products were digested and gel purified according to the method described in sections 3.1.4 
and 3.1.5. The two purified fragments were joined together using Gibson assembly according 
to the method described in the section 3.1.11 and the sequences were verified by sequencing 
according to the method described in the section 3.1.13. Both pENTR1a and pLVTPT 
lentivectors were previously modified with Gateway cloning cassettes (AttL1 and AttL2 or 
AttR1 and AttR2 sequences, respectively), thus enabling the dsRed and shRNA fragments in 
pENTR1a to be introduced via the AttR1 and AttR2 cassette in the pLVTPT lentivector 
(Figure 5.6). Gateway cloning was conducted according to the method described in section 
3.1.12. The shRNA containing lentivector pLVTPT miR30 shRNA was then used to produce 





Figure 5.6: miR30 shRNA inducible knock down system construction. This flow chart 
includes several main steps: Step 1. Preparation of fragments to be introduced into the final 
pLVTPT miR30 shRNA vector. This involved (A) digestion of the pENTR1a vector with 
XhoI and EcoRV and (B) amplification of the 97-mer template containing shRNA by PCR; 
Step 2. Ligation of the amplified shRNA template into pENTR1a vector by Gibson assembly, 
which results the pENTR1a miR30 shRNA (C). This product is used for sequencing. Step 3. 
Insertion of the sequencing verified shRNA fragment into the pLVTPT lentivector (D) by 
Gateway cloning, resulting in the pLVTPT miR30 shRNA vector (E). Schematic diagrams of 
the DNA fragments used indicate the following components: dsRED (red), red fluorescent 
protein; pTRE3G (orange), Tet-On 3G promoter; pPGK (dark yellow), PGK promoter; Tet-
On3G (yellow), Tet-On 3G transactivator; IRES (green), internal ribosome entry site; Puro 
(pink), puromycin resistance gene; AttL1, AttL2, AttR1, AttR2, AttB1, AttB2, Gateway 
cloning recombination sites; CmR, chloramphenicol resistance protein; ccdB, Toxin CcdB. 
5.2.4 pENTR1a miR30 shRNA verification  
The Ligation of pENTR1a miR30 shRNA was conducted according to the method described 
in section 3.1.11 using Gibson Assembly. After the insertion of each shRNA into the 
pENTR1a vector, EcoRI restriction digestion was used to screen for successful ligation. The 
EcoRI digestion cut the pENTR1a into two fragments of 2385bp and 872bp (Appendix 1), 
pLVTPT pTRE3G PuroIRESAttR1 CmR ccdB AttR2 pPGK Tet-On3GpEF1a
Gateway  Cloning
pTRE3G PuroIRESpPGK Tet-On3GpEF1a AttB1 dsRED AttB2
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whereas it cut the pENTR1a miR30 shRNA vector into two fragments of 2385bp and 969bp 
(Appendix 2), due to the insertion of the 97 mer shRNA fragment.  
All eight of the shRNA sequences that target the hIR and the hIGF-1R were mixed at equal 
concentrations with the pENTR1a vector backbone in one ligation reaction. When the 
fragments were mixed equally, theoretically each has an equal chance to ligate with the vector. 
Thirteen out of the 16 colonies picked after ligation contained miR30 shRNA fragments (81% 
efficiency). These constructs were sequenced before the shRNA inserts were cloned into the 
pLVTPT lentivector. The 13 ligated vectors contained all 8 different miR30 shRNA 






Figure 5.7: pENTR1a shRNA verification. pENTR1a shRNA ligation products (number 1-16) 
were digested with EcoRI using the original pENTR1a vector as a control. Digestion products 
were separated by electrophoresis on a 2% TBE agarose gel and visualized using GelRed 













5.2.5 pLVTPT miR30 shRNA verification 
The Gateway LR cloning was used to construct the pLVTPT miR 30 shRNA according to the 
methods described in section 3.1.12. Individual pENTR miR30 shRNA vector was combined 
with the pLVTPT vector in a total of eight reactions. The shRNA fragment flanked by AttL1 
and AttL2 in pENTR1a miR30 shRNA vector was introduced into the complementary region 
in the pLVTPT flanked by AttR1 and AttR2. pLVTPT miR30 shRNA vectors were used to 
transform the E. coli strain DH5α and were selected on kanamycin plates. Successful cloning 
of the shRNA sequences into the pLVTPT vector was detected by EcoRV digestion, which 
was expected to yield 3 fragments (7962bp, 1183bp and 1378bp, Appendix 4), while the 
digest of the empty pLVTPT vector yielded 7962bp, 1713bp and 1378bp fragments 
(Appendix 3). The clones contained the expected fragements indicating successful 
introduction of the shRNA sequences into the pLVTPT vector (Figure 5.8).  
 
Figure 5.8: pLVTPT miR30 shRNA verification. pLVTPT miR30 shRNA vectors targeting 
IR (#1-4) or IGF-1R mRNA (#5-#8) were digested with EcoRV and using pLVTPT as a 
control. Digestion products were separated by electrophoresis on 1% TBE agarose gels and 













5.2.6 Virus infection optimization and stable cell line selection 
Having successfully constructed four shRNA pLVTPT vectors to target the IR and four 
targeting the IGF-1R the next step was to produce lentivirus and infect the MCF-7 and MDA-
MB-231 cells.  An additional vector (shGL3) was constructed in the Whitelaw lab (The 
University of Adelaide) to target the Luciferase gene and was used as shRNA negative 
control. A total of 18 stable cell lines were generated (Table 5.1). 
The lentivirus was produced by transient transfection of the lentivector pLVTPT miR30 
shRNA and virus packaging vectors in human embryonic kidney (HEK) 293T cells according 
to the protocol described in section 3.3.3. Virus-containing supernatants were used for the 
infection of MDA-MB-231 and MCF-7 cells. 
In order to facilitate the establishment of the stable cell lines through miR30 RNA genomic 
integration, the lentivirus infection conditions were first optimized with the following 
parameters: cell density, virus:medium ratio, virus cell contact time  and condition. MDA-
MB-231 cells were used initially to determine optimal viral infection conditions and then 
these were applied to MCF-7 cells. The Doxycycline (Dox) was added the next day to induce 
the reporter protein (dsReD) expression (Figure 5.9-A). The dsRed was confirmed using the 
fluorescence microscope (Cy3 filter, 575-625nm) to detect dsRed expression. In the absence 
of Dox, dsRed was undetectable as expected as under these conditions the Tet-On-3G cannot 
bind the TRE3G promoter. In the presence of Dox, the dsRed was robustly expressed. By 
overlaying the images of cells taken under the light microscope and the fluorescence 
microscope, the infection efficiency could be calculated. Ideally above 80% infection 
efficiency would be reached.  
Firstly, the ratio of virus: medium (volume:volume) was optimized using the ratios of 1:1,1:3 
and 1:9. A ratio of 1:1 led to the highest infection rate with 20% of cells being infected 
(Figure 5.9-B). This condition was used for further refinement. There are basically two ways 
to increase the infection rate: prolong the virus-cell contact time (overnight virus-cell 
	
	 101	
incubation, from now on referred to as the “overnight incubation method”) and improve 
virus-cell contact (increase virus-cell contact by centrifuge, from now on referred to as the 
“spin method”). When comparing the two methods (described in section 3.3.4) the overnight 
incubation method generally resulted in a higher infection rate than the spin method (Figure 
5.9-C). The effect of cell seeding density on virus infection rate was also optimized using 
cells seeded at 10,000, 20,000, 50,000 cells per well. Low cell seeding density improved the 
infection rate to an approximately 40% (overnight incubation method, virus: medium ratio of 
1:1). Below this seeding density the cells did not grow well and therefore lower densities 
were not tested. Stable cell lines were selected according to the method described in section 
3.3.6.  
Interestingly, using the same conditions on MCF-7 cells only a 26.2% infection rate was 
achieved, compared to the 40% infection rate with MDA-MB-231 cells. Even though the 
infection rate was not as high as expected, stable cell lines were also successfully selected 
according to the method described in section 3.3.6. Obviously, it was sufficient to select the 





Figure 5.9: Virus infection optimization. MDA-MB-231 cells were seeded into 6-well plates 
and infected with lentivirus produced in 293T cells. Two days after infection, 1 μg/ml of Dox 
was added into medium and dsRED fluorescence was detected 24 hours later. Fluorescent cell 
to total cell ratio was calculated to provide an indication of infection rate. (A) Cells were 
detected under the light microscope or with the Cy3 filter (575-625nm) with or without Dox 
induction. Factors affecting the infection rate were optimized: (B) ratio of virus to medium 
(volume:volume), and (C) infection method and cell density. No significant differences were 
found between cell densities with spin method. The bars show the S.E.M. of 5 technical 
replicates. Statistical significance was determined by one-way ANOVA in Figure 5.9-B and 































































































5.2.7 shRNA selection 
Following the selection of the cell lines, the knock down efficiency of each shRNA was 
measured. Initially the knockdown efficiency of shRNAs was measured in the MDA-MB-231 
cell lines. shRNA expression was induced by adding Dox (1 μg/ml) into the culture medium 
for four days. Cells were then lysed and the receptor levels were measured with Western-
blotting according to the methods described in section 3.2.4.  
Even though all four shRNAs targeting the IGF-1R passed the selection parameters described 
above(Dow et al., 2012), significant differences in knock down efficiency were seen between 
individual shRNAs. The shIGF-1R2 induced knock down by 91%, shIGF-1R4 by 46%, while 
shIGF-1R1 and shIGF-1R3 did not induce knock down. Interestingly, shIGF-1R2 and shIGF-
1R4 targeted the CDS region, while shIGF-1R1 and shIGF-1R3 targeted the 3’-UTR region. 
The possible explanation of these differences is that the disruption of CDS region would 
directly decrease the protein translation. Importantly, the IR level was not significantly 
affected by IGF-1R knock down (Figure 5.10-A, C). The raw data of Figure 5.11-A, C are 
shown in Appendix 14. 
Similarly, differences in knock down efficiency were seen between the shRNAs targeting the 
IR. The shIR4 induced knock down by 93%, shIR-3 by 80%, shIR-1 by 50% and shIR-2 by 
20%. The IGF-1R levels in each cell line was not significantly affected by IR knock down 
(Figure 5.10-B, D). The results were consistent with the shRNAs targeting the IGF-1R, the 
most efficient shRNA targeting the IR (shIR4) also targeted the CDS region. The shIR1, 
shIR2 and shIR3 targeted the 3’-UTR, but they were effective to varying degrees at reducing 
IR expression. From these results, it can be concluded that shRNAs designed to target CDS 
regions are possibly more reliable than those targeting the 3’UTR. As shIR4 and shIGF-1R2 
were verified to induce desirable knock down effect of the receptors, these two cell lines were 





Figure 5.10: shIGF-1R (A and C) and shIR (B and D) screening in MDA-MB-231 cell lines. 
Four different shRNA that target different areas of IGF-1R or IR mRNA were designed and 
the shRNA that targets the luciferase gene (pGL3) was used as a negative control. The 
expression of each shRNA was induced in duplicate by adding Doxycycline (1 μg/ml) into the 
medium (+) of two replicate wells. After four days, cells were lysed and receptor levels were 
measured by immunoblot with Anti-Insulin Receptor beta antibody [C18C4] (Abcam 
#ab69508) and IGF-I Receptor β Antibody (Cell signalling #3027) according to the methods 
described in section 3.2.4. Quantitation of shIGF-1R (C) and shIR (D) knockdown 
immunoblots showed the differences in efficiency of knockdown of the different shRNAs. 
The bars show the S.E.M. of 3 biological replicates, each with technical duplicates. Statistical 
significance was determined by one-way ANOVA (* represents P<0.05). The raw data of 
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5.2.8 shRNA knock down time course 
In order to further understand the knock down kinetics and to select the optimal conditions for 
the knock down a time course was conducted with shIGF-1R2 in both MDA-MB-231 (Figure 
5.11-A, B) and MCF-7 (Figure 5.11-C, D) cells. The raw data of Figure 5.11-A, C are shown 
in Appendix 15. 
The knock down effect started as early as 24 hours with Dox induction and the knock down 
effects increased with longer Dox induction time. The maximum knock down by shIGF-1R2 
was reached in MDA-MB -231 (91%) and MCF-7 (72%) cells after 96 hours of Dox 





Figure 5.11: shIGF-1R2 time course in MDA-MB-231 (A and B) and MCF-7 (C and D) cells. 
The expression of shRNA was induced in duplicate by adding Doxycycline (1 μg/ml) into 
medium of two replicate wells. Samples were taken each day for 5 days. Cells were lysed and 
receptor levels were measured according to the methods described in section 3.2.4. Biological 
duplicates were conducted. Bars represent the average of biological duplicates. The raw data 
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5.2.9 IR-A transduces insulin and IGF-II signals in MDA-MB-231 IGF-1R KD cells 
Cell lines were then subjected to a series of assays to measure the in vitro response to insulin 
and IGFs with the aim to understand the relative contribution of the IR-A and IGF-1R to 
biological responses to these ligands. Initially a small scale experiment using just the MDA-
MB-231 wild-type, shGL3 and shIGF-1R2 (shIGF-1R) cell lines was conducted to see if we 
could detect any difference between the response to insulin and IGF-II in cells expressing 
only the IR-A (ie in the MDA-MB-231 shIGF-1R cell line). 
Phosphorylation of proteins from Akt and MAPK signalling pathways were detected in 
MDA-MB-231 wild-type, shRNA negative control- shGL3 and shIGF-1R with/without Dox 
induced knock down (Figure 5.12). The cells were seeded and incubated with/without Dox in 
medium for 3 days before overnight starvation, then cells were stimulated with 10 nM insulin 
or 100 nM IGF-II for 10 minutes and lysed immediately. The concentrations of 10 nM insulin 
and 100 nM IGF-II were chosen to take into account the difference in IR-A binding affinities 
(see Table 1.1). Western blotting was conducted according to the method described in section 
3.2.4.  
All MDA-MB-231 cell lines responded to insulin and IGF-II stimulation with an increase in 
Akt phosphorylation (pSer473 and pThr308, Figure 5.12-B,C). The Akt responses of the wild 
type and GL-3 control cell lines were similar. In both cell lines there was a greater response to 
100 nM IGF-II than 10 nM insulin. There was also a greater response to 100 nM IGF-II than 
10 nM insulin in the MDA-MB-231 shIGF-1R cells without Dox. As these cells express both 
the IR-A and the IGF-1R it is possible that this response reflects predominantly IGF-1R 
signalling or hybrid receptor signalling. 
Interestingly, upon IGF-1RKD the Akt phosphorylation response to insulin was markedly 
increased and reached the same level as seen with 100nM IGF-II stimulation. In this cell line 
the predominant receptor expressed is the IR-A and there are no hybrid receptors. No increase 
in IGF-II response was detected with Dox induction of IGF-1R KD. This could be due 
maximum activation having been reached, although this is yet to be determined with dose 
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response study. Importantly, this result demonstrates that these MDA-MB-231 IGF-1RKD 
cells respond to both insulin and IGF-II via the IR-A. 
In MDA-MB-231 wild-type, GL-3 and IGF-1RKD cell lines the phosphorylation levels of 
90RSK (pSer380), 44/42 MAPK (pThr202/pTyr204) and S6 (pSer235/236) did not increase 
as compared to the non-stimulated state, regardless of whether it was in response to insulin or 
IGF-II (Figure 5.12-D, E, F). These findings suggest that in these cells lines the MAPK 
signalling pathway is not activated above basal by insulin and IGF-II. The raw data of Figure 






Figure 5.12: Phosphorylation of signalling proteins in Akt and MAPK signalling pathways in 
response to insulin or IGF-II. MDA-MB-231 cells were cultured with/without Dox for 3 days 
and starved in serum-free medium with 1% BSA overnight. Cells were then treated with 
10nM insulin or 100 nM IGF-II for 10 min. (A) Whole-cell lysates were immunoblotted for 
IGF-1R, tubulin, phosphorylated pAkt (pS308) and PathScan® Multiplex Western Cocktail I 
(Cell signalling #5301). (B) Akt phosphorylation (pSer473), (C) Akt phosphorylation 
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(pSer235/236). Figure shows the representative result of biological triplicates. The raw data of 





5.2.10 Proliferation of MDA-MB-231 cell lines  
Next, the ability of IGFs and insulin to stimulate proliferation through activation of the IR or 
IGF-1R expressed by the MDA-MB-231 cell lines was assessed (Figure 5.13). The control 
GL3, shIR4 and shIGF-1R2 of MDA-MB-231 cell lines (Table 5.1) were cultured in medium 
containing Dox for three days to induce the knock down of IR or IGF-1R. All cell lines 
(including wild type MDA-MB-231 cells) were then seeded into two 48 well plates (4,000 
cells/well) and were grown at least 24 hours in medium containing 10% FBS. They were then 
starved in medium containing 2% charcoal treated FBS overnight to get rid of the endogenous 
ligands. One plate was stimulated with IGFs and insulin at 0 nM, 1 nM, 10 nM and 100 nM 
diluted in medium containing 2% charcoal treated FBS. The other plate was immediately 
stained with crystal violet to determine the cell number at t=0 as described in section 3.3.11. 
Four days later, crystal violet staining was used to estimate the number of stimulated cells.  
The response of each cell line to increasing ligand doses was measured (Figure 5.13-A). The 
growth rates of each cell line stimulated with ligand were normalized to the growth rates of 
that cell line without ligand stimulation (0 nM ligand, 2% charcoal treated FBS). Despite 
activation of downstream Akt signalling (Figure 5.12) the MDA-MB-231 wild-type cells had 
no significant response to any ligand (insulin, IGF-I and IGF-II) stimulation, even with ligand 
concentrations as high as 100 nM (Figure 5.13-A). Similar results were also shown with other 
MDA-MB-231 cell lines-shGL3, IRKD and IGF-1RKD (Figure 5.13-A). 
The data was then re-analysed to compare relative growth rates between the different MDA-
MB-231 cell lines, this time normalizing to the growth rate of MDA-MB-231 wild-type under 
starvation conditions (0 nM, 2% charcoal treated FBS). Growth differences between cell lines 
in response to ligands (insulin, IGF-I and IGF-II) were compared (Figure 5.13-B). The growth 
rate of the shRNA negative control-GL3 cell line was not significantly different to the wild-
type MDA-MB-231 cells, indicating the introduction of lentivirus and the integration of 
shGL3 doesn’t change the characteristics of cells. Most strikingly, the IR knock down in 
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MDA-MB-231 cells (IRKD) significantly enhanced cell growth by 3-5 fold compared to wild 
type MDA-MB-231 cells (Figure 5.13-B). In contrast, the IGF-1R knock down in MDA-MB-
231 cells (IGF-1RKD) significantly inhibited growth compared to wild type cells (Figure 
5.13-B).  
In summary, wild type MDA-MB-231 cells were unresponsive to all three ligands. Knock 
down of the IR and IGF-1R resulted in changes in growth rates independent of insulin, IGF-I 
or IGF-II, suggesting that these receptors are playing an important role in regulating cell 
proliferation driven by other growth factors within FCS. These cells were maintained in 2% 
FCS and were not viable in medium containing lower concentrations. In this medium their 
doubling time was ~ 2 days. 
 
  
Figure 5.13: 	Growth of MDA-MB 231 cell lines in response to insulin and IGFs (0 nM, 1 nM, 
10 nM and 100 nM).  Crystal violet assay was conducted to assess the proliferation rate 
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measured (A). The growth rates in response to ligands (insulin, IGF-I and IGF-II) were 
normalized to the individual cell line growth rate in absence of ligand (0 nM, 2% charcoal 
treated FBS). The growth differences between cell lines were also compared (B). All growth 
rates were normalized to the MDA-MB-231 wild-type growth rate under starvation conditions 
(0 nM, 2% charcoal treated FBS). The bars show the S.E.M. of 3 biological replicates, each 
with technical triplicates. Statistical significance was determined by two-way ANOVA (ns, P 




5.2.11 Proliferation of MCF-7 cell lines  
Proliferation assays were also used to assess the effect of IR or IGF-1R knock down on the 
proliferation of MCF-7 cells in response to IGF and insulin stimulation (Figure 5.14). As 
there was no difference in receptor expression in the shGL3 control MCF-7 cells (Figure 5.11) 
and the lentivirus infection and integration of shGL3 into the genome did not affect the cell 
characteristics in MDA-MB-231, this control cell line was not used in proliferation assays. 
The assay was conducted in the same way as the MDA-MB-231 cell proliferation assays 
described in section 5.3.8. 
Firstly, the response of each MCF-7 cell line to increasing concentrations of each ligand was 
measured (Figure 5.14-A). Again, the growth rates of each cell line stimulated with ligand 
were normalized to the growth rates of that cell line without ligand stimulation (0 nM ligand, 
2% charcoal treated FBS). The MCF-7 wild-type cells responded significantly to all the 
ligands (insulin, IGF-I and IGF-II) and the responses reached a maximum at 10 nM. Similar 
results were also shown with other cell lines- IRKD and IGF-1RKD. 
The data was then re-analysed to compare relative growth rates between the different MCF-7 
cell lines, this time normalizing to the growth rate of MCF-7 wild-type under starvation 
conditions (0 nM, 2% charcoal treated FBS). Growth differences between cell lines in 
response to ligands (insulin, IGF-I and IGF-II) were compared (Figure 5.14-B). The MCF-7 
IR knock down cells (IRKD) responded to a similar extent to the wild-type MCF-7 cells to all 
the ligands (insulin, IGF-I and IGF-II), with the ligand stimulation concentration ranging 
from 0 nM to 100 nM (Figure 5.14-B). However, the growth of the MCF-7 IGF-1R knock 
down cells (IGF-1RKD) was significantly inhibited compared to wild type MCF-7 cells, 
while there was still an increasing response to all the ligands (Insulin, IGF-I and IGF-II), with 
the increasing ligand concentrations ranging from 0 nM to 100 nM (Figure 5.14-B). 
In summary, MCF-7 cells grew in response to insulin, IGF-I and IGF-II. Higher growth rates 
were identified with increasing ligand concentrations. While the lack of the IR did not change 
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the growth rate of cells, the lack of IGF-1R significantly inhibited the cell growth. This 






Figure 5.14: 	Growth of MCF-7 cell lines in response to insulin and IGFs (0 nM, 1 nM, 10 nM 
and 100 nM). Crystal violet assay was conducted to assess the proliferation rate according to 
the method described in section 3.3.11. The dose response of each cell line was measured (A). 
The growth rates were normalized to the individual cell line growth rate in starving conditions 
(0 nM, 2% charcoal treated FBS). The growth differences between cells in response to ligands 
(insulin, IGF-I and IGF-II) were also compared (B). All growth rates were normalized to the 
MCF-7 wild-type growth rate under starvation conditions (0 nM, 2% charcoal treated FBS). 
The bars show the S.E.M. of 3 biological replicates, each with technical triplicates. Statistical 
significance was determined by two-way ANOVA (ns, P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; 












































































































































































































































5.2.12 IGF-1R knock down enhanced the migration rate of MDA-MB-231 
Wound healing assays were used to assess the effect of IR or IGF-1R knock down on the 
migration of MDA-MB-231 cells (Figure 5.15). MDA-MB-231 cells were cultured in 
medium containing Dox (1 μg/ml) to induce the knock down of IR or IGF-1R. Then cells 
were seeded into 24-well plates to grow until confluent. Cells were starved in serum-free 
medium for 16 hours. A wound was made with a 200μl pipette tip and 10 nM of ligand 
(insulin, IGF-I or IGF-II) or 10% Fetal calf serum (FBS) were added to stimulate migration. 
Photographs were taken and the wound area was measured using CellProfiler software (Jones 
et al., 2008). Migration was monitored by comparing the wound area at t=0 at the time of 
making the wound and after 24 hours (No significant migration was found after 6 hours). 
Firstly, the responses of MDA-MB-231with shRNA integration were compared to wild-type 
(Figure 5.15-A). With or without ligand stimulation the migration of MDA-MB-231 GL3 and 
IRKD cells was not significantly different to the wild type MDA-MB-231 cells. However, the 
IGF-1RKD enhanced the migration of MDA-MB-231 cells compared to wild type MDA-MB-
231 cells (smaller wound area at 24 hours), even in the absence of ligand stimulation. 
Secondly, the ligand effect of increasing ligand concentrations on migration of individual 
MDA-MB-231 cell lines was assessed (Figure 5.15-B). The extent of migration of MDA-MB-
231 wild type cells was significantly greater in response to insulin, IGF-I and FBS compared 
to no treatment. The migration of the MDA-MB-231 GL3 cell line was similar to wild type 
MDA-MB-231 cells, although there was no significant response to insulin. In fact, all cells 
migrated to a greater extent in response to FCS compared to no treatment. While it appeared 
that IGF-II promoted increased migration in all of the MDA-MB-231 cell lines this effect was 
not statistically significant. All cell lines responded significantly to IGF-I except for the 
MDA-MB-231 IGF-1RKD cell line. Migration of the MDA-MB-231 IRKD cell line was 
slower than wild type cells and significant responses were only seen to insulin and FCS. The 
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migration of IGF-1RKD was only significantly enhanced in response to FBS, and not to any 
other ligand.  
In summary, insulin, IGF-I and IGF-II were found to promote the migration of MDA-MB-231 
cells. The MDA-MB-231 cells lacking the IGF-1R had enhanced migration with or without 
the ligand stimulation. This suggests that signalling via the IR-A when present as homodimers 
(rather than hybrids) promotes migration of MDA-MB-231 cells. At same time, the migration 
of MCF-7 cells was also measured with the same method. However, no migration was 
detected in any type of the MCF-7. Because MCF-7 is a well-known non-metastatic cell line, 
this result was not unexpected.  





Figure 5.15: Migration of MDA-MB-231 cell lines in response to ligand stimulation (10nM) 
or FBS (10%). Wound healing assays were conducted to assess the migration rate according 
to the method described in section 3.3.9. The migration rates are expressed as the ratio of 
wound area after 24 hours compared to the starting wound area. Photographs were taken and 
the wound area was measured using CellProfiler software (Jones et al., 2008). 
These data were either expressed as a comparison of response to each ligand between cells (A) 
or as a comparison of the responses to the ligands of each cell line (B). The unstimulated 
conditions (“None”) were serum-free DMEM medium containing 1% BSA. Cells were 
stimulated with 10 nM of individual ligand diluted in serum-free DMEM medium containing 
1% BSA. The bars show the S.E.M. of 3 biological replicates, each with technical triplicates. 
Statistical significance was determined by two-way ANOVA (ns, P > 0.05; *, P ≤ 0.05; **, P 
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5.2.13 The E-cadherin levels in MDA-MB-231 cell lines 
An increased migration was seen with IGF-1RKD in MDA-MB-231 even in the absence of 
stimulating ligand. Since the epithelial mesenchymal transition (EMT) usually precedes 
migration and a feature of EMT is the decrease in expression of E-cadherin, we assume the 
expression level of E-cadherin will be lower in IGF-1RKD cells comparing the MDA-MB-
231 wild-type. However, Taliaferro-Smith et al., reported that the level of E-cadherin was 
increased after knock down of the IGF-1R (Taliaferro-Smith et al., 2015). We thus decided to 
measure the E-cadherin level in all of the MDA-MB-231 cell lines and to see if there was a 
change in the IGF-1RKD cells that could account for the increased migration (Figure 5.16). 
Interestingly, contrary to the report by Taliaferro-Smith et al., E-cadherin was not detected in 
any of the MDA-MB-231 cell lines (wild-type, GL3, IRKD or IGF-1RKD). MCF-7 is a well 
known non-metastatic cell line and is known to express E-cadherin, so MCF-7 mRNA was 
used as a positive control in this PCR. High levels of E-cadherin mRNA level were detected 
in MCF-7 cells.  
In summary, IGF-1RKD in MDA-MB-231 improved the migration ability compared to wild 





Figure 5.16: E-cadherin mRNA levels in MDA-MB-231 and MCF-7 cell lines. The cells were 
cultured in DMEM medium with/without Dox for 4 days. The mRNA was extracted and 











































































We aim to investigate the biological role of IGF-II/IR-A in breast cancer cells in this chapter. 
Because the IR and IGF-1R are co-expressed in the cells, we constructed a miR30 shRNA 
knock down system to inducibly knock down the IR or IGF-1R of breast cancer cell lines 
described in the first part of this chapter. The shRNAs that target the CDS and 3’UTR region 
were designed for each receptor. We have found that shRNA that targets the CDS region of 
mRNA always induced better knock down effects than shRNA targeting the 3’UTR region, 
although both CDS and 3’ UTR region were identified as effective targeting region for siRNA 
and shRNA design (Lai et al., 2013). However, the effectiveness of the shRNA can be caused 
by other factors, such as the thermostability of the secondary structure of shRNA (Lai et al., 
2013; Saito and Saetrom, 2010), which could account for the difference between the designed 
shRNAs. 
The relative receptor levels of IGF-1R and two isoforms of IR (IR-A and IR-B) were 
measured in MCF-7 (ER+, PR+, HER-) and MDA-MB -231 (ER-, PR-, HER-) cells. MCF-7 
was found to express high IGF-1R levels, while MDA-MB-231 expressed low IGF-1R levels. 
Both MCF-7 and MDA-MB-231 expressed similar IR level. However, MCF-7 expressed 
similar levels of IR-A and IR-B, while MDA-MB-231 mainly expressed IR-A. Our data is 
consistent with Zhang et al and Mancini et al ((Mancini et al., 2014; Zhang et al., 2007). 
However, this data is partially different to that reported by Davison et al, which showed by 
immunoblotting that the two cell lines express similar high levels of IGF-1R (Davison et al., 
2011). The report by Davison et al is in doubt because no loading control was showed in their 
data.  
The phosphorylation of signalling proteins in Akt and MAPK signalling pathways in response 
to insulin or IGF-II were also measured in MDA-MB-231 cells and MDA-MB-231 cells with 
IGF-1RKD. The wild-type cells had low insulin sensitivity, which was indicated by the 
activation of Akt. The IGF-1RKD increased its insulin sensitivity. A similar result was found 
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in other studies (Zhang et al., 2007). One possible explanation is that the IR/IGF-1R hybrid 
preferentially transduces the IGF signals, but is barely activated by insulin (Slaaby, 2015; 
Slaaby et al., 2006; Zhang et al., 2007). We also found that IGF-II was more potent in 
activating the Akt than insulin, which indicates that insulin and IGF-II might induce different 
signalling pathways.  
These different receptor expression levels of the breast cancer cells could very likely affect 
their ligand responses. Both IGFs and insulin could promote MCF-7 proliferation, while 
MDA-MB-231 cells failed to proliferate in response to any ligand. The ligand responses of 
MCF-7 found in this study are consistent with other reports (Bartucci et al., 2001; Chappell et 
al., 2001; Lundby et al., 2015; ter Braak et al., 2014). Controversy still exists as to whether 
MDA-MB-231 cells proliferate in response to IGFs and insulin. Davison et al. reported that 
IGF-I stimulated MDA-MB-231proliferation (Davison et al., 2011), while many others 
reported that they did not respond to IGF-I (Bartucci et al., 2001; Belfiore et al., 1996; 
Costantino et al., 1993; Rose and Vona-Davis, 2012; Sasi et al., 2014). Other triple negative 
breast cancer cell lines have also been shown to not respond to IGF stimulation (Jackson and 
Yee, 1999; Sepplorenzino et al., 1994). IGF-1R expression level was originally thought to be 
the main reason for the lack of response. MDA-MB-157 cells that express approximately 5 
times more IGF-1R than MDA-MB-231 were reported to have higher growth rate in response 
to IGFs and insulin stimulation than MDA-MB-231 (Sciacca et al., 1999). However, IGF-1R 
overexpression in MDA-MB-231 cells still failed to restore a response to insulin or IGFs 
(Bartucci et al., 2001).   
With the successively selected breast cancer cell lines with IRKD or IGF-1RKD, the 
biological activities were assessed in order to investigate the roles of IR/IGF-1R in breast 
cancer cells. IR knock down inhibited the proliferation in a minor way, while IGF-1R knock 
down drastically inhibited the growth in MCF-7, whereby similar observations have been 
previously reported by others (Bartucci et al., 2001; Chappell et al., 2001). The down 
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regulation of IGF-1R expression on MCF-7 cells was also found to lead to a decrease in the 
ERα and GPER level, thus inducing multiple effects on the cells (De Marco et al., 2013; 
Mendoza et al., 2011). The IRKD in MDA-MB-231 cells increased cell proliferation, while 
the IGF-1RKD drastically inhibited the cell growth. Brierley et al. also reported that knock 
down of IR increased the viability of colon cancer cells (Brierley et al., 2010). The increased 
viability with IRKD cells could account for the increased cell proliferation. The reason for the 
increased proliferation rate of MDA-MB-231 with IRKD is most likely due to the disruption 
of IR/IGF-1R hybrid formation. The depletion of IR increased the IGF-1R homodimers. Here 
indicated the potency of IR/IGF-1R hybrid is lower than the IGF-1R homodimers.  
Even though IGFs and insulin did not stimulate proliferation of MDA-MB-231 cells, they did 
promote their migration. The IGF-1RKD in MDA-MB-231 increased their migration rate. 
This is in contrast to the report of Chen et al. who found that the depletion of IGF-1R in 
MDA-MB-231 cells inhibited migration in a transwell migration assay (Chen et al., 2012). 
The different assay methods could account for these differences. Because the would healing 
assay is to examine the ability of cell monolayer to close the wound, while the transwell 
migration assay is to examine the ability of single cell to migrate towards specific stimulant. 
The wound healing assay is also affected by the epithelial-mesenchymal transition (EMT) 
process. Clinical studies supporting the idea that IGF-IR level negatively correlates with 
metastasis potential in tumours, which explains the enhanced metastasis potential of IGF-
1RKD cells (Pezzino et al., 1996; Schnarr et al., 2000; Surmacz, 2000). However, there are 
also experiments indicating that the IGF-1R is positively correlated with the metastasis 
potential (Chen et al., 2012; Taliaferro-Smith et al., 2015). Further understanding is needed to 
elucidate the discrepancy in clinical study and lab experiment. 
The mRNA level of E-cadherin was also measured because it is a marker of the EMT process. 
The mRNA level of E-cadherin was not detected in MDA-MB-231 with and without knock 
down of IR/IGF-1R. This indicates that the MDA-MB-231 still had high metastasis potential 
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with/without IRKD and IGF-1RKD. This was contradictory to the study by Taliaferro-Smith 
et al., which demonstrated that the level of E-cadherin was increased after knock down of the 
IGF-1R (Taliaferro-Smith et al., 2015). Other study supported our results, which found the 
IGF-1RKD induced more aggressive phenotypes in MMTV-Wnt1 tumor cells (Rota et al., 
2014).  
In R-IR-A cells, both insulin and IGF-II were found to promote the proliferation (Frasca et al., 
1999; Sacco et al., 2009), which was also observed in MCF-7 cells with IGF-1RKD. In 
addition, the migration rate of R-IR-A was also increased with insulin and IGF-II stimulation 
(Denley et al., 2006; Denley et al., 2007). Furthermore, insulin and IGF-II had been verified 
to activate different signalling pathways and gene expression patterns in R-IR-A (Frasca et al., 
1999; Morcavallo et al., 2011; Pandini et al., 2003; Rajapaksha and Forbes, 2015; Sacco et al., 
2009). In this study, even though we discovered that insulin and IGF-II activated the Akt at a 
different potency in MDA-MB-231 cells with IGF-1RKD, the further phosphoproteomics 
study would provide more detailed downstream signalling. 
In conclusion, we investigated the role of IR/IGF-1R in different types of breast cancer cell 
lines. IGF-1R was more important for mediating proliferation signals in both MCF-7 and 
MDA-MB-231 cells. In fact, the disruption of IR increased the proliferation rate in MDA-
MB-231 cells. However, the depletion of IGF-1R will increase the migration rate of MDA-
MB-231 cells and didn’t promote the mesenchymal to epithelial transition (MET), which was 
indicated by an increase of E-cadherin mRNA expression. The IGF-1RKD in MDA-MB-231 
was found to increase the insulin sensitivity. However, insulin and IGF-II still had different 
potencies to activate the Akt signalling. Further studies would help to elucidate the 








The insulin receptor isoform A (IR-A) has attracted interest because of its ability to bind to 
insulin and IGF-II with high affinity (Frasca et al., 1999; Morcavallo et al., 2014a; Sciacca et 
al., 2002). The IR-A plays important roles in embryonic and foetal development (Belfiore et 
al., 2009). In adult life, IR-A is mainly expressed in tissues that are not related to glucose 
regulation by insulin, such as the brain and spleen (Frasca et al., 1999). In cancers of the 
breast, lung or colon, the insulin receptor isoform B (IR-B) mRNA expression decreases, 
thereby increasing the IR-A/IR-B ratio (Frasca et al., 1999; Huang et al., 2011). Total 
knockdown of the IR (both isoforms) inhibits prostate cancer proliferation, while IR-B 
specific knockdown has no effect (Heidegger et al., 2014; Heidegger et al., 2012) suggesting 
that IR-A signalling plays a role in cancer cell proliferation. In addition, deregulation of IGF-
II is found in many types of cancer (including breast, colon and prostate), and the IGF-II/IR-A 
autocrine loop is found to promote mitogenic signaling in these cancers (Morcavallo et al., 
2014a; Rota et al., 2014; Sciacca et al., 2002). Furthermore, the IGF-II/IR-A autocrine loop 
provides an alternative pathway that promotes cancer growth for cancer cells that are resistant 
to anti-IGF-1R drugs (Avnet et al., 2009; Rota et al., 2014; Sciacca et al., 2002).  
Several studies have used R-IR-A cells (IR-A overexpressing mouse fibroblast cells from 
IGF-1R knock out mice) as a model to investigate IR biological activities of the IR (Denley et 
al., 2006; Denley et al., 2007; Frasca et al., 1999; Morcavallo et al., 2012; Pandini et al., 
2003). R- IR-A cells proliferate in response to insulin and IGF-II (Frasca et al., 1999; 
Morcavallo et al., 2014b; Morcavallo et al., 2012; Morrione et al., 1997). Insulin and IGF-II 
were also able to promote survival and migration of R-IR-A cells (Denley et al., 2006; Denley 
et al., 2007). Higher IGF-II and IR-A expression also enhanced the β-catenin stability, and 
thus promoting more aggressive phenotypes (Rota et al., 2014). 
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Binding of different ligands to the IR-A can lead to different biological outcomes. Insulin 
stimulation via the IR-A leads primarily to metabolic effects (measured by glucose uptake), 
while IGF-II leads primarily to mitogenic effects (measured by [3H]thymidine DNA synthesis 
assays) (Frasca et al., 1999; Morrione et al., 1997). Notably, insulin can also promote 
mitogenic effects, an undesirable property for patients who rely on  long-term insulin 
treatments. Thus, many studies have been dedicated to optimise insulin analogues in order to 
minimise the mitogenic effects (Zaykov et al., 2016). For example, S597, an optimised 
peptidomimetic, has a similar binding affinity to the IR and a similar potency to lower blood 
glucose in vivo compared to insulin, but barely stimulates proliferation (Jensen et al., 2007; 
Rajapaksha and Forbes, 2015).  
These different biological activities were associated with selective changes in gene expression, 
differential recruitment and activation of intracellular substrates, receptor internalization and 
activation time (Jensen et al., 2008; Morcavallo et al., 2011; Morrione et al., 1997; Pandini et 
al., 2004; Pandini et al., 2003; Sciacca et al., 2002). Pandini et al (Pandini et al., 2003) found 
that insulin and IGF-II induced different gene expression patterns via IR-A. Among a total of 
6,000 functionally characterized murine genes and 6,000 expressed sequence tags (ESTs) 
measured in this experiment, a majority of the regulated genes (214 out of 259) were similarly 
regulated by insulin and IGF-II. This demonstrated that there is a high similarity between 
insulin and IGF-II signaling. A total of 45 transcripts (27 genes and 18 ESTs) were 
differentially regulated: 12 transcripts (7 genes and 5 ESTs) were regulated only by insulin: 6 
transcripts (3 genes and 3 ESTs) were regulated only by IGF-II and 27 transcripts (17 genes 
and 10 ESTs) were regulated by both ligands but IGF-II was more potent than insulin. This 
study provided one way of understanding the biological function of IR-A (Pandini et al., 
2003). Similarly, S597 and insulin also promoted different gene expression patterns via IR-A. 
Almost half of the differentially expressed genes are involved in growth and proliferation 
(Jensen et al., 2008). The gene expression data verifies that different ligands (insulin, IGF-II 
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or S597) induce different outcomes through the activation of IR-A. However, this approach 
does not reveal which signalling pathways are involved in promoting these different gene 
expression profiles. 
These different gene expression patterns most likely arise due to quantitative and temporal 
differences of docking protein activation (Denley et al., 2006; Denley et al., 2007).  Here in 
the Forbes laboratory, we have shown that Akt (Protein kinase B) and mTOR (mechanistic 
target of rapamycin) activation kinetics are different in R-IR-A cells in response to insulin, 
IGF-II or S597 stimulation (Figure 6.1). IGF-II also induces a higher p70S6K/Akt ratio than 
insulin (Sacco et al., 2009). This quantitative tyrosine phosphoproteomics approach revealed 
more details of insulin and IGF-II induced signaling pathways (Morcavallo et al., 2011) albeit 
the information is still limited. As such, a global phosphoproteomics approach would enable 
us to obtain a better understanding of the pathways involved. 
In addition, comparison of IGF-II/IR-A signalling between R-  cells (mouse fibroblast cells 
from IGF-1R knock out mice) cells and cancer cells showed differences in signalling 
(Morcavallo et al., 2011). For example, Eph4B activation by insulin or IGF-II was not 
consistent between R- and MCF-7 cells (Morcavallo et al., 2011). Differences in expression of 
adaptor or downstream protein groups in each cell type could explain this effect. This 
observation highlights the fact that it would be preferable to use a cancer cell line when 
seeking to understand IR-A signalling mechanisms in cancer.  
Therefore, we hypothesised that insulin/IR-A and IGF-II/IR-A signalling pathways are 
different in cancer cells. To test this hypothesis, we choose the triple negative MDA-MB-231 
breast cancer cell line as the study model. I aim to compare the insulin/IR-A and IGF-II/IR-A 
signalling pathways in the MDA-MB-231 breast cancer line (with IGF-1R depleted by 




Protein phosphorylation is an important process for signal transduction and regulation. 
However, the phosphorylation step can be transient and reversible. Thus, a fundamental 
understanding of the signalling processes requires the capture of low abundance 
phosphorylated peptides. Mass spectrometry provides a powerful tool to conduct a global 
analysis of the proteome. Recently, many methods were developed to enrich phosphopeptides 
for mass spectrometry detection. These methods include antibody-based pull down of 
phosphopeptides, metal ion-based affinity capture and ion exchange chromatography (von 
Stechow et al., 2015). Of these methods the titanium dioxide (TiO2) method has been well 
developed and has robustly enabled detection of high numbers of phosphopeptides (Baker et 
al., 2011; Humphrey et al., 2015; Larsen et al., 2005; Thingholm et al., 2006).  
Quantitative proteomics allows us to identify protein expression changes between two states 
eg. Disease and healthy. Stable isotope labelling of amino acids in cell culture (SILAC) is a 
metabolic labelling strategy that can incorporate stable isotope-labelled amino acids via a 
growth medium into the cellular proteome. It provides an easy and robust method for 
quantitative analysis (Geiger et al., 2011; Ong and Mann, 2006). Combining SILAC, 
phosphopeptide enrichment and mass spectrometry we can compare the phosphorylation 
network in different conditions quantitatively.  
Methodology 
Previously in our lab, Rajapaksha conducted a time course experiment to investigate Akt and 
MAPK phosphorylation using R-IR-A cells in response to insulin and IGF-II stimulation 
(Rajapaksha and Forbes, 2015). Here, it was found that at approximately 10 min, both Akt 
and MAPK were phosphorylated at near maximal levels (Figure 6.1). At this time point, 
tyrosine phosphorylation of the initial mediators of the pathway (such as IRS-1, IRS-2 and 
Shc) lead to increased serine phosphorylation of later mediators, such as Akt or mTOR 
substrates (Monetti et al., 2011). Based on that study we chose to use the following conditions 
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for this phosphoproteomics study: cells were serum starved in DMEM medium 
(supplemented with 1% BSA) overnight and stimulated with 10 nM insulin or 100 nM IGF-II 
for 10 minutes according to the protocol described in section 3.3.8. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 
Figure 6.1: Phosphorylation of Akt (pS473) (left) and MAPK (right) time course. Serum-
starved R-IR-A cells were treated with 10 or 100 nM insulin, IGF-II, qIGF-I, or S597 for 
10 min. Whole-cell lysates were immunoblotted for phosphorylated pAkt (pS473) (A) and 
pMAPK (B). Edited from Rajapaksha (Rajapaksha and Forbes, 2015). 
The initial quantitative phosphoprotomics workflow used in this study is shown in Figure 6.2. 
First, the cells were labelled with different isotope labelled amino acids. SILAC labelling was 
achieved by culturing cells for at least 3 passages in light, medium, or heavy isotope labelled 
amino acid containing media according to the protocol described in section 3.4.1. The 
incorporation efficiency was determined according to the protocol described in section 3.4.2 
and above 95% efficiency was achieved. 
Cells were lysed and mixed with 1:1:1 ratio. The mixture was then Trypsin and Lys-C 
digested. The combination of Trypsin and Lys-C increased the digestion efficiency because 
the Lys-C complements the low efficiency of trypsin toward Lysine residues (Giansanti et al., 
2016; Glatter et al., 2012). Phosphopeptides were enriched with TiO2 and analysed by LC–
MS/MS. Peptide identification and relative changes in the extent of phosphorylation were 
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determined using MaxQuant (Version 1.5.8.3). Statistical analysis to determine significant 
changes in phosphosites was performed using Perseus or Excel. Network analysis was 
performed with InnateDB database or NetworkAnalyst (Breuer et al., 2013; Xia et al., 2014; 
Xia et al., 2015).  





Figure 6.2: Workflow of quantitative phosphoproteomics. SILAC labeled cells were achieved 
by culturing cells for at least five doubling times in light, medium, or heavy isotope labeled 
amino acid containing media, serum starved in DMEM medium (supplemented with 1% BSA) 
overnight and stimulated with 10 nM insulin or 100 nM IGF-II for 10 minutes. Starved, 
insulin and IGF-II treated cells were lysed and mixed by ratio of 1:1:1. The mixture was then 
Trypsin and Lys-C digested. Phosphopeptides were enriched with TiO2 and analysed by LC–
MS/MS. Peptide identification and relative changes in the extent of phosphorylation were 
determined using MaxQuant (Version 1.5.8.3). Statistical analysis to determine significant 
changes in phosphosites was performed using Perseus or Excel. Network analysis was 
performed with InnateDB database or NetworkAnalyst. 
SILAC label with 2H4-Lys/13C6-Arg 
(medium) and 13C615N2-Lys/13C615N4-Arg 
(heavy)
Treat cells & mix lysates in 1:1:1 ratio
Lys-C and Tryptic digest 
(or Tryptic digest)
Phosphopeptide enrichment on TiO2 
beads
Detection of peptides by LC MS/MS
(LTQ Orbitrap XL mass spectrometer) 







6.2 Results and Discussion 
















Figure 6.3: Phosphopeptide enrichment flow chart. Prior to the phosphopeptide enrichment 
optimisation, enzyme digests from Filter Aided Sample preparation and acetone precipitated 
protein were compared (Green box). The phosphopeptide enrichment involved TiO2 binding, 
washing, elution and desalting (Red box) were also optimised. The steps optimised are 
marked in red. All the samples from each step were analysed by MALDI-TOF mass 
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Figure 6.4: Analysis of enzymatic digestion of MDA-MB-231 lysate by SDS-PAGE and mass spectrometry. A: 20 μg of each sample was subjected to SDS-
PAGE. “Lysate” refers to the MDA-MB-231 lysate in GdmCl lysis buffer. “After precipitation” refers to the MDA-MB-231 lysate in TFE buffer after 
acetone precipitation. “Digestion” is acetone-precipitated sample that has been trypsin digested. B and C show the MALDI-TOF mass spectrometry analysis 
of MDA-MB-231 lysates trypsin/Lys-C digested by different methods. B: 8ng of MDA-MB-231 lysate digested with FASP method. C: 8ng of acetone 













β-casein peptides mixed with HCCA (alpha-Cyano-4-hydroxycinnamic Acid) and DHB (2,5-
Dihydroxybenzoic acid) matrices (Condina et al., 2010). The	expected	m/z	values	from	
Trypsin	and	Lys-C	digestion	of	β-casein are	shown	in	Appendix	5.	The complete digestion 
of β-casein by Trypsin and Lys-C yields two phosphopeptides: peptides with singly 
phosphorylated amino acid (m/z at 2061) and peptides with four phosphorylated amino acids 
(m/z at 3121.2). The peptides with four phosphorylated serines of β-casein (m/z at 3121.2) 
was identified with DHB matrix (Figure 6.5-B), but not with HCCA matrix (Figure 6.5-A). 
However, the singly phosphorylated phosphopeptide (m/z at 2061) was not seen with either of 






Figure 6.5: The peptide detection of trypsin digested β-casein with MALDI-TOF mass spectrometry with different matrix:  HCCA matrix (A), DHB matrix 
(B).
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methodology	is	shown	in	Figure	6.3.	Before enrichment, only one phosphopeptide 
(m/z=3122) was detected and had low abundance (Figure 6.6-A). After the enrichment, TiO2 
bead elutes were directly detected with MALDI-TOF mass spectrometry (Figure 6.6-D). The 
other phosphopeptide (m/z=2062) was also enriched in binding buffer (30mg/ml DHB in 2% 
TFA, Figure 6.6-D), even though there were still phosphopeptides found in the flow through 
with this binding condition (Figure 6.6-B). No phosphopeptides were washed off from the 
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Figure 6.6: MALDI-TOF mass spectrometry of β-casein digestion (A), TiO2 beads flow through (B) and wash buffer (C) and phosphopeptide eluate (D). The 
two expected phosphopeptides are m/z=2061 and m/z=3122.
C. TiO2 beads washing 






D. TiO2 beads elute 


























against	the human SwissProt database (downloaded on September 2015), with a false-













Figure 6.7: HPLC-ESI-MS/MS of MDA-MB-231 eluted with 0.83% (elute1) and 2.5% 
NH4OH (elute2). A total of 200 μg of MDA-MB-231 lysate were used for enrichment, and 
phosphopeptides were eluted with 0.83% (elute1) followed by 2.5 % NH4OH (elute2). One 
twentieth of each elute was desalted with a Ziptip and subjected to HPLC-ESI-MS/MS 
analysis. (A) The percentage of phosphopeptides containing different numbers of phosphate 
groups and a comparison between elute1 and elute 2. (B) The numbers of specific and shared 
phosphopeptides identified from different elutes. The singly and multiply phosphorylated 
peptides are named as 1p, 2p, or 3p (some peptides were both singly and multiply 
phosphorylated and occur in more than one category). One experiment was conducted. Raw 
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In the experiment above, the binding buffer condition (30 mg/ml DHB in 2% TFA) had not 
been optimised. The phosphopeptides only accounted for about 62% of the total peptides 
identified (Figure 6.8), suggesting that there were non-specific peptides binding to the TiO2 
beads. Even though the phosphopeptide identification number increased dramatically from 
nearly no identification at all before enrichment, it still needed to be improved. A high 
percentage (~90%) of phosphopeptides was necessary to increase the number of 
phosphopeptides identified. In order to minimise the non-specific binding, two strategies were 
combined. Firstly, the TFA concentration in the binding buffer was increased from 2% to 6% 
in order to neutralise the negative charge of certain amino acids (i.e. aspartic acid and, 
glutamic acid). Secondly, the DHB concentration was increased from 30 mg/ml to 200 mg/ml. 
A higher concentration of DHB is crucial because DHB is very efficient in reducing the 
binding of non-phosphorylated peptides to TiO2 while retaining its high binding affinity for 
phosphorylated peptides (Larsen et al., 2005). By introducing both of these strategies the 





Figure 6.8: Proportion of phosphopeptides detected in Trypsin/Lys-C digested MDA-MB-231 
lysates identified with HPLC-MS/MS before and after TiO2 bead enrichment. Digested 
peptides were incubated with TiO2 beads in different buffers: 30 mg/ml DHB in 2% TFA or 
200 mg/ml DHB in 6% TFA. Peptides were desalted with a C18 ziptip before HPLC-MS/MS. 
A total of 729 unique phospeptides was identified after enrichment with the buffer condition 
of 30 mg/ml DHB in 2% TFA, while A total of 721 unique phospeptides was identified after 
enrichment with the buffer condition of 200 mg/ml DHB in 6% TFA. Due to the high cost of 


















































































Figure 6.9: Total number of unique phosphopeptides and proportion of unique 
phosphopeptides identified by HPLC-MS/MS. Phosphopeptides eluted from TiO2 beads were 
desalted with a C18 stagetip, SDB-RPS stagetip or C18 Ziptip according to the methods 
described in section 3.4.8.  Only one experiment was conducted. 
6.2.2 Quantitative phosphoproteomic analysis of the Insulin/IR-A and IGF-II/IR-A 
signalling pathways 
The detailed phosphorylation of MDA-MB-231 IGF-1RKD cells in response to insulin or 
IGF-II stimulation was investigated in the last part of this chapter.  
Three biological replicates (B1, B2, B3) were conducted to stimulate the MDA-MB-231 IGF-
1RKD cells and collected the protein samples. For each biological replicate, the 
phosphopeptides were enriched on TiO2 beads and gradually eluted twice with different 
concentrations of elution buffer (first elution or E1 with 0.85% NH4OH, and second elution or 
E2 with 2.5% NH4OH). In order to minimise the machine errors, each elute was analysed 







































total of 12 MS/MS runs were conducted with the above samples. Additionally, the sample of 
biological 1 was enriched in order to test the experimental conditions. Its first elute was 
analysed twice by HPLC-MS/MS, thus these two runs were named “B1_E1_R1_Old” and 
“B1_E1_R2_Old” separately. I also tried to test whether the flow through from the TiO2 
beads still contained phosphopeptides, thus the flow through from the TiO2 beads of 
biological replicate 2 (B2) was reapplied to a second lot of fresh beads and eluted once (E1, 
0.85% NH4OH). This sample is named as “B2_2nd binding. Thus, a total of 15 MS/MS runs 
were conducted (Table 6.1) and all of the raw files were analysed together using Maxquant 




File name Sample name Explanation 
1 B1_E1_R1_Old Biological 1_Elute1_Replicate 1_Old experiment 
2 B1_E1_R2_Old Biological 1_Elute1_Replicate 2_Old experiment 
3 B1_E1_R1 Biological 1_Elute1_Replicate 1 
4 B1_E1_R2 Biological 1_Elute1_Replicate 1 
5 B1_E2_R1 Biological 1_Elute2_Replicate 1 
6 B1_E2_R2 Biological 1_Elute2_Replicate 2 
7 B2_2nd binding Biological 2_Second binding 
8 B2_E1_R1 Biological 2_Elute1_Replicate 1 
9 B2_E1_R2 Biological 2_Elute1_Replicate 2 
10 B2_E2_R1 Biological 2_Elute2_Replicate 1 
11 B2_E2_R2 Biological 2_Elute2_Replicate 2 
12 B3_E1_R1 Biological 3_Elute1_Replicate 1 
13 B3_E1_R2 Biological 3_Elute1_Replicate 2 
14 B3_E2_R1 Biological 3_Elute2_Replicate 1 
15 B3_E2_R2 Biological 3_Elute2_Replicate 2 





6.2.2.1.1 MBR (Match Between Runs) 
The use of the match between runs (MBR) alignments during a Maxquant search enables 
optimal peptide identification and verification from different MS/MS runs. However, an 
inappropriate time window could cause many false discoveries. To determine whether this 
was occurring during my Maxquant search, the Maxquant output was evaluated with the 
program PTXQC (Bielow et al., 2016) according to the protocol described in section 3.4.11.  
MBR alignment is the first of two steps (1=align, 2=transfer) of the Match-between-runs. 
Following the PTXQC analysis, it was evident that the MaxQuant retention time (RT) shift 
window was small (most of the time less than 4 minutes) and the residual ΔRT (RT of 
identification in individual file compared to the reference Raw file) was small (most of the 
dots in the less than 0.7 minutes window) across all biological and technical replicates (Figure 
6.10). Overall, this result indicated the MBR-alignment set up in the method described in 





Figure 6.10: Match between run alignments. Here the first enrichment experiment of 
Biological 1_Elute1_Technical Replicate 1 (B1_E1_R1_Old) was used as a reference to 
assess the alignment between runs. The plots were based on real MS/MS identifications. 
Ideally, RTs of identical peptides should be equal (i.e. very small residual ΔRT) across Raw 
files after alignment. MaxQuant’s RT correction was shown in blue – it should be well within 
the alignment search window (20 min by default) set during MaxQuant configuration. The 
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resulting residual Δ RT after RT alignment (compared to a reference Raw file) was shown as 
green/red dots, respectively. One dot represents one peptide identification pair that exists in 
both the individual file and reference file. Every dot (peptide) outside an allowed residual 
ΔRT (0.7min by default) was coloured red. All others were coloured green. SC represents the 
score of RT alignment within a 0.7 minute window (range from 0-100%). File numbers are 




MBR Transfer is the second of the two steps (1=align, 2=transfer) during Match-between-
runs. After retention times have been calibrated, MaxQuant transfers peptideIDs from one 
Raw file to any other Raw file, assigning a peptide ID to unlabelled three-dimensional (3D) 
peaks (the mass (x-axis) and intensity (y-axis) of the peptide peaks in a mass spectrometry 
(MS) spectrum are assembled into 3D peaks over the m/z retention time (z-axis)  plane) thus 
increase the number of peptide identifications. However, a bad alignment of 3D peaks from 
the matched runs usually leads to a low identification value or large false positive 
identification value. Here, this quality control is to check the transfer of identifications across 
all the files. In our Maxquant search, almost all of the peptides (close to 100%) were 
identified once across all biological and technical replicates (Figure 6.11). This means that 





Figure 6.11: MBR Transfer: Last of two steps (1=align, 2=transfer) during Match-between-
runs. The first enrichment experiment of Biological 1_Elute1_Technical Replicate 1 
(B1_E1_R1_Old) was used as the reference. The same peptide should not be annotated twice 
(or more) at vastly different points in RT. This plot shows three columns: - left: the ‘genuine’ 
situation (represent no peptide identification was assigned to the unknown peptide spectra); - 
middle: looking only at transferred IDs (represent peptide identification was assigned to 
unknown peptide spectra); - right: combined picture (a mixture of left + middle, represent the 
identified peptide and the assigned peptide identification). If the peptide peak was identified 
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only once-either genuine OR a transferred ID, it is true identification (good, green). If the 
peptide peak was identified more than once, but their retention times are very close. We 
assume these identifications are also trustful (in group, also good). However, if the retention 
times of the identified peptide peak have huge differences, we assume this is false 




6.2.2.1.2 Biological and technical replicate correlation 
In the raw data, all of the phosphopeptide identifications were found in the first elute. So the 
correlation analysis among the first elutes (Figure 6.12) and second elute (Figure 6.13) was 
conducted separately. The peptide intensities from “medium” isotope labelled samples (M = 
insulin treated, 13C2H) were compared to the peptide intensity from “light” isotope labelled 
samples (L = untreated, 12C14N) and a ratio of intensities (M/L) was derived. This ratio 
represents the fold change in abundance of a particular phosphopeptide in response to insulin 
stimulation. Similarly, the peptide intensities from “heavy” isotope labelled samples (H = 
IGF-II treated, 13C15N) were compared to the peptide intensities from “light isotope labelled 
samples (L, untreated). The H/L ratio represents fold change in abundance of a particular 
phosphopeptide in response to IGF-II stimulation. The ratios of M/L and H/L from every 
individual peptide were studied. A mean correlation between measurements of 0.7-0.8 (Figure 
6.12 and 6.13) was seen, where >0.7 indicates a strong positive correlation. We, therefore, 




Figure 6.12: Multi-scatter plots represent pairwise comparisons of the normalized log 2 ratios (M/L and H/L, representing insulin/control and IGF-II/control, 
respectively) measured in each experiment of M/L (A) and H/L (B) from first elute. Biological replicate (B1 or B2), Technical replicate (R1 or R2). 
 





































































































Figure 6.13: Multi-scatter plots represent pairwise comparisons of the normalized log 2 ratios (M/L and H/L, representing insulin/control and IGF-II/control, 
respectively) measured in each experiment of M/L (A) and H/L (B) from second elute. Biological replicate (B1 or B2), Technical replicate (R1 or R2). 
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6.2.2.1.3 Scatter plot 
To ensure the data in each replicate experiment was normally distributed and properly 
normalized, the log2 transformed peptide ratios were viewed as histograms. The median value 
of each plot is close to zero (Figure 6.14), indicating very little variability between 
experiments. The small variances indicated equal mixing of light, medium and heavy isotope 





Figure 6.14: The distribution of normalized, log 2 transformed ratios of phosphopeptides enriched from insulin or IGF-II treated MDA-MB-231 cells 
compared to control cells (M/L or H/L) of the first elute (A) and seconde elute (B). The histograms of SILAC encoded peptide ratios measured in all 





6.2.2.2.1 Phosphoproteome profiling of insulin or IGF-II stimulated MDA-MB-231 IGF-
1RKD cells  
In the whole experiment, 3291 unique phosphosites were identified with a false discovery rate 
of less than 1%, including 2265 Class I phosphosites (the phosphorylation probability of this 
site is above 0.75). Approximately 1500 phosphosites were present in at least two different 
biological replicates (Appendix 6). A total of 307 sites (including 188 Class I phosphosites) 
have not previously been reported according to the largest phosphorylation site database, 
http://www.phosphosite.org (Figure 6.15). 
 
Figure 6.15: Summary of number of phosphosites identified and quantified in the dataset and 
those regulated in response to insulin (M/L) or IGF-II (H/L). Class I: Phosphorylation 
probability above 0.75 in MaxQuant search. Novel Phosphosites: not reported according to 
the phosphorylation site database, http://www.phosphosite.org analysed with Perseus 














A commonly used method for identifying differentially regulated proteins is to measure the 
fold change (FC) between two treatment groups. By this approach, proteins with an FC larger 
than a defined cut off (e.g. 1.5) are classified as differentially regulated. Since many of the 
phosphopeptides were only quantified in one biological experiment, we first extracted the 
phosphorylated peptides observed that exhibited more than 1.5 fold change (log2>0.58 or 
log2<-0.58) (Figure 6.16-A). Using this approach, a total of 118 sites were identified as only 
regulated with insulin stimulation (60 up regulated and 58 down regulated), while a total of 
192 sites were regulated with only IGF-II stimulation (56 up regulated and 136 down 
regulated). A total of 233 sites (84 up regulated and 149 down regulated) were regulated by 
both insulin and IGF-II stimulation. Interestingly, six sites were regulated by both insulin and 
IGF-II, but in opposite directions.  
As t-tests have been widely used to identify deviation from the mean, phosphosites with a 
minimum 1.5 fold change in at least two biological replicates combined with a p < 0.05 were 
considered significant for further analysis (Figure 6.16-B). A total of 38 sites were regulated 
only by insulin stimulation (18 up regulated and 20 down regulated), while a total of 64 sites 
were regulated by IGF-II stimulation (11 up regulated and 53 down regulated). A total of 80 
sites (42 up regulated and 38 down regulated) were regulated by both insulin and IGF-II 
stimulation. The regulated sites are shown in Appendix 7-12. An example of a raw spectrum 





Figure 6.16: Venn diagram showing the number of phosphopeptides regulated by Insulin 
and/or IGF-II with above 1.5 fold change (log2>0.58 or log2<-0.58). (A) Phosphosites with a 
minimum of 1.5 fold change. (B) Phosphosites with a minimum 1.5 fold change in at least 
























Using pathway analysis it was seen that the insulin receptor signalling pathway is enriched 
using the insulin regulated phosphosites list (Appendix 7, 8, 9, and 10). These analyses 
verified that MDA-MB-231 IGF-1RKD cells are responsive to insulin stimulation. 
Several studies have investigated the IR signalling pathway in response to insulin stimulation 
using a range of cell types (Humphrey et al., 2015; Humphrey et al., 2013; Morcavallo et al., 
2011; Parker et al., 2015). The fold changes of the phosphosites generated in this study were 
compared to these published data. It appears that the phosphosites regulated by insulin are 
highly conserved between human and mouse, as many were identified in this study and the 
study by Humphrey et al (Humphrey et al., 2015; Humphrey et al., 2013), which measured the 
phosphorylation states of a mouse adipocyte cell line and in mice in response to insulin 
stimulation (Humphrey et al., 2015; Humphrey et al., 2013). Commonly identified 
phosphosites include TBC1D4 (Akt substrate of 160 kDa, also known as AS160), which is 
activated (phosphorylation of site S591 increased) in response to insulin stimulation to 
promote glucose transport (Kramer et al., 2006; Peck et al., 2006), and PEA-15, which 
regulates the insulin-dependent Glut4 transportation (Condorelli et al., 1998).  
6.2.2.2.2 Comparative analysis of insulin and IGF-II phosphoproteomes 
The 38 insulin only regulated phosphosites are from a total of 30 unique proteins (Appendix 9 
and 10) and the 64 IGF-II-only regulated phosphosites are from a total of 43 unique proteins 
(Appendix 11 and 12). However, insulin and IGF-II regulate different phosphosites on 5 
common proteins (ARHGAP17, EGFR, DYNC1LI1, MAP1B, and SCRIB). Thus they were 
omitted for further analysis.  
To determine the biological processes that emerged as being enriched in insulin or IGF-II 
regulated phosphoproteomes, I performed Gene Ontology Biological Process (GOBP) 
analysis (Figure 6.17) against the entire human database using InnateDB and NetworkAnalyst 
online with the 25 insulin only regulated proteins or 38 IGF-II only regulated proteins (Breuer 
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et al., 2013; Xia et al., 2014; Xia et al., 2015). Biological process annotations with a p-value 
less than 0.05 were retained in this analysis. The predicted annotations were first ranked by 
the p-value. Then from this list the top significantly enriched GOBP annotations were 
identified (the first 10 annotations ranked by p-value, red box). Following this a further list of 
GOBP annotations were identified that were associated with >3 protein entries (Figure 6.17, 
green box). Enriched pathways included the dUTP metabolic process and glucosamine 
biosynthetic process, indicating the metabolic function of insulin. The other enriched 
processes (such as cell division) indicated the mitogenic function of insulin. Not surprisingly, 
IGF-II regulated the mitogenic pathways, indicated by many enriched processes, such as gene 
expression, mRNA processing, translational initiation, and many others. In addition, cell-cell 
signalling involved in cell-cell junction organization, positive regulation of microtubule motor 
activity, microtubule-based movement, Notch signalling pathway and transforming growth 
factor beta receptor signalling pathways were among the enriched processes under IGF-II 
only stimulated condition. Moreover, the phosphorylation sites on proteins involved in these 
processes were identified (Table 6.2). For example, phosphorylation of S125 and S131 of 
tight junction protein ZO-1 (TJP1) were specifically inhibited by IGF-II. The annotated 
MS/Ms spectrum identifying the phosphorylation of S125 and S131 of tight junction protein 
ZO-1 (TJP1) is shown in appendix 18. 
To characterize the specific signalling pathways that are modulated by insulin and IGF-II, a 
pathway enrichment analysis was conducted using the REACTOME database. The top 
significantly enriched pathways were determined (Figure 6.18). Similar to the GOBP result, 
the pathways related to mitogenic signalling were enriched when searching with proteins 
regulated by both insulin and IGF-II. Again, searching with proteins only regulated by IGF-II 
the Notch1 signalling pathway and TGF-β signalling pathways were enriched. These data 
indicated the IGF-II/IR-A signalling pathway might be involved in cell-cell connections and 
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communication. However, the functions of many of these phosphorylation sites are not 
understood yet (www.phosphosite.org).  
Figure 6.17: Gene Ontology Biological Process (GOBP) analysis of the insulin (above) and 
IGF-II (below) regulated proteins. The GOBP annotations with a p-value less than 0.05 are 
shown. Those GOBP terms with the smallest p-value shown in ascending order and 
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highlighted in red. The green area represents the GOBP terms identified as (not the first 10 
annotations ranked by p-value) but have large number of gene entries. Red area represents the 
top (the first 10 annotations ranked by p-value) annotations. Star represents the annotations 
related to the insulin or IGF-II functions in breast cancer cells.  
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Figure 6.18: Pathway analysis of the insulin (top) and IGF-II (bottom) regulated proteins 
against the REACTOME database. The annotations with a p-value less than 0.05 were 
retained. Star represents the annotations related to the insulin or IGF-II that would be relevant 
to functions in breast cancer cells.  
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Insulin and IGF-II, through the IR-A, activate overlapping signals. However, many studies 
show that they also have unique signalling cascades, even though these cascades are not fully 
defined yet (Frasca et al., 1999; Morcavallo et al., 2011; Rajapaksha and Forbes, 2015; Sacco 
et al., 2009). I thus addressed this gap in this chapter. 
In the first part of this chapter, MALDI-TOF MS and HPLC-MS/MS were used to optimise 
the phosphopeptide enrichment method. The DHB matrix was proved to be a better matrix for 
phosphopeptides detection with MDLDI-TOF MS. Higher concentrations of TFA and DHB 
used in TiO2 binding buffer were found to inhibit non-specific peptide binding to the TiO2 
beads. Additionally, C18 stagetips was also found to be a good method to clean up the TiO2 
elutes before HPLC-MS/MS. This optimisation provided a good platform for future work.  
In the second part of this chapter, the insulin/IR-A and IGF-II/IR-A signalling pathways were 
quantitatively compared by combining the optimised phosphopeptide enrichment method and 
SILAC labelling technology in MDA-MB-231 cells with IGF-1R depletion constructed in 
Chapter 5. Here, the MDA-MB-231 IGF-1RKD cells were SILAC labelled, stimulated with 
10 nM insulin or 100 nM IGF-II for 10 minutes with no stimulation as the control in order to 
study the intermediate signalling cascades. This study is the first quantitative 
phosphoproteomics study comparing the insulin/IR-A and IGF-II/IR-A cascades in breast 
cancer cells. This is also by far the largest dataset to show the differences between the 
insulin/IR-A and IGF-II/IR-A signalling pathways. The quantitative phosphoproteomics 
technique and statistical analysis provide accurate identification, large-scale quantification 
and reliable information. Approximately 3300 phosphosites were identified to be related to 
IR-A signalling cascades. The differentially phosphorylated proteins by insulin stimulation 
identified in this study were found to be highly consistent with previous studies with other 
cell lines or mouse models (Humphrey et al., 2015; Humphrey et al., 2013). This indicated a 
high conservation of the insulin signalling pathway. For example, TBC1D4 (Akt substrate of 
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160 kDa, also known as AS160) is activated (phosphorylation of site S591 increased) in 
response to insulin stimulation, which promotes glucose transport (Kramer et al., 2006; Peck 
et al., 2006). The GOBP analysis verified the role of insulin in energy homeostasis, indicated 
by the enriched glucosamine biosynthetic and dUTP metabolic processes. Phosphorylation of 
S243 of GFPT1 (Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1) was 
only increased in response to insulin stimulation, and not in response to IGF-II. Its 
phosphorylation regulates the hexosamine biosynthesis and surprisingly promotes 
angiogenesis. It is an AMP-activated protein kinase (AMPK) substrate (Li et al., 2007; 
Zibrova et al., 2017). The GOBP and pathway analysis also confirmed the mitogenic function 
of both insulin and IGF-II, because many biological processes and pathway enriched, such as 
gene expression, mRNA processing and cell division, induce mitogenic outcome. For 
example, HMGA1 is already confirmed to be an insulin receptor signalling targeted nuclear 
factor, and its phosphorylation regulates the gene transcription (Chiefari et al., 2012). The 
phosphorylation of S44 of HMGA1 (High mobility group protein HMG-I/HMG-Y) was 
increased in response to insulin stimulation. Many unique proteins that are regulated only by 
IGF-II indicated its role in cell-cell interaction and migration, shown by the GOBP processes 
such as cell-cell signalling involved in cell-cell junction organization, positive regulation of 
microtubule motor activity. Phosphorylation of S168 of tight junction protein ZO-1 (TJP1) 
disrupts the cell- cell contact ion and promotes cell migration (Hamalisto et al., 2013). Here, 
the phosphorylation of S125 and S131 of TJP1 was decreased by the IGF-II stimulation. 
Further experiments are necessary to verify whether the phosphorylation of S125 and S131 
has similar or different roles to phosphorylation of S168 in regulating TJP1 function. 
Microtubule cross-linking factor 1 (SOGA2, MTCL1) is also found to involve in microtubule 
dynamics regulation (Sato et al., 2014), however, the molecular mechanism and its relation to 
IGF-II signalling is unknown. Notably, the Notch and TGF-β (Transforming growth factor 
beta) signalling pathways were enriched with the IGF-II regulated phosphoproteins. These 
	
	 174	
two pathways play important roles in EMT process and are indicated to be the reasons of 
failure of anti-IGF-1R drugs in cancers (Li et al., 2017; Rota and Wood, 2015). Furthermore, 
the inhibition of IGF-1R is found to amplify the Notch signalling in triple negative breast 
cancer cells through increased IR-A signalling, thus induce the tumour development (Rota 
and Wood, 2015). The findings from this study will help us better understand IR-A signalling 
in a large picture. Hopefully, these identified proteins can be candidate drug targets for anti-






The involvement of IR-A in insulin resistance and cancer has drawn much attention. IR-A is 
able to bind insulin and IGF-II with similar affinities and transduce their metabolic and 
mitogenic biological activities. Studies have shown that insulin and IGF-II induce different 
signalling pathways through IR-A (Frasca et al., 1999; Morcavallo et al., 2011; Sacco et al., 
2009). More importantly, the IGF-II/IR-A signalling pathway provides an alternative pathway 
for anti-IGF-1R drug resistant cancer growth (Frasca et al., 1999; Sciacca et al., 2002). The 
main purpose of this thesis is to identify the signalling proteins involved in IGF-II/IR-A 
signalling in breast cancer cells. These may provide novel drug targets. Additionally, in the 
process of characterizing IR phosphorylation kinetics our lab discovered that Thr1148 
phosphorylation was only detected on peptides lacking phosphorylation of neighbouring 
Tyr1146, Tyr1150 and Tyr 1151 residues (phosphorylation of these three Tyr are necessary for IR 
activation). We hypothesised that the Thr1148 phosphorylation affect the IR activation, thus a 
study was conducted to evaluate its function of Thr1148 phosphorylation in IR activation. The 
above information and present studies in this field were introduced in Chapter 1 and the 
materials and methods used in this thesis were elaborated in Chapter 2 and 3. 
As described earlier, the phosphorylation of the activation loop is necessary for the IR 
activation (Cabail et al., 2015). The ligand binding induces the ectodomain structural change 
and thus induces intracellular domain structural change (Ward et al., 2013). The structure of 
the inactivated state and activated states of the tyrosine kinase domain have been extensively 
studied (Cabail et al., 2015; Hubbard, 1997; Hubbard et al., 1994). In the inactivated state, the 
activation loop inhibits the access of substrates to the catalytic site thus holding the IR in an 
inactivate state (Hubbard et al., 1994). After ligand binding, the Tyr1150 is phosphorylated first, 
followed by the phosphorylation of the other two tyrosines: Tyr1146, and Tyr 1151. When these 
three Tyr are phosphorylated, they provide docking sites for the downstream signalling 
molecules and the structural change induces the phosphorylation of the other sites in the IR 
(Hubbard, 1997). It has only been recently recognised that Thr1148, which lies in between the 
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three Tyr1146, Tyr1150 and Tyr 1151 on the activation loop, is phosphorylated. In chapter 4, the 
role of Thr1148 phosphorylation in IR-A was investigated. In this chapter, recombinant wild 
type and mutants with Thr1148 mutated to Ala or Asp were generated and overexpressed in R- 
cells. The Thr1148Ala and Thr1148Asp mutants were introduced to either prevent 
phosphorylation or mimic a constitutively phosphorylated state at that residue, respectively. 
Both Thr1148Ala and Thr1148Asp were found to be significantly less responsive to insulin than 
the wild type IR-A. This data indicates that phosphorylation of Thr1148 is related to IR 
activation. At the same time, Petersen et al also investigated the role of Thr1160 in IR-B (which 
equals Thr1148 in IR-A) by mutate the Thr to Ala and Glu respectively (Petersen et al., 2016). 
Petersen et al also found that Thr1148Glu inhibited the IR activation (Petersen et al., 2016). 
However, Petersen et al found that Thr1148Ala increased the IR activation, which measured by 
the phosphorylated Tyr1162 (equals to Tyr1150 in IR-A) (Petersen et al., 2016). As I used the 
phosphorylated Tyr1146, 1150, 1151 to measure the activated IR, I believe we measured the different 
stages of IR activation. As shown previously, the phosphorylation of Tyr1146, 1150, 1151 are 
conducted sequentially (Hubbard, 1997). Petersen et al showed the Thr1148Ala mutation did 
not affect the first step: phosphorylation of Tyr1150, while my data showed the following step, 
phosphorylations of Tyr1146 and Tyr1151, is inhibited.  
Recent evidence has demonstrated mechanisms that regulate Thr1148 phosphorylation. In vitro 
studies by Petersen et al and Marin et al provide in vitro evidence that phospholipase C 
epsilon (PKCε) and protein kinase CK2 can act as kinases at Thr1148 (Marin et al., 1996; 
Petersen et al., 2016). Also, when present on a synthetic peptide the phosphorylation of three 
tyrosine sites Tyr1146,1150,1151, especially that of Tyr1151, was found to be necessary for the 
phosphorylation of Thr1148 by CK2 (Marin et al., 1996). Whether this is the case on the intact 
receptor has not been investigated, but these experiments indicate that Thr1148 phosphorylation 
may be required for for IR inactivation.  
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Phosphatases (T-Cell Protein Tyrosine Phosphatase) and adaptor proteins (Growth factor 
receptor-bound protein 7,10,14) are known to dephosphorylate the phosphorylated Tyr1146, 
Tyr1150, Tyr1151 (Goenaga et al., 2009; Goldstein et al., 2000; Han et al., 2001; Stein et al., 2001; 
Walchli et al., 2000). The introduction of Ala and Asp by the Thr1148Ala and Thr1148Asp 
mutants may induce the conformational change in the activation loop and negative charged 
acidic side chain of Asp by Thr1148Asp mutant might also induce the electrostatic repulsion. 
To explain the differences between the data generated in this thesis, which suggests Thr1148 is 
sensitive to mutation and inhibits IR activation, and that of Petersen showing that mutation of 
Thr1148 to Ala promotes IR activation will require further investigation. A kinetic study using 
antibodies directed to both Tyr1146, Tyr1150, and Tyr1151 and to Tyr1146 alone would be the next 
step. With the wild-type IR and the mutants constructed in this study, an IR activation time 
course could be conducted in response to insulin. In addition, the antibodies that target the 
phosphorylated Tyr1150 alone, or Tyr1146, Tyr1150, and Tyr1151 will be used to measure the 
phosphorylation kinetics. We would expect that the Thr1148 phosphorylation might affect the 
Tyr1146, Tyr1150, and Tyr1151 phosphorlyation at a different rate than Tyr1146phosphorylation. 
Another experiment would be to investigate the potential phosphatases from the 
immunoprecipitated IR with antibody that target the phosphorylated Thr1148.  Structural 
studies of the IR kinase domain with Cryo-electron microscopy are more promising to 
investigate the intermediate steps of IR activation and how the Thr1148 affect the IR 
phosphorylation. These experiments will provide us more understanding of IR activation.  
In chapter 5, we assessed the roles of IR and IGF-1R in breast cancer cells. Firstly, I verified 
that insulin and IGF-II activates the Akt signalling pathway through IR in MDA-MB-231 
cells. In wild type cells expressing equal levels of IGF-1R and IR the cells responded poorly 
to 10 min stimulation of 10 nM insulin. This indicated that IR/IGF-1R hybrids are barely able 
to transduce insulin signalling. The existence of IR/IGF-1R hybrids decreases the insulin 
sensitivity, while they have no effect on IGF-II sensitivity of MDA-MB-231 cells. This is 
	
	 179	
likely because the IGF-II can act via three kinds of receptors. A similar result was found in 
other studies (Zhang et al., 2007). One possible explanation is that the IR/IGF-1R hybrids 
preferentially transduce IGF signals, but are barely activated by insulin (Slaaby, 2015; Slaaby 
et al., 2006; Zhang et al., 2007). As the expression levels of IR and IGF-1R are similar in 
MDA-MB-231 cells, IR/IGF-1R probably is the main isoforms thus inhibit the insulin 
signalling. We can learn from this study that silencing the expression of one protein can 
increase signalling of other pathways, a fact that should be carefully considered if taking this 
approach to target signalling pathways for therapeutic purposes. 
There is evidence to suggest that hybrid receptor formation is stochastic (Bailyes et al., 1997; 
Frattali et al., 1992a). However, in some cancer tissues, some unknown factors affect the 
hybrid formation and the proportion of IR in hybrids is not random  (Pandini et al., 1999). In 
the future, a systematic study on the expression levels of receptor homodimers and 
heterodimers in different tissues, normal tissues and cancer tissues should be conducted. The 
biological significance of IR/IGF-1R and the reason that they are less sensitive to insulin is 
poorly understood. A study to measure the IR/IGF-1R level in insulin resistant patients should 
be measured, even though there are studies shown the IR-A is upregulated in cancers (Frasca 
et al., 1999; Vella et al., 2002); this will give us a new information in order to design more 
effective insulin analogues. From a structural perspective, the IR/IGF-1R does not affect the 
binding of IGF to the ectodomain, while the affinity for insulin is decreased. A structural 
study to compare the differences between insulin and IGF bound to a hybrid receptor, while 
technically extremely challenging, would be helpful for development of drugs that inhibit the 
IR/IGF-1R transduced signals in cancer cells. 
I also found that MDA-MB-231 and MCF-7 have different biological responses to ligand 
stimulation in both cell lines, IGF-1R is necessary for cell proliferation. Both IGFs and insulin 
promoted MCF-7 proliferation. IR knock down had a minimal affect on proliferation, while 
IGF-1R knock down drastically inhibited growth. This is the same as other studies (Bartucci 
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et al., 2001; Chappell et al., 2001; Saxena et al., 2008). In contrast, MDA-MB-231 did not 
respond to either ligand in this study. However, the IRKD increased cell proliferation, while 
the IGF-1R knock down drastically inhibited MDA-MB-231 cell growth. Low expression 
level of IGF-1R was thought to be the main reason for the lack of response to IGF in MDA-
MB-231 cells (Sciacca et al., 1999). However, MDA-MB-231 with IGF-1R overexpression 
still failed to respond to ligands (Bartucci et al., 2001). MCF-7 is a well known cancer cell 
with low metastatic potential. Neither IR KD nor IGF-1R KD changed its migration response 
to ligands and therefore its likely metastatic potential in vivo. In contrast, MDA-MB-231 cells 
have high metastatic potential, and the IGF-1RKD in MDA-MB-231 increased the MDA-
MB-231 migration rate in this study. This result also indicates that silencing the expression of 
IGF-1R in cancer may not be wise without perhaps also targeting the IR at the same time.  
Since the epithelial mesenchymal transition (EMT) usually precedes migration and a feature 
of EMT is the decrease in expression of E-cadherin, theoretically we could propose that the 
expression level of E-cadherin will be lower in IGF-1RKD cells compared to the MDA-MB-
231 wild-type. Taliaferro-Smith et al., surprisingly reported that MDA-MB-231 cells express 
E-cadherin protein and this occurs after knock down of the IGF-1R (Taliaferro-Smith et al., 
2015). Consistent with the metastatic phenotype of MDA-MB-231 cells I  did not detect any 
E-cadherin in wild-type MDA-MB-231 or IRKD or IGF-1RKD using PCR method. This 
result also correlates with the migration results. Therefore, the molecular mechanisms 
responsible for the change in migration rate with IGF-1RKD remain unknown. For this reason 
I decided to perform a detailed signalling pathway analysis as outlined in Chapter 6.  
In the first part of chapter 6, MALDI-TOF and HPLC-MS/MS were used to optimise the 
phosphopeptides enrichment method, which provides a good starting point for a later 
molecular mechanism study. In the second part of chapter 6, insulin/IR-A and IGF-II/IR-A 
signalling pathways were compared with phosphoproteomics in MDA-MB-231 breast cancer 
cell with IGF-1RKD. This study is the first quantitative phosphoproteomics study comparing 
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the insulin/IR-A and IGF-II/IR-A signalling cascades in cancer. The phosphosites with a 
minimum 1.5 fold change in at least two biological replicates combined with a p<0.05 were 
considered to be significantly regulated. I found 188 novel sites in IR downstream signalling 
that have not been reported on the largest phosphorylation site database 
(http://www.phosphosite.org). There were 38 insulin only regulated sites, 64 IGF-II only 
regulated sites, and 80 insulin and IGF-II regulated sites. 
The proteins identified as being differentially regulated by insulin or IGF-II were subjected to 
Gene Ontology and KEGG pathway analysis, which further confirmed the insulin/IR-A and 
IGF-II/IR-A signalling pathways induce different biological outcomes. The IGF-II/IR-A 
stimulated signalling pathways related to cell migration, and included cell-cell signalling 
pathways involving cell-cell junction organisation, microtubule based movement and Notch 
signalling. This data supports the finding in chapter 5 that the IGF-1R KD increases the 
MDA-MB-231 migration ability.  
A more detailed analysis of individual phosphosites revealed interesting sites regulated 
specifically by IGF-II. Notably, Ser185 of PCBP2 (hnRNP E2) is preferentially 
phosphorylated in response to IGF-II compared to insulin. PCBP2 is known to play a role in 
cancer cell growth. The phosphorylation of this site by ERK1/2 is necessary to maintain its 
stability in BCR/ABL-expressing myeloid precursors, and causes the arrest of differentiation- 
a feature of chronic myelogenous leukemia cells (Chang et al., 2007; Perrotti et al., 2002). 
Additionally, high levels of PCBP2 predicts poor overall and disease-free survival of gastric 
carcinoma and it promotes gastric carcinoma (Hu et al., 2014). Further experiments are 
needed to understand the relation of PCBP2 with IGF-II/IR-A signalling pathway. Several 
other phosphosites were preferentially phosphorylated or dephosphorylated in response to 
IGF-II including PGRMC1 (known to be overexpressed and regulated by phosphorylation 
(Neubauer et al., 2008; Neubauer et al., 2013) and CCAR1 (Cell division cycle and apoptosis 
regulator 1, regulates apoptosis (Muthu et al., 2014; Muthu et al., 2015). These and the 
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PCBP2 example listed above are primary candidates (selected as being significantly regulated 
by IGF-II, fold change >1.5 and p<0.05) among others that need now to be verified. Possible 
methods of verification of the MS/MS data include direct detection using antibodies that 
target the specific phosphorylated proteins. However, this method is limited by the lack of 
availability of specific antibodies. Alternatively, multiple reaction monitoring (MRM) mass 
spectrometry would be an ideal method to validate the data from this study. Following this 
knock down experiments would also allow an in vivo confirmation of the function of specific 
phosphosites in candidate signalling proteins. Ultimately inhibitors of these validated IGF-
II/IR-A signalling specific targets could be developed and tested in animal models as potential 
breast cancer therapies. 
At present, the IR/IGF-1R targeting strategies have not been successful for cancer treatment 
in clinical trials, especially phase III trials. Co-targeting several hallmarks of cancer is likely 
to be more effective. For example, NT157, which targets both IGF-1R and STAT3 (a protein 
in inflammation signalling pathway), has shown promising effect (Sanchez-Lopez et al., 
2016). Due to its capabilities of decreasing insulin resistance, metformin has become a hot 
research topic again, inhibiting cancer growth and inducing longevity. Combination therapy 
using this drug and IR/IGF-1R signalling inhibitors could be a more effective approach than 
using IR/IGF-1R signalling inhibitors alone. Also, ultimately it would be good to conduct in 
vivo experiments to test the efficacy of targeting both the IGF-1R and the novel IGF-II/IR-A 
signalling inhibitors developed against targets identified in this study. Another possible reason 
for the failure of the IR/IGF-1R targeting strategies so far is that cancer patients in these trials 
might not be have had tumours dependent on IR/IGF-1R signalling. At the time of the clinical 
trials there were no specific, validated biomarkers. In general, an adequate biomarker should 
help to identify the tumours that are sensitive to a specific therapy. As such investigation 
should be continued to define specific IR/IGF-1R signalling biomarkers that would be 
invaluable in future clinical trials with mono and combined therapy approaches. Some of the 
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specific IGF-II/IR-A signalling pathway components identified in this study could be 
investigated as biomarkers in the future. 
In summary, I have shown that Thr1148 mutation inhibits IR activation. I verified IGF-1R is 
necessary for proliferation in both MCF-7 and MDA-MB-231 cells. I found the silence of 
IGF-1R expression increases the insulin sensitivity of MDA-MB-231 cells and increases its 
migration ability. In the quantitative phosphoproteomics study comparing the insulin/IR-A 
and IGF-II/IR-A signalling pathways in MDA-MB-231 cells with IGF-1R silenced. Proteins 
related to migration are regulated by IGF-II stimulation. The findings in this thesis provide 






Abe, H., Yamada, N., Kamata, K., Kuwaki, T., Shimada, M., Osuga, J., Shionoiri, F., 
Yahagi, N., Kadowaki, T., Tamemoto, H., et al. (1998). Hypertension, hypertriglyceridemia, 
and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor 
substrate-1. J Clin Invest 101, 1784-1788. 
Adams, T.E., Epa, V.C., Garrett, T.P., and Ward, C.W. (2000). Structure and function of 
the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57, 1050-1093. 
Ahmed, Z., Smith, B.J., Kotani, K., Wilden, P., and Pillay, T.S. (1999). APS, an adapter 
protein with a PH and SH2 domain, is a substrate for the insulin receptor kinase. Biochem J 
341 ( Pt 3), 665-668. 
Alvino, C.L., McNeil, K.A., Ong, S.C., Delaine, C., Booker, G.W., Wallace, J.C., 
Whittaker, J., and Forbes, B.E. (2009). A novel approach to identify two distinct receptor 
binding surfaces of insulin-like growth factor II. The Journal of biological chemistry 284, 
7656-7664. 
Avnet, S., Sciacca, L., Salerno, M., Gancitano, G., Cassarino, M.F., Longhi, A., Zakikhani, 
M., Carboni, J.M., Gottardis, M., Giunti, A., et al. (2009). Insulin receptor isoform A and 
insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer 
research 69, 2443-2452. 
Bailyes, E.M., Nave, B.T., Soos, M.A., Orr, S.R., Hayward, A.C., and Siddle, K. (1997). 
Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: 
quantification of individual receptor species by selective immunoprecipitation and 
immunoblotting. Biochem J 327 ( Pt 1), 209-215. 
Baker, J., Liu, J.P., Robertson, E.J., and Efstratiadis, A. (1993). Role of insulin-like growth 
factors in embryonic and postnatal growth. Cell 75, 73-82. 
Baker, M.A., Smith, N.D., Hetherington, L., Pelzing, M., Condina, M.R., and Aitken, R.J. 
(2011). Use of titanium dioxide to find phosphopeptide and total protein changes during 
epididymal sperm maturation. Journal of proteome research 10, 1004-1017. 
Bartucci, M., Morelli, C., Mauro, L., Ando, S., and Surmacz, E. (2001). Differential 
insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive 
MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer research 61, 6747-6754. 
Baserga, R. (2013). The decline and fall of the IGF-I receptor. J Cell Physiol 228, 675-679. 
Beardsall, K., Diderholm, B.M., and Dunger, D.B. (2008). Insulin and carbohydrate 
metabolism. Best practice & research Clinical endocrinology & metabolism 22, 41-55. 
Beckwith, H., and Yee, D. (2015). Minireview: Were the IGF Signaling Inhibitors All Bad? 
Molecular endocrinology 29, 1549-1557. 
Belfiore, A., Costantino, A., Frasca, F., Pandini, G., Mineo, R., Vigneri, P., Maddux, B., 
Goldfine, I.D., and Vigneri, R. (1996). Overexpression of membrane glycoprotein PC-1 in 
MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine 
kinase activity. Molecular endocrinology 10, 1318-1326. 
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., and Vigneri, R. (2009). Insulin receptor 
isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and 
disease. Endocr Rev 30, 586-623. 
Belfiore, A., and Malaguarnera, R. (2011). Insulin receptor and cancer. Endocrine-related 
cancer 18, R125-147. 
Bendell, J.C., Jones, S.F., Hart, L., Spigel, D.R., Lane, C.M., Earwood, C., Infante, J.R., 
Barton, J., and Burris, H.A. (2015). A phase Ib study of linsitinib (OSI-906), a dual inhibitor 
	
	 186	
of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients 
with refractory metastatic colorectal cancer. Invest New Drugs 33, 187-193. 
Benyoucef, S., Surinya, K.H., Hadaschik, D., and Siddle, K. (2007). Characterization of 
insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and 
the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem 
J 403, 603-613. 
Bersten, D.C., Sullivan, A.E., Li, D., Bhakti, V., Bent, S.J., and Whitelaw, M.L. (2015). 
Inducible and reversible lentiviral and Recombination Mediated Cassette Exchange (RMCE) 
systems for controlling gene expression. PLoS One 10, e0116373. 
Bielow, C., Mastrobuoni, G., and Kempa, S. (2016). Proteomics Quality Control: Quality 
Control Software for MaxQuant Results. Journal of proteome research 15, 777-787. 
Bodzin, A.S., Wei, Z., Hurtt, R., Gu, T., and Doria, C. (2012). Gefitinib resistance in HCC 
mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, 
and enhancement of IGF-1R nuclear translocation. J Cell Physiol 227, 2947-2952. 
Boes, M., Booth, B.A., Sandra, A., Dake, B.L., Bergold, A., and Bar, R.S. (1992). Insulin-
like growth factor binding protein (IGFBP)4 accounts for the connective tissue distribution of 
endothelial cell IGFBPs perfused through the isolated heart. Endocrinology 131, 327-330. 
Braiman, L., Alt, A., Kuroki, T., Ohba, M., Bak, A., Tennenbaum, T., and Sampson, S.R. 
(2001). Insulin induces specific interaction between insulin receptor and protein kinase C 
delta in primary cultured skeletal muscle. Molecular endocrinology 15, 565-574. 
Breuer, K., Foroushani, A.K., Laird, M.R., Chen, C., Sribnaia, A., Lo, R., Winsor, G.L., 
Hancock, R.E., Brinkman, F.S., and Lynn, D.J. (2013). InnateDB: systems biology of innate 
immunity and beyond--recent updates and continuing curation. Nucleic Acids Res 41, D1228-
1233. 
Brierley, G.V., Macaulay, S.L., Forbes, B.E., Wallace, J.C., Cosgrove, L.J., and Macaulay, 
V.M. (2010). Silencing of the insulin receptor isoform A favors formation of type 1 insulin-
like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR 
activation and viability of human colon carcinoma cells. Endocrinology 151, 1418-1427. 
Burnier, J.V., Wang, N., Michel, R.P., Hassanain, M., Li, S., Lu, Y., Metrakos, P., Antecka, 
E., Burnier, M.N., Ponton, A., et al. (2011). Type IV collagen-initiated signals provide 
survival and growth cues required for liver metastasis. Oncogene 30, 3766-3783. 
Cabail, M.Z., Li, S., Lemmon, E., Bowen, M.E., Hubbard, S.R., and Miller, W.T. (2015). 
The insulin and IGF1 receptor kinase domains are functional dimers in the activated state. Nat 
Commun 6, 6406. 
Chang, J.S., Santhanam, R., Trotta, R., Neviani, P., Eiring, A.M., Briercheck, E., Ronchetti, 
M., Roy, D.C., Calabretta, B., Caligiuri, M.A., et al. (2007). High levels of the BCR/ABL 
oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-
driven myeloid differentiation. Blood 110, 994-1003. 
Chao, W., and D'Amore, P.A. (2008). IGF2: epigenetic regulation and role in development 
and disease. Cytokine & growth factor reviews 19, 111-120. 
Chappell, J., Leitner, J.W., Solomon, S., Golovchenko, I., Goalstone, M.L., and Draznin, B. 
(2001). Effect of insulin on cell cycle progression in MCF-7 breast cancer cells - Direct and 
potentiating influence. Journal of Biological Chemistry 276, 38023-38028. 
Chen, Y., Zhu, C., Peng, Z., Dai, Y., and Gu, Y. (2012). Lentivirus-mediated short-hairpin 




Chernicky, C.L., Tan, H., Yi, L., Loret de Mola, J.R., and Ilan, J. (2002). Treatment of 
murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor 
decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and 
reduces tumorigenesis in vivo. Mol Pathol 55, 102-109. 
Cheung, L.W., Mak, A.S., Cheung, A.N., Ngan, H.Y., Leung, P.C., and Wong, A.S. (2011). 
P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic 
signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin. Oncogene 
30, 2964-2974. 
Chiefari, E., Nevolo, M.T., Arcidiacono, B., Maurizio, E., Nocera, A., Iiritano, S., Sgarra, 
R., Possidente, K., Palmieri, C., Paonessa, F., et al. (2012). HMGA1 is a novel downstream 
nuclear target of the insulin receptor signaling pathway. Scientific reports 2, 251. 
Condina, M.R., Gustafsson, J.O., Klingler-Hoffmann, M., Bagley, C.J., McColl, S.R., and 
Hoffmann, P. (2010). EZYprep LC-coupled MALDI-TOF/TOF MS: an improved matrix 
spray application for phosphopeptide characterisation. Proteomics 10, 2516-2530. 
Condorelli, G., Vigliotta, G., Iavarone, C., Caruso, M., Tocchetti, C.G., Andreozzi, F., 
Cafieri, A., Tecce, M.F., Formisano, P., Beguinot, L., et al. (1998). PED/PEA-15 gene 
controls glucose transport and is overexpressed in type 2 diabetes mellitus. The EMBO 
journal 17, 3858-3866. 
Constancia, M., Hemberger, M., Hughes, J., Dean, W., Ferguson-Smith, A., Fundele, R., 
Stewart, F., Kelsey, G., Fowden, A., Sibley, C., et al. (2002). Placental-specific IGF-II is a 
major modulator of placental and fetal growth. Nature 417, 945-948. 
Costantino, A., Milazzo, G., Giorgino, F., Russo, P., Goldfine, I.D., Vigneri, R., and 
Belfiore, A. (1993). Insulin-resistant MDA-MB231 human breast cancer cells contain a 
tyrosine kinase inhibiting activity. Molecular endocrinology 7, 1667-1676. 
Crowell, A.M., Wall, M.J., and Doucette, A.A. (2013). Maximizing recovery of water-
soluble proteins through acetone precipitation. Analytica chimica acta 796, 48-54. 
Cullen, B.R. (2004). Transcription and processing of human microRNA precursors. Mol 
Cell 16, 861-865. 
Davison, Z., de Blacquiere, G.E., Westley, B.R., and May, F.E. (2011). Insulin-like growth 
factor-dependent proliferation and survival of triple-negative breast cancer cells: implications 
for therapy. Neoplasia 13, 504-515. 
Dawson, S.J., Rueda, O.M., Aparicio, S., and Caldas, C. (2013). A new genome-driven 
integrated classification of breast cancer and its implications. The EMBO journal 32, 617-628. 
De Marco, P., Bartella, V., Vivacqua, A., Lappano, R., Santolla, M.F., Morcavallo, A., 
Pezzi, V., Belfiore, A., and Maggiolini, M. (2013). Insulin-like growth factor-I regulates 
GPER expression and function in cancer cells. Oncogene 32, 678-688. 
De Meyts, P. (2004). Insulin and its receptor: structure, function and evolution. BioEssays : 
news and reviews in molecular, cellular and developmental biology 26, 1351-1362. 
De Meyts, P., and Whittaker, J. (2002). Structural biology of insulin and IGF1 receptors: 
implications for drug design. Nat Rev Drug Discov 1, 769-783. 
Denley, A., Bonython, E.R., Booker, G.W., Cosgrove, L.J., Forbes, B.E., Ward, C.W., and 
Wallace, J.C. (2004). Structural determinants for high-affinity binding of insulin-like growth 
factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Molecular 
endocrinology 18, 2502-2512. 
Denley, A., Brierley, G.V., Carroll, J.M., Lindenberg, A., Booker, G.W., Cosgrove, L.J., 
Wallace, J.C., Forbes, B.E., and Roberts, C.T. (2006). Differential activation of insulin 
	
	 188	
receptor isoforms by insulin-like growth factors is determined by the C domain. 
Endocrinology 147, 1029-1036. 
Denley, A., Carroll, J.M., Brierley, G.V., Cosgrove, L., Wallace, J., Forbes, B., and 
Roberts, C.T., Jr. (2007). Differential activation of insulin receptor substrates 1 and 2 by 
insulin-like growth factor-activated insulin receptors. Mol Cell Biol 27, 3569-3577. 
Denley, A., Cosgrove, L.J., Booker, G.W., Wallace, J.C., and Forbes, B.E. (2005). 
Molecular interactions of the IGF system. Cytokine Growth Factor Rev 16, 421-439. 
Dickins, R.A., Hemann, M.T., Zilfou, J.T., Simpson, D.R., Ibarra, I., Hannon, G.J., and 
Lowe, S.W. (2005). Probing tumor phenotypes using stable and regulated synthetic 
microRNA precursors. Nat Genet 37, 1289-1295. 
Dool, C.J., Mashhedi, H., Zakikhani, M., David, S., Zhao, Y., Birman, E., Carboni, J.M., 
Gottardis, M., Blouin, M.J., and Pollak, M. (2011). IGF1/insulin receptor kinase inhibition by 
BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective 
than metformin in the treatment of experimental insulin-responsive breast cancer. Endocrine-
related cancer 18, 699-709. 
Dow, L.E., Premsrirut, P.K., Zuber, J., Fellmann, C., McJunkin, K., Miething, C., Park, Y., 
Dickins, R.A., Hannon, G.J., and Lowe, S.W. (2012). A pipeline for the generation of shRNA 
transgenic mice. Nature protocols 7, 374-393. 
Eliasz, S., Liang, S., Chen, Y., De Marco, M.A., Machek, O., Skucha, S., Miele, L., and 
Bocchetta, M. (2010). Notch-1 stimulates survival of lung adenocarcinoma cells during 
hypoxia by activating the IGF-1R pathway. Oncogene 29, 2488-2498. 
Emanuelli, B., Peraldi, P., Filloux, C., Sawka-Verhelle, D., Hilton, D., and Van Obberghen, 
E. (2000). SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 
275, 15985-15991. 
Fair, A.M., Dai, Q., Shu, X.O., Matthews, C.E., Yu, H., Jin, F., Gao, Y.T., and Zheng, W. 
(2007). Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer 
detection and prevention 31, 214-219. 
Farooq, A., Plotnikova, O., Zeng, L., and Zhou, M.M. (1999). Phosphotyrosine binding 
domains of Shc and insulin receptor substrate 1 recognize the NPXpY motif in a 
thermodynamically distinct manner. J Biol Chem 274, 6114-6121. 
Fassnacht, M., Berruti, A., Baudin, E., Demeure, M.J., Gilbert, J., Haak, H., Kroiss, M., 
Quinn, D.I., Hesseltine, E., Ronchi, C.L., et al. (2015). Linsitinib (OSI-906) versus placebo 
for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, 
randomised, phase 3 study. Lancet Oncol 16, 426-435. 
Fellmann, C., Zuber, J., McJunkin, K., Chang, K., Malone, C.D., Dickins, R.A., Xu, Q.K., 
Hengartner, M.O., Elledge, S.J., Hannon, G.J., et al. (2011). Functional Identification of 
Optimized RNAi Triggers Using a Massively Parallel Sensor Assay. Molecular Cell 41, 733-
746. 
Fierz, Y., Novosyadlyy, R., Vijayakumar, A., Yakar, S., and LeRoith, D. (2010). Insulin-
sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. 
Diabetes 59, 686-693. 
Fiore, E., Campani, D., Muller, I., Belardi, V., Giustarini, E., Rossi, G., Pinchera, A., and 
Giani, C. (2010). IGF-II mRNA expression in breast cancer: predictive value and relationship 
to other prognostic factors. Int J Biol Markers 25, 150-156. 
Firth, S.M., and Baxter, R.C. (2002). Cellular actions of the insulin-like growth factor 
binding proteins. Endocrine reviews 23, 824-854. 
	
	 189	
Fox, E.M., Miller, T.W., Balko, J.M., Kuba, M.G., Sanchez, V., Smith, R.A., Liu, S.Y., 
Gonzalez-Angulo, A.M., Mills, G.B., Ye, F., et al. (2011). A Kinome-Wide Screen Identifies 
the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in 
Breast Cancer. Cancer research 71, 6773-6784. 
Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I.D., 
Belfiore, A., and Vigneri, R. (1999). Insulin receptor isoform A, a newly recognized, high-
affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19, 3278-
3288. 
Frattali, A.L., Treadway, J.L., and Pessin, J.E. (1992a). Insulin/IGF-1 hybrid receptors: 
implications for the dominant-negative phenotype in syndromes of insulin resistance. J Cell 
Biochem 48, 43-50. 
Frattali, A.L., Treadway, J.L., and Pessin, J.E. (1992b). Transmembrane signaling by the 
human insulin receptor kinase. Relationship between intramolecular beta subunit trans- and 
cis-autophosphorylation and substrate kinase activation. J Biol Chem 267, 19521-19528. 
Freier, S., Weiss, O., Eran, M., Flyvbjerg, A., Dahan, R., Nephesh, I., Safra, T., Shiloni, E., 
and Raz, I. (1999). Expression of the insulin-like growth factors and their receptors in 
adenocarcinoma of the colon. Gut 44, 704-708. 
Friedbichler, K., Hofmann, M.H., Kroez, M., Ostermann, E., Lamche, H.R., Koessl, C., 
Borges, E., Pollak, M.N., Adolf, G., and Adam, P.J. (2014). Pharmacodynamic and 
antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and 
mechanistic rationale for combination with rapamycin. Molecular cancer therapeutics 13, 
399-409. 
Gee, J.M., Robertson, J.F., Gutteridge, E., Ellis, I.O., Pinder, S.E., Rubini, M., and 
Nicholson, R.I. (2005). Epidermal growth factor receptor/HER2/insulin-like growth factor 
receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocrine-related 
cancer 12 Suppl 1, S99-S111. 
Geiger, T., Wisniewski, J.R., Cox, J., Zanivan, S., Kruger, M., Ishihama, Y., and Mann, M. 
(2011). Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in 
quantitative proteomics. Nature protocols 6, 147-157. 
Giansanti, P., Tsiatsiani, L., Low, T.Y., and Heck, A.J. (2016). Six alternative proteases for 
mass spectrometry-based proteomics beyond trypsin. Nature protocols 11, 993-1006. 
Glatter, T., Ludwig, C., Ahrne, E., Aebersold, R., Heck, A.J., and Schmidt, A. (2012). 
Large-scale quantitative assessment of different in-solution protein digestion protocols reveals 
superior cleavage efficiency of tandem Lys-C/trypsin proteolysis over trypsin digestion. 
Journal of proteome research 11, 5145-5156. 
Goenaga, D., Hampe, C., Carre, N., Cailliau, K., Browaeys-Poly, E., Perdereau, D., Holt, 
L.J., Daly, R.J., Girard, J., Broutin, I., et al. (2009). Molecular determinants of Grb14-
mediated inhibition of insulin signaling. Molecular endocrinology 23, 1043-1051. 
Goldstein, B.J., Bittner-Kowalczyk, A., White, M.F., and Harbeck, M. (2000). Tyrosine 
dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine 
phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 
adaptor protein. J Biol Chem 275, 4283-4289. 
Gu, T.L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V., Wang, Y., Deng, G., 
Zhu, L., Tan, Z., et al. (2011). Survey of tyrosine kinase signaling reveals ROS kinase fusions 
in human cholangiocarcinoma. PLoS One 6, e15640. 
	
	 190	
Gualberto, A., and Pollak, M. (2009). Emerging role of insulin-like growth factor receptor 
inhibitors in oncology: early clinical trial results and future directions. Oncogene 28, 3009-
3021. 
Gupte, A., and Mora, S. (2006). Activation of the Cbl insulin signaling pathway in cardiac 
muscle; dysregulation in obesity and diabetes. Biochem Biophys Res Commun 342, 751-757. 
Haluska, P., Menefee, M., Plimack, E.R., Rosenberg, J., Northfelt, D., LaVallee, T., Shi, L., 
Yu, X.Q., Burke, P., Huang, J., et al. (2014). Phase I dose-escalation study of MEDI-573, a 
bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced 
solid tumors. Clin Cancer Res 20, 4747-4757. 
Haluska, P., Shaw, H.M., Batzel, G.N., Yin, D., Molina, J.R., Molife, L.R., Yap, T.A., 
Roberts, M.L., Sharma, A., Gualberto, A., et al. (2007). Phase I dose escalation study of the 
anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with 
refractory solid tumors. Clin Cancer Res 13, 5834-5840. 
Hamalisto, S., Pouwels, J., de Franceschi, N., Saari, M., Ivarsson, Y., Zimmermann, P., 
Brech, A., Stenmark, H., and Ivaska, J. (2013). A ZO-1/alpha5beta1-integrin complex 
regulates cytokinesis downstream of PKCepsilon in NCI-H460 cells plated on fibronectin. 
PLoS One 8, e70696. 
Han, D.C., Shen, T.L., and Guan, J.L. (2001). The Grb7 family proteins: structure, 
interactions with other signaling molecules and potential cellular functions. Oncogene 20, 
6315-6321. 
Hanke, S., and Mann, M. (2009). The phosphotyrosine interactome of the insulin receptor 
family and its substrates IRS-1 and IRS-2. Molecular & cellular proteomics : MCP 8, 519-534. 
Heidegger, I., Kern, J., Ofer, P., Klocker, H., and Massoner, P. (2014). Oncogenic 
functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell 
migration and angiogenesis. Oncotarget 5, 2723-2735. 
Heidegger, I., Ofer, P., Doppler, W., Rotter, V., Klocker, H., and Massoner, P. (2012). 
Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: 
proliferation in cancer cells and differentiation in noncancerous cells. Endocrinology 153, 
4633-4643. 
Heldin, C.H., and Ostman, A. (1996). Ligand-induced dimerization of growth factor 
receptors: variations on the theme. Cytokine & growth factor reviews 7, 3-10. 
Herkert, B., Kauffmann, A., Molle, S., Schnell, C., Ferrat, T., Voshol, H., Juengert, J., 
Erasimus, H., Marszalek, G., Kazic-Legueux, M., et al. (2016). Maximizing the Efficacy of 
MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R 
Inhibition. Cancer research 76, 390-402. 
Hills, C.E., and Brunskill, N.J. (2008). Intracellular signalling by C-peptide. Exp Diabetes 
Res 2008, 635158. 
Hribal, M.L., Federici, M., Porzio, O., Lauro, D., Borboni, P., Accili, D., Lauro, R., and 
Sesti, G. (2000). The Gly-->Arg972 amino acid polymorphism in insulin receptor substrate-1 
affects glucose metabolism in skeletal muscle cells. The Journal of clinical endocrinology and 
metabolism 85, 2004-2013. 
Hu, C.E., Liu, Y.C., Zhang, H.D., and Huang, G.J. (2014). The RNA-binding protein 
PCBP2 facilitates gastric carcinoma growth by targeting miR-34a. Biochem Biophys Res 
Commun 448, 437-442. 
	
	 191	
Huang, J., Morehouse, C., Streicher, K., Higgs, B.W., Gao, J., Czapiga, M., Boutrin, A., 
Zhu, W., Brohawn, P., Chang, Y., et al. (2011). Altered expression of insulin receptor 
isoforms in breast cancer. PLoS One 6, e26177. 
Hubbard, S.R. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in 
complex with peptide substrate and ATP analog. The EMBO journal 16, 5572-5581. 
Hubbard, S.R. (2013). The insulin receptor: both a prototypical and atypical receptor 
tyrosine kinase. Cold Spring Harb Perspect Biol 5, a008946. 
Hubbard, S.R., and Till, J.H. (2000). Protein tyrosine kinase structure and function. Annual 
review of biochemistry 69, 373-398. 
Hubbard, S.R., Wei, L., Ellis, L., and Hendrickson, W.A. (1994). Crystal structure of the 
tyrosine kinase domain of the human insulin receptor. Nature 372, 746-754. 
Humbel, R.E. (1990). Insulin-like growth factors I and II. European journal of 
biochemistry / FEBS 190, 445-462. 
Humphrey, S.J., Azimifar, S.B., and Mann, M. (2015). High-throughput 
phosphoproteomics reveals in vivo insulin signaling dynamics. Nat Biotechnol 33, 990-995. 
Humphrey, S.J., Yang, G., Yang, P., Fazakerley, D.J., Stockli, J., Yang, J.Y., and James, 
D.E. (2013). Dynamic adipocyte phosphoproteome reveals that Akt directly regulates 
mTORC2. Cell Metab 17, 1009-1020. 
Hwa, V., Oh, Y., and Rosenfeld, R.G. (1999). The insulin-like growth factor-binding 
protein (IGFBP) superfamily. Endocrine reviews 20, 761-787. 
Inoue, H., Nojima, H., and Okayama, H. (1990). High efficiency transformation of 
Escherichia coli with plasmids. Gene 96, 23-28. 
Irie, H.Y., Pearline, R.V., Grueneberg, D., Hsia, M., Ravichandran, P., Kothari, N., 
Natesan, S., and Brugge, J.S. (2005). Distinct roles of Akt1 and Akt2 in regulating cell 
migration and epithelial-mesenchymal transition. J Cell Biol 171, 1023-1034. 
Jackson, J.G., and Yee, D. (1999). IRS-1 expression and activation are not sufficient to 
activate downstream pathways and enable IGF-I growth response in estrogen receptor 
negative breast cancer cells. Growth Hormone & Igf Research 9, 280-289. 
Jaquish, D.V., Yu, P.T., Shields, D.J., French, R.P., Maruyama, K.P., Niessen, S., Hoover, 
H., D, A.C., Cravatt, B., and Lowy, A.M. (2011). IGF1-R signals through the RON receptor 
to mediate pancreatic cancer cell migration. Carcinogenesis 32, 1151-1156. 
Jensen, M., Hansen, B., De Meyts, P., Schaffer, L., and Urso, B. (2007). Activation of the 
insulin receptor by insulin and a synthetic peptide leads to divergent metabolic and mitogenic 
signaling and responses. J Biol Chem 282, 35179-35186. 
Jensen, M., Palsgaard, J., Borup, R., de Meyts, P., and Schaffer, L. (2008). Activation of 
the insulin receptor (IR) by insulin and a synthetic peptide has different effects on gene 
expression in IR-transfected L6 myoblasts. Biochem J 412, 435-445. 
Jones, A.G., and Hattersley, A.T. (2013). The clinical utility of C-peptide measurement in 
the care of patients with diabetes. Diabet Med 30, 803-817. 
Jones, T.R., Kang, I.H., Wheeler, D.B., Lindquist, R.A., Papallo, A., Sabatini, D.M., 
Golland, P., and Carpenter, A.E. (2008). CellProfiler Analyst: data exploration and analysis 
software for complex image-based screens. BMC Bioinformatics 9, 482. 
Kasus-Jacobi, A., Bereziat, V., Perdereau, D., Girard, J., and Burnol, A.F. (2000). 
Evidence for an interaction between the insulin receptor and Grb7. A role for two of its 
binding domains, PIR and SH2. Oncogene 19, 2052-2059. 
	
	 192	
Kishi, K., Mawatari, K., Sakai-Wakamatsu, K., Yuasa, T., Wang, M., Ogura-Sawa, M., 
Nakaya, Y., Hatakeyama, S., and Ebina, Y. (2007). APS-mediated ubiquitination of the 
insulin receptor enhances its internalization, but does not induce its degradation. Endocr J 54, 
77-88. 
Kramer, H.F., Witczak, C.A., Taylor, E.B., Fujii, N., Hirshman, M.F., and Goodyear, L.J. 
(2006). AS160 regulates insulin- and contraction-stimulated glucose uptake in mouse skeletal 
muscle. J Biol Chem 281, 31478-31485. 
Lai, C.F., Chen, C.Y., and Au, L.C. (2013). Comparison between the repression potency of 
siRNA targeting the coding region and the 3'-untranslated region of mRNA. Biomed Res Int 
2013, 637850. 
Lamhamedi-Cherradi, S.E., Menegaz, B.A., Ramamoorthy, V., Vishwamitra, D., Wang, Y., 
Maywald, R.L., Buford, A.S., Fokt, I., Skora, S., Wang, J., et al. (2016). IGF-1R and mTOR 
Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing 
Sarcoma. J Natl Cancer Inst 108. 
Langer, C.J., Novello, S., Park, K., Krzakowski, M., Karp, D.D., Mok, T., Benner, R.J., 
Scranton, J.R., Olszanski, A.J., and Jassem, J. (2014). Randomized, phase III trial of first-line 
figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin 
alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 32, 2059-2066. 
Larsen, M.R., Thingholm, T.E., Jensen, O.N., Roepstorff, P., and Jorgensen, T.J. (2005). 
Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium 
dioxide microcolumns. Molecular & cellular proteomics : MCP 4, 873-886. 
Lewis, R.E., Cao, L., Perregaux, D., and Czech, M.P. (1990a). Threonine 1336 of the 
Human Insulin-Receptor Is a Major Target for Phosphorylation by Protein Kinase-C. 
Biochemistry 29, 1807-1813. 
Lewis, R.E., Wu, G.P., MacDonald, R.G., and Czech, M.P. (1990b). Insulin-sensitive 
phosphorylation of serine 1293/1294 on the human insulin receptor by a tightly associated 
serine kinase. J Biol Chem 265, 947-954. 
Lewitt, M.S., Saunders, H., Phuyal, J.L., and Baxter, R.C. (1994). Complex formation by 
human insulin-like growth factor-binding protein-3 and human acid-labile subunit in growth 
hormone-deficient rats. Endocrinology 134, 2404-2409. 
Li, H., Batth, I.S., Qu, X., Xu, L., Song, N., Wang, R., and Liu, Y. (2017). IGF-IR 
signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and 
new insights. Mol Cancer 16, 6. 
Li, S., Covino, N.D., Stein, E.G., Till, J.H., and Hubbard, S.R. (2003). Structural and 
biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region 
of the insulin receptor. J Biol Chem 278, 26007-26014. 
Li, S., Wang, N., and Brodt, P. (2012). Metastatic cells can escape the proapoptotic effects 
of TNF-alpha through increased autocrine IL-6/STAT3 signaling. Cancer research 72, 865-
875. 
Li, Y., Roux, C., Lazereg, S., LeCaer, J.P., Laprevote, O., Badet, B., and Badet-Denisot, 
M.A. (2007). Identification of a novel serine phosphorylation site in human 
glutamine:fructose-6-phosphate amidotransferase isoform 1. Biochemistry 46, 13163-13169. 
Liu, J.P., Baker, J., Perkins, A.S., Robertson, E.J., and Efstratiadis, A. (1993). Mice 
carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 
IGF receptor (Igf1r). Cell 75, 59-72. 
	
	 193	
Lundby, A., Bolvig, P., Hegelund, A.C., Hansen, B.F., Worm, J., Lutzen, A., Billestrup, N., 
Bonnesen, C., and Oleksiewicz, M.B. (2015). Surface-expressed insulin receptors as well as 
IGF-I receptors both contribute to the mitogenic effects of human insulin and its analogues. 
Journal of applied toxicology : JAT 35, 842-850. 
Malaguarnera, R., and Belfiore, A. (2011). The insulin receptor: a new target for cancer 
therapy. Front Endocrinol (Lausanne) 2, 93. 
Mancini, M., Gariboldi, M.B., Taiana, E., Bonzi, M.C., Craparotta, I., Pagin, M., and 
Monti, E. (2014). Co-targeting the IGF system and HIF-1 inhibits migration and invasion by 
(triple-negative) breast cancer cells. British journal of cancer 110, 2865-2873. 
Manza, L.L., Stamer, S.L., Ham, A.J.L., Codreanu, S.G., and Liebler, D.C. (2005). Sample 
preparation and digestion for proteomic analyses using spin filters. Proteomics 5, 1742-1745. 
Marin, O., Meggio, F., Perich, J.W., and Pinna, L.A. (1996). Phosphotyrosine specifies the 
phosphorylation by protein kinase CK2 of a peptide reproducing the activation loop of the 
insulin receptor protein tyrosine kinase. Int J Biochem Cell Biol 28, 999-1005. 
Martinez-Quetglas, I., Pinyol, R., Dauch, D., Torrecilla, S., Tovar, V., Moeini, A., Alsinet, 
C., Portela, A., Rodriguez-Carunchio, L., Sole, M., et al. (2016). IGF2 is Upregulated by 
Epigenetic Mechanisms in Hepatocellular Carcinomas and is an Actionable Oncogene 
Product in Experimental Models. Gastroenterology. 
McKern, N.M., Lawrence, M.C., Streltsov, V.A., Lou, M.Z., Adams, T.E., Lovrecz, G.O., 
Elleman, T.C., Richards, K.M., Bentley, J.D., Pilling, P.A., et al. (2006). Structure of the 
insulin receptor ectodomain reveals a folded-over conformation. Nature 443, 218-221. 
Mendoza, R.A., Enriquez, M.I., Mejia, S.M., Moody, E.E., and Thordarson, G. (2011). 
Interactions between IGF-I, estrogen receptor-alpha (ERalpha), and ERbeta in regulating 
growth/apoptosis of MCF-7 human breast cancer cells. The Journal of endocrinology 208, 1-9. 
Mireuta, M., Birman, E., Barmash, M., and Pollak, M. (2014). Quantification of binding of 
IGF-1 to BI 836845, a candidate therapeutic antibody against IGF-1 and IGF-2, and effects of 
this antibody on IGF-1:IGFBP-3 complexes in vitro and in male C57BL/6 mice. 
Endocrinology 155, 703-715. 
Mlinar, B., Marc, J., Janez, A., and Pfeifer, M. (2007). Molecular mechanisms of insulin 
resistance and associated diseases. Clinica chimica acta; international journal of clinical 
chemistry 375, 20-35. 
Moller, D.E., Yokota, A., Caro, J.F., and Flier, J.S. (1989). Tissue-specific expression of 
two alternatively spliced insulin receptor mRNAs in man. Molecular endocrinology 3, 1263-
1269. 
Monetti, M., Nagaraj, N., Sharma, K., and Mann, M. (2011). Large-scale phosphosite 
quantification in tissues by a spike-in SILAC method. Nature methods 8, 655-658. 
Morali, O.G., Delmas, V., Moore, R., Jeanney, C., Thiery, J.P., and Larue, L. (2001). IGF-
II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme 
transition. Oncogene 20, 4942-4950. 
Morcavallo, A., Buraschi, S., Xu, S.Q., Belfiore, A., Schaefer, L., Iozzo, R.V., and 
Morrione, A. (2014a). Decorin differentially modulates the activity of insulin receptor 
isoform A ligands. Matrix Biology 35, 82-90. 
Morcavallo, A., Buraschi, S., Xu, S.Q., Belfiore, A., Schaefer, L., Iozzo, R.V., and 
Morrione, A. (2014b). Decorin differentially modulates the activity of insulin receptor 
isoform A ligands. Matrix Biol 35, 82-90. 
	
	 194	
Morcavallo, A., Gaspari, M., Pandini, G., Palummo, A., Cuda, G., Larsen, M.R., Vigneri, 
R., and Belfiore, A. (2011). Research resource: New and diverse substrates for the insulin 
receptor isoform A revealed by quantitative proteomics after stimulation with IGF-II or 
insulin. Mol Endocrinol 25, 1456-1468. 
Morcavallo, A., Genua, M., Palummo, A., Kletvikova, E., Jiracek, J., Brzozowski, A.M., 
Iozzo, R.V., Belfiore, A., and Morrione, A. (2012). Insulin and insulin-like growth factor II 
differentially regulate endocytic sorting and stability of insulin receptor isoform A. J Biol 
Chem 287, 11422-11436. 
Morrione, A., Valentinis, B., Xu, S.Q., Yumet, G., Louvi, A., Efstratiadis, A., and Baserga, 
R. (1997). Insulin-like growth factor II stimulates cell proliferation through the insulin 
receptor. Proceedings of the National Academy of Sciences of the United States of America 
94, 3777-3782. 
Muthu, M., Cheriyan, V.T., Munie, S., Levi, E., Frank, J., Ashour, A.E., Singh, M., and 
Rishi, A.K. (2014). Mechanisms of neuroblastoma cell growth inhibition by CARP-1 
functional mimetics. PLoS One 9, e102567. 
Muthu, M., Cheriyan, V.T., and Rishi, A.K. (2015). CARP-1/CCAR1: a biphasic regulator 
of cancer cell growth and apoptosis. Oncotarget 6, 6499-6510. 
Neubauer, H., Clare, S.E., Wozny, W., Schwall, G.P., Poznanovic, S., Stegmann, W., 
Vogel, U., Sotlar, K., Wallwiener, D., Kurek, R., et al. (2008). Breast cancer proteomics 
reveals correlation between estrogen receptor status and differential phosphorylation of 
PGRMC1. Breast Cancer Res 10, R85. 
Neubauer, H., Ma, Q., Zhou, J., Yu, Q., Ruan, X., Seeger, H., Fehm, T., and Mueck, A.O. 
(2013). Possible role of PGRMC1 in breast cancer development. Climacteric 16, 509-513. 
Ong, S.E., and Mann, M. (2006). A practical recipe for stable isotope labeling by amino 
acids in cell culture (SILAC). Nature protocols 1, 2650-2660. 
Orci, L. (1986). The insulin cell: its cellular environment and how it processes (pro)insulin. 
Diabetes Metab Rev 2, 71-106. 
Pandini, G., Conte, E., Medico, E., Sciacca, L., Vigneri, R., and Belfiore, A. (2004). IGF-II 
binding to insulin receptor isoform A induces a partially different gene expression profile 
from insulin binding. Ann N Y Acad Sci 1028, 450-456. 
Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R., and Belfiore, A. (2002a). 
Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics 
depending on the insulin receptor isoform involved. Journal of Biological Chemistry 277, 
39684-39695. 
Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R., and Belfiore, A. (2002b). 
Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics 
depending on the insulin receptor isoform involved. J Biol Chem 277, 39684-39695. 
Pandini, G., Medico, E., Conte, E., Sciacca, L., Vigneri, R., and Belfiore, A. (2003). 
Differential gene expression induced by insulin and insulin-like growth factor-II through the 
insulin receptor isoform A. J Biol Chem 278, 42178-42189. 
Pandini, G., Vigneri, R., Costantino, A., Frasca, F., Ippolito, A., Fujita-Yamaguchi, Y., 
Siddle, K., Goldfine, I.D., and Belfiore, A. (1999). Insulin and insulin-like growth factor-I 
(IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor 




Park, J.H., Choi, Y.J., Kim, S.Y., Lee, J.E., Sung, K.J., Park, S., Kim, W.S., Song, J.S., 
Choi, C.M., Sung, Y.H., et al. (2016a). Activation of the IGF1R pathway potentially mediates 
acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors 
in advanced non-small cell lung cancer. Oncotarget 7, 22005-22015. 
Park, J.Y., Lee, J.Y., Zhang, Y., Hoffman, R.M., and Bouvet, M. (2016b). Targeting the 
insulin growth factor-1 receptor with fluorescent antibodies enables high resolution imaging 
of human pancreatic cancer in orthotopic mouse models. Oncotarget. 
Parker, B.L., Yang, G., Humphrey, S.J., Chaudhuri, R., Ma, X., Peterman, S., and James, 
D.E. (2015). Targeted phosphoproteomics of insulin signaling using data-independent 
acquisition mass spectrometry. Sci Signal 8, rs6. 
Pavelic, J., Matijevic, T., and Knezevic, J. (2007). Biological & physiological aspects of 
action of insulin-like growth factor peptide family. The Indian journal of medical research 
125, 511-522. 
Pawson, T. (1995). Protein modules and signalling networks. Nature 373, 573-580. 
Peck, G.R., Ye, S., Pham, V., Fernando, R.N., Macaulay, S.L., Chai, S.Y., and Albiston, 
A.L. (2006). Interaction of the Akt substrate, AS160, with the glucose transporter 4 vesicle 
marker protein, insulin-regulated aminopeptidase. Molecular endocrinology 20, 2576-2583. 
Perrotti, D., Cesi, V., Trotta, R., Guerzoni, C., Santilli, G., Campbell, K., Iervolino, A., 
Condorelli, F., Gambacorti-Passerini, C., Caligiuri, M.A., et al. (2002). BCR-ABL suppresses 
C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 30, 48-58. 
Petersen, M.C., Madiraju, A.K., Gassaway, B.M., Marcel, M., Nasiri, A.R., Butrico, G., 
Marcucci, M.J., Zhang, D., Abulizi, A., Zhang, X.M., et al. (2016). Insulin receptor Thr(1160) 
phosphorylation mediates lipid-induced hepatic insulin resistance. Journal of Clinical 
Investigation 126, 4361-4371. 
Pezzino, V., Papa, V., Milazzo, G., Gliozzo, B., Russo, P., and Scalia, P.L. (1996). Insulin-
like growth factor-I (IGF-I) receptors in breast cancer. Ann N Y Acad Sci 784, 189-201. 
Pierre-Eugene, C., Pagesy, P., Nguyen, T.T., Neuille, M., Tschank, G., Tennagels, N., 
Hampe, C., and Issad, T. (2012). Effect of insulin analogues on insulin/IGF1 hybrid receptors: 
increased activation by glargine but not by its metabolites M1 and M2. PLoS One 7, e41992. 
Pisani, P. (2008). Hyper-insulinaemia and cancer, meta-analyses of epidemiological 
studies. Archives of physiology and biochemistry 114, 63-70. 
Pivonello, C., Negri, M., De Martino, M.C., Napolitano, M., de Angelis, C., Provvisiero, 
D.P., Cuomo, G., Auriemma, R.S., Simeoli, C., Izzo, F., et al. (2016). The dual targeting of 
insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated 
antitumor efficacy in hepatocellular carcinoma. Oncotarget. 
Pollak, M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nature 
reviews Cancer 8, 915-928. 
Pollak, M. (2012). The insulin and insulin-like growth factor receptor family in neoplasia: 
an update. Nature reviews Cancer 12, 159-169. 
Radhakrishnan, V.K., Hernandez, L.C., Anderson, K., Tan, Q., De Leon, M., and De Leon, 
D.D. (2015). Expression of Intratumoral IGF-II Is Regulated by the Gene Imprinting Status in 
Triple Negative Breast Cancer from Vietnamese Patients. Int J Endocrinol 2015, 401851. 
Rajapaksha, H., and Forbes, B.E. (2015). Ligand-Binding Affinity at the Insulin Receptor 
Isoform-A and Subsequent IR-A Tyrosine Phosphorylation Kinetics are Important 
Determinants of Mitogenic Biological Outcomes. Front Endocrinol (Lausanne) 6, 107. 
	
	 196	
Rappsilber, J., Mann, M., and Ishihama, Y. (2007). Protocol for micro-purification, 
enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nature 
protocols 2, 1896-1906. 
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W.S., and Khvorova, A. (2004). 
Rational siRNA design for RNA interference. Nature Biotechnology 22, 326-330. 
Rinderknecht, E., and Humbel, R.E. (1976). Amino-terminal sequences of two 
polypeptides from human serum with nonsuppressible insulin-like and cell-growth-promoting 
activities: evidence for structural homology with insulin B chain. Proceedings of the National 
Academy of Sciences of the United States of America 73, 4379-4381. 
Rose, D.P., and Vona-Davis, L. (2012). The cellular and molecular mechanisms by which 
insulin influences breast cancer risk and progression. Endocrine-related cancer 19, R225-241. 
Rota, L.M., Albanito, L., Shin, M.E., Goyeneche, C.L., Shushanov, S., Gallagher, E.J., 
LeRoith, D., Lazzarino, D.A., and Wood, T.L. (2014). IGF1R inhibition in mammary 
epithelia promotes canonical Wnt signaling and Wnt1-driven tumors. Cancer research 74, 
5668-5679. 
Rota, L.M., and Wood, T.L. (2015). Crosstalk of the Insulin-Like Growth Factor Receptor 
with the Wnt Signaling Pathway in Breast Cancer. Front Endocrinol (Lausanne) 6, 92. 
Sacco, A., Morcavallo, A., Pandini, G., Vigneri, R., and Belfiore, A. (2009). Differential 
signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin 
receptor isoform A. Endocrinology 150, 3594-3602. 
Saito, T., and Saetrom, P. (2010). MicroRNAs--targeting and target prediction. N 
Biotechnol 27, 243-249. 
Saldana, S.M., Lee, H.H., Lowery, F.J., Khotskaya, Y.B., Xia, W., Zhang, C., Chang, S.S., 
Chou, C.K., Steeg, P.S., Yu, D., et al. (2013). Inhibition of type I insulin-like growth factor 
receptor signaling attenuates the development of breast cancer brain metastasis. PLoS One 8, 
e73406. 
Sanchez-Lopez, E., Flashner-Abramson, E., Shalapour, S., Zhong, Z., Taniguchi, K., 
Levitzki, A., and Karin, M. (2016). Targeting colorectal cancer via its microenvironment by 
inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene 35, 
2634-2644. 
Sanderson, M.P., Apgar, J., Garin-Chesa, P., Hofmann, M.H., Kessler, D., Quant, J., 
Savchenko, A., Schaaf, O., Treu, M., Tye, H., et al. (2015). BI 885578, a novel IGF1R/INSR 
tyrosine kinase inhibitor with pharmacokinetic properties that dissociate anti-tumor efficacy 
and perturbation of glucose homeostasis. Molecular cancer therapeutics. 
Sasi, W., Ye, L., Jiang, W.G., Mokbel, K., and Sharma, A. (2014). Observations on the 
effects of Suppressor of Cytokine Signaling 7 (SOCS7) knockdown in breast cancer cells: 
their in vitro response to Insulin Like Growth Factor I (IGF-I). Clin Transl Oncol 16, 476-487. 
Sato, Y., Hayashi, K., Amano, Y., Takahashi, M., Yonemura, S., Hayashi, I., Hirose, H., 
Ohno, S., and Suzuki, A. (2014). MTCL1 crosslinks and stabilizes non-centrosomal 
microtubules on the Golgi membrane. Nat Commun 5, 5266. 
Sawka-Verhelle, D., Tartare-Deckert, S., White, M.F., and Van Obberghen, E. (1996). 
Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding 
domain and through a newly identified domain comprising amino acids 591-786. J Biol Chem 
271, 5980-5983. 
Saxena, N.K., Taliaferro-Smith, L., Knight, B.B., Merlin, D., Anania, F.A., O'Regan, R.M., 
and Sharma, D. (2008). Bidirectional crosstalk between leptin and insulin-like growth factor-I 
	
	 197	
signaling promotes invasion and migration of breast cancer cells via transactivation of 
epidermal growth factor receptor. Cancer research 68, 9712-9722. 
Scagliotti, G.V., Bondarenko, I., Blackhall, F., Barlesi, F., Hsia, T.C., Jassem, J., 
Milanowski, J., Popat, S., Sanchez-Torres, J.M., Novello, S., et al. (2015). Randomized, 
phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients 
with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol 26, 497-504. 
Schillaci, R., Salatino, M., Cassataro, J., Proietti, C.J., Giambartolomei, G.H., Rivas, M.A., 
Carnevale, R.P., Charreau, E.H., and Elizalde, P.V. (2006). Immunization with murine breast 
cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor 
receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand 
cytotoxic pathway. J Immunol 176, 3426-3437. 
Schnarr, B., Strunz, K., Ohsam, J., Benner, A., Wacker, J., and Mayer, D. (2000). Down-
regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression 
in advanced human breast cancer. Int J Cancer 89, 506-513. 
Sciacca, L., Costantino, A., Pandini, G., Mineo, R., Frasca, F., Scalia, P., Sbraccia, P., 
Goldfine, I.D., Vigneri, R., and Belfiore, A. (1999). Insulin receptor activation by IGF-II in 
breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18, 2471-2479. 
Sciacca, L., Mineo, R., Pandini, G., Murabito, A., Vigneri, R., and Belfiore, A. (2002). In 
IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and 
protection from apoptosis via the insulin receptor isoform A. Oncogene 21, 8240-8250. 
Scotlandi, K., Maini, C., Manara, M.C., Benini, S., Serra, M., Cerisano, V., Strammiello, 
R., Baldini, N., Lollini, P.L., Nanni, P., et al. (2002). Effectiveness of insulin-like growth 
factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 9, 296-
307. 
Sepplorenzino, L., Rosen, N., and Lebwohl, D.E. (1994). Insulin and Insulin-Like Growth-
Factor Signaling Are Defective in the Mda Mb-468 Human Breast-Cancer Cell-Line. Cell 
Growth Differ 5, 1077-1083. 
Sesti, G. (2000). Insulin receptor substrate polymorphisms and type 2 diabetes mellitus. 
Pharmacogenomics 1, 343-357. 
Slaaby, R. (2015). Specific insulin/IGF1 hybrid receptor activation assay reveals IGF1 as a 
more potent ligand than insulin. Scientific reports 5, 7911. 
Slaaby, R., Schaffer, L., Lautrup-Larsen, I., Andersen, A.S., Shaw, A.C., Mathiasen, I.S., 
and Brandt, J. (2006). Hybrid receptors formed by insulin receptor (IR) and insulin-like 
growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the 
IR splice variant. J Biol Chem 281, 25869-25874. 
Smith, B.J., Huang, K., Kong, G., Chan, S.J., Nakagawa, S., Menting, J.G., Hu, S.Q., 
Whittaker, J., Steiner, D.F., Katsoyannis, P.G., et al. (2010). Structural resolution of a tandem 
hormone-binding element in the insulin receptor and its implications for design of peptide 
agonists. Proceedings of the National Academy of Sciences of the United States of America 
107, 6771-6776. 
Soh, C.L., McNeil, K., Owczarek, C.M., Hardy, M.P., Fabri, L.J., Pearse, M., Delaine, 
C.A., and Forbes, B.E. (2015). Exogenous administration of protease-resistant, non-matrix-
binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer. British journal 
of cancer 113, 1640. 
Soni, P., Lakkis, M., Poy, M.N., Fernstrom, M.A., and Najjar, S.M. (2000). The 
differential effects of pp120 (Ceacam 1) on the mitogenic action of insulin and insulin-like 
	
	 198	
growth factor 1 are regulated by the nonconserved tyrosine 1316 in the insulin receptor. Mol 
Cell Biol 20, 3896-3905. 
Stegmeier, F., Hu, G., Rickles, R.J., Hannon, G.J., and Elledge, S.J. (2005). A lentiviral 
microRNA-based system for single-copy polymerase II-regulated RNA interference in 
mammalian cells. Proceedings of the National Academy of Sciences of the United States of 
America 102, 13212-13217. 
Stein, E.G., Gustafson, T.A., and Hubbard, S.R. (2001). The BPS domain of Grb10 inhibits 
the catalytic activity of the insulin and IGF1 receptors. FEBS Lett 493, 106-111. 
Surmacz, E. (2000). Function of the IGF-I receptor in breast cancer. J Mammary Gland 
Biol Neoplasia 5, 95-105. 
Svensson, J., Kindblom, J., Shao, R., Moverare-Skrtic, S., Lagerquist, M.K., Andersson, N., 
Sjogren, K., Venken, K., Vanderschueren, D., Jansson, J.O., et al. (2008). Liver-derived IGF1 
enhances the androgenic response in prostate. The Journal of endocrinology 199, 489-497. 
Taliaferro-Smith, L., Oberlick, E., Liu, T., McGlothen, T., Alcaide, T., Tobin, R., Donnelly, 
S., Commander, R., Kline, E., Nagaraju, G.P., et al. (2015). FAK activation is required for 
IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative 
breast cancer cells. Oncotarget 6, 4757-4772. 
Taniguchi, C.M., Emanuelli, B., and Kahn, C.R. (2006). Critical nodes in signalling 
pathways: insights into insulin action. Nature reviews Molecular cell biology 7, 85-96. 
Tennagels, N., Telting, D., Parvaresch, S., Maassen, J.A., and Klein, H.W. (2001). 
Identification of Ser(1275) and Ser(1309) as autophosphorylation sites of the human insulin 
receptor in intact cells. Biochem Biophys Res Commun 282, 387-393. 
Tennant, M.K., Thrasher, J.B., Twomey, P.A., Drivdahl, R.H., Birnbaum, R.S., and 
Plymate, S.R. (1996). Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-
like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human 
prostate carcinoma compared to benign prostate epithelium. The Journal of clinical 
endocrinology and metabolism 81, 3774-3782. 
ter Braak, B., Siezen, C.L.E., Kannegieter, N., Koedoot, E., van de Water, B., and van der 
Laan, J.W. (2014). Classifying the adverse mitogenic mode of action of insulin analogues 
using a novel mechanism-based genetically engineered human breast cancer cell panel. Arch 
Toxicol 88, 953-966. 
Thingholm, T.E., Jorgensen, T.J., Jensen, O.N., and Larsen, M.R. (2006). Highly selective 
enrichment of phosphorylated peptides using titanium dioxide. Nature protocols 1, 1929-1935. 
Tomari, Y., and Zamore, P.D. (2005). Perspective: machines for RNAi. Gene Dev 19, 517-
529. 
Toretsky, J.A., and Helman, L.J. (1996). Involvement of IGF-II in human cancer. The 
Journal of endocrinology 149, 367-372. 
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M.Y., Geiger, T., Mann, M., and 
Cox, J. (2016). The Perseus computational platform for comprehensive analysis of 
(prote)omics data. Nature methods 13, 731-740. 
Uhles, S., Moede, T., Leibiger, B., Berggren, P.O., and Leibiger, I.B. (2003). Isoform-
specific insulin receptor signaling involves different plasma membrane domains. J Cell Biol 
163, 1327-1337. 
Ulanet, D.B., Ludwig, D.L., Kahn, C.R., and Hanahan, D. (2010). Insulin receptor 
functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-
	
	 199	
1R targeted therapy. Proceedings of the National Academy of Sciences of the United States of 
America 107, 10791-10798. 
Vella, V., Pandini, G., Sciacca, L., Mineo, R., Vigneri, R., Pezzino, V., and Belfiore, A. 
(2002). A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates 
growth of thyroid cancer. The Journal of clinical endocrinology and metabolism 87, 245-254. 
von Stechow, L., Francavilla, C., and Olsen, J.V. (2015). Recent findings and 
technological advances in phosphoproteomics for cells and tissues. Expert Rev Proteomics 12, 
469-487. 
Walchli, S., Curchod, M.L., Gobert, R.P., Arkinstall, S., and Hooft van Huijsduijnen, R. 
(2000). Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A 
brute force approach based on "substrate-trapping" mutants. J Biol Chem 275, 9792-9796. 
Ward, C.W., Menting, J.G., and Lawrence, M.C. (2013). The insulin receptor changes 
conformation in unforeseen ways on ligand binding: Sharpening the picture of insulin 
receptor activation. Bioessays 35, 945-954. 
Whittaker, L., Hao, C., Fu, W., and Whittaker, J. (2008). High-affinity insulin binding: 
insulin interacts with two receptor ligand binding sites. Biochemistry 47, 12900-12909. 
Wisniewski, J.R., Zougman, A., Nagaraj, N., and Mann, M. (2009). Universal sample 
preparation method for proteome analysis. Nature methods 6, 359-362. 
Wu, J., Tseng, Y.D., Xu, C.F., Neubert, T.A., White, M.F., and Hubbard, S.R. (2008). 
Structural and biochemical characterization of the KRLB region in insulin receptor substrate-
2. Nat Struct Mol Biol 15, 251-258. 
Xia, J., Benner, M.J., and Hancock, R.E. (2014). NetworkAnalyst--integrative approaches 
for protein-protein interaction network analysis and visual exploration. Nucleic Acids Res 42, 
W167-174. 
Xia, J., Gill, E.E., and Hancock, R.E. (2015). NetworkAnalyst for statistical, visual and 
network-based meta-analysis of gene expression data. Nature protocols 10, 823-844. 
Xu, P., Jacobs, A.R., and Taylor, S.I. (1999). Interaction of insulin receptor substrate 3 
with insulin receptor, insulin receptor-related receptor, insulin-like growth factor-1 receptor, 
and downstream signaling proteins. J Biol Chem 274, 15262-15270. 
Yamaguchi, Y., Flier, J.S., Benecke, H., Ransil, B.J., and Moller, D.E. (1993). Ligand-
binding properties of the two isoforms of the human insulin receptor. Endocrinology 132, 
1132-1138. 
Yoon, S., and Seger, R. (2006). The extracellular signal-regulated kinase: multiple 
substrates regulate diverse cellular functions. Growth factors 24, 21-44. 
Youngren, J.F. (2007). Regulation of insulin receptor function. Cell Mol Life Sci 64, 873-
891. 
Yu, H., and Rohan, T. (2000). Role of the insulin-like growth factor family in cancer 
development and progression. J Natl Cancer Inst 92, 1472-1489. 
Zaykov, A.N., Mayer, J.P., and DiMarchi, R.D. (2016). Pursuit of a perfect insulin. Nat 
Rev Drug Discov 15, 425-439. 
Zeisberg, M., and Neilson, E.G. (2009). Biomarkers for epithelial-mesenchymal transitions. 
J Clin Invest 119, 1429-1437. 
Zeng, Y., Wagner, E.J., and Cullen, B.R. (2002). Both natural and designed micro RNAs 




Zhang, H., Fagan, D.H., Zeng, X., Freeman, K.T., Sachdev, D., and Yee, D. (2010). 
Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. 
Oncogene 29, 2517-2527. 
Zhang, H., Pelzer, A.M., Kiang, D.T., and Yee, D. (2007). Down-regulation of type I 
insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. 
Cancer research 67, 391-397. 
Zhao, H., Desai, V., Wang, J., Epstein, D.M., Miglarese, M., and Buck, E. (2012). 
Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-
906 in hepatocellular carcinoma cell lines. Molecular cancer therapeutics 11, 503-513. 
Zhong, H., Fazenbaker, C., Chen, C., Breen, S., Huang, J., Yao, X., Ren, P., Yao, Y., 
Herbst, R., and Hollingsworth, R.E. (2016). Overproduction of IGF-2 drives a subset of 
colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and 
combination therapies. Oncogene. 
Zibrova, D., Vandermoere, F., Goransson, O., Peggie, M., Marino, K.V., Knierim, A., 
Spengler, K., Weigert, C., Viollet, B., Morrice, N.A., et al. (2017). GFAT1 phosphorylation 
by AMPK promotes VEGF-induced angiogenesis. Biochem J 474, 983-1001. 
Ziegler, A.N., Chidambaram, S., Forbes, B.E., Wood, T.L., and Levison, S.W. (2014). 
Insulin-like growth factor-II (IGF-II) and IGF-II analogs with enhanced insulin receptor-a 







Appendix 1 pENTR1a-dsRed-miR30c 
 
Appendix 1: Map of pENTR1a-dsRed-miR30c. KanR: Kanamycin resistance gene; pUC 
origin: origin of replication; dsRed: DsRed-expressed fluorescent protein gene. Restriction 
sites and their locations used for construction are also shown. 
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Appendix 2.  pENTR1a-dsRed-miR30c-shRNA 
 
Appendix 2: Map of pENTR1a-dsRed-miR30c-shRNA. KanR: Kanamycin resistance gene; 
pUC origin: origin of replication; dsRed: DsRed-expressed fluorescent protein gene. shRNA 
(shIGF-1R2 used as example), Restriction sites and their locations used for construction are 
also shown.  
 
  


















Appendix 3: Map of pLVTPT. Beta-lactamase AmpR: Ampicillin resistance gene; 5’ LTR: 
Acts as an RNA pol II promoter; 3’ LTR: Terminates transcription started by 5' LTR by the 
addition of a poly A tract just after the R sequence. RRE: Rev Response Element; TRE3G 
promoter: which provides the lowest basal expression of any tetracycline-inducible promoter 
in the absence of bound transactivator. attR1, attR2: recombination sites; ccdB: Toxin CcdB 
gene; PGK promoter: phosphoglycerate kinase promoter; Tet-on3G: Tet-On 3G transactivator, 
which binds to and activates expression from TRE promoters in the presence of doxycycline 
(Dox); PuroR: puromycin resistance gene; Restriction sites and their locations used for 






























Appendix 4 pLVTPT shRNA 
 
Appendix 4: Map of pLVTPT shRNA. Beta-lactamase AmpR: Ampicillin resistance gene; 5’ 
LTR: Acts as an RNA pol II promoter; 3’ LTR: Terminates transcription started by 5' LTR by 
the addition of a poly A tract just after the R sequence. RRE: Rev Response Element; TRE3G 
promoter: which provides the lowest basal expression of any tetracycline-inducible promoter 
in the absence of bound transactivator. attB1, attB2: recombination sites; ccdB: PGK 
promoter: phosphoglycerate kinase promoter; Tet-on3G: Tet-On 3G transactivator, which 
binds to and activates expression from TRE promoters in the presence of doxycycline (Dox); 
PuroR: puromycin resistance gene; shRNA (shIGF-1R2 as example) and its context, 


































Appendix 5: Predicted trypsin digested β-casein peaks with MALDI-TOF detection. 
  
No. Range Mono MH+ Partials Sequence Composition
2 [  1- 28] 3477.488 1 RELEELNVPGEIVESLSSSEESITRINK(4*Phospho(ST)) C133H229N37O63P4
1 [  1- 25] 3122.266 0 RELEELNVPGEIVESLSSSEESITR(4*Phospho(ST),) C117H200N32O59P4
38 [177-202] 2997.602 1 AVPYPQRDMPIQAFLLYQEPVLGPVR C140H217N35O36S1
41 [184-209] 2909.6 1 DMPIQAFLLYQEPVLGPVRGPFPIIV C140H217N31O34S1
9 [ 29- 48] 2560.145 2 KIEKFQSEEQQQTEDELQDK(1*Phospho(ST)) C104H167N28O45P1
11 [ 30- 48] 2432.05 1 IEKFQSEEQQQTEDELQDK(1*Phospho(ST)) C98H155N26O44P1
40 [184-202] 2186.168 0 DMPIQAFLLYQEPVLGPVR C102H160N24O27S1
13 [ 33- 48] 2061.828 0 FQSEEQQQTEDELQDK(1*Phospho(ST),) C81H125N22O39P1
24 [100-113] 1640.829 2 EAMAPKHKEMPFPK C74H117N19O19S2
35 [170-183] 1591.932 1 VLPVPQKAVPYPQR C75H122N20O18
21 [ 98-107] 1138.64 2 VKEAMAPKHK C50H87N15O13S1
26 [106-113] 1013.524 1 HKEMPFPK C47H72N12O11S1
23 [100-107] 911.477 1 EAMAPKHK C39H66N12O11S1
20 [ 98-105] 873.486 1 VKEAMAPK C38H68N10O11S1
6 [ 26- 32] 872.556 2 INKKIEK C39H73N11O11
37 [177-183] 830.452 0 AVPYPQR C38H59N11O10
34 [170-176] 780.498 0 VLPVPQK C37H65N9O9
28 [108-113] 748.37 0 EMPFPK C35H53N7O9S1
42 [203-209] 742.45 0 GPFPIIV C38H59N7O8
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Appendix 6  
Phosphosites that were quantified and were present in at least two different biological 
replicates. Ratio normalized M/L (log2) = Insulin regulated phosphosites; Ratio normalized 
H/L (log2) = IGF-II regulated phosphosites; Known sites = Known phosphorylation sites in 
PhosPhoSitePlus Database (http://www.phosphosite.org); Localization Prob = 
phosphorylation probability; PEP = localization probability and occupancy error; Score = 
Andromeda score for the best associated MS/MS spectrum; Delta Score = Score difference to 
the second best identified peptide; Up arrow = number above 0.58 (1.5 fold upregulation), 
upregulated; Down arrow = number below -0.58 (1.5 fold downregualtion), downregulated; 



































































AAK1 S_623 + -0.13 -0.04 0.83 0.0119111 55.097 16.082
AAK1 T_620 + -0.09 -0.01 0.99 0.00779702 59.84 16.082
AAK1 S_624 + -0.13 -0.06 0.81 0.00779702 59.84 56.46
AATF S_316 + 0.21 0.13 1.00 7.60E-06 75.539 59.479
AATF S_320 + 0.21 0.13 1.00 7.60E-06 75.539 59.479
AATF S_321 + 0.21 0.13 1.00 7.60E-06 75.539 59.479
ABCF1 S_140 + 0.24 0.17 + + 1.00 5.25E-26 124.82 124.82
ABCF1 S_105 + -0.17 -0.22 + + 1.00 6.86E-06 76.889 57.858
ABCF1 T_108 + -0.06 -0.15 + 1.00 1.43E-38 147.1 74.896
ABCF1 S_109 + 0.20 -0.18 + 1.00 1.43E-38 147.1 74.896
ABLIM3 S_392 + 0.04 0.31 + 1.00 0.00241852 59.709 31.16
ABLIM3 S_393 + 0.04 0.31 + 1.00 0.00241852 59.709 31.16
ACACA S_25 + 0.02 0.17 0.84 5.12E-10 94.955 94.955
ACACA S_23 + 0.23 0.21 + 0.97 0.00010447 74.382 74.382
ACACA S_29 + 0.22 0.11 + 1.00 1.03E-44 149.9 149.9
ACAP2 S_521 + 0.18 0.23 + + 0.99 4.24E-05 92.952 63.875
ACIN1 S_240 + 0.21 0.09 0.76 3.30E-10 95.223 95.223
ACIN1 S_478 + -0.09 -0.11 + 0.99 8.05E-24 114.66 99.599
ACIN1 S_482 + -0.09 -0.11 + 0.75 8.05E-24 114.66 99.599
ACIN1 T_414 + -0.04 -0.34 0.94 0.00071537 57.248 37.171
ACIN1 T_408 + -0.44 -0.69 + 0.80 0.00057802 59.574 59.574
ACIN1 S_410 + 0.12 -0.01 0.90 1.48E-11 90.757 90.757
ACLY S_481 + -0.04 -0.05 1.00 0.00011263 87.99 87.99
ACSS2 S_30 + -0.05 -0.18 + + 1.00 4.71E-08 102.97 69.779
ACSS2 S_267 + -0.15 -0.39 + + 0.98 0.00050767 69.256 33.049
ACTA1;ACTA2;ACTB;ACTBL2;ACTC1;ACTG1;ACTG2;POTEE;POTEF;POTEKPS_197 + 0.26 0.03 0.98 1.97E-05 77.221 57.902
ADAM17 S_791 + 0.80 1.10 + + 1.00 2.84E-05 97.223 59.566
ADD3 S_645 + -0.01 0.10 + + 0.99 1.22E-36 149.19 149.19
ADD3 S_641 + -0.42 -0.25 + + 1.00 1.22E-36 149.19 149.19
ADNP S_953 + 0.12 0.11 1.00 0.00200153 49.924 49.924
ADNP S_955 + 0.12 0.11 1.00 0.00200153 49.924 49.924
AFAP1 S_265 + -0.72 -0.98 + + 0.71 0.00669236 44.735 44.735
AFF4 S_703 + 0.14 -0.02 1.00 0.00298035 53.037 52.009
AFF4 S_706 + 0.14 -0.02 0.98 0.00298035 53.037 52.009
AHCTF1 S_1541 + -0.25 0.07 1.00 0.00712214 72.433 28.84
AHNAK S_5752 + -0.02 -0.18 1.00 3.92E-51 155.47 155.47
AHNAK S_210 + -0.04 0.12 0.99 1.12E-64 163.49 163.49
AHNAK S_177 + -0.05 0.08 + 1.00 3.31E-75 176.18 113.45
AHNAK S_135 + 0.23 0.34 + + 1.00 2.35E-156 217.18 189.15
AHNAK S_5731 + -0.01 0.07 1.00 1.31E-77 180.76 140.28
AHNAK S_4993 + -0.11 -0.20 + 0.68 0.00040676 63.625 63.625
AHNAK S_5110 + -0.34 -0.24 + 1.00 4.09E-06 91.087 44.959
AHNAK S_212 + -0.12 -0.13 + + 0.78 2.93E-16 118.15 118.15
AHNAK S_511 + 0.05 0.03 1.00 2.33E-48 157.73 157.73
AHNAK S_216 + 0.18 0.06 1.00 1.55E-51 181.54 105.2







AHNAK S_5763 + -0.10 -0.16 + + 1.00 6.39E-181 228.99 228.99
AHNAK S_5448 + 0.21 0.07 + 1.00 0.00463215 55.337 29.263
AHNAK S_115 + 0.03 -0.05 1.00 6.83E-05 70.112 52.1
AHNAK S_41 + -0.04 -0.16 1.00 7.69E-96 182.77 182.77
AHNAK S_5749 + 0.41 0.12 + 1.00 3.92E-51 155.47 155.47
AHNAK S_5790 + -0.12 -0.36 + 0.96 8.77E-09 85.518 85.518
AHNAK T_5794 + 0.23 -0.17 + 0.55 3.22E-12 93.529 93.529
AKAP11 S_1240 + -0.23 -0.01 0.78 0.00017979 75.743 50.789
AKAP11 T_1100 + -0.37 -0.55 + + 0.99 1.87E-09 99.092 72.544
AKAP2 S_375 + -0.82 -0.59 + + 0.99 0.00064809 53.278 33.564
AKAP2 S_152 + -0.07 0.12 0.98 1.93E-33 130.05 130.05
AKAP2 S_393 + -0.26 -0.14 + + 1.00 7.37E-74 165 165
AKAP2 S_631 + -0.21 -0.38 + + 0.66 0.0188398 54.412 33.158
AKAP2 S_630 + -0.21 -0.38 + + 0.50 0.0188398 54.412 33.158
AKT1S1 S_212 + -0.26 0.15 0.91 1.69E-05 79.455 29.233
AKT1S1 S_183 + 0.44 0.67 + + 1.00 4.07E-18 119.17 119.17
AKT1S1 S_108 + -0.95 -0.95 + + 0.94 9.64E-10 84.674 84.674
AKT1S1 S_112 + -0.84 -0.95 + 0.95 9.64E-10 84.674 84.674
ALKBH5 S_58 + 0.13 0.23 + 0.56 0.00015306 68.261 40.194
ALKBH5 S_53 + 0.11 0.23 + 0.93 0.00015306 68.261 40.194
ANKRD17 S_1808 + -0.49 -0.29 + + 1.00 9.27E-05 79.326 52.384
ANKS1A S_666 + 0.09 0.33 1.00 5.74E-05 92.096 49.854
ANKS1A S_663 + 0.06 0.24 0.98 2.04E-13 110.04 81.141
ANLN S_524 + 0.03 0.29 0.76 0.00039993 98.188 52.648
ANLN S_525 + -0.14 -0.03 0.50 0.00039993 70.26 54.16
ANLN S_182 + -0.13 -0.39 + 0.93 0.00248265 47.68 47.68
ANXA1 S_5 + 0.96 1.12 + + 1.00 0.0271567 55.064 22.744
AP2M1 T_154 + 0.35 0.29 + + 1.00 1.26E-15 116.58 116.58
AP2M1 S_151 + 0.42 0.27 + + 0.64 0.00247635 57.798 29.816
AP3D1 S_463 + -0.13 -0.30 + 1.00 2.18E-05 63.701 63.701
AP3D1 S_465 + -0.13 -0.30 + 1.00 2.18E-05 63.701 63.701
AP3D1 S_467 + -0.13 -0.30 + 1.00 2.18E-05 63.701 63.701
ARAP1 S_229 + -0.16 -0.48 + + 1.00 7.98E-09 87.098 85.387
ARFGAP1 S_230 + 0.43 0.36 + + 0.95 2.93E-10 99.409 70.085
ARFGEF2 S_227 + -0.23 -0.16 + 1.00 1.48E-06 97.621 72.256
ARFGEF2 S_218 + -0.18 -0.14 1.00 0.00628622 53.327 36.97
ARHGAP12 S_240 + 0.02 -0.12 + 1.00 8.21E-05 70.121 49.951
ARHGAP12 T_230 + 0.02 -0.12 + 0.50 8.21E-05 70.121 49.951
ARHGAP12 T_231 + 0.02 -0.12 + 0.50 8.21E-05 70.121 49.951
ARHGAP12 S_213 + 0.46 0.17 + 0.87 0.00129307 61.096 41.403
ARHGAP17 S_209 + -0.62 -0.40 + 0.52 0.00023005 62.028 41.964
ARHGAP17 T_215 + -0.62 -0.40 + 0.78 0.00063745 55.128 40.557
ARHGAP17 S_108 + -0.47 -0.80 + + 1.00 6.27E-10 77.907 77.907
ARHGAP17 S_207 + -0.28 -0.74 + 0.78 0.00020105 63.158 25.632
ARHGAP18 S_24 + 0.54 0.75 + + 0.98 0.00012869 63.674 44.327
ARHGAP18 S_21 + 0.49 0.71 + 0.82 0.00012869 63.674 44.327
ARHGAP29 S_176 + 0.94 1.11 + + 0.77 3.41E-07 91.733 74.162
ARHGAP29 S_171 + 0.67 0.88 + + 1.00 3.41E-07 91.733 74.162
ARHGAP29 S_1029 + 0.11 0.08 1.00 0.00506458 60.161 14.882
ARHGAP29 S_499 + 0.74 0.16 1.00 0.00142585 65.855 65.855







ARHGAP35 S_1176 + 0.27 0.14 0.96 8.56E-13 109.28 75.111
ARHGAP35 S_1179 + 0.52 0.34 + + 1.00 8.56E-13 109.28 75.111
ARHGAP5 S_1218 + 0.15 0.05 + 0.74 0.00412126 94.325 49.934
ARHGAP5 T_1217 + 0.15 0.05 + 0.50 0.00530656 74.742 28.041
ARHGEF1 S_830 + -0.04 -0.03 1.00 8.07E-05 80.541 17.45
ARHGEF18 S_1124 + -0.64 -0.55 + + 0.89 0.00134796 51.966 31.36
ARHGEF2 S_147 + 0.20 0.32 + + 0.95 0.00052366 83.856 53.944
ARHGEF2 S_124 + 0.13 0.30 0.77 0.00110748 69.422 45.787
ARHGEF2 S_928 + -0.57 -0.42 + + 0.55 0.00675209 40.086 16.173
ARHGEF2 S_932 + -0.57 -0.42 + + 0.74 0.00675209 40.086 16.173
ARHGEF2 S_858 + 0.17 0.04 + 1.00 2.24E-25 123.87 123.87
ARHGEF2 S_668 + 0.06 -0.34 0.94 3.33E-17 99.641 72.291
ARHGEF6;ARHGEF7S_334 + 0.12 0.19 + 1.00 0.00284999 72.289 72.289
ARID1A S_313 + -0.33 -0.45 + + 1.00 3.05E-15 112.34 112.34
ARID4B T_474 + 0.31 0.38 + 0.99 1.39E-30 138.96 101.84
ARID4B S_471 + 0.15 0.16 + 1.00 8.72E-64 166.38 144.18
ARID4B Y_476 + 0.31 0.16 + 0.99 8.72E-64 166.38 144.18
ARL6IP4 S_137 + 0.28 0.19 + 1.00 4.73E-114 194.1 135.94
ASAP1 S_717 + 0.17 0.22 + 1.00 0.00461444 44.045 44.045
ATN1 S_101 + 0.02 -0.33 0.87 0.0086285 41.988 27.195
ATN1 S_107 + 0.02 -0.33 0.96 0.0086285 41.988 27.195
ATP2B1 T_1129 + -0.14 -0.27 + 1.00 4.05E-08 84.371 66.018
ATP2B1 S_1119 + -0.12 -0.38 + 1.00 1.23E-31 129.02 129.02
ATRX S_392 + -0.15 0.13 0.75 0.0118226 46.89 29.826
ATRX S_473 + 0.11 0.02 0.97 2.82E-05 77.554 52.57
ATXN2L S_111 + -0.18 -0.14 + + 1.00 5.42E-21 120.32 120.32
ATXN2L S_594 + -0.06 -0.14 1.00 1.92E-64 161.59 138.06
ATXN2L S_559 + 0.10 -0.33 0.92 1.43E-15 115.91 115.91
ATXN2L T_632 + -0.64 -0.97 + + 0.62 1.13E-15 95.746 65.571
ATXN2L S_634 + -0.76 -1.36 + + 0.93 1.13E-15 95.746 65.571
BAG3 S_173 + 0.02 -0.04 0.79 1.62E-23 111.38 104.97
BAG3 T_285 + -0.43 -0.55 + + 0.81 2.92E-07 100.4 61.509
BAG3 S_289 + -0.52 -0.55 + + 0.98 2.92E-07 100.4 61.509
BAG3 S_291 + -0.27 -0.42 + + 0.79 0.0001821 87.99 53.03
BAG3 S_171 + 0.10 -0.20 + 0.72 4.84E-17 104.97 104.97
BAG3 S_381 + -0.62 -0.84 0.67 0.0171806 42.639 18.361
BAG3 S_386 + -0.89 -1.05 + + 0.89 2.07E-48 141.82 141.82
BAG3 S_385 + -0.85 -1.18 + + 0.57 2.07E-18 166.62 135
BAG3 S_377 + -1.02 -1.56 + + 1.00 2.07E-48 166.62 135
BAG6 S_1003 + 0.09 -0.19 + 1.00 2.38E-06 85.397 85.397
BAP18 S_62 + -0.20 -0.14 1.00 2.39E-08 96.464 96.464
BAZ1B S_1464 + 0.19 -0.01 + 1.00 1.71E-39 145.73 127.71
BCL9L S_970 + -0.07 0.02 1.00 0.0019293 65.231 65.231
BCL9L S_944 + -0.19 -0.11 0.90 0.00088334 72.21 46.623
BCL9L S_929 + -0.17 -0.09 + 0.99 0.00066039 90.872 50.258
BCLAF1 S_510 + -0.06 0.06 1.00 6.89E-36 147.73 117.62
BCLAF1 S_395 + 0.15 0.18 + + 1.00 1.06E-115 238.49 209.85
BCLAF1 S_485 + 0.14 0.11 + + 1.00 4.59E-13 111.52 53.251
BCLAF1 Y_282 + -0.20 -0.14 + + 0.77 0.00853315 44.662 35.164
BCLAF1 S_283 + -0.16 -0.15 + 0.78 0.0155124 50.178 38.277







BCLAF1 S_288 + -0.15 -0.11 0.75 0.0129369 47.088 47.088
BCLAF1 S_383 + 0.14 0.09 + 1.00 3.56E-51 157.38 138.56
BECN1 S_421 -0.11 -0.15 0.94 0.00051297 59.242 59.242
BECN1 T_406 + -0.11 -0.15 0.69 0.00051297 59.242 59.242
BIN1 S_265 + -0.21 -0.34 + 0.93 5.69E-06 81.639 47.244
BIN1 S_267 + -0.16 -0.16 + 0.81 5.69E-06 84.249 44.518
BLOC1S3 S_65 + 0.13 -0.26 1.00 0.00583738 55.977 26.69
BLOC1S3 T_63 + 0.13 -0.26 1.00 0.00583738 55.977 26.69
BMP2K S_947 + 0.33 0.09 0.50 1.41E-05 78.025 39.84
BMP2K S_949 + 0.33 0.09 0.50 1.41E-05 78.025 39.84
BMS1 S_639 + 0.13 -0.02 0.87 8.03E-16 118.23 58.524
BOD1L1 S_2986 + -0.06 0.24 1.00 0.00651428 52.464 33.112
BOD1L1 S_482 + 0.07 0.07 + + 1.00 5.85E-48 156.08 123.77
BOD1L1 S_484 + 0.07 0.07 + + 1.00 5.85E-48 156.08 123.77
BPTF S_2339 + -0.20 -0.35 + + 1.00 1.58E-07 87.323 70.082
BRD2 S_178 + -0.13 -0.69 + 1.00 1.43E-10 119.16 95.287
BRD2 S_181 + -0.13 -0.69 + 0.99 1.43E-10 119.16 95.287
BRD3 S_263 + -0.15 -0.34 0.98 0.00494479 55.196 55.196
BRD8 T_124 + -0.37 -0.09 + + 1.00 0.00116601 69.979 69.979
BRD8 S_128 + -0.58 -0.54 + + 1.00 0.00116601 69.979 69.979
BYSL S_98 + -0.13 -0.23 + + 1.00 3.83E-22 123.65 92.259
C11orf84 S_251 + -0.46 -0.53 + 0.61 0.00046341 65.207 48.913
C11orf84 S_308 + -0.40 -0.52 + 0.99 0.0346018 47.217 27.463
C11orf84 S_248 + -0.31 -0.49 + 0.89 0.00046341 65.207 48.913
C15orf52 S_133 + 0.02 0.12 1.00 0.00026887 77.899 77.899
C1orf52 S_158 + 0.08 0.05 1.00 5.43E-112 199.91 136.45
C2CD2L S_662 + 0.20 0.29 + + 0.80 0.0143094 42.123 21.523
C2CD5 S_260 + -0.19 -0.18 + + 0.80 0.0200834 41.838 26.397
C2orf49 S_185 + -0.25 -0.09 + 1.00 0.0189399 72.187 15.66
C9orf142 S_148 + -0.08 0.16 1.00 0.00047025 82.651 63.408
CAD S_1859 + 0.13 0.19 1.00 0.00212881 55.98 38.839
CANX S_475 + 0.26 0.26 + + 1.00 2.89E-18 121.95 74.316
CAP1 S_309 + -0.31 -0.44 + + 1.00 6.54E-93 185.96 185.96
CAP1 S_307 + 0.04 -0.28 + 0.98 6.54E-93 185.96 185.96
CAP1 T_306 + 0.01 -0.27 + + 0.86 4.06E-27 130.52 130.52
CARHSP1 S_41 + -0.15 -0.13 + + 1.00 9.23E-05 89.26 65.882
CAST S_125 + -0.05 -0.13 + 0.97 2.46E-39 131.69 104.28
CCAR1 S_360 4.76 1.95 + + 1.00 0.00043531 72.489 32.33
CCAR1 T_348 4.76 1.95 + + 0.99 0.00043531 72.489 32.33
CCAR1 Y_347 4.76 1.95 + + 0.98 0.00043531 72.489 32.33
CCDC43 T_139 + 0.33 0.38 + + 1.00 4.73E-25 126.45 126.45
CCDC6 S_240 + -0.24 -0.09 + 1.00 1.22E-25 130.77 101.81
CCDC6 S_244 + -0.05 0.10 + 1.00 1.22E-25 130.77 101.81
CCDC86 S_47 + -0.22 -0.35 + + 0.99 9.32E-24 110.44 110.44
CCDC86 S_18 + -0.04 -0.14 0.65 0.00240013 53.008 53.008
CCDC86 S_80 + -0.31 -0.48 + + 1.00 4.06E-11 91.64 91.64
CCDC86 S_91 + -0.22 -0.50 + + 1.00 4.24E-89 175.26 156.71
CCDC94 S_211 + -0.43 -0.47 + + 1.00 0.00014177 67.645 33.497
CCDC94 S_213 + -0.43 -0.47 + + 1.00 0.00014177 67.645 33.497
CCNL1 S_352 + 0.00 0.02 1.00 0.00053016 80.916 45.298








CCNL1 S_338 + -0.29 -0.37 + 0.88 7.39E-13 92.034 65.315
CCNL1 S_335 + -0.07 -0.07 + 0.99 7.39E-13 92.034 65.315
CCNL1 S_342 + -0.27 -0.39 + 0.78 7.39E-13 92.034 65.315
CCNY S_272 + 0.18 0.22 + + 0.83 8.53E-05 81.789 23.195
CCNYL1 S_274 + 0.39 0.12 + 1.00 4.44E-48 160.03 131.64
CD2AP S_458 + 0.95 1.09 + + 1.00 5.17E-75 173.19 134.61
CD3EAP S_136 + 0.20 -1.15 + 1.00 8.43E-05 65.801 45.195
CD44 S_304 + -0.12 -0.01 + 1.00 1.76E-05 82.651 56.003
CDC23 S_470 + 0.12 0.12 0.71 0.00216651 54.004 28.304
CDC23 T_478 + 0.12 0.12 1.00 0.00177253 84.479 53.058
CDC26 S_42 + 0.45 -0.11 + 1.00 1.26E-07 78.3 78.3
CDC37 S_13 + 0.22 0.40 + 0.93 0.00020784 51.659 31.538
CDC42EP1 S_192 + 0.03 0.12 1.00 5.56E-15 109.72 61.877
CDC42EP1 S_121 + -0.04 -0.13 1.00 0.00015837 70.994 70.994
CDC42EP1 S_195 + 0.04 0.12 + 1.00 5.56E-15 109.72 61.877
CDC42EP1 S_343 + 0.44 0.03 1.00 0.00996573 88.108 63.693
CDC42EP1 S_346 + 0.44 0.03 1.00 0.00996573 88.108 63.693
CDC42EP2 S_141 + -0.33 -0.53 0.88 0.00401204 45.237 29.577
CDC42EP2 T_137 + -0.33 -0.53 1.00 0.00401204 45.237 29.577
CDC42EP3 S_89 + -0.41 -0.34 + 0.57 0.00266957 61.709 61.709
CDC42EP3 S_100 + -0.19 -0.12 + 0.99 8.98E-08 89.029 55.482
CDK1;CDK2;CDK3Y_15 + 0.10 0.25 + 1.00 3.09E-25 132.06 68.899
CDK1;CDK2;CDK3T_14 + -0.13 -0.01 + 1.00 9.17E-35 144.77 54.619
CDK11A;CDK11BS_124 + 0.22 -0.24 1.00 7.98E-05 68.434 52.773
CDK11A;CDK11BT_123 + 0.22 -0.24 1.00 7.98E-05 68.434 52.773
CDK11A;CDK11BS_14 + 0.17 0.12 1.00 5.96E-37 146.28 146.28
CDK12 S_684 + -0.35 -0.61 + + 1.00 2.77E-26 110.6 110.6
CDK12 S_680 + -0.39 -0.74 + + 1.00 2.77E-26 110.6 110.6
CDK13 S_395 + -0.07 0.15 + 1.00 6.74E-08 104.16 64.733
CDK13 S_397 + -0.07 0.15 + 1.00 6.74E-08 104.16 64.733
CDK13 S_400 + -0.07 0.15 + 0.98 6.74E-08 104.16 64.733
CDK13 S_437 + 0.12 0.02 0.95 0.0175624 45.452 45.452
CDYL S_160 + 0.05 -0.29 0.64 3.28E-05 54.711 54.711
CEP170 S_356 + -0.03 0.04 1.00 6.46E-18 120.59 83.99
CEP170 S_359 + -0.03 0.04 1.00 6.46E-18 120.59 83.99
CEP55 S_428 + -0.40 -0.26 + 0.96 1.82E-27 133.35 133.35
CFL1 S_3 + 0.05 0.25 + + 1.00 2.78E-91 184.51 127.24
CFL2 S_3 + 0.14 0.29 + + 1.00 6.55E-05 93.424 38.177
CHAMP1 S_217 + -0.49 -0.45 + 0.74 5.02E-05 70.837 70.837
CHAMP1 S_282 + -0.25 -0.37 + 1.00 0.00055854 90.453 52.153
CHAMP1 S_653 + 0.11 0.13 0.92 0.00061976 65.887 46.926
CHAMP1 S_204 + -0.46 -0.51 + + 1.00 3.83E-05 72.433 72.433
CHAMP1 S_214 + -0.46 -0.51 + + 0.90 3.83E-05 72.433 72.433
CHAMP1 S_459 + -0.06 -0.11 0.87 0.00945577 64.104 20.334
CHAMP1 S_427 + -0.37 -0.58 + + 1.00 5.51E-06 76.133 76.133
CHAMP1 S_432 + -0.37 -0.58 + + 1.00 5.51E-06 76.133 76.133
CHAMP1 S_436 + -0.37 -0.58 + + 1.00 5.51E-06 76.133 76.133
CHAMP1 S_286 + -0.33 -0.42 0.93 0.00056142 90.453 52.153
CHAMP1 S_627 + 0.26 0.12 + 0.93 0.00022566 71.263 46.309








CHAMP1 S_651 + 0.27 0.26 + 0.81 6.09E-05 75.718 58.294
CHAMP1 S_452 + -0.08 0.00 0.99 0.00706419 46.89 33.991
CHAMP1 S_652 + 0.38 0.07 0.81 6.09E-05 75.718 58.294
CHD4 T_1553 + -0.72 -0.95 0.97 0.0103178 43.501 17.039
CHD8 S_1141 + 0.12 0.16 1.00 1.18E-06 82.59 69.165
CHD8 S_1145 + 0.12 0.16 1.00 1.18E-06 82.59 69.165
CHTF18 S_453 + -0.08 -0.02 1.00 1.60E-08 86.617 69.266
CIC S_1373 + -0.36 -0.70 + + 0.91 5.46E-05 66.401 48.561
CIC S_1382 + -0.36 -0.70 + + 0.57 5.46E-05 66.401 48.561
CIR1 S_202 + 0.51 0.20 1.00 0.00102108 57.145 38.823
CLASP2 S_596 + 0.09 0.03 0.86 0.0015513 81.854 51.115
CLASP2 S_525 + -0.14 -0.01 + 0.80 0.00745797 53.861 53.861
CLASP2 S_529 + -0.14 -0.01 + 1.00 0.00745797 53.861 53.861
CLIC6 S_293 + 0.33 0.00 0.96 5.81E-07 69.77 69.77
CLIP1 S_197 + -0.09 0.50 + 0.62 0.00531593 66.777 29.281
CLIP1 S_204 + 0.05 0.27 + 1.00 3.73E-21 124.85 75.078
CLIP1 S_200 + 0.05 0.20 + 1.00 3.73E-21 124.85 75.078
CLNS1A S_102 + -0.05 -0.13 + 1.00 2.05E-89 179.33 179.33
CLSPN S_225 + 0.00 0.07 1.00 2.09E-39 135.64 114.87
COIL T_122 + -0.11 -0.14 1.00 0.00054127 79.837 54.218
COPA S_173 + 0.10 0.13 + 1.00 4.12E-05 93.106 93.106
COPB2 S_830 + 0.11 -0.01 0.92 0.0001357 63.128 63.128
COPB2 T_832 + -0.08 -0.09 0.76 0.00139608 54.985 54.985
CPD T_1123 + 0.04 0.02 0.96 0.00140006 48.567 39.527
CSNK2B S_2 + 0.32 0.38 0.65 0.00226909 79.489 52.83
CSNK2B S_3 + 0.32 0.38 0.69 0.00226909 79.489 52.83
CSNK2B S_4 + 0.32 0.38 0.65 0.00793297 43.164 29.556
CTAGE5 S_456 + 0.68 0.61 1.00 7.96E-05 85.576 70.456
CTNNA1 S_271 + 0.15 -0.07 + 1.00 5.42E-181 229.68 202.52
CTNND1 S_248 + -0.07 -0.10 1.00 0.00740127 51.466 26.999
CTNND1 S_251 + -0.07 -0.10 1.00 0.00740127 51.466 26.999
CTNS S_394 -3.12 -1.50 0.82 0.0293247 43.946 16.265
CTNS S_397 + -3.12 -1.50 0.76 0.0293247 43.946 16.265
CTNS S_392 -3.43 -2.57 0.51 0.0293247 41.513 15.076
CTNS S_396 -3.43 -2.57 0.81 0.0293247 43.946 16.265
CTPS1 S_344 + -0.01 0.18 0.97 5.50E-14 118.55 118.55
CTPS1 S_342 + 0.11 0.06 0.84 0.00113256 69.379 44.924
CTPS1 S_343 + 0.21 0.12 0.98 0.00113256 69.379 44.924
CTR9 T_925 + 0.20 0.03 + 1.00 1.54E-13 101.62 78.189
CTTN S_389 + 0.72 0.92 + + 0.79 0.0249585 47.499 10.576
CTTN S_380 + 0.04 0.03 0.67 1.80E-09 108.18 92.639
CTTN S_381 + 0.40 0.18 + + 1.00 4.71E-94 191.36 163.42
CTTN T_362 + -0.18 -0.45 + + 0.89 2.55E-29 136.77 98.718
CTTN S_368 + -0.14 -0.49 + + 1.00 2.52E-51 160.12 123.67
CTTN T_364 + 0.27 -0.34 + 1.00 2.52E-51 160.12 123.67
CTTNBP2NL S_481 + 0.21 -0.03 0.94 0.00015856 70.986 70.986
CXADR S_291 + -0.49 -0.11 + 0.88 0.00587273 54.09 14.36
DAP S_51 + 0.08 -0.01 0.99 2.40E-08 83.395 69.53
DAXX S_596 + -0.48 -0.29 + 0.94 9.67E-05 69.986 69.986








DBN1 S_339 + -0.40 -0.38 + + 0.75 3.20E-51 151.2 109.09
DBN1 T_335 + -0.53 -0.58 + 0.82 2.13E-21 108.57 108.57
DBN1 S_337 + -0.37 -0.47 + + 0.84 1.04E-22 127.9 92.859
DCAF6 S_649 + -0.07 -0.42 0.97 7.53E-05 73.865 73.865
DCAF6 S_657 + 0.12 -0.07 0.98 6.66E-05 73.865 73.865
DCAF6 T_654 + 0.08 -0.34 0.95 6.66E-05 67.153 44.613
DCAF8 S_99 + 0.45 0.45 + 1.00 0.00810893 54.875 29.617
DCP1A S_281 + -0.72 -0.49 + + 0.89 3.18E-09 79.512 79.512
DCP1A S_277 + -0.72 -0.43 + + 0.98 3.18E-09 79.512 79.512
DCP1A T_283 + -0.78 -0.51 + + 0.88 9.16E-05 52.721 52.721
DDX21 S_121 + -0.40 -0.30 + + 1.00 2.49E-37 145.73 98.105
DDX41 S_21 + 0.14 0.59 + 0.80 0.00269044 43.696 33.257
DDX41 S_23 + 0.02 -0.05 1.00 0.00269044 51.688 35.048
DDX42 S_109 + -0.04 -0.08 1.00 2.93E-06 87.496 63.139
DDX42 S_111 + -0.04 -0.08 1.00 2.93E-06 87.496 63.139
DDX46 S_804 + 0.15 0.12 + 1.00 0.00041846 56.225 45.566
DDX54 T_70 -0.62 -0.89 + + 0.62 2.50E-24 119.37 86.102
DDX55 S_151 + 0.23 0.11 1.00 1.31E-10 97.059 97.059
DEK T_15 + -0.09 -0.03 0.97 2.23E-09 85.496 85.496
DHX16 S_106 + 0.09 -0.04 + 1.00 1.62E-13 117.22 117.22
DHX16 S_103 + 0.08 0.16 + + 1.00 1.62E-13 117.22 117.22
DHX16 S_107 + 0.07 0.05 1.00 5.70E-13 112.56 43.533
DHX29 S_200 + -0.15 -0.37 1.00 1.27E-07 88.951 88.951
DIDO1 S_1040 + -0.14 0.03 + 1.00 2.89E-05 91.355 91.355
DIDO1 S_805 + -0.35 -0.46 + 1.00 0.00349625 54.12 48.852
DKC1 S_453 + -0.55 -0.02 + 1.00 8.02E-07 99.078 51.476
DKC1 S_451 + -0.52 0.11 + 1.00 8.02E-07 99.078 51.476
DKC1 S_455 + -0.23 -0.02 0.99 8.02E-07 85.362 36.455
DNAJC1 S_480 + -0.16 0.14 0.96 3.42E-08 88.385 88.385
DNAJC1 S_479 + -0.10 0.16 0.96 3.42E-08 88.385 88.385
DNAJC1 S_484 + 0.01 0.11 0.95 0.00277675 63.681 14.089
DNAJC2 S_60 + -0.03 0.16 1.00 0.00177956 78.484 47.095
DNAJC2 S_63 + -0.03 0.16 1.00 0.00177956 78.484 47.095
DNAJC5 S_10 + 0.14 0.32 + + 0.92 1.08E-08 97.49 97.49
DNM1L S_413 + -0.48 -0.40 + + 1.00 1.70E-05 88.385 67.138
DNM2 S_758 + -0.24 0.33 0.53 9.94E-08 60.194 60.194
DNMT1 S_378 + -0.69 -0.60 + + 1.00 1.09E-09 88.239 64.301
DOCK5 S_1789 + -0.23 -0.70 + 1.00 3.41E-05 74.703 35.045
DOCK5 T_1794 + -0.23 -0.70 + 1.00 3.41E-05 74.703 35.045
DOCK7 T_907 + -0.02 -0.43 0.82 3.73E-14 98.747 64.675
DOCK7 S_900 + -0.11 -0.53 + 0.99 3.79E-69 178.42 135.19
DOCK9 S_37 + 0.13 0.05 1.00 1.28E-15 110.1 110.1
DOK1 S_142 + 0.13 -0.53 + 1.00 0.00112461 56.453 21.979
DOK1 S_152 + -0.02 -0.86 + 0.99 0.00061782 61.241 61.241
DSP S_2008 + -0.08 0.24 0.69 4.20E-08 83.082 65.32
DSP S_2007 + -0.08 0.24 0.67 4.20E-08 83.082 65.32
DSTN S_3 + 0.35 0.35 + + 1.00 2.54E-35 141.85 116.38
DTNBP1 S_235 + 0.61 0.53 + 0.94 0.00079661 49.503 34.704
DTNBP1 S_240 + 0.61 0.53 + 0.99 0.00079661 49.503 34.704








DYNC1I2 S_104 + 0.23 0.19 0.61 0.00886435 42.029 13.636
DYNC1LI1 T_512 + -0.60 -0.46 + + 0.91 1.56E-42 143.52 143.52
DYNC1LI1 T_513 + -0.49 -0.44 + + 0.94 1.56E-42 143.52 143.52
DYNC1LI1 S_207 + -0.14 -0.41 + + 1.00 3.18E-31 146.67 95.596
DYNC1LI1 T_515 + -0.32 -0.61 + + 0.72 4.76E-18 110.91 110.91
DYNC1LI1 S_510 + -0.10 -0.59 + + 0.89 1.17E-06 82.449 82.449
DYNC1LI1 S_516 + -0.31 -0.71 + + 0.92 6.01E-26 127.58 127.58
DYNC1LI2 S_117 + 0.10 0.01 + 1.00 1.27E-15 110.13 73.534
EAF1 S_165 + -0.26 -0.34 + 1.00 0.0197078 58.32 11.018
EBAG9 S_36 + 0.27 -0.44 1.00 0.00037769 62.203 62.203
EEF1B2 S_106 + 0.50 0.38 + + 1.00 7.33E-11 156.02 126.84
EEF1B2 S_95 + 0.13 -0.04 1.00 4.17E-135 206.95 206.95
EEF1D S_109 + -0.19 -0.08 + + 0.60 0.0382145 42.976 31.861
EEF1D S_138 + -0.12 -0.11 1.00 3.27E-68 158.89 158.89
EFHD2 S_74 + -0.19 -0.20 + 0.99 2.44E-19 119.37 87.476
EGFR S_1166 + 0.60 0.52 + + 0.99 4.55E-05 88.637 51.862
EGFR S_1162 + 0.48 0.60 + + 0.65 3.81E-15 108.25 108.25
EGFR T_693 + -0.05 -0.39 + 1.00 1.87E-42 142.93 142.93
EHBP1 S_391 + -0.04 0.36 0.73 2.47E-08 95.153 78.588
EHBP1 S_401 + -0.04 0.14 1.00 5.37E-11 103.92 84.514
EHBP1 S_393 + -0.08 0.06 0.86 5.37E-11 103.51 84.209
EHBP1 S_397 + -0.31 -0.38 + + 1.00 5.37E-11 103.92 84.514
EHD2 S_302 + 0.10 0.06 1.00 1.75E-08 104.38 74.342
EIF2A S_292 + -0.27 -0.42 + + 1.00 7.84E-62 165.16 145.87
EIF2A S_289 + -0.16 -0.30 0.84 6.14E-07 85.166 85.166
EIF2S2 S_2 + 0.11 0.16 1.00 0.00073484 61.165 61.165
EIF3C;EIF3CL S_39 + 0.00 0.04 1.00 1.79E-27 138.98 104.23
EIF3G S_42 + -0.42 -0.45 + + 0.96 2.27E-51 150.23 150.23
EIF3G T_38 + -0.52 -1.02 + + 0.71 1.20E-08 87.352 61.942
EIF3G T_41 + -0.36 -0.82 + + 0.96 2.27E-51 150.23 150.23
EIF3J S_11 + 0.25 0.32 + + 1.00 6.68E-28 116.73 116.73
EIF3J S_13 + 0.22 0.15 + + 1.00 2.13E-56 144.33 127.06
EIF4B S_93 + -0.13 -0.31 + 1.00 4.78E-44 146.17 146.17
EIF4EBP1 Y_34 + 0.13 0.00 0.95 0.00016534 64.583 48.277
EIF4EBP1 T_50 + 0.05 -0.02 0.78 2.61E-15 94.841 72.85
EIF4EBP1 T_46 + 0.08 -0.05 0.84 8.88E-23 108.31 104.32
EIF4EBP1 T_37 + 0.08 0.00 + 0.95 8.88E-23 108.31 104.32
EIF4EBP2 T_46 + 0.34 0.28 + 0.96 1.36E-09 79.663 65.025
EIF4EBP2 T_37 + 0.34 -0.11 + 0.90 1.36E-09 79.663 65.025
EIF5B S_107 + -0.06 0.70 + + 1.00 1.42E-93 187.04 144.4
EIF5B S_113 + 0.16 0.16 + + 1.00 1.42E-93 188.16 131.86
EIF5B S_214 + 0.00 0.02 1.00 1.66E-100 189.07 189.07
ELMO3 S_51 -0.15 -0.07 + 0.72 0.0126158 46.324 16.514
EME1 S_84 + 0.36 0.15 + 1.00 0.00190249 66.772 38.445
EME1 S_85 + 0.36 0.15 + 1.00 0.00190249 66.772 38.445
EME1 S_87 + 0.36 0.15 + 1.00 0.00190249 66.772 38.445
EPB41L2 S_87 + 0.17 -0.01 0.86 0.0420283 43.297 11.079
EPHA2 S_899 + -0.35 -0.10 + 0.98 1.58E-05 94.487 94.487
EPHA2 S_897 + -0.06 0.07 + 0.98 2.51E-08 105.19 75.558




EPHA2 T_898 + -0.11 0.07 + 0.87 4.27E-07 99.069 69.489
EPN1 T_444 + -0.06 -0.27 0.99 1.53E-14 100.01 100.01
EPN1 S_447 + 0.44 -0.01 0.82 0.00010382 67.396 46.088
EPRS S_880 + -0.12 -0.33 + 0.65 0.00116539 64.705 58.864
EPRS S_886 + -0.28 -0.72 + + 0.90 9.95E-19 109.5 78.819
EPRS S_885 + -0.10 -0.62 + 0.77 1.91E-25 124.7 71.67
EPS15 S_500 + -0.16 -0.46 + + 1.00 2.10E-13 113.73 113.73
ERCC5 S_384 + 0.06 0.09 1.00 5.23E-13 114.03 89.53
ERCC5 S_563 + 0.08 0.24 1.00 8.01E-08 103.67 60.692
ERCC5 S_562 + 0.08 0.16 1.00 8.01E-08 103.67 60.692
ERCC6 S_429 + 0.16 -0.13 0.97 1.85E-05 60.029 31.753
ERCC6 S_430 + 0.16 -0.13 0.97 1.85E-05 60.029 31.753
ESF1 S_657 + 0.00 -0.13 1.00 0.00017606 66.31 52.505
ESF1 S_663 + 0.00 -0.13 1.00 0.00017606 66.31 52.505
ESYT2 T_160 + 0.04 -0.30 + 0.98 3.14E-14 103.85 103.85
ESYT2 S_168 + -0.02 -0.41 + 1.00 3.14E-14 103.85 103.85
ESYT2 S_165 + 0.03 -0.34 + 0.99 3.14E-14 103.85 103.85
ESYT2 S_162 + -0.02 -0.52 + 0.97 1.29E-10 97.94 97.94
EVA1A S_114 + 0.12 0.17 + 1.00 2.90E-26 136.6 98.887
EVI2B T_267 + 0.41 0.14 0.97 0.00115967 68.123 50.916
EVI2B S_268 + 0.26 0.24 + + 0.99 1.17E-18 127.2 127.2
EVI2B S_295 0.11 0.00 + 0.55 0.00027813 73.294 52.022
EVI2B S_271 + 0.17 0.26 + + 1.00 1.17E-18 127.2 127.2
EVI2B S_294 + 0.23 0.01 + 0.90 1.31E-13 115.74 115.74
EXOC7 S_250 + -0.11 -0.21 + 0.97 0.00260892 59.585 12.523
EXOSC9 S_222 + -0.09 -0.16 + + 0.98 1.75E-19 129.17 89.508
EXOSC9 T_221 + -0.14 -0.09 0.50 0.00039442 92.039 92.039
FAM122A S_143 + -0.55 -0.24 + + 1.00 0.00513729 73.675 33.033
FAM122A S_147 + -0.55 -0.24 + + 0.99 0.00513729 73.675 33.033
FAM129A S_602 + 0.70 0.53 + + 0.96 3.82E-06 74.222 52.272
FAM129A S_646 + 0.29 -0.06 + 0.59 0.00676944 44.743 44.743
FAM129B S_628 + -0.35 -0.20 + + 1.00 1.01E-20 102.76 102.76
FAM129B S_633 + -0.26 -0.38 + + 0.99 1.01E-20 102.76 102.76
FAM129B S_683 + -0.34 -0.61 + + 1.00 2.33E-14 105.71 105.71
FAM129B S_678 + -0.35 -0.44 + + 0.94 2.33E-14 105.71 105.71
FAM129B S_679 + -0.29 -1.13 + + 0.92 7.05E-10 93.712 93.712
FAM134C S_118 + 0.20 0.33 + 0.99 9.02E-08 84.166 65.143
FAM134C S_125 + 0.25 0.01 + 0.89 9.02E-08 84.166 65.143
FAM178A S_710 + 0.06 0.27 + 1.00 0.00122432 58.461 37.513
FAM178A T_711 + 0.06 0.27 + 1.00 0.00122432 58.461 37.513
FAM195B S_21 + 0.14 -0.11 + 0.97 0.00113368 62.099 40.856
FAM208A S_1042 + -0.25 -0.08 + 0.87 0.0125388 45.722 20.38
FAM219A T_102 + -0.27 -0.13 + + 1.00 4.88E-21 126.96 126.96
FAM219A S_104 + -0.28 -0.13 + + 1.00 4.88E-21 126.96 126.96
FAM21A S_539 + 0.33 0.44 + + 1.00 4.05E-55 153.93 153.93
FAM21A;FAM21CS_443 + 0.12 0.37 1.00 0.0003355 70.02 43.089
FAM21A;FAM21CS_595 + 0.34 0.39 0.99 0.00081248 59.912 59.912
FAM21A;FAM21CS_596 + 0.34 0.39 0.99 0.00081248 59.912 59.912
FAM21A;FAM21CS_278 + 0.29 0.25 + + 0.95 0.0014773 72.615 33.942





FASN T_2204 + -0.14 -0.10 1.00 3.67E-67 150.64 135.27
FCHO2 S_463 + -0.19 -0.53 0.75 8.72E-07 76.351 60.364
FCHO2 S_455 + -0.33 -0.54 + + 1.00 8.72E-07 76.351 60.364
FCHO2 S_500 + 0.31 -0.28 + 0.78 9.58E-09 84.674 84.674
FERMT2 S_159 + 0.21 -0.16 1.00 4.75E-06 62.034 62.034
FGFR1OP S_160 + -0.38 -0.16 + 1.00 0.00103406 53.254 53.254
FGFR1OP S_156 + -0.33 -0.23 + 0.93 0.00103406 53.254 53.254
FKBP15 S_1154 + 0.20 0.21 1.00 5.88E-08 105 105
FKBP15 S_1152 + 0.20 0.22 + + 0.58 5.88E-08 105 105
FKBP15 S_1151 + 0.31 0.24 0.89 0.00147277 99.813 59.536
FLII S_801 + -0.25 -0.17 + + 1.00 4.69E-13 114.55 90.27
FLNA S_2144 + -0.04 0.15 + 1.00 1.44E-07 104.68 69.639
FLNB S_1927 + 0.30 0.07 + 1.00 3.82E-39 144.4 111.96
FLNB S_2301 + 0.50 0.25 + + 0.97 7.77E-05 72.286 72.286
FLNC S_2200 + 1.57 1.50 + + 1.00 4.00E-13 112.5 83.436
FMNL1 S_184 + 0.18 0.33 + + 1.00 2.90E-36 144.3 121.72
FNBP4 S_116 + -0.14 -0.03 0.98 0.00118506 53.995 31.013
FNDC3B S_208 + 0.06 0.03 1.00 0.00413432 62.162 25.634
FOSL1 S_74 + -0.68 -0.41 + + 1.00 1.80E-47 151.04 151.04
FOSL2 S_161 + -0.23 0.14 + 1.00 0.00216242 73.219 29.922
FOXK1 S_213 + -0.52 -0.51 + + 1.00 2.30E-14 103.6 86.989
FOXK1 S_223 + -0.52 -0.51 + + 1.00 2.30E-14 103.6 86.989
FOXK1 S_253 + -0.44 -0.57 + + 0.53 0.0297469 42.639 15.263
FOXK1 S_257 + -0.44 -0.57 + + 0.83 0.0297469 42.639 15.263
FOXK2 S_30 + -0.23 -0.22 + + 0.97 1.92E-05 47.128 19.574
FRMD6 S_167 + -0.16 0.31 + 1.00 3.28E-12 112.53 85.023
FRMD6 S_164 + 0.12 0.08 0.99 3.28E-12 112.53 85.023
FRMD6 S_186 + 0.17 0.10 1.00 6.31E-13 108.68 76.255
FTSJ3 S_336 + 0.22 0.40 + + 0.99 1.82E-12 96.923 96.923
FTSJ3 S_335 + 0.25 0.41 + + 0.99 1.82E-12 96.923 96.923
FXR2 S_601 + 0.25 0.28 + + 0.99 1.14E-06 80.031 80.031
FXR2 S_603 + 0.20 0.28 + + 1.00 3.68E-19 110.94 110.94
FXR2 T_598 + 0.29 0.28 0.75 3.68E-19 110.94 110.94
G3BP1 S_149 + -0.20 0.05 1.00 8.99E-14 117.21 93.911
G3BP1 S_232 + -0.13 -0.35 + 0.78 8.65E-22 121.45 114.78
GALT T_2 0.12 0.42 0.83 0.0103817 60.55 9.2487
GALT T_15 0.12 0.42 0.84 0.0103817 60.55 9.2487
GATAD2A S_107 + -0.34 -0.25 + + 1.00 4.18E-05 74.029 74.029
GATAD2A S_100 + -0.10 -0.31 + + 1.00 2.60E-14 99.371 99.371
GATAD2A S_114 + -0.10 -0.31 + + 1.00 2.60E-14 99.371 99.371
GATAD2A S_113 + 0.05 -0.41 0.81 0.0019131 71.709 42.398
GATAD2B S_122 + 0.03 0.01 1.00 4.93E-15 99.549 80.596
GATAD2B T_120 + 0.03 0.01 1.00 4.93E-15 99.549 80.596
GATAD2B S_129 + -0.06 0.06 1.00 4.93E-15 99.549 80.596
GATAD2B S_135 + -0.16 -0.03 1.00 4.93E-15 99.549 80.596
GBF1 S_1298 + -0.13 -0.23 + 0.89 4.08E-05 68.211 68.211
GBF1 S_1300 + -0.09 -0.35 0.69 0.00152862 55.012 55.012
GFPT1 T_244 + 0.55 0.45 + + 0.65 8.07E-18 127.66 127.66
GFPT1 S_243 + 0.67 0.48 + + 0.99 1.29E-36 147.7 147.7




GIGYF2 S_26 + -0.15 -0.46 + 0.99 5.95E-44 149.64 110.92
GIGYF2 S_30 + -0.15 -0.46 + 1.00 5.95E-44 149.64 110.92
GIGYF2 T_25 + -0.11 -0.59 0.64 2.48E-09 88.627 88.627
GIT2 S_337 + 1.26 0.87 0.99 0.000531 106.1 70.107
GOLGA4 S_71 + 0.29 0.13 + 1.00 0.00665995 65.232 28.85
GOLGA4 S_266 + 0.11 -0.15 + 1.00 2.85E-33 130.72 88.434
GPALPP1 S_105 + -0.09 -0.38 1.00 0.00012345 64.89 40.861
GPATCH1 S_6 + 0.10 -0.22 1.00 1.61E-27 109.19 95.901
GPATCH1 S_8 + 0.10 -0.22 1.00 1.61E-27 109.19 95.901
GPATCH8 S_1029 + 0.00 0.17 1.00 1.09E-36 140.96 112.67
GPATCH8 S_662 + -0.35 -0.67 + + 0.96 1.60E-06 84.581 84.581
GPR39 S_425 0.16 0.33 0.76 2.86E-07 92.792 87.808
GPR39 S_427 + 0.15 0.12 + 0.99 2.86E-07 92.792 87.808
GPR39 S_430 + 0.16 -0.08 1.00 1.78E-05 79.025 50.194
GRK5;GRK6 S_484 + 0.11 0.16 1.00 9.18E-47 154.81 106.6
GRK5;GRK6 T_485 + 0.11 0.16 1.00 9.18E-47 154.81 106.6
GSG2 S_93 + -0.09 -0.19 + 0.94 0.0166938 64.265 11.783
GSK3A;GSK3BY_216 + 0.12 0.17 + 0.74 0.0004025 84.892 56.315
GTF2F1 T_389 + 0.66 0.87 0.99 4.87E-10 88.108 71.868
GTF2F1 S_385 + -0.20 0.02 + 1.00 1.92E-33 132.37 82.664
GTF2F1 S_391 + 0.54 0.68 0.79 1.92E-33 132.37 82.664
GTSE1 S_575 + -0.15 -0.24 + 1.00 0.00090125 65.179 36.276
GTSE1 S_580 + -0.15 -0.24 + 1.00 0.00090125 65.179 36.276
HACD3 S_114 + 0.28 0.05 + 1.00 1.85E-47 158.65 158.65
HCFC1 S_597 + -0.21 -0.22 + 1.00 1.17E-06 86.258 66.838
HDAC2 S_364 + -0.02 -0.30 + 1.00 0.0016135 46.404 34.319
HDGF S_158 + -0.06 0.03 1.00 0.00018443 84.507 55.551
HDLBP S_31 + 0.25 0.27 1.00 2.06E-29 133.93 133.93
HEATR6 S_642 + -0.09 -0.31 + 0.55 0.00043956 67.648 51.577
HIRIP3 S_227 + -0.20 -0.40 1.00 4.18E-38 150.01 115.43
HIST1H1C S_2 + -0.12 -0.33 + + 0.91 0.00058827 69.747 11.624
HIST1H1E T_18 + -0.62 -0.79 + + 1.00 5.39E-56 157.12 110.25
HJURP S_388 + -0.16 -0.10 + 0.97 0.0210184 42.395 22.632
HMGA1 S_36 + -0.13 -0.15 + + 1.00 2.56E-10 98.421 72.31
HMGA1 S_44 + 0.72 0.32 + 1.00 1.16E-07 92.034 92.034
HMHA1 S_23 + -0.23 -0.28 + 1.00 0.00348382 94.639 39.629
HN1 S_41 + 0.22 0.26 + + 1.00 3.10E-62 170.22 125.53
HNRNPA1 S_4 + -0.33 -0.17 + 0.99 9.09E-27 132.74 103.53
HNRNPA1 S_6 + 0.00 -0.02 + 1.00 9.09E-27 132.74 103.53
HNRNPA3 S_333 + 0.12 0.05 0.65 0.00040884 61.429 44.188
HNRNPC S_180 + 0.27 0.31 + + 1.00 2.85E-16 121.1 102.75
HNRNPH1;HNRNPH2T_100 + -0.08 0.06 0.60 0.00285258 59.75 59.75
HNRNPH1;HNRNPH2S_104 + -0.13 -0.02 + 0.98 2.79E-21 121.77 86.149
HNRNPU S_252 + -0.04 -0.37 0.90 0.00047091 44.698 31.609
HNRNPUL1 S_151 + -0.03 -0.27 1.00 2.52E-07 72.859 64.203
HNRNPUL2 S_161 + 0.07 -0.14 0.99 0.00014132 62.765 62.765
HSF1 S_303 + -0.21 -0.25 + 1.00 0.0265852 46.844 27.185
HSF1 S_307 + -0.21 -0.25 + 1.00 0.0265852 46.844 27.185
HSF1 S_314 + -0.01 -0.10 0.97 0.00100104 51.46 51.46
HSF1 S_326 + -0.01 -0.10 0.88 0.00100104 51.46 51.46
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HSP90AA1 S_252 + 0.03 -0.05 0.99 0.00201916 45.913 45.913
HSP90AA1;HSP90AA2P;HSP90AA5PS_263 + 0.08 0.10 + + 1.00 6.06E-267 262.59 262.59
HSP90AB1;HSP90AB2PS_177 + 0.09 0.18 + + 1.00 2.56E-27 136.43 136.43
HSP90AB1;HSP90AB3PS_205 + 0.03 0.15 + 1.00 0.00148509 73.951 53.212
HSP90B1 S_306 + 2.15 2.20 + + 1.00 3.26E-134 204.51 183.23
HSPB1 S_82 + 0.82 1.22 + + 1.00 8.74E-06 96.229 35.832
HSPH1 S_516 + 0.05 0.23 0.98 3.81E-21 101.39 83.091
HTATSF1 S_713 + 0.06 0.17 + 1.00 7.92E-19 128.85 128.85
HTATSF1 S_714 + 0.06 0.17 + 1.00 7.92E-19 128.85 128.85
HTATSF1 S_676 + 0.15 0.09 + + 1.00 5.48E-12 108.5 85.061
HTT S_432 + 0.67 0.12 0.84 0.00011115 90.388 55.596
HTT S_419 + 0.94 0.24 0.82 0.00011115 90.388 55.596
HUWE1 T_3908 + -0.51 0.99 + 0.98 0.00065372 55.208 55.208
HUWE1 S_3800 + -0.11 -0.01 0.89 6.44E-07 66.884 51.708
HUWE1 S_1898 + 0.35 0.24 + + 1.00 5.45E-27 132.5 90.676
HUWE1 S_3903 + -0.41 -0.80 + 1.00 6.20E-06 73.603 51.363
IFI16 S_153 + 0.18 -0.08 + 0.99 4.16E-12 94.671 60.982
IGF2BP2 S_101 + -0.16 -0.26 1.00 6.71E-06 82.635 45.638
IGF2BP2 S_105 + -0.18 -0.53 + + 0.94 1.14E-07 93.215 67.339
IGF2R S_2409 + 0.19 0.12 + 1.00 1.69E-23 111.01 111.01
INF2 T_1148 + -0.38 -0.05 0.68 1.04E-09 84.025 58.858
INF2 S_1147 + 0.17 0.17 0.77 4.79E-17 93.712 72.469
INPPL1 S_132 + -0.19 -0.62 + + 1.00 0.00026443 67.415 67.415
IRF2BP2 S_175 + 0.01 -0.30 + 1.00 0.00540084 47.227 47.227
IRF2BPL S_547 + -0.07 -0.20 + + 1.00 8.61E-06 87.654 64.123
IRS1 S_348 + -0.04 0.27 0.94 5.12E-09 105.01 86.806
IRS2 S_391 + -0.31 -0.29 1.00 2.70E-62 169.06 136.8
IRS2 S_306 + 0.40 0.46 + 0.87 4.78E-05 79.467 31.179
IRS2 S_308 + 0.56 0.33 + 0.60 2.86E-11 103.71 103.71
IRS2 S_1203 + -0.15 -0.44 + + 0.90 9.10E-14 99.378 99.378
IRS2 S_388 + -0.04 -0.05 1.00 1.60E-05 89.816 89.816
IRS2 S_915 + -0.07 -0.11 1.00 1.96E-39 147.28 117.2
IRS2 T_1202 + -0.10 -0.35 + 0.55 5.58E-14 102.97 102.97
ITGB4 S_1387 + 0.25 -0.38 + + 0.97 0.00076687 63.662 51.346
ITGB4 T_1385 + 0.49 -0.37 + + 0.89 0.00076687 63.662 51.346
ITGB4 S_1384 + 0.19 -0.50 + 0.94 0.00076687 63.662 51.346
IWS1 S_287 + 0.06 -0.02 1.00 4.54E-06 94.176 77.881
IWS1 S_289 + 0.06 -0.02 1.00 4.54E-06 94.176 77.881
KANK2 S_19 + -0.37 -0.87 + 1.00 0.00113753 64.349 64.349
KANK2 T_14 + -0.37 -0.87 + 1.00 0.00113753 64.349 64.349
KCTD12 S_185 + -0.26 -0.44 + + 0.84 1.26E-56 160.23 160.23
KCTD12 S_187 + -0.25 -0.49 + + 0.66 8.04E-44 143.36 118.65
KDM1A S_166 + -0.62 -0.83 + + 1.00 4.92E-05 60.527 42
KHSRP S_184 + -0.22 0.14 0.98 0.00014286 85.576 85.576
KHSRP S_181 + 0.17 0.29 + 0.98 1.78E-05 94.007 66.326
KIAA0930 S_255 + 0.03 0.03 0.92 0.0204684 50.534 29.474
KIAA1429 S_1578 + 0.08 0.09 0.94 3.54E-05 94.82 57.311
KIF23 S_499 + -1.13 -1.00 0.78 1.33E-06 128.52 70.539
KIF23 S_501 + -1.13 -1.00 0.84 1.33E-06 128.52 70.539
KIF23 S_503 + -0.50 -0.83 + 0.97 5.91E-44 145.2 145.2
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KLC1 S_521 + -0.16 0.31 + 1.00 6.07E-12 112.91 62.04
KLC1 S_524 + -0.16 0.31 + 1.00 6.07E-12 112.91 62.04
KLC1 S_547 + 0.19 0.13 + + 0.96 4.65E-12 110.6 86.78
KLC2 S_505 + 0.12 0.22 + + 1.00 1.12E-37 150.09 107.28
KMT2A S_1799 + -0.69 -0.84 + + 0.92 0.00137458 56.081 26.499
KMT2A T_1807 + -0.68 -0.86 + + 0.99 0.00137458 56.081 26.499
KPNA2 T_61 + 0.03 -0.11 + + 0.95 3.45E-50 155.49 120.36
KPNA2 S_62 + 0.04 -0.32 + + 0.96 1.50E-64 167.89 167.89
KPNA3 S_60 + 0.08 0.03 + 1.00 2.49E-96 182.48 142.55
KRI1 S_171 + 0.22 0.16 + + 1.00 5.55E-49 170.51 120.28
L1CAM S_1172 + 0.45 0.17 + 0.99 1.80E-12 111.11 98.007
LARP1 S_697 + -0.70 -0.50 0.99 0.00023182 83.53 62.216
LARP1 S_471 + 0.22 0.35 + + 0.70 0.00020384 70.15 38.45
LARP1 S_689 + 0.44 0.47 + + 0.96 0.00167041 68.525 68.525
LARP1 S_90 + -0.20 -0.38 + + 1.00 1.25E-13 83.764 83.764
LARP4B S_601 + -0.33 -0.20 + + 0.97 0.00262141 61.213 31.208
LARP6 S_447 + 0.19 -0.40 1.00 0.00500289 84.173 48.878
LARP6 S_451 + 0.19 -0.40 0.99 0.00500289 84.173 48.878
LARP7 S_337 + 0.29 0.35 + 1.00 0.00172874 74.537 53.703
LARP7 T_338 + 0.29 0.35 + 1.00 0.00172874 74.537 53.703
LARP7 S_258 + 0.31 0.23 + + 0.97 2.76E-21 119.34 92.795
LARP7 S_261 + 0.49 0.37 + + 1.00 2.76E-21 119.34 92.795
LARP7 T_257 + 0.14 0.15 + 0.81 1.07E-10 98.747 78.683
LEO1 S_197 + 0.19 -0.06 + 1.00 0.00080542 83.856 57.306
LEO1 T_188 + 0.19 -0.06 + 1.00 0.00080542 83.856 57.306
LEO1 S_598 + 0.74 0.23 + 1.00 0.00019447 92.611 64.379
LIG1 S_46 + -0.40 -0.28 + + 1.00 4.27E-134 204.38 204.38
LIG1 T_164 + -0.26 -0.09 + 1.00 1.19E-113 198.98 154.29
LIG1 S_36 + -0.26 -0.39 + + 1.00 4.27E-134 204.38 204.38
LIMA1 S_188 + -0.13 -0.04 + 1.00 9.81E-07 97.129 97.129
LIMA1 S_225 + 0.01 0.19 + 0.77 9.53E-05 62.582 49.17
LIMCH1 S_217 + 0.14 -0.06 0.99 0.00676797 47.223 25.126
LIMCH1 T_215 + 0.14 -0.06 0.68 0.00676797 47.223 25.126
LIMCH1 S_1103 + 0.18 -0.06 + 1.00 4.33E-38 149.52 149.52
LMNA S_516 + 0.27 0.35 + + 1.00 8.56E-40 148.01 148.01
LMNA S_280 + 0.05 -0.01 0.99 6.85E-12 112.12 70.103
LMNA S_346 + 0.24 0.38 + 1.00 1.02E-12 114.56 72.648
LMNA S_283 + -0.02 0.01 0.98 6.33E-26 134.38 85.553
LMNA S_278 + 0.02 0.03 1.00 6.33E-26 134.38 85.553
LMNB1;LMNB2S_393 + -0.26 -0.18 + 0.91 0.00258179 66.784 47.513
LMNB1;LMNB2S_391 + -0.18 -0.10 + 1.00 0.00258179 66.784 47.513
LMO7 S_1176 + 0.73 0.69 + + 1.00 0.00070243 77.027 77.027
LMO7 S_342 + 0.80 0.70 + + 1.00 2.47E-29 132.74 132.74
LMO7 S_370 + 0.48 0.38 + + 0.99 5.58E-27 134.4 87.506
LMO7 S_471 + 0.74 0.78 + + 1.00 1.33E-26 138.28 138.28
LMO7 S_533 + 0.15 -0.07 + + 0.97 6.44E-24 112.37 112.37
LMO7 S_657 + 0.15 -0.22 + + 0.95 7.81E-101 190.99 190.99
LMO7 T_656 + -0.06 -0.30 + 0.84 5.20E-25 120.8 120.8
LMO7 S_660 + 0.35 -0.18 0.73 4.45E-21 104.77 104.77
LMO7 S_654 + 0.14 -0.32 + + 1.00 7.81E-101 190.99 190.99
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LRCH1 S_536 + -0.05 -0.19 0.98 8.04E-25 120.44 120.44
LRCH1 S_532 + -0.13 -0.25 1.00 8.04E-25 120.44 120.44
LRRFIP1 T_114 + -0.17 -0.10 0.90 0.0010829 69.771 37.418
LRRFIP1 S_677 + -0.29 0.05 0.54 2.73E-05 72.916 54.548
LRRFIP2 S_168 + 0.67 0.36 0.99 8.20E-05 93.342 57.616
LRWD1 S_243 + -0.35 -0.53 + + 0.92 1.85E-12 108.71 85.199
LSM14A S_175 + -0.19 -0.20 + + 1.00 0.00194971 62.035 58.116
LSM14A S_142 -0.16 -0.25 + + 0.60 0.0101447 60.157 24.563
LSR S_209 + -0.03 0.17 + 0.81 1.26E-06 96.805 69.375
LSR S_490 + 0.09 0.24 + + 1.00 1.71E-13 118.9 118.9
LSR S_374 + 0.24 0.12 0.98 0.00153487 56.719 35.881
LSR S_487 + 0.27 0.18 + + 1.00 1.71E-13 118.9 118.9
LSR S_337 + 0.01 -0.10 1.00 6.98E-44 144.11 144.11
LSR T_345 + -0.02 -0.12 0.97 1.57E-14 107.49 107.49
LSR S_308 + -0.14 -0.76 + 1.00 1.50E-06 81.128 64.549
LUZP1 S_659 + 0.27 0.27 + + 1.00 5.27E-07 85.563 65.895
LYN S_13 + 0.16 0.18 + + 1.00 1.65E-12 116.9 57.675
MACF1 S_2398 + 0.31 0.16 1.00 0.00087689 77.185 41.662
MACF1 T_3506 + 0.43 0.18 + 0.68 5.04E-08 79.416 79.416
MAP1B S_2209 + -0.70 0.07 + 1.00 0.00555103 65.511 47.554
MAP1B S_2211 + -0.70 0.07 + 1.00 0.00555103 65.511 47.554
MAP1B S_1779 + 0.03 0.34 1.00 7.33E-11 90.729 90.729
MAP1B S_1016 + 0.17 0.35 + + 1.00 9.29E-06 76.351 65.808
MAP1B S_1618 + -0.58 -0.38 + + 1.00 0.00141968 48.244 48.244
MAP1B S_1620 + -0.58 -0.38 + + 1.00 0.00141968 48.244 48.244
MAP1B S_1625 + -0.58 -0.38 + + 1.00 0.00141968 48.244 48.244
MAP1B S_831 + -0.01 0.15 + 1.00 2.35E-74 172.57 123.38
MAP1B S_832 + -0.01 0.15 + 1.00 2.35E-74 172.57 123.38
MAP1B T_1302 + -0.16 -0.04 + + 0.93 7.31E-05 65.197 43.849
MAP1B T_1949 + -0.13 0.11 1.00 2.01E-07 99.813 70.45
MAP1B S_1262 + -0.47 -0.58 + + 0.93 9.54E-27 134.08 91.099
MAP1B T_1503 + -0.10 -0.18 0.74 7.53E-11 100.69 100.69
MAP1B S_1256 + -0.65 -0.61 + + 0.99 1.63E-60 162.92 95.983
MAP1B S_936 + -0.03 0.09 0.89 2.53E-08 153.36 124.48
MAP1B S_1881 + -0.06 0.12 1.00 5.50E-131 206.13 206.13
MAP1B S_828 + -0.17 -0.04 0.94 0.00762393 54.859 9.7751
MAP1B S_1501 + -0.10 -0.07 + 1.00 4.58E-12 107.88 107.88
MAP1B S_1785 + -0.16 -0.15 + 1.00 2.39E-08 99.941 99.941
MAP1B T_1788 + -0.16 -0.15 + 1.00 7.33E-11 99.941 99.941
MAP1B S_992 + 0.28 0.20 + 1.00 0.00123009 51.619 47.499
MAP1B S_1782 + -0.34 -0.23 + + 1.00 7.33E-11 90.729 90.729
MAP1B S_1965 + -0.41 -0.30 + 0.99 0.00011932 83.964 58.434
MAP1B S_1915 + -0.14 -0.08 + + 0.99 1.47E-37 149.31 149.31
MAP1B S_995 + 0.50 0.63 + 1.00 0.00123009 51.619 47.499
MAP1B S_1396 + -0.16 -0.13 + + 1.00 8.55E-56 142.32 142.32
MAP1B T_2034 + -0.14 -0.01 1.00 0.00020931 87.429 56.431
MAP1B S_1265 + -0.02 -0.02 1.00 1.63E-60 162.92 95.983
MAP1B S_1793 + -0.29 -0.32 + + 0.57 5.66E-51 153.14 153.14
MAP1B S_1298 + -0.37 -0.44 + + 0.98 7.31E-05 65.197 43.849
MAP1B S_937 + 0.10 0.07 0.89 2.53E-08 153.36 124.48
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MAP1B S_1258 + -0.60 -0.73 + + 1.00 9.54E-27 134.08 91.099
MAP1B S_1154 + 0.04 0.13 0.66 4.82E-05 66.041 43.155
MAP1B S_1312 + 0.16 -0.04 0.92 8.74E-06 71.905 71.905
MAP1B S_1378 + -0.45 -0.61 + + 0.87 4.62E-19 115.85 78.757
MAP1B S_1376 + -0.45 -0.61 + + 0.79 4.62E-19 115.85 78.757
MAP1B T_948 + 0.15 0.17 1.00 2.40E-23 108.79 94.685
MAP1B S_1400 + 0.10 -0.05 1.00 8.55E-56 142.32 142.32
MAP1B S_1387 + -0.34 -0.36 0.70 7.65E-11 97.784 65.277
MAP1B S_1389 + -0.07 -0.59 + + 0.99 3.67E-68 162.72 162.72
MAP1B S_1797 + 0.09 -0.38 + + 1.00 5.66E-51 153.14 153.14
MAP1B S_1260 + 0.07 -0.38 + + 1.00 1.63E-60 162.92 95.983
MAP1B S_1322 + 0.35 -0.22 + 0.91 0.00016665 60.562 46.37
MAP1S S_629 + -0.38 0.08 + 0.99 0.00571366 64.104 31.809
MAP1S S_631 + 0.13 0.08 1.00 0.00571366 64.104 31.809
MAP1S S_733 + -0.12 -0.25 0.81 3.47E-14 101.53 79.886
MAP2K1 T_360 + 0.09 -0.03 0.61 0.00156986 42.709 42.709
MAP2K1;MAP2K2S_186 + 0.09 0.23 0.98 8.12E-11 88.574 88.574
MAP2K1;MAP2K2S_192 + -0.17 0.08 + 1.00 5.50E-08 80.236 52.312
MAP2K1;MAP2K2S_196 + 0.20 0.15 1.00 1.15E-24 135.1 94.052
MAP2K2 S_293 + -0.12 -0.03 0.78 0.032888 41.838 23.522
MAP3K7 S_412 + -0.10 0.08 1.00 2.18E-07 135.55 93.502
MAP4 T_571 + -0.08 0.15 1.00 2.97E-19 128.73 104.79
MAP4 S_1073 + 0.32 0.22 + 1.00 1.65E-06 85.518 85.518
MAP4 S_507 + -0.05 0.08 1.00 1.15E-26 132.87 110.96
MAP4 S_552 + -0.03 -0.20 + 0.94 4.36E-07 92.538 30.945
MAP4 T_521 + -0.09 -0.15 + 1.00 2.72E-47 152.94 152.94
MAP4 S_510 + -0.04 0.10 0.99 1.15E-26 132.87 110.96
MAP7D1 S_116 + -0.31 0.21 + 0.54 0.00127296 54.764 40.46
MAPK1 T_185 + 0.00 -0.04 1.00 9.43E-12 98.077 98.077
MAPK1 Y_187 + 0.18 -0.03 1.00 9.43E-12 98.077 98.077
MAPK1IP1L S_15 + -0.20 -0.56 + + 1.00 2.22E-64 168.3 136.51
MAPK3 Y_204 + 0.12 0.18 0.99 1.28E-06 77.576 77.576
MAPK3 T_202 + 0.08 0.03 0.99 1.28E-06 77.576 77.576
MARCKS S_101 + -0.20 -0.27 + + 1.00 2.23E-51 154.08 154.08
MARCKS S_29 + -0.22 -0.12 0.88 5.79E-07 83.751 83.751
MARCKS S_27 + 0.01 -0.10 0.79 4.44E-26 127.32 112.59
MARCKS S_170 + -0.12 -0.28 + 1.00 0.0206493 53.013 25.585
MARCKS T_120 + 0.08 -0.17 + 0.89 1.89E-05 62.049 62.049
MARCKS S_167 + -0.02 -0.10 0.96 4.27E-05 90.561 51.528
MARCKS S_163 + -0.02 -0.10 1.00 4.27E-05 90.561 51.528
MARCKSL1 S_101 + -0.77 -1.41 + + 1.00 0.00066054 82.529 29.082
MARCKSL1 S_104 + -0.77 -1.41 + + 1.00 0.00066054 82.529 29.082
MATR3 S_478 + 0.23 0.12 1.00 9.02E-06 72.676 63.201
MCM2 S_139 + -0.30 -0.23 + + 1.00 2.74E-08 97.08 97.08
MCM2 S_108 + 0.02 -0.01 0.92 0.00098405 54.521 54.521
MCM2 S_13 + -0.11 -0.09 + 0.98 3.75E-11 105.01 105.01
MCRS1 S_12 0.11 -0.03 0.64 0.00861778 47.155 11.114
MDC1 S_495 + -0.18 -0.27 1.00 0.00725168 57.316 43.276
MDC1 S_498 + -0.18 -0.27 1.00 0.00725168 57.316 43.276
MDC1 S_329 + -0.04 0.01 1.00 1.42E-29 136.88 112.11
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MDC1 T_331 + -0.04 0.01 1.00 1.42E-29 136.88 112.11
MECP2 S_80 + 0.01 -0.40 + 0.79 2.04E-05 75.334 61.139
MED1 T_1051 + -0.12 -0.18 + + 0.94 0.00158367 78.401 40.798
MEF2D S_205 + -0.61 -0.65 + + 0.98 0.0340063 41.542 41.542
MELK S_162 + 0.31 0.36 0.93 0.0153705 45.138 17.085
MFAP1 S_52 + 0.12 0.03 + 1.00 7.31E-08 144.33 120.3
MFAP1 S_53 + 0.12 0.03 + 1.00 7.31E-08 144.33 120.3
MFAP1 S_116 + 0.18 0.07 + 1.00 3.67E-83 174.76 174.76
MFAP1 S_118 + 0.18 0.07 + 1.00 3.67E-83 174.76 174.76
MFAP1 T_267 + 0.56 0.29 + 0.99 0.00252613 48.771 26.337
MKI67 S_1984 + -0.58 -0.35 1.00 0.0104714 48.391 25.61
MKI67 S_224 + -0.64 -0.48 + + 1.00 5.69E-05 86.497 68.176
MKI67 S_308 + 0.11 0.11 1.00 1.99E-05 74.873 74.873
MKI67 S_1015 + -0.47 -0.49 + + 0.82 4.35E-06 80.545 60.873
MPHOSPH8 S_136 + -0.07 0.04 1.00 0.00016311 71.842 71.842
MPHOSPH8 S_138 + -0.07 0.04 1.00 0.00016311 71.842 71.842
MPHOSPH8 S_51 + 0.26 0.23 + + 1.00 3.34E-100 183.1 183.1
MPRIP S_224 + 0.00 -0.15 0.98 3.90E-08 84.025 65.67
MPRIP S_226 + -0.08 -0.20 + 0.88 6.55E-05 69.649 35.432
MPRIP S_220 + -0.09 -0.39 0.99 3.90E-08 84.025 65.67
MPRIP S_294 + -0.20 -0.78 + 0.67 0.00051259 59.372 59.372
MPRIP T_295 + -0.20 -0.78 + 0.67 0.00051259 59.372 59.372
MRE11A S_621 + 0.42 0.09 0.99 0.00204277 53.355 38.114
MSH6 S_227 + -0.09 -0.12 + + 1.00 8.96E-51 155.86 133.29
MTCL1 S_1448 + -0.22 -0.12 0.84 0.00469122 43.955 32.054
MTCL1 S_1061 + -0.13 -0.11 1.00 2.63E-18 122.01 96.587
MTCL1 T_1057 + -0.13 -0.11 1.00 2.63E-18 122.01 96.587
MTCL1 S_258 + -0.39 -0.51 + + 0.97 5.76E-16 98.443 74.414
MTCL1 S_262 + -0.16 -0.54 + + 1.00 1.45E-23 111.93 111.93
MTCL1 T_261 + -0.16 -0.66 1.00 1.45E-23 111.93 111.93
MTCL1 S_263 + -0.31 -0.89 + + 1.00 1.24E-12 115.39 76.396
MTDH S_426 + 0.15 0.11 + + 1.00 8.44E-184 233.54 181.02
MTOR T_1162 + 0.72 1.09 + 0.68 0.00196082 77.662 12.438
MUC19 S_5279 0.02 0.07 + 0.83 0.0264493 45.707 15.144
MVB12A S_170 + 0.81 0.99 + + 1.00 5.51E-37 143.14 95.023
MYBBP1A S_1163 + -0.25 -0.08 + 0.58 0.0310477 41.383 24.971
MYBBP1A S_11 + -0.04 -0.24 + 1.00 3.55E-39 140.84 106.4
MYBBP1A S_1267 + -0.15 -0.26 + 0.91 4.69E-22 124.04 78.828
MYCBP2 S_3467 + -0.17 -0.23 0.99 0.00511084 54.768 54.768
MYEF2 S_17 + -0.37 -1.11 + + 1.00 3.56E-12 96.562 69.782
MYH9 S_1365 + 0.55 0.15 + 1.00 4.29E-12 92.613 78.912
MYL12A;MYL12B;MYL9T_18 + 0.07 0.14 + + 1.00 1.48E-114 200.04 200.04
MYL12A;MYL12B;MYL9S_19 + 0.37 0.41 + + 1.00 1.48E-114 200.04 200.04
MYO18A S_1568 + 0.23 0.20 + + 1.00 1.61E-26 130.09 114.7
MYO18A S_1570 + 0.23 0.20 + + 1.00 1.61E-26 130.09 114.7
MYO18A S_1639 + 0.35 0.25 + + 1.00 4.46E-19 115.77 100.84
MYO18A S_1643 + 0.35 0.25 + + 1.00 4.46E-19 115.77 100.84
MYO18A S_1067 + 0.14 -0.17 0.79 0.00055082 50.723 50.723
MYO9B S_1290 + -0.02 0.15 0.99 0.00508347 46.324 28.696
MYO9B T_1271 + -0.63 -0.60 + + 1.00 0.00189458 99.881 51.349
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MYO9B S_1267 + -0.02 -0.42 + 1.00 0.00189458 99.881 51.349
MYOF S_132 + 0.38 0.31 + 0.70 5.94E-08 100.43 64.319
NACA S_166 + 0.27 0.19 + 0.98 3.68E-08 75.035 50.714
NAF1 S_315 + -0.10 -0.44 + + 1.00 7.00E-16 117.53 92.293
NAP1L1 S_10 + -0.03 0.19 + 1.00 4.01E-18 107.58 84.23
NAP1L4 S_12 + -0.10 -0.22 0.98 4.47E-16 117.22 117.22
NASP S_141 + 0.10 0.31 1.00 3.48E-06 86.987 60.985
NASP T_138 + -0.01 0.07 0.77 8.54E-05 68.291 39.233
NASP S_164 + 0.25 0.20 + 1.00 1.91E-05 74.278 74.278
NBN S_432 + -0.03 0.04 + 0.92 0.00068703 75.89 39.598
NCAPD2 S_1330 + -0.34 0.04 0.94 0.00041908 101.71 54.898
NCAPD2 S_1333 + -0.63 -0.23 + 0.96 2.96E-33 130.38 110.1
NCAPD2 T_1331 + -0.38 0.05 0.68 1.28E-13 98.973 85.387
NCAPG S_674 + -0.06 0.10 + 1.00 2.10E-31 139.55 139.55
NCOR1 S_2081 + -0.17 0.11 + 1.00 8.19E-06 94.61 94.61
NCOR2 S_1001 + -1.04 -0.66 + + 0.79 2.90E-11 112.47 86.057
NCOR2 S_2252 + -0.29 -0.20 + 1.00 0.00057014 67.234 67.234
NCOR2 S_149 + -0.70 -1.25 + + 1.00 6.62E-06 85.054 57.783
NCOR2 S_152 + -0.74 -1.36 + + 1.00 6.62E-06 85.054 57.783
NCOR2 T_156 + -0.30 -1.07 + + 0.83 0.0056392 44.238 18.828
NDRG1 S_249 + 1.47 1.82 + + 0.90 4.83E-07 93.371 93.371
NEDD1 S_427 + 0.13 -0.09 0.72 5.46E-11 96.591 65.722
NEDD4L S_182 + -0.37 0.09 + 0.94 0.00256323 61.265 61.265
NEDD4L S_307 + -0.28 -0.04 + 0.75 6.23E-41 150.13 115.04
NEDD4L S_305 + -0.33 -0.03 + 0.81 7.81E-12 108.25 108.25
NEDD4L S_334 + -0.42 -0.68 + + 0.84 0.0004607 66.041 43.075
NELFB S_557 + -0.44 -0.99 + + 1.00 3.74E-13 120.23 89.363
NELFE S_115 + 0.95 1.25 + + 1.00 4.44E-08 102.5 70.828
NEMF S_375 + 0.10 0.16 1.00 9.88E-26 120.72 99.035
NEMF S_705 + 0.22 0.26 + 1.00 5.76E-06 81.017 61.321
NEMF S_706 + 0.22 0.26 + 1.00 5.76E-06 81.017 61.321
NFATC2IP S_204 + -0.30 3.09 1.00 0.00287178 90.379 43.487
NFIC S_306 + -0.02 0.17 1.00 6.68E-36 144.25 86.538
NFIC S_290 + -0.10 -0.44 0.98 2.90E-19 120.74 81.735
NIFK T_234 + -0.40 -0.40 0.92 0.0006059 72.082 44.124
NIFK T_238 + -0.40 -0.40 0.99 0.0006059 72.082 44.124
NIPBL S_2658 + -0.06 0.09 1.00 0.0012272 72.523 72.523
NMD3 T_470 + 0.13 -0.10 + 1.00 2.88E-22 186.74 147.55
NMD3 S_468 + 0.01 -0.14 + + 1.00 2.88E-22 186.74 147.55
NOL8 S_822 + 0.09 0.05 1.00 7.48E-79 176.88 161.07
NOL8 T_820 + 0.09 0.05 1.00 7.48E-79 176.88 161.07
NOLC1 S_698 + 0.16 0.26 1.00 2.75E-29 131.72 131.72
NOLC1 T_607 + -0.43 -0.35 + + 1.00 1.81E-18 119.39 97.73
NOLC1 T_610 + -0.43 -0.35 + + 1.00 1.81E-18 119.39 97.73
NOP2 S_728 + -0.28 0.08 + 1.00 5.09E-19 121.51 97.631
NOP2 S_782 + -0.35 -0.35 + + 0.98 0.00165346 72.531 43.468
NOP56 S_570 + -0.41 0.01 + 1.00 7.96E-05 85.576 62.459
NOP56 S_569 + -0.30 0.09 + 1.00 0.00053667 72.772 50.871
NOP56 S_520 + 0.05 -0.11 1.00 2.06E-25 125.73 125.73
NOP56 S_519 + -0.07 -0.27 1.00 2.64E-06 78.225 60.329
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NOP58 S_514 + -0.34 -0.40 + + 1.00 1.96E-68 171.89 132.43
NOP58 S_502 + 0.10 -0.16 + 1.00 2.24E-83 193.64 152.92
NOTCH2 S_1778 + -0.18 -0.18 1.00 2.47E-21 122.64 88.426
NPM1 S_125 + 0.22 0.08 + 1.00 6.96E-05 56.774 56.774
NPM1 S_70 + -0.02 -0.14 + 1.00 2.68E-68 166.65 166.65
NRBP1 T_433 + 0.00 0.10 0.99 0.0057331 73.802 42.731
NRBP1 T_431 + -0.14 -0.06 0.94 0.00823078 69.261 25.581
NRBP1 S_2 + 0.05 -0.10 1.00 1.16E-06 87.356 67.263
NRBP1 S_422 + -0.09 -0.52 + 0.92 0.00787351 47.732 32.944
NRD1 S_94 + -0.10 -0.13 + 0.99 0.00011173 80.746 50.742
NSFL1C S_114 + -0.07 0.12 1.00 1.40E-07 101.53 101.53
NSL1 S_4 + -0.05 -0.33 1.00 2.66E-19 122.97 98.604
NSRP1 S_33 + 0.07 -0.08 1.00 6.44E-74 165.77 165.77
NUCKS1 S_113 + 0.04 0.24 1.00 5.96E-07 131.98 107.24
NUCKS1 S_19 + 0.27 0.28 + + 1.00 3.24E-210 234.03 234.03
NUCKS1 S_164 + -0.06 -0.12 + 1.00 1.35E-55 153.59 128.35
NUCKS1 S_174 + -0.07 -0.19 + + 1.00 1.35E-55 153.59 128.35
NUCKS1 T_162 + -0.06 -0.09 + 1.00 1.35E-55 153.59 128.35
NUDC S_139 + -0.04 0.10 1.00 5.95E-15 101.38 99.409
NUFIP2 S_652 + 0.70 0.67 + + 1.00 7.03E-36 145.52 114.37
NUFIP2 S_629 + -0.02 -0.15 + 0.98 2.40E-48 140.63 114.8
NUMA1 S_169 + -0.15 -0.56 + + 0.99 1.02E-07 81.878 81.878
NUMA1 S_1743 + 0.03 -0.50 + 1.00 3.29E-68 163.6 107.62
NUMB T_113 + -0.04 0.04 0.72 3.56E-06 64.16 64.16
NUMB S_107 + -0.17 0.02 0.89 3.56E-06 64.16 64.16
NUP188 S_1598 + -0.35 -0.26 + + 0.71 0.00892418 45.916 26.247
NUP214 T_437 + -0.17 -0.49 + + 0.94 5.19E-06 84.68 59.207
NUP214 S_433 + -0.18 -0.49 + + 0.65 1.24E-05 79.942 59.205
NUP98 S_595 + 0.04 -0.04 1.00 5.05E-92 181.69 181.69
NUP98 S_871 + 0.13 0.00 + 1.00 9.35E-11 105.72 93.427
NUP98 S_917 + -0.19 -0.52 + + 0.98 1.20E-06 86.222 86.222
NUP98 S_606 + 0.12 -0.13 + 1.00 1.95E-64 166.93 141.9
OGFR S_537 + -0.60 -0.65 + + 1.00 2.05E-08 103.11 68.727
OGFR S_565 + -1.02 -1.14 + + 1.00 1.79E-05 68.401 43.994
OGFR S_559 -0.59 -0.91 + + 0.92 0.00025771 60.951 27.078
OGFR S_539 -0.88 -0.84 + + 0.77 0.00102931 58.848 58.848
OGFR T_561 + -0.95 -1.32 + + 0.99 1.79E-05 68.401 43.994
OPTN S_469 + 0.18 0.40 + + 0.90 1.16E-47 154.46 93.799
OSBP S_190 + 0.48 0.34 + + 1.00 3.63E-139 212.72 172.4
OSBP S_351 + 0.42 0.03 + 1.00 1.01E-27 118.98 118.98
OSBP S_193 + 0.65 0.26 + + 1.00 3.63E-139 212.72 172.4
OSBPL11 S_181 + -0.10 -0.04 0.83 1.10E-05 87.647 47.769
OSBPL8 S_765 + 0.03 0.36 0.69 0.00706942 43.956 43.956
OSBPL8 S_766 + 0.03 0.36 0.69 0.00706942 43.956 43.956
OSBPL8 S_768 + 0.03 0.36 0.59 0.00706942 43.956 43.956
OTUD4 S_1023 + 0.19 0.26 + + 1.00 1.89E-19 125.96 125.96
OTUD4 S_1024 + 0.19 0.27 + + 1.00 1.89E-19 125.96 125.96
OXR1 S_133 + 0.25 0.56 + + 0.99 1.54E-08 103.73 76.694
OXR1 S_136 + 0.23 0.46 + + 0.90 1.54E-08 103.73 76.694




PAFAH1B2 S_2 + 0.50 0.14 0.98 2.74E-11 92.258 92.258
PAG1 S_298 + 0.14 0.22 0.93 0.019494 58.04 42.034
PAG1 S_295 + 0.22 0.25 0.79 0.019494 58.04 42.034
PAICS S_27 + 0.01 -0.04 1.00 0.00148507 85.163 35.055
PAK2 S_141 + -0.09 0.18 + + 1.00 1.53E-75 174.23 174.23
PAK2 S_2 + -1.52 -1.48 1.00 0.0148047 45.436 45.436
PAK2 S_197 + -0.04 -0.13 + 1.00 1.07E-14 105.65 105.65
PAK4 S_181 + -0.26 -0.34 + + 0.64 0.00622795 40.384 40.384
PAK4 S_309 + 0.11 -0.14 + 1.00 1.30E-64 169.49 169.49
PAM S_839 + 0.53 0.47 + + 0.81 0.00582771 49.036 27.641
PAM T_836 + 0.53 0.47 + + 0.68 0.00582771 49.036 27.641
PATL1 S_177 + 0.62 0.68 + + 0.55 0.00573632 61.165 61.165
PATL1 S_184 + 0.51 0.54 + + 1.00 0.00105483 61.165 61.165
PCBP1 S_173 + 0.07 0.05 1.00 6.09E-79 172.09 172.09
PCBP2 S_185 + -0.15 4.36 + 0.95 1.10E-05 100.69 59.127
PCM1 S_65 + 0.26 0.13 1.00 9.93E-38 148.52 148.52
PCM1 S_69 + 0.04 0.01 0.97 3.68E-27 133.94 107.58
PCM1 S_1710 + 0.46 0.26 1.00 0.00116285 54.072 32.379
PCM1 S_1713 + 0.46 0.26 1.00 0.00116285 54.072 32.379
PCNP S_119 + -0.15 -0.32 + + 1.00 0.00697532 61.304 40.898
PCYT1A S_347 + -0.21 -0.06 + + 1.00 0.00106605 82.529 64.139
PCYT1A S_343 + -0.21 -0.05 + + 0.89 0.00106605 82.529 64.139
PDCD4 S_83 + 0.37 0.16 + + 0.50 0.00290478 77.662 41.238
PDCD4 T_82 + 0.37 0.16 + + 0.50 0.00290478 77.662 41.238
PDIA6 S_425 + 1.12 1.04 + + 1.00 1.82E-49 149.09 149.09
PDLIM5 S_251 + -0.07 -0.21 + 0.96 0.00022617 67.644 67.644
PDPK1;PDPK2PS_114 + 0.18 -0.01 1.00 4.04E-15 107.95 88.601
PDS5B T_1370 + -0.30 0.00 0.84 6.47E-06 114.05 79.785
PDS5B S_1283 + -0.36 -0.30 + + 1.00 0.00743563 91.926 44.199
PDS5B S_1358 + -0.01 -0.10 1.00 4.31E-65 168.17 168.17
PDYN S_101 + 0.31 -0.14 + 1.00 0.00734241 70.908 8.4441
PEA15 S_116 + 1.01 1.04 + + 1.00 3.18E-06 97.502 67.43
PEBP1 S_54 + 0.45 -0.38 0.53 0.00096595 65.511 65.511
PFKP S_378 + 0.43 0.45 + + 1.00 0.00447807 61.423 17.981
PGM1 S_117 + 0.06 -0.30 + 0.98 9.27E-08 79.88 59.016
PGM1 T_115 + 0.21 -0.26 + 0.82 7.75E-09 87.196 64.214
PGM3 T_62 + 0.23 -0.05 0.85 0.00024247 63.691 63.691
PGRMC1 S_129 + -0.12 -0.31 1.00 8.83E-77 176.44 138.27
PGRMC1 S_57 + -0.35 -0.94 + + 1.00 1.77E-55 157.73 157.73
PGRMC1 S_54 + -0.41 -0.76 + + 0.99 2.33E-25 120.27 119.69
PGRMC2 T_211 + 0.11 0.16 + 0.95 3.11E-08 93.495 93.495
PGRMC2 S_208 + 0.55 0.35 + 0.87 6.81E-64 159.1 159.1
PGRMC2 Y_210 + 0.35 0.09 + 0.54 0.00166763 50.392 50.392
PHC2 S_36 + -0.09 -0.12 0.96 0.00092313 51.557 51.557
PHC3 T_590 + -0.22 -0.30 + + 1.00 0.0053438 88.565 62.203
PHC3 S_597 + -0.19 -0.41 + + 1.00 0.0053438 88.565 62.203
PHIP S_1783 + 0.18 0.11 1.00 5.55E-77 180.31 180.31
PHLDB2 S_384 + 0.30 0.56 + + 1.00 9.56E-40 146.65 126.62
PHLDB2 S_387 + 0.30 0.56 + + 1.00 9.56E-40 146.65 126.62
PHRF1 T_916 + 0.00 0.08 + 0.83 2.05E-08 80.412 80.412
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PHRF1 S_914 + 0.38 0.17 + 0.54 2.05E-08 80.412 80.412
PI4K2A S_47 + -0.10 -0.06 + 1.00 0.00033609 72.315 72.315
PI4K2A S_51 + -0.16 -0.26 + + 1.00 0.00033609 72.315 72.315
PI4KB S_413 + 0.22 0.15 + 1.00 0.00085831 65.954 65.954
PIP4K2B S_326 + 0.21 0.19 + 0.86 6.34E-05 51.758 37.41
PIP4K2B T_322 + 0.21 0.19 + 0.64 6.34E-05 51.758 37.41
PITPNC1 S_299 + -0.33 0.26 1.00 0.0191152 44.312 24.869
PKN2 S_256 + 0.17 0.45 + + 0.50 0.00019215 81.01 50.834
PKN2 S_257 + 0.29 0.40 + + 0.95 4.10E-37 147.53 100.29
PKP2 S_155 + 0.31 0.23 + 1.00 0.00439374 101.28 46.767
PKP2 S_151 + 0.29 0.12 + 1.00 0.00439374 101.28 46.767
PLEC T_4454 + 0.27 0.35 0.64 7.32E-08 94.49 66.35
PLEC S_1563 + 0.94 0.72 1.00 0.00408592 55.912 55.912
PLEC S_4239 + 0.10 0.07 0.67 1.91E-45 131.97 109.5
PLEC S_4213 + 0.70 0.61 + + 1.00 4.71E-12 93.812 65.196
PLEC S_4447 + -0.02 -0.04 0.97 2.72E-51 152.63 115.02
PLEC S_4453 + 0.26 0.31 0.80 2.16E-08 96.052 87.05
PLEC T_19 + 0.14 0.13 0.73 2.06E-47 158.91 158.91
PLEC S_4457 + 0.08 0.07 + 0.95 1.58E-08 96.052 64.495
PLEC S_4216 + 0.68 0.61 + + 0.87 2.18E-156 215.43 215.43
PLEC S_21 + 0.31 0.19 + + 0.95 1.37E-36 147.53 144.51
PLEC S_4217 + 0.88 0.77 + + 0.86 3.46E-51 156.08 156.08
PLEC S_4215 + 0.57 0.27 + + 0.88 2.18E-156 215.43 215.43
PLEC S_4444 + -0.16 -0.50 1.00 0.00048268 94.49 66.35
PLEC S_4220 + 0.60 0.46 + 0.99 2.18E-156 215.43 215.43
PLEC S_4227 + -0.04 -0.50 + + 1.00 1.59E-22 128.4 86.213
PLEKHA5 S_1021 + -0.02 -0.18 + 0.94 1.88E-10 102.72 77.037
PLEKHA6 S_848 + -0.54 -0.31 0.63 0.0405586 44.391 26.495
PLEKHA6 S_777 + -0.35 -0.06 0.84 3.41E-08 99.392 78.659
PLEKHA6 T_779 + 0.03 -0.07 + 0.88 0.0003992 102.03 63.8
PLEKHF1 S_227 + 0.16 -0.02 + 1.00 0.00023831 67.668 49.93
PLEKHG3 S_1040 + -0.36 -0.32 + + 1.00 2.52E-27 135.81 135.81
PLEKHG3 S_1037 + -0.36 -0.37 + + 1.00 2.52E-27 135.81 135.81
PLEKHM1 T_434 + 0.28 0.51 + 0.66 0.00412493 67.952 36.23
PLEKHM1 S_435 + 0.37 0.57 + + 0.88 0.00412493 77.192 26.488
PML S_470 + -0.17 0.00 + 1.00 0.00209268 65.765 65.765
PML S_479 + -0.17 0.00 + 1.00 0.00209268 65.765 65.765
PNKP T_118 + -0.30 -0.63 + + 1.00 1.40E-13 113.65 67.081
POLR2A S_1913 + -0.43 -0.24 + 0.99 7.76E-09 107.72 50.357
POLR2A T_1919 + -0.35 -0.61 0.67 2.09E-05 94.325 60.142
PPA2 S_151 + -0.53 -0.28 1.00 5.25E-26 131.17 131.17
PPAN S_359 + 0.02 0.12 + 1.00 5.45E-27 132.5 105.73
PPP1R12A T_356 + 0.35 0.43 0.83 0.00205938 75.564 62.801
PPP1R12A S_358 + 0.31 0.25 + + 0.94 1.40E-36 140.89 117.5
PPP1R13L T_308 + -0.09 -0.04 + 0.95 0.00273414 78.324 56.952
PPP1R2;PPP1R2P3S_121 + 0.38 0.39 + 1.00 1.30E-99 182.21 182.21
PPP1R2;PPP1R2P3S_122 + 0.34 -0.03 + 1.00 1.30E-99 182.21 182.21
PPP6R3 S_537 + 0.15 0.05 + 1.00 2.45E-157 221.21 194.75
PRCC T_261 + 0.09 -0.17 + 0.95 0.0001243 65.887 65.887
PRCC S_267 + 0.17 -0.24 + 0.95 1.23E-16 99.603 99.603
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PRKAR1A S_83 + -0.49 -0.15 + + 1.00 6.91E-93 183.73 183.73
PRKAR2A S_99 + 0.14 0.10 + + 1.00 4.54E-44 143.33 95.426
PRKAR2A S_78 + 0.12 0.00 + 1.00 7.95E-233 251.7 251.7
PRKAR2A S_80 + 0.12 0.00 + 1.00 7.95E-233 251.7 251.7
PRKAR2B S_114 + 0.20 -0.10 + 1.00 3.66E-07 80.382 67.107
PRKCA S_226 + 0.46 0.42 + + 1.00 7.77E-13 121.51 66.653
PRKCA S_13 0.19 0.25 0.71 0.00347403 56.719 32.623
PRKCA;PRKCB;PRKCGT_401 + -0.02 -0.31 + 1.00 1.83E-118 196.1 174.06
PRKCD S_506 + -0.27 -0.37 + 0.50 1.84E-68 164.46 164.46
PRKCD T_507 + -0.27 -0.37 + 0.50 1.84E-68 164.46 164.46
PRPF31 T_455 + -0.01 0.05 1.00 0.00019398 64.508 47.818
PRPF4B S_431 + 0.21 0.12 + + 1.00 1.59E-05 96.745 47.296
PRPF4B S_437 + 0.22 0.12 + + 1.00 1.59E-05 96.745 47.296
PRPF4B Y_849 + -0.12 -0.26 0.96 2.02E-12 96.379 96.379
PRRC2A S_1085 + 0.03 0.17 0.51 0.00019257 72.566 57.712
PRRC2A S_1092 + 0.22 0.41 + 0.92 1.50E-05 76.909 57.887
PRRC2A S_1089 + 0.21 0.42 0.95 1.50E-05 76.909 57.887
PRRC2C S_1862 + -0.15 -0.12 1.00 3.03E-20 129.37 129.37
PSEN1 S_332 + 0.00 -0.01 0.73 0.00124784 64.423 40.765
PSEN1 S_333 + -0.01 -0.11 0.75 1.46E-18 112.74 83.29
PSEN1 S_334 + -0.13 -0.35 0.79 1.46E-18 112.74 83.29
PSMD1 S_315 + -0.16 -0.15 + + 1.00 7.71E-08 88.627 88.627
PSMD1 T_311 + -0.16 -0.15 + + 1.00 7.71E-08 88.627 88.627
PSMD2 S_16 + -0.63 -0.69 + + 1.00 2.97E-14 103.35 96.133
PTK2 T_222 + -0.14 -0.39 + 0.50 0.00101154 65.149 39.163
PTK2 S_218 + -0.03 -0.47 + + 0.96 0.00101154 65.149 39.163
PTMA S_2 + 0.11 0.07 + 1.00 2.60E-09 108.25 108.25
PTPN12 T_468 -0.03 -0.14 0.78 0.00092212 58.635 35.298
PTPN12 S_543 + 0.00 -0.26 0.99 0.0128138 45.614 45.614
PTPN12 S_476 + -0.05 -0.17 0.93 0.00092212 58.635 35.298
PTPN12 S_473 + -0.05 -0.17 0.98 0.00737881 54.465 54.465
PTPN14 S_314 + -0.14 -0.05 + 0.98 9.86E-20 128.82 71.97
PTPN14 S_312 + -0.15 -0.20 + 0.86 0.00015574 85.28 59.285
PTPN14 S_593 + -0.03 -0.37 0.99 1.41E-18 127.88 102.81
PTPN14 S_594 + -0.10 -0.78 1.00 1.41E-18 127.88 102.81
PTPN2 S_304 + -0.43 -0.36 0.99 0.00087187 66.738 35.063
PTRF S_173 + 0.06 0.06 + 1.00 8.26E-31 119.43 119.43
PTRF S_174 + 0.06 0.06 + 1.00 8.26E-31 119.43 119.43
PTRF S_112 + 0.16 0.14 + 1.00 4.06E-31 115.08 115.08
PTRF S_113 + 0.16 0.14 + 1.00 4.06E-31 115.08 115.08
PURB S_101 + -0.27 -0.06 0.91 8.24E-07 72.728 59.367
PWP1 S_50 + 0.20 -0.11 1.00 2.05E-24 117.62 93.967
PWWP2A S_81 + -0.43 0.08 + 1.00 1.93E-27 137.27 118.3
PXN S_85 + 0.01 0.21 0.76 0.00075996 66.022 66.022
PXN T_132 + -0.40 -0.41 + 0.77 0.00049766 54.875 54.875
PXN S_106 + 0.25 0.23 + 1.00 9.23E-51 181.51 108.61
PXN S_126 + -0.11 -0.29 + 0.97 0.00043371 64.767 49.221
PXN S_130 + 0.01 -0.30 0.91 0.00043371 64.767 49.221
PXN S_84 + -0.12 -0.32 0.76 0.00293338 58.246 58.246
QSOX2 S_578 + 0.34 0.23 0.76 9.34E-31 125.37 125.37
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RAB11FIP5 S_356 0.45 0.56 + + 0.59 6.92E-10 91.883 66.473
RAB11FIP5 S_176 + 0.31 0.27 0.99 0.00017021 86.016 58.687
RAB12 S_21 + 0.29 0.03 1.00 0.00174106 54.985 36.572
RABL6 S_640 + 0.28 0.28 + + 1.00 1.86E-05 71.969 55.045
RABL6 S_641 + 0.28 0.28 + + 1.00 1.86E-05 71.969 55.045
RABL6 S_596 + -0.24 -0.76 + + 1.00 0.00021797 75.524 44.164
RABL6 T_599 + -0.24 -0.76 + + 1.00 0.00021797 75.524 44.164
RAD18 S_471 + -0.20 0.07 + 1.00 0.00038141 84.892 59.443
RAD23A S_205 -0.41 0.19 0.91 0.00212095 41.889 31.341
RAD23A S_123 + -0.16 -0.27 + 0.83 9.13E-06 65.766 65.766
RAD23B T_162 + -0.17 -0.06 0.54 0.00051722 60.561 47.958
RAD23B S_160 + -0.07 -0.25 + 1.00 0 274.34 245.71
RAD50 S_496 + 0.77 0.84 + + 1.00 1.11E-29 136.67 107.09
RAF1 S_29 + 0.17 0.06 0.88 1.31E-48 145.04 145.04
RALY S_119 + -0.30 -0.35 + + 1.00 0.00165449 68.277 44.206
RANBP2 S_1400 + -0.01 -0.43 0.79 0.00097263 52.432 52.432
RANBP2 T_1396 + -0.19 -0.29 0.87 0.00097263 52.432 52.432
RANBP2;RGPD1;RGPD2;RGPD3;RGPD4;RGPD5;RGPD8S_1463 + 0.29 0.29 + + 1.00 0.00965613 62.287 46.915
RANBP2;RGPD1;RGPD2;RGPD3;RGPD4;RGPD5;RGPD8T_1459 + 0.29 0.29 + + 1.00 0.00965613 62.287 46.915
RAVER1 S_14 + -0.03 -0.11 + 0.99 0.00157399 61.561 35.013
RB1 S_807 + -0.62 -0.50 + + 1.00 3.00E-29 133.21 133.21
RB1 S_811 + -0.62 -0.50 + + 1.00 3.00E-29 133.21 133.21
RB1 T_826 + -0.50 -0.49 + + 1.00 3.83E-19 129.43 88.443
RB1 T_821 + -0.50 -0.50 + + 1.00 3.83E-19 129.43 88.443
RB1 T_373 + -0.51 -0.46 + 1.00 0.00692652 50.077 50.077
RB1 T_823 + -0.40 -0.58 + + 0.95 0.0001787 87.654 44.836
RBBP6 S_1294 + 0.17 0.33 + + 1.00 1.65E-12 116.9 116.9
RBM10 S_658 + 0.13 0.24 + + 1.00 4.65E-22 147.26 103.5
RBM10 S_660 + 0.13 0.24 + + 1.00 4.65E-22 147.26 103.5
RBM15 S_250 + 0.23 0.10 + 1.00 0.00112868 73.834 46.153
RBM39 S_114 + -0.01 -0.10 1.00 8.18E-22 120.74 104
RBM5 S_624 + 0.14 0.28 + + 1.00 9.01E-44 148.1 148.1
RCAN1;RCAN3S_108 + 0.28 -0.02 1.00 1.89E-05 88.282 65.955
RCAN1;RCAN3S_112 + 0.28 -0.02 1.00 1.89E-05 88.282 65.955
RCSD1 S_216 + 0.01 0.11 0.99 0.00138795 78.419 37.052
RCSD1 S_179 + 0.20 0.18 + + 0.98 7.16E-08 103.87 78.31
REEP4 S_152 + 0.36 0.41 + + 1.00 0.0152581 63.473 25.478
REPS1 S_170 + -0.01 -0.09 0.98 0.00050085 51.577 51.577
REPS1 S_162 + -0.18 -0.16 0.99 0.00050085 51.577 51.577
REPS1 S_166 + -0.18 -0.16 0.99 0.00050085 51.577 51.577
REPS1 S_174 + -0.18 -0.22 0.61 0.00050085 51.577 51.577
REPS1 T_173 + -0.36 -0.40 0.77 0.00050085 51.577 51.577
RFC1 S_71 + 0.03 0.16 + 0.97 2.31E-50 155.08 117.44
RFC1 S_69 + 0.00 0.16 1.00 2.31E-50 155.08 117.44
RFC1 S_73 + -0.02 -0.02 0.60 1.21E-38 141.93 141.93
RFFL S_229 + 0.08 -0.36 + 0.98 4.39E-05 85.185 59.567
RFFL S_226 + 0.12 -0.27 + 0.95 4.39E-05 85.185 59.567
RHBDF2 S_296 + -0.19 -0.42 + + 0.93 0.0080591 53.861 53.861
RHBDF2 S_299 + -0.19 -0.42 + + 1.00 0.0080591 53.861 53.861
RIC8A S_430 + 0.32 0.14 + 0.91 2.31E-06 103.4 75.959
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RIC8A T_435 + 0.32 -0.08 + 0.96 2.31E-06 103.4 75.959
RIOK1 S_21 + 0.18 0.03 0.81 6.26E-05 75.877 51.455
RNF113A S_85 + 0.25 0.15 + + 0.96 1.53E-07 81.574 81.574
RNF113A S_84 + 0.31 0.14 + + 0.96 2.11E-08 83.064 64.818
RNF113A Y_80 + 0.31 0.10 0.82 2.11E-08 83.064 64.818
RNF20 S_138 + -0.68 -0.53 + + 0.98 5.13E-09 112.57 61.137
RNF4 S_94 + 0.21 0.35 0.98 0.00158384 51.851 51.851
RNF4 S_95 + 0.21 0.35 0.89 0.00158384 51.851 51.851
ROCK1 S_1105 + -0.22 -0.43 0.92 3.93E-05 71.426 71.426
ROCK1 S_1098 + -0.22 -0.43 0.84 3.93E-05 71.426 71.426
RPL27A S_68 + 0.74 0.68 + + 1.00 2.69E-08 106.87 75.518
RPLP1;RPLP2S_104 + -0.06 -0.02 1.00 2.47E-39 152.88 121.74
RPRD1A S_120 + 0.11 -0.20 + 0.92 0.00106716 57.347 57.347
RPRD1B S_166 + 0.08 -0.13 0.73 4.53E-05 52.556 32.572
RPRD2 S_337 + 0.22 0.15 + 1.00 4.88E-21 119.66 80.645
RPS3 T_221 + -0.17 -0.01 + 1.00 3.02E-200 235.93 175.39
RPTOR T_707 + 0.24 -0.03 0.87 0.00026435 76.051 76.051
RPTOR S_701 + 0.04 -0.24 0.83 0.0042124 58.324 58.324
RPTOR S_705 + 0.34 0.18 + 0.98 9.28E-09 96.153 96.153
RRAGC Y_16 1.14 1.06 + 0.60 0.00630979 54.097 37.507
RRAGC S_2 + 1.30 1.12 + + 0.99 0.00023253 59.888 47.662
RRAS2 S_109 + -0.41 -0.53 + + 1.00 2.25E-61 164.69 116.17
RRAS2 T_113 + -0.39 -0.89 0.87 1.38E-152 220.64 171.57
RRM2 S_20 + -0.87 -1.30 + + 1.00 4.85E-12 107.83 107.83
RRP12 S_1019 + 0.25 0.24 + + 1.00 8.68E-17 103.88 103.88
RSF1 S_1093 + -0.03 0.02 1.00 3.08E-76 174.87 174.87
RSF1 T_1053 + 0.25 0.11 1.00 0.00197262 52.898 40.518
RSL1D1 S_141 + -0.24 -0.43 + + 0.99 4.16E-22 127.5 127.5
RSRC2 S_168 + -0.23 -0.16 1.00 0.00167056 50.884 27.416
RSRC2 S_170 + -0.23 -0.16 1.00 0.00167056 50.884 27.416
RSRC2 S_174 + -0.23 -0.16 1.00 0.00167056 50.884 27.416
RSRC2 T_172 + -0.23 -0.16 1.00 0.00167056 50.884 27.416
RTN4 S_182 + 0.41 0.82 + + 0.82 1.19E-17 106.89 77.291
RTN4 S_7 + -0.27 -0.06 + 1.00 7.68E-09 84.113 84.113
RTN4 S_181 + 0.22 0.34 + + 0.88 1.19E-17 106.89 77.291
RTN4 T_188 + 0.27 0.49 + + 0.93 1.19E-17 106.89 77.291
RTN4 S_15 + -0.01 -0.04 1.00 8.65E-50 146.18 146.18
RTN4 S_13 + 0.05 0.07 + 0.53 7.92E-06 72.09 72.09
RTN4 S_184 + 0.31 0.31 + + 0.95 1.19E-17 106.89 77.291
RTN4 S_107 + 0.05 -0.04 0.87 0.0077606 41.69 41.69
SAP30 S_131 + -0.60 0.71 0.99 0.0013845 51.321 27.431
SAP30BP S_18 + 0.06 -0.09 0.54 0.00035317 42.709 42.709
SAP30BP S_22 + 0.06 -0.09 0.79 0.00035317 42.709 42.709
SART3 S_10 + -0.11 -0.35 0.86 0.0157908 47.217 47.217
SCAF1 S_734 + 0.18 0.16 + + 1.00 2.43E-13 118.02 118.02
SCAF1 S_738 + 0.18 0.16 + + 1.00 2.43E-13 118.02 118.02
SCAF1 T_1001 + -0.27 -0.17 0.99 0.00135445 69.581 69.581
SCAF11 S_481 + -0.17 -0.10 0.97 0.00561904 61.495 40.487
SCAF11 S_487 + -0.17 -0.10 0.97 0.00561904 61.495 40.487
SCFD1 S_206 + 0.22 -0.23 0.62 3.53E-10 91.932 35.953
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SCRIB S_1267 + -0.55 -0.50 + + 0.91 1.58E-11 81.345 51.49
SCRIB S_1272 + -0.78 -0.73 0.79 0.00091358 43.34 43.34
SCRIB T_1261 + -0.62 -0.51 + + 0.99 0.00033878 46.412 32.173
SCRIB S_1367 + 0.04 -0.19 0.99 0.00037921 69.024 69.024
SCRIB S_1139 + 0.29 0.17 + + 1.00 0.00176376 84.895 54.89
SCRIB S_423 + -0.03 -0.25 + 0.94 5.20E-27 128.66 128.66
SCRIB S_1485 + -0.20 -0.69 + 0.99 6.80E-08 57.563 43.645
SCRIB S_1466 + 0.15 -0.58 0.63 6.80E-08 57.563 43.645
SDAD1 S_488 + 0.09 0.21 + 1.00 7.57E-12 109.07 87.402
SDE2 S_183 + -0.09 -0.37 + 0.50 0.00886033 42.705 42.705
SDE2 T_179 + -0.09 -0.37 + 0.50 0.00886033 42.705 42.705
SDPR S_287 + 0.24 0.09 + 0.50 0.00946064 52.463 40.405
SDPR S_293 + 0.24 -0.06 + 0.99 1.26E-05 95.954 95.954
SDPR S_288 + 0.20 -0.06 + 0.61 1.26E-05 95.954 95.954
SEC22B S_137 + 0.66 0.82 + + 1.00 8.78E-13 112.14 77.011
SEC31A S_522 + 0.50 0.18 + + 0.95 0.00455425 45.878 45.878
SEMA4B S_788 + 0.10 0.12 1.00 0.00814835 68.123 22.054
SEPT9 S_218 + 0.08 0.02 + 1.00 1.32E-63 161.1 124.53
SEPT9 S_11 0.76 0.47 + + 1.00 3.92E-79 175.77 175.77
SERBP1 S_231 + -0.09 -0.01 0.85 7.83E-21 107.88 85.222
SF1 S_207 + -0.10 -0.08 1.00 3.86E-13 118.31 92.19
SF1 S_205 + -0.31 -0.41 + + 1.00 3.86E-13 118.31 92.19
SF1 S_214 + -0.35 -0.56 + + 0.80 0.00074357 55.128 49.555
SF3A1 S_264 + 0.31 0.12 1.00 6.75E-08 135.64 83.27
SF3B2 S_309 + 0.20 0.36 + + 1.00 6.44E-68 164.48 124.16
SF3B2 S_302 + 0.40 0.41 + + 0.84 6.44E-68 164.48 124.16
SF3B2 S_307 + 0.20 0.38 + + 0.97 5.36E-43 144.43 124.9
SF3B2 S_303 + 0.38 0.22 0.86 0.015239 44.474 19.743
SGPP1 S_112 + 0.32 0.30 + + 0.99 3.44E-06 96.82 65.472
SGPP1 T_114 + 0.50 0.11 + 0.96 0.00058729 70.54 42.258
SH3BP4 S_296 + -0.15 0.05 0.95 0.00061223 59.561 59.561
SH3BP4 S_246 + 0.36 0.34 + 0.98 3.89E-25 145.82 112.89
SIPA1 S_884 + -0.08 -0.35 + 0.87 1.13E-05 69.272 55.649
SIRT1 S_14 + 0.19 0.21 0.97 1.45E-07 82.859 82.859
SKA3 S_155 + 0.07 0.14 + 1.00 1.85E-07 99.238 54.356
SLC26A6 S_692 + 0.03 0.10 1.00 0.00017486 86.411 43.369
SLC26A6 S_695 + 0.03 -0.08 0.99 0.00017486 86.411 43.369
SLC9A1 S_703 + 0.06 0.03 1.00 0.00039423 84.753 67.731
SLC9A3R1 S_135 + 0.51 0.06 + 0.90 2.19E-96 183.63 183.63
SLTM S_122 + -0.07 -0.13 1.00 0.00406431 58.817 37.563
SMAP S_17 + 0.10 0.19 + + 0.85 8.54E-125 199.3 199.3
SMAP S_15 + 0.22 0.14 + + 0.50 8.54E-125 199.3 199.3
SMARCA4 S_1419 + -0.46 -0.24 + + 1.00 0.00646561 57.149 38.48
SMC4 S_41 + -0.06 -0.03 + 0.98 7.32E-52 158.53 158.53
SMC4 S_22 + -0.35 -0.46 + + 1.00 1.23E-06 103.9 61.587
SMC4 S_27 + -0.75 -1.28 + + 0.71 2.84E-06 94.588 58.225
SMC4 S_28 + -0.71 -1.28 + + 0.90 2.84E-06 94.588 58.225
SMCO3 S_138 -0.21 0.00 + 1.00 0.00134861 74.89 39.363
SMCO3 T_141 -0.21 0.00 + 0.56 0.00134861 74.89 39.363
SMN1 S_31 + 0.11 0.24 + + 1.00 9.30E-115 198.32 133.13
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SMN1 S_28 + 0.32 0.22 + + 1.00 9.30E-115 198.32 133.13
SMN1 T_25 + 0.47 0.28 + + 0.88 5.79E-07 87.748 87.748
SNAP23 S_110 + 0.27 0.24 + 1.00 6.18E-08 106.47 80.737
SNRNP200 S_225 + 0.22 0.19 + + 1.00 6.06E-96 187.75 187.75
SNTB1 S_87 + -0.05 -0.37 + 1.00 0.00382297 46.514 29.899
SNTB2 S_393 + 0.10 0.26 + 0.96 7.49E-05 87.138 64.021
SNTB2 S_95 + -0.26 -0.17 + 1.00 0.00116233 78.615 43.812
SNTB2 S_233 + 0.12 -0.31 0.72 1.24E-06 72.228 72.228
SNW1 S_232 + -0.40 -0.33 + + 0.99 0.00020957 81.904 39.429
SNW1 S_224 + -0.42 -0.41 + + 1.00 0.00020957 81.904 39.429
SNW1 S_234 + -0.50 -0.72 + + 0.96 0.00271411 62.617 62.617
SON S_1690 + 0.20 0.01 1.00 0.0047066 61.815 40.13
SON S_1378 + 0.10 0.10 + 1.00 8.10E-19 124.04 89.19
SON S_1692 + 0.38 0.33 1.00 0.0047066 62.633 38.168
SON S_1694 + 0.38 0.33 1.00 0.0047066 62.633 38.168
SORBS3 S_188 + -0.21 0.00 + 0.95 4.52E-08 135.23 91.64
SORBS3 T_187 + -0.05 0.06 0.85 8.14E-18 120.63 120.63
SP100 S_372 + 0.41 0.54 + 1.00 0.00012228 64.27 64.27
SP100 S_374 + 0.41 0.54 + 1.00 0.00012228 64.27 64.27
SP100 S_375 + 0.41 0.54 + 1.00 0.00012228 64.27 64.27
SP100 S_327 + 0.26 0.00 + 1.00 2.81E-65 170.5 170.5
SPANXB1 S_13 + 0.03 -0.16 + 1.00 3.60E-15 111.11 77.939
SPANXB1 T_34 -0.44 -0.72 0.93 1.43E-05 81.526 49.767
SPRY4 S_125 + -0.31 -0.41 + + 1.00 0.00048131 69.331 55.389
SPTAN1 S_1197 + 0.25 0.18 + 1.00 0.0220953 46.796 10.112
SPTBN1 S_2169 + -0.07 0.00 + 1.00 1.72E-27 139.76 93.1
SPTBN1 S_2165 + -0.07 -0.02 + 1.00 1.72E-27 139.76 93.1
SPTBN1 S_14 + 0.60 0.58 + + 0.98 1.38E-12 92.798 77.748
SPTBN1 S_2125 + -0.08 -0.17 + 1.00 7.61E-115 200.04 170.31
SPTBN1 S_2164 + -0.06 -0.15 + 0.79 0.0018127 62.338 50.484
SPTBN1 T_2328 + 0.29 -0.08 + 1.00 0.00107526 69.084 69.084
SPTBN1 S_2340 + 0.17 0.05 0.54 1.22E-07 86.997 72.901
SPTBN1 S_2332 + 0.36 0.12 + 0.69 0.00022113 67.01 67.01
SPTBN1 S_2341 + -0.16 -0.51 + + 1.00 9.57E-34 136.81 105.72
SQSTM1 S_193 + -0.61 -0.09 0.82 0.0033757 83.964 46.487
SQSTM1 S_191 + -0.55 0.02 + 0.77 2.38E-13 118.05 73.808
SQSTM1 S_188 + -0.57 -0.18 + + 1.00 3.24E-39 141.79 111.66
SQSTM1 T_185 + -0.52 -0.08 + + 1.00 3.24E-39 141.79 111.66
SQSTM1 S_24 + -0.92 -0.57 + + 0.91 0.00068517 53.589 34.48
SQSTM1 T_194 + -0.55 -0.26 + 0.68 3.78E-27 137.73 104.45
SQSTM1 S_248 + -0.07 0.09 + 1.00 1.17E-10 86.449 73.423
SQSTM1 S_282 + -0.38 -0.09 0.63 1.08E-15 96.123 73.135
SQSTM1 S_192 + -0.37 -0.13 + 0.82 1.00E-26 133.78 133.78
SRC S_17 + -0.23 -0.56 + 1.00 0.00312242 49.497 31.995
SRRM1 S_775 + -0.74 -0.74 + + 0.67 0.00034586 60.635 40.326
SRRM1 T_220 + -0.20 -0.23 + + 1.00 1.39E-07 105.95 77.742
SRRM1 S_771 + -0.48 -0.45 0.99 0.00158771 49.076 49.076
SRRM1 S_872 + 0.15 0.14 + + 1.00 2.87E-134 203.59 158.35
SRRM1 T_870 + 0.35 0.54 + + 1.00 1.17E-114 197.07 185.58
SRRM1 S_773 + -0.42 -0.45 + + 0.92 1.96E-06 76.693 76.693
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SRRM1 S_767 + -0.42 -0.56 + + 1.00 1.96E-06 76.693 76.693
SRRM1 S_388 + 0.00 -0.14 + + 1.00 5.49E-05 81.643 81.643
SRRM1 S_402 + -0.41 -0.40 + + 1.00 0.0128581 58.98 25.139
SRRM1 S_392 + 0.05 -0.14 + + 1.00 5.49E-05 81.643 81.643
SRRM1 S_779 + -0.55 -0.91 + + 0.92 2.25E-05 68.634 68.634
SRRM1 S_390 + 0.07 -0.11 + + 1.00 5.49E-05 81.643 81.643
SRRM2 S_424 + -0.62 0.16 + 1.00 0.00063018 108.94 71.604
SRRM2 S_398 + -1.15 -1.49 + + 0.81 5.27E-19 101.58 101.58
SRRM2 S_875 + 0.03 0.11 + 1.00 4.88E-18 123.92 123.92
SRRM2 S_2272 + 0.21 0.21 + 1.00 6.40E-08 98.902 93.228
SRRM2 S_1320 + 0.01 0.13 + 1.00 0.00055966 63.46 44.957
SRRM2 S_2031 + -0.11 -0.17 + + 1.00 7.97E-15 106.3 53.266
SRRM2 S_1329 + 0.00 0.02 1.00 1.97E-07 98.654 98.654
SRRM2 S_876 + -0.04 -0.03 1.00 1.46E-91 185.32 185.32
SRRM2 S_2274 + 0.12 0.15 + + 1.00 6.40E-08 98.902 36.01
SRRM2 S_2276 + 0.12 0.15 + + 1.00 6.40E-08 98.902 36.01
SRRM2 S_1103 + 0.49 0.41 + + 0.99 2.72E-12 113.37 92.476
SRRM2 S_1102 + 0.12 0.21 + + 0.86 9.61E-12 113.37 59.509
SRRM2 S_2032 + 0.04 0.01 1.00 2.10E-11 101.39 38.86
SRRM2 T_2034 + 0.04 0.01 1.00 2.10E-11 101.39 38.86
SRRM2 S_215 + 0.00 0.00 0.88 0.00017173 61.963 44.923
SRRM2 S_1179 + -0.04 -0.14 + + 1.00 1.11E-05 88.781 88.781
SRRM2 S_2398 + 0.10 0.00 + 0.79 0.00074384 78.113 44.024
SRRM2 S_1124 + 0.18 0.17 1.00 0.0029808 66.393 39.981
SRRM2 S_2067 + 0.05 0.00 1.00 3.09E-08 102.15 102.15
SRRM2 S_2071 + 0.05 0.00 1.00 3.09E-08 102.15 102.15
SRRM2 T_2069 + 0.05 0.00 1.00 3.09E-08 102.15 102.15
SRRM2 S_1099 + 0.19 0.20 + + 1.00 2.72E-12 112.41 92.476
SRRM2 S_1326 + -0.04 -0.21 1.00 0.00056859 84.046 50.781
SRRM2 S_1101 + 0.16 0.07 + + 1.00 2.72E-12 112.41 92.476
SRRM2 S_377 + -0.29 -0.50 + + 0.99 5.27E-19 101.58 101.58
SRRM2 S_857 + 0.07 -0.12 0.92 0.00073415 66.925 49.683
SRRM2 S_1318 + 0.52 0.21 + 1.00 0.00055966 63.46 43.796
SRRM2 T_1231 + 0.34 0.21 + + 0.70 0.00089276 59.585 32.074
SRRM2 T_866 + 0.00 -0.32 + 0.98 0.00073415 68.291 48.199
SRRM2 S_255 + -0.25 -0.43 0.78 0.0005891 45.14 26.277
SRRM2 S_257 + -0.25 -0.43 0.74 0.0005891 45.14 26.277
SRRM2 S_261 + -0.25 -0.43 0.77 0.0005891 45.14 26.277
SRSF10 S_131 + 0.18 0.24 + + 1.00 0.00883553 65.038 65.038
SRSF10 S_133 + 0.18 0.24 + + 1.00 0.00883553 65.038 65.038
SRSF2 S_200 + -0.18 -0.08 1.00 2.63E-15 109.56 109.56
SRSF2 S_194 + -0.15 -0.17 1.00 2.63E-15 109.56 109.56
SRSF2 S_196 + -0.15 -0.17 1.00 2.63E-15 109.56 109.56
SRSF6 S_303 + -0.22 -0.19 + + 1.00 2.32E-18 125.33 125.33
SRSF9 S_216 + -0.17 -0.12 + + 1.00 0.00012646 87.669 87.669
SRSF9 S_211 + 0.10 0.09 1.00 0.00012646 87.669 87.669
SSFA2 S_584 + 0.59 0.59 + + 1.00 3.01E-18 120.4 89.455
SSFA2 S_586 + 0.59 0.59 + + 1.00 3.01E-18 120.4 89.455
ST13;ST13P4 S_75 + -0.30 -0.27 1.00 6.04E-177 223.93 223.93
ST13;ST13P4 S_71 + 0.00 0.22 0.98 0.00177677 66.152 44.545
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ST13;ST13P4 S_72 + 0.05 0.06 1.00 6.04E-177 223.93 223.93
STEAP3 S_20 + 0.10 0.30 + 0.74 2.72E-07 93.062 75.167
STEAP3 S_17 + 0.13 0.27 1.00 2.72E-07 93.062 75.167
STK10 S_438 + 0.09 0.02 1.00 2.10E-19 120.79 120.79
STK10 T_952 + -0.14 -0.21 + + 1.00 4.25E-154 222.93 176.05
STK24 S_4 + -0.01 -0.26 1.00 0.0050225 64.5 20.064
STMN1 S_25 + 0.04 0.29 + + 1.00 3.55E-110 195.87 169.16
STMN1 S_38 + -0.23 -0.09 + + 1.00 2.89E-06 112.02 65.293
STMN1 S_16 + 0.77 0.45 + + 1.00 2.58E-19 125.08 99.492
STMN1;STMN2S_46 + 0.59 0.74 1.00 0.0061168 66.023 18.031
STRIP1 S_63 + 0.06 0.39 + 0.59 0.00044007 58.796 41.171
STRIP1 S_240 + -0.04 -0.08 + 1.00 4.97E-11 105.96 74.916
STRN S_233 + 0.28 0.17 + + 1.00 6.48E-102 191.53 163.49
SUDS3 S_236 + -0.13 -0.18 0.75 0.0016175 48.354 48.354
SUDS3 S_234 + -0.21 -0.22 + + 0.98 3.73E-05 67.396 67.396
SUDS3 S_237 + -0.28 -0.34 0.85 3.73E-05 67.396 67.396
SUMO1 S_2 + -0.16 0.00 + 1.00 9.55E-05 81.016 81.016
SVIL S_270 + 0.02 -0.17 + 1.00 5.89E-05 87.729 60.701
SVIL S_261 + 0.03 -0.22 + 0.95 5.89E-05 87.729 60.701
SVIL T_426 + -0.04 -0.15 1.00 5.23E-30 138.54 115.69
SYMPK S_1173 + -0.30 -0.49 0.81 0.00050468 56.553 38.657
TACC2 S_21 + -0.11 -0.14 + 1.00 3.95E-08 84.166 70.565
TACC2 S_2321 + -0.11 -0.14 + 1.00 3.95E-08 84.166 70.565
TANC2 S_1530 + -0.23 -0.10 + 1.00 0.0205049 50.102 32.871
TANC2 S_1534 + -0.23 -0.10 + 1.00 0.0205049 50.102 32.871
TANC2 S_1442 + -0.09 -0.54 + 1.00 0.0150497 49.076 49.076
TANC2 S_1445 0.04 -0.70 + 0.94 0.0150497 49.076 49.076
TBC1D10B S_658 + -0.22 -0.39 + + 0.78 0.00048046 69.704 41.155
TBC1D10B S_661 + -0.18 -0.29 + + 1.00 0.00048046 69.704 41.155
TBC1D15 S_658 + -0.05 0.36 + 1.00 7.89E-05 80.733 22.945
TBC1D22A S_113 + -0.48 -0.41 0.98 0.00341702 51.524 51.524
TBC1D4 S_588 + 0.67 0.61 + + 1.00 6.38E-06 93.237 45.386
TBC1D4 S_591 + 0.73 0.61 + + 1.00 6.38E-06 93.237 44.753
TCEAL3 S_65 + 1.00 1.82 + + 1.00 0.00208755 64.522 42.47
TCOF1 S_1151 + -0.30 -0.11 + + 0.88 8.05E-06 94.673 94.673
TCOF1 S_1301 + -0.49 -0.48 + + 0.98 0.0004477 69.07 46.741
TERF2IP S_203 + 0.08 -0.06 0.88 8.26E-13 111.11 86.853
TFDP1 S_23 + -0.33 -0.54 + 1.00 0.00290201 62.68 44.722
TFPT S_180 + -0.91 -0.86 1.00 0.00014086 66.152 66.152
THRAP3 T_685 + 0.07 0.16 0.66 2.42E-35 143.04 64.267
THRAP3 S_682 + -0.01 0.18 1.00 1.17E-26 132.17 79.781
THRAP3 S_320 + -0.17 0.00 + 0.99 6.96E-07 81.357 81.357
THRAP3 S_253 + 0.00 0.02 1.00 5.19E-13 110.53 58.427
THRAP3 S_315 + -0.15 0.00 + 1.00 6.96E-07 81.357 81.357
THRAP3 S_939 + 0.23 0.17 + + 0.99 1.07E-51 157.53 127.17
THRAP3 S_379 + 0.67 0.54 + + 0.82 0.00163463 67.102 52.592
THUMPD1 S_86 + -0.03 -0.02 1.00 5.56E-100 187.75 156.83
THUMPD1 S_88 + -0.03 -0.02 1.00 5.56E-100 187.75 156.83
TJAP1 S_470 + 0.46 0.43 + + 1.00 3.35E-62 167.9 128.15
TJAP1 S_225 + 0.07 0.07 1.00 5.65E-19 120.63 95.173
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TJP1 S_125 + -0.08 -0.58 + 1.00 5.75E-09 81.763 66.081
TJP1 S_131 + -0.08 -0.58 + 0.55 5.75E-09 81.763 66.081
TJP2 T_902 + 0.20 0.45 + + 0.94 3.73E-10 82.126 82.126
TJP2 T_910 + 0.20 0.45 + + 0.95 3.73E-10 82.126 82.126
TJP2 S_371 + 0.10 0.09 0.55 0.00071018 57.21 57.21
TJP2 S_375 + 0.10 0.09 0.55 0.00071018 57.21 57.21
TJP2 S_377 + 0.10 0.09 0.87 0.00071018 57.21 57.21
TJP2 S_1012 + 0.20 0.25 + 1.00 3.11E-76 179.9 170.47
TJP2 S_679 + 0.66 0.54 + 0.50 0.00565282 47.774 47.774
TJP2 T_684 + 0.66 0.54 + 0.50 0.00565282 47.774 47.774
TJP2 S_107 + -0.09 -0.18 + 1.00 2.93E-11 107.07 107.07
TJP2 S_1017 + -0.41 -0.50 + + 1.00 5.85E-06 93.181 76.047
TJP2 S_1009 + 0.03 -0.03 0.89 0.00529713 40.92 26.502
TK1 S_13 + -0.52 -0.43 + + 0.99 3.01E-19 122.12 122.12
TK1 S_15 + -0.56 -0.55 + + 0.85 0.00019041 77.42 77.42
TLE3 S_196 + -0.06 0.46 0.90 2.43E-06 95.429 60.531
TLN1 S_425 + -0.03 0.07 0.76 0.00062361 48.616 48.616
TMEM230 S_24 + 0.17 0.62 0.66 0.00039795 73.296 46.025
TMF1 S_344 + 0.37 0.55 + + 1.00 1.25E-19 127.53 96.053
TMOD3 S_25 + -0.02 -0.06 0.99 5.24E-06 79.942 48.265
TMPO T_74 + -0.21 -0.32 + + 1.00 9.32E-09 84.948 84.948
TMPO S_168 + -0.31 -0.23 + 0.65 1.89E-05 78.419 58.145
TMPO T_160 + 0.04 -0.23 0.73 4.17E-15 113.73 113.73
TMPO S_158 + -0.06 -0.11 0.68 7.01E-64 162.42 112.14
TMPO S_306 + -0.32 -0.40 1.00 0.00068248 68.168 68.168
TMPO S_159 + -0.03 -0.12 0.71 7.01E-64 162.42 112.14
TMPO S_67 + -0.11 -0.30 + + 1.00 2.10E-67 152.63 152.63
TMPO S_66 + 0.06 -0.21 + + 1.00 2.10E-67 152.63 152.63
TMSB4X S_31 + 0.93 0.35 + + 0.99 1.10E-12 114.06 114.06
TMSB4X T_34 + 0.80 0.26 + + 1.00 0.00266155 63.091 50.251
TMX1 S_247 + 0.16 0.22 + + 1.00 2.92E-119 194.59 194.59
TNKS1BP1 S_287 + 0.92 0.94 + + 1.00 3.18E-05 94.281 74.984
TNKS1BP1 S_1620 + 0.08 0.09 + 1.00 3.29E-27 134.58 104.77
TNKS1BP1 S_344 + 0.10 0.52 + + 0.79 0.00020295 63.869 47.254
TNKS1BP1 S_498 + -0.05 -0.05 0.95 7.02E-37 129.08 113.79
TNKS1BP1 S_494 + -0.05 -0.05 0.99 7.02E-37 129.08 113.79
TNKS1BP1 S_1621 + 0.25 0.06 + 1.00 3.29E-27 134.58 104.77
TNRC6B S_879 + -0.02 -0.45 1.00 2.52E-06 84.166 66.184
TNS1 S_1177 + 0.23 -0.03 + 0.99 0.00642082 52.451 52.451
TNS1 S_1271 + 0.17 -0.25 0.95 0.01879 55.258 36.158
TNS3 S_536 + 0.31 0.46 + 1.00 9.18E-20 117.96 87.716
TNS3 S_420 + -0.43 -0.43 + + 0.97 0.00028001 71.354 71.354
TOE1 S_5 + -0.22 0.05 1.00 6.80E-11 96.181 65.092
TOM1L1 S_246 + -0.04 -0.79 + 0.99 0.00148346 55.406 55.406
TOMM22 S_15 + 0.25 0.00 + 1.00 8.31E-34 134.29 134.29
TOP1 S_10 + 0.27 0.30 + + 1.00 0.0019017 53.037 53.037
TOP2A S_1247 + -0.19 0.25 + 1.00 5.79E-20 163.61 115.88
TOP2A S_1377 + 0.15 0.43 + + 1.00 2.97E-12 113.65 85.973
TOP2A S_1374 + 0.89 1.15 + + 1.00 6.88E-08 106.6 69.653
TOP2B S_1521 + -0.03 0.10 1.00 1.98E-50 152.4 152.4
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TOP2B S_1461 + -0.08 0.01 1.00 1.01E-25 126.96 100.8
TOP2B S_1466 + 0.00 -0.34 0.54 0.00077198 65.105 65.105
TOP2B S_1519 + -0.02 -0.01 1.00 2.84E-29 133.51 133.51
TOP2B S_1517 + 0.00 -0.04 1.00 1.98E-50 152.4 152.4
TOP2B S_1576 + -0.44 -0.53 + 0.64 2.79E-08 84.689 84.689
TOPORS S_33 + -1.47 -1.19 + + 0.80 0.00898579 50.158 31.768
TOR1AIP1 S_156 + 0.16 0.13 + 1.00 1.35E-05 74.561 64.997
TOR1AIP1 S_154 + 0.15 0.13 + 1.00 1.35E-05 74.561 64.997
TOR1AIP1 S_157 + 0.64 0.16 + 1.00 1.35E-05 74.561 64.997
TOR1AIP1 T_147 + -0.27 -0.69 0.81 0.00026326 64.454 48.142
TOR1AIP1 S_143 + -0.15 -0.98 0.82 0.00919251 56.424 35.413
TP53 S_6 + -0.34 -1.14 0.98 0.00906027 59.339 27.113
TP53BP1 S_1114 + 0.40 0.46 0.86 3.60E-39 136.61 113.48
TP53BP1 S_500 + 0.18 0.21 + + 1.00 1.21E-51 160.05 160.05
TP53BP1 S_1067 + 0.29 0.22 0.50 0.00733981 76.301 41.975
TP53BP1 S_1068 + 0.29 0.22 0.50 0.00733981 76.301 41.975
TP53BP1 S_1113 + 0.23 0.19 0.99 1.14E-11 96.848 57.852
TP53BP1 S_294 + 0.16 -0.12 + + 1.00 6.97E-19 112.37 112.37
TP53BP1 S_1426 + 0.01 -0.29 + 1.00 1.87E-11 95.141 95.141
TP53BP1 S_1430 + 0.01 -0.29 + 1.00 1.87E-11 95.141 95.141
TP53BP1 S_1759 + 0.32 -0.13 + 0.61 0.00046028 57.366 43.151
TP53BP1 S_1758 + 0.30 -0.17 0.61 0.00046028 57.366 43.151
TP53BP1 T_1756 + 0.30 -0.17 0.99 0.00046028 57.366 43.151
TPD52L2 S_12 + 0.00 -0.04 1.00 7.63E-37 142.23 119.6
TPI1 S_21 + 0.11 0.22 + + 1.00 2.29E-93 182.77 182.77
TPR S_2155 + -0.03 0.02 1.00 0.00028001 71.354 71.354
TPX2 S_738 + -0.30 -0.28 + + 1.00 0.0006972 70.438 36.547
TRA2A S_2 + -0.01 0.15 1.00 0.00412934 66.059 48.043
TRA2A S_14 + 0.18 0.09 1.00 0.018849 57.248 57.248
TRAF2 T_7 + -0.17 0.52 1.00 0.00066549 77.221 42.132
TRAF2 S_11 + -0.15 0.35 1.00 0.00066549 77.221 42.132
TRAFD1 S_415 + 0.19 -0.04 + 0.98 2.07E-76 177.04 146.93
TRIM28 S_50 + -0.26 -0.15 + 0.84 3.83E-10 76.208 63.317
TRIM28 S_19 + -0.11 -0.25 + + 0.98 3.18E-21 107.09 107.09
TRIM56 S_469 + 0.00 0.04 + 1.00 0.00017904 64.377 53.625
TRIM56 S_475 + -0.06 -0.19 1.00 7.13E-06 75.608 58.005
TRIM56 S_471 + -0.29 -0.35 1.00 7.13E-06 75.608 58.005
TRIO S_2400 + -0.21 -0.33 + 0.71 3.35E-05 76.557 76.557
TRIO S_2396 + -0.23 -0.42 + 0.87 3.35E-05 76.557 76.557
TRIP10 S_299 + -0.01 0.03 0.98 3.53E-06 81.594 62.77
TRIP10 S_296 + -0.05 -0.23 1.00 2.06E-06 81.594 62.77
TRIP12 S_312 + 0.00 0.19 + 0.99 0.00802692 51.235 15.558
TSC22D4 S_279 + -0.14 0.33 1.00 5.80E-60 160.84 124.16
TTC1 S_83 + 0.00 0.05 1.00 5.37E-19 110.89 84.757
TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA3ET_16 + -0.14 -0.18 0.62 0.00409681 62.028 27.88
TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA3ES_13 + -0.11 -0.18 0.86 6.60E-07 84.159 58.901
TUBA1B;TUBA4AS_224 + -0.12 -0.05 1.00 2.34E-05 92.671 71.611
UBAP2L S_468 + -0.27 -0.49 + 0.63 0.00084405 50.858 50.858
UBAP2L S_460 + -0.22 -0.36 + + 0.89 9.09E-08 77.51 77.51
UBAP2L S_447 + -0.69 -1.26 + + 0.93 1.77E-19 113.05 113.05
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UNC13D S_150 + -0.08 -0.18 + + 0.99 8.30E-81 163.6 163.6
UNC13D S_153 + -0.02 -0.19 0.63 0.00046925 55.751 55.751
USP10 S_576 + -0.04 0.14 1.00 0.0001637 65.854 53.931
USP15 S_229 + -0.40 -0.09 + 1.00 0.0008364 77.726 55.814
USP24 S_2561 + -0.02 -0.74 0.87 0.00200874 56.972 56.972
UTP14A S_29 + 0.41 0.24 + 1.00 8.39E-14 118.85 79.065
UTP14A S_31 + 0.41 0.24 + 1.00 8.39E-14 118.85 79.065
UTP3 S_365 + 0.13 0.18 1.00 7.37E-42 191.13 119.45
UTP3 S_368 + 0.13 0.18 1.00 7.37E-42 191.13 119.45
VAMP4 S_30 + 0.11 0.09 + 1.00 7.23E-40 149.18 149.18
VAT1 S_18 + 0.12 -0.01 0.86 0.00446691 80.508 51.293
VCL S_288 + 0.29 0.05 0.70 0.00277365 60.093 26.332
VCL S_290 + 0.32 0.17 + 1.00 2.37E-27 131.37 98.224
VCL S_721 + 0.62 0.44 + + 1.00 0.00066658 77.633 49.523
VDAC1 S_104 + -0.12 -0.14 + + 1.00 6.39E-20 129.05 96.895
VIM S_420 + 0.26 0.62 + + 0.79 1.64E-61 166.45 166.45
VIM S_51 + -0.23 0.19 0.99 6.68E-37 145.79 145.79
VIM S_419 + 0.42 0.60 + + 0.90 4.79E-77 180.48 180.48
VIM S_430 + 0.39 0.70 + + 1.00 5.95E-05 82.709 42.064
VIM S_56 + -0.19 0.02 0.99 2.69E-61 163.44 163.44
VIM S_55 + -0.11 -0.01 + 0.95 2.21E-61 164.82 164.82
VIM S_39 + 1.10 0.99 + + 0.99 0.00026966 79.23 50.167
VIM S_27 + 0.09 0.32 + 0.75 0.0167382 44.925 18.634
VIPR1 S_237 + 0.40 0.50 + + 0.89 0.00918891 51.286 22.33
VIPR1 S_238 + 0.40 0.50 + + 0.56 0.00918891 58.172 24.855
VIPR1 S_239 + 0.19 0.58 + + 0.56 0.00918891 58.172 24.855
WAPAL S_226 + -0.31 -0.13 + + 1.00 2.16E-36 148.97 86.279
WAPAL S_221 + -0.31 -0.15 + + 1.00 2.16E-36 148.97 86.279
WAPAL S_223 + -0.34 -0.26 + + 0.98 0.00043024 82.663 82.663
WAPAL S_120 + 0.01 -0.25 + 0.99 1.88E-05 72.316 72.316
WDFY3 S_1011 -4.17 -2.61 0.98 0.0146208 46.847 7.6586
WDFY3 S_1015 -4.17 -2.61 0.99 0.0146208 46.847 7.6586
WDHD1 S_745 + -0.01 0.16 1.00 0.0032171 48.025 33.669
WDR62 S_1228 + -0.08 0.00 0.88 1.74E-25 122.6 122.6
WRAP53 S_90 + -0.31 -0.24 0.94 7.51E-06 81.133 55.622
WRAP53 S_85 + -0.21 -0.44 0.97 7.51E-06 81.133 55.622
WRAP53 T_489 + -0.03 -0.43 0.80 8.46E-05 66.536 62.617
YAP1 T_63 + 0.08 0.19 0.72 1.35E-08 122.53 74.797
YAP1 S_61 + -0.09 0.11 0.90 1.05E-64 163.96 163.96
YBX1;YBX2;YBX3S_102 + -0.04 0.12 1.00 3.45E-15 111.45 85.483
YTHDC1 S_308 + 0.09 0.23 1.00 0.0003172 77.674 38.37
ZBTB7A S_525 + -0.11 -0.49 + 0.79 0.00028823 64.589 46.273
ZC3H13 S_370 + -0.08 -0.24 0.58 0.00112127 59.857 45.751
ZC3H13 S_381 + -0.08 -0.24 0.97 0.00112127 59.857 45.751
ZC3H13 Y_374 + -0.08 -0.24 0.60 0.00112127 59.857 45.751
ZC3H13 S_207 + -0.17 0.00 + 1.00 3.70E-05 91.592 50.609
ZC3H13 S_209 + -0.17 0.00 + 0.94 3.70E-05 91.592 50.609
ZC3H13 S_265 + -0.40 -0.71 + 1.00 4.75E-79 178.57 178.57
ZC3H13 T_263 + -0.40 -0.71 + 1.00 4.75E-79 178.57 178.57




ZC3H18 S_500 + -0.01 -0.03 1.00 0.0108202 68.168 36.009
ZC3HC1 S_314 + -0.25 -0.24 0.61 1.29E-08 99.409 99.409
ZDHHC5 S_568 + -0.26 -0.21 + 1.00 2.29E-07 88.486 68.132
ZDHHC5 S_641 + -0.27 -0.39 + + 0.54 0.0101594 43.326 43.326
ZDHHC5 S_379 + 0.24 0.21 + + 1.00 3.78E-156 217.73 170.81
ZDHHC5 S_327 + 0.27 0.17 + 0.66 0.0100876 42.947 16.004
ZEB1 S_612 + -0.39 -0.59 + + 0.99 0.00262116 51.39 51.39
ZFYVE19 S_179 + 0.28 0.12 + + 1.00 2.22E-156 219.96 190.49
ZMYM4 T_118 + -0.07 0.05 0.50 9.18E-05 75.316 75.316
ZMYM4 S_122 + -0.06 0.27 0.78 9.18E-05 75.316 75.316
ZNF185 S_64 + 1.98 1.79 + + 0.78 0.00238864 70.47 53.799
ZNF185 S_103 + 0.24 0.23 + 0.98 0.00032205 70.072 43.06
ZNF185 T_210 + -0.14 -0.67 + + 0.99 4.20E-43 144.43 107.52
ZNF579 T_482 -0.48 -0.65 + 0.58 0.00026371 67.655 46.347
ZNF579 S_483 + -0.69 -1.21 + + 0.79 4.23E-06 83.666 61.999
ZRANB2 S_310 + -0.27 0.00 0.67 0.00996677 46.282 31.009
ZRANB2 S_305 + -0.08 0.13 + + 1.00 1.33E-12 109.23 109.23
ZRANB2 S_307 + -0.08 0.13 + + 1.00 1.33E-12 109.23 109.23
ZRANB2 S_153 + 0.08 0.27 + 1.00 4.45E-55 153.06 153.06
ZRANB2 S_188 + -0.01 0.10 + 1.00 2.15E-61 169.6 138.45
ZRANB2 S_181 + -0.26 -0.14 1.00 6.38E-05 86.214 69.991
ZRANB2 S_120 + 0.18 0.00 + 1.00 7.28E-05 89.136 76.344
ZYX S_142 + 0.12 0.25 + 0.50 5.14E-19 111.24 111.24
ZYX S_143 + 0.12 0.25 + 0.50 5.14E-19 111.24 111.24




Gene Protein Site M/L(log2) H/L(log2) 
CCAR1 Cell division cycle and  
apoptosis regulator 
protein 1 
S_360 4.76 1.95 
CCAR1 Cell division cycle and  
apoptosis regulator 
protein 1 
T_348 4.76 1.95 
CCAR1 Cell division cycle and  
apoptosis regulator 
protein 1 
Y_347 4.76 1.95 
ZNF185 Zinc finger protein 185 S_64 1.98 1.79 
RRAGC Ras-related GTP-
binding protein C 
S_2 1.30 1.12 
TBC1D4 TBC1 domain family 
member 4 
S_591 0.73 0.61 
PLEC Plectin S_4217 0.88 0.77 
VIM Vimentin S_39 1.10 0.99 
LMO7 LIM domain only 
protein 7 
S_342 0.80 0.70 
PLEC Plectin S_4213 0.70 0.61 
RRAGC Ras-related GTP-
binding protein C 
Y_16 1.14 1.06 
PDIA6 Protein disulfide-
isomerase A6 
S_425 1.12 1.04 
PLEC Plectin S_4216 0.68 0.61 
FLNC Filamin-C S_2200 1.57 1.50 
TBC1D4 TBC1 domain family 
member 4 
S_588 0.67 0.61 
RPL27A 60S ribosomal protein 
L27a 
S_68 0.74 0.68 
LMO7 LIM domain only 
protein 7 
S_1176 0.73 0.69 




S_652 0.70 0.67 
SPTBN1 Spectrin beta chain, 
non-erythrocytic 1 
S_14 0.60 0.58 
SSFA2 Sperm-specific antigen 
2 
S_584 0.59 0.59 
SSFA2 Sperm-specific antigen 
2 
S_586 0.59 0.59 
TNKS1BP1 182 kDa tankyrase-1-
binding protein 




S_116 1.01 1.04 
LMO7 LIM domain only 
protein 7 
S_471 0.74 0.78 
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Gene Protein Site M/L(log2) H/L(log2) 
HSP90B1 Endoplasmin S_306 2.15 2.20 
PATL1 Protein PAT1 homolog 
1 
S_177 0.62 0.68 
RAD50 DNA repair protein 
RAD50 
S_496 0.77 0.84 
CD2AP CD2-associated 
protein 
S_458 0.95 1.09 
SEC22B Vesicle-trafficking 
protein SEC22b 
S_137 0.66 0.82 
ANXA1 Annexin A1 S_5 0.96 1.12 
ARHGAP29 Rho GTPase-activating 
protein 29 
S_176 0.94 1.11 
MVB12A Multivesicular body 
subunit 12A 
S_170 0.81 0.99 
CTTN Src substrate cortactin S_389 0.72 0.92 
ARHGAP29 Rho GTPase-activating 
protein 29 
S_171 0.67 0.88 
TOP2A DNA topoisomerase 2-
alpha 
S_1374 0.89 1.15 
NELFE Negative elongation 
factor E 
S_115 0.95 1.25 




S_791 0.80 1.10 
NDRG1 Protein NDRG1 S_249 1.47 1.82 
MTOR Serine/threonine-
protein kinase mTOR 
T_1162 0.72 1.09 
HSPB1 Heat shock protein 
beta-1 
S_82 0.82 1.22 
ARHGAP32 Rho GTPase-activating 
protein 32 
T_565 0.73 1.30 
TCEAL3 Transcription 
elongation factor A 
protein-like 3 
S_65 1.00 1.82 
Appendix 7: The significant phosphorylation changes up-regulated by both insulin (M/L) 





Gene  Protein sites  M/L(log2) H/L(log2) 
NCOR2 Nuclear receptor 
corepressor 2 
S_1001 -1.04 -0.66 
TOPORS E3 ubiquitin-protein 
ligase Topors 
S_33 -1.47 -1.19 
AKAP2 A-kinase anchor 
protein 2 
S_375 -0.82 -0.59 
DNMT1 DNA (cytosine-5)-
methyltransferase 1 
S_378 -0.69 -0.60 
MAP1B Microtubule-
associated protein 1B 
S_1256 -0.65 -0.61 
OGFR Opioid growth factor 
receptor 
S_539 -0.88 -0.84 
MYO9B Unconventional 
myosin-IXb 
T_1271 -0.63 -0.60 
AKT1S1 Proline-rich AKT1 
substrate 1 




S_775 -0.74 -0.74 
MEF2D Myocyte-specific 
enhancer factor 2D 
S_205 -0.61 -0.65 
OGFR Opioid growth factor 
receptor 
S_537 -0.60 -0.65 
PSMD2 26S proteasome non-
ATPase regulatory 
subunit 2 
S_16 -0.63 -0.69 
AKT1S1 Proline-rich AKT1 
substrate 1 
S_112 -0.84 -0.95 
OGFR Opioid growth factor 
receptor 
S_565 -1.02 -1.14 
MAP1B Microtubule-
associated protein 1B 
S_1258 -0.60 -0.73 
KMT2A Histone-lysine N-
methyltransferase 2A 
S_1799 -0.69 -0.84 
BAG3 BAG family 
molecular chaperone 
regulator 3 
S_386 -0.89 -1.05 
HIST1H1E Histone H1.4 T_18 -0.62 -0.79 
KMT2A Histone-lysine N-
methyltransferase 2A 




S_166 -0.62 -0.83 
AFAP1 Actin filament-
associated protein 1 
S_265 -0.72 -0.98 
DDX54 ATP-dependent RNA 
helicase DDX54 
T_70 -0.62 -0.89 
OGFR Opioid growth factor 
receptor 
S_559 -0.59 -0.91 
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Gene  Protein sites  M/L(log2) H/L(log2) 
ATXN2L Ataxin-2-like protein T_632 -0.64 -0.97 
BAG3 BAG family 
molecular chaperone 
regulator 3 




S_398 -1.15 -1.49 
OGFR Opioid growth factor 
receptor 




S_20 -0.87 -1.30 
ZNF579 Zinc finger protein 
579 
S_483 -0.69 -1.21 
SMC4 Structural maintece of 
chromosomes protein 
4 
S_27 -0.75 -1.28 
BAG3 BAG family 
molecular chaperone 
regulator 3 
S_377 -1.02 -1.56 
NCOR2 Nuclear receptor 
corepressor 2 
S_149 -0.70 -1.25 
SMC4 Structural maintece of 
chromosomes protein 
4 
S_28 -0.71 -1.28 
UBAP2L Ubiquitin-associated 
protein 2-like 
S_447 -0.69 -1.26 
ATXN2L Ataxin-2-like protein S_634 -0.76 -1.36 
NCOR2 Nuclear receptor 
corepressor 2 
S_152 -0.74 -1.36 
MARCKSL1 MARCKS-related 
protein 
S_101 -0.77 -1.41 
MARCKSL1 MARCKS-related 
protein 
S_104 -0.77 -1.41 
Appendix 8: The significant phosphorylation changes down-regulated by both insulin (M/L) 





Gene  Protein sites  M/L(log2) 
EGFR Epidermal growth factor 
receptor 
S_1166 0.60 
DTNBP1 Dysbindin S_235 0.61 
DTNBP1 Dysbindin S_240 0.61 
TJP2 Tight junction protein 
ZO-2 
S_679 0.66 
TJP2 Tight junction protein 
ZO-2 
T_684 0.66 




PLEC Plectin S_4220 0.60 
FAM129A Protein Niban S_602 0.70 






SEPT9 Septin-9 S_11 0.76 











associated protein LEO1 
S_598 0.74 
TMSB4X Thymosin beta-4 T_34 0.80 
TMSB4X Thymosin beta-4 S_31 0.93 
Appendix 9: The significant phosphorylation changes up regulated by insulin (M/L) only 
with respect to the untreated samples are shown (log2 > 0.58, P < 0.05). The changes by IGF-





Gene  Protein sites  M/L(log2) 
SRRM2 Serine/arginine 




























ARHGAP17 Rho GTPase-activating 
protein 17 
S_209 -0.62 
ARHGAP17 Rho GTPase-activating 
protein 17 
T_215 -0.62 
MKI67 Antigen KI-67 S_224 -0.64 
RNF20 E3 ubiquitin-protein 
ligase BRE1A 
S_138 -0.68 
DYNC1LI1 Cytoplasmic dynein 1 









SCRIB Protein scribble 
homolog 
T_1261 -0.62 
ARHGEF18 Rho guanine nucleotide 
exchange factor 18 
S_1124 -0.64 
BRD8 Bromodomain-
containing protein 8 
S_128 -0.58 
Appendix 10: The significant phosphorylation changes down regulated by insulin (M/L) 
only with respect to the untreated samples are shown (log2 < -0.58, P < 0.05). The changes by 









EIF5B Eukaryotic translation 






RTN4 Reticulon-4 S_182 0.82 
VIM Vimentin S_420 0.62 
VIM Vimentin S_430 0.70 
AKT1S1 Proline-rich AKT1 
substrate 1 
S_183 0.67 
ARHGAP18 Rho GTPase-activating 
protein 18 
S_21 0.71 
ARHGAP18 Rho GTPase-activating 
protein 18 
S_24 0.75 
VIM Vimentin S_419 0.60 
EGFR Epidermal growth 
factor receptor 
S_1162 0.60 
Appendix 11: The significant phosphorylation changes up-regulated by IGF-II (H/L) only 
with respect to the untreated samples are shown (log2 > 0.58, P < 0.05). The changes by 















ZEB1 Zinc finger E-box-
binding homeobox 1 
S_612 -0.59 
SNW1 SNW domain-
containing protein 1 
S_234 -0.72 
ACIN1 Apoptotic chromatin 
condensation inducer in 
the nucleus 
T_408 -0.69 






FAM129B Niban-like protein 1 S_683 -0.61 
DYNC1LI1 Cytoplasmic dynein 1 
light intermediate chain 
1 
T_515 -0.61 
GPATCH8 G patch domain-
containing protein 8 
S_662 -0.67 













CIC Protein capicua 
homolog 
S_1373 -0.70 








repetitive matrix protein 
1 
S_779 -0.91 
DYNC1LI1 Cytoplasmic dynein 1 














ARHGAP17 Rho GTPase-activating 
protein 17 
S_207 -0.74 
EIF3G Eukaryotic translation 
initiation factor 3 
subunit G 
T_41 -0.82 
DOCK5 Dedicator of 
cytokinesis protein 5 
S_1789 -0.70 
DOCK5 Dedicator of 
cytokinesis protein 5 
T_1794 -0.70 
SCRIB Protein scribble 
homolog 
S_1485 -0.69 
DYNC1LI1 Cytoplasmic dynein 1 
light intermediate chain 
1 
S_510 -0.59 
EIF3G Eukaryotic translation 
initiation factor 3 
subunit G 
T_38 -1.02 
KANK2 KN motif and ankyrin 
repeat domain-
containing protein 2 
S_19 -0.87 
KANK2 KN motif and ankyrin 
repeat domain-
containing protein 2 
T_14 -0.87 
TJP1 Tight junction protein 
ZO-1 
S_125 -0.58 
TJP1 Tight junction protein 
ZO-1 
S_131 -0.58 
RABL6 Rab-like protein 6 S_596 -0.76 








ZNF185 Zinc finger protein 185 T_210 -0.67 




containing protein 2 
S_178 -0.69 
BRD2 Bromodomain-
containing protein 2 
S_181 -0.69 
MPRIP Myosin phosphatase 
Rho-interacting protein 
S_294 -0.78 




linking factor 1 
S_263 -0.89 
PGRMC1 Membrane-associated S_57 -0.94 
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MYEF2 Myelin expression 
factor 2 
S_17 -1.11 
TANC2 Protein TANC2 S_1445 -0.70 
TOM1L1 TOM1-like protein 1 S_246 -0.79 
NCOR2 Nuclear receptor 
corepressor 2 
T_156 -1.07 
DOK1 Docking protein 1 S_152 -0.86 
FAM129B Niban-like protein 1 S_679 -1.13 
CD3EAP DNA-directed RNA 
polymerase I subunit 
RPA34 
S_136 -1.15 
Appendix 12: The significant phosphorylation changes down regulated by IGF-II (H/L) 
only with respect to the untreated samples are shown (log2 < -0.58, P < 0.05). The changes by 
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Appendix 14: Raw data of Figure 5.10. In this diagram non specific bands are present as a 
long exposure time was used in order to show the molecular weight markers. However, the 










































































































































































































































































































































































Appendix 16. Raw data of Figure 5.12-A. 
  
p44/42 MAPK (Thr202/Tyr204), 42,44 KDa
IGF-1R, 95 KDa
p90RSK (Ser380), 90 KDa
pAkt (Ser473), 60 KDa
pAkt (Thr308), 60 KDa





- - - + + +
- - -+ +-
- - -+ + -
shIGF-1R
- - -+ +-

























Appendix 17. Raw HPLC spectra of mass spectrometry runs used to generate Figure 6.7. (A) 




















































































400 600 800 1000 1200 1400 1600 1800 2000
Raw file Scan Method Score m/z
ORB160513_YY_16-031_E1-C18_10uL_01 4221 ITMS; CID 81.76 1175.5
- V Q I P
y₂₆²⁺
V
y₂₅²⁺
S
b₆
R
b₇
P
y₂₂²⁺
D
y₂₁²⁺
b₉
P
y₂₀²⁺
E
y₁₉²⁺
b₁₁
P V S
ph
D
y₁₅²⁺
b₁₅
N
y₁₄²⁺
b₁₆
E
b₁₇
E
y₁₂²⁺
D
y₁₁
S
ph
Y D
b₂₂²⁺
E
y₇
E I
y₅
H
y₄
b₂₆²⁺
D
y₃
b₂₇²⁺
P R -
